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Continuing metabolism is crucial for the function
and cellular integrity of the ischaemic myocardium,
and may be critically dependent on the substrate used.
It can be manipulated by changing arterial substrate
concentrations and/or by altering the metabolic re¬
gulation of the ischaemic myocardium directly, leading
to a reduction in the severity of the ischaemic injury.
One approach to alter metabolism is the use of
anti-lipolytic drugs, which reduced in a series of
independent studies ischaemia induced ST-segment ele¬
vation .
On the other hand glucose utilisation may be
enhanced, by a drug, dichloroacetate, shown to be
effective in the normal myocardium. Enhanced glucose
utilisation by the ischaemic zone after administration
of dichloroacetate was associated with reduced ST-
segment elevation, and a reduction in lactate release.
Intralipid/heparin as a model to raise plasma free
fatty acids was re-examined with improved methodology
avoiding in vitro lipolysis. Arterial plasma free fatty
acid concentrations were in the physiological range and
related to fatty acid turnover.
19
Plasma free fatty acid concentrations were raised
without severe haemodynamic and arrhythmic side-effects
by direct infusion of sodium oleate in normal dogs using
a continuous blood cell separator. Sodium oleate was
also infused during acute myocardial ischaemia, and did
not precipitate serious ventricular arrhythmias. Ischaemic
myocardial extraction of free fatty acids was raised, and
did not influence that of glucose.
The reduction in ST-segment elevation and free fatty
acid extraction by the ischaemic myocardium after the
administration of anti-lipolytic drugs support and extend
other evidence that they reduce the severity of myocardial
ischaemic injury. The most likely mechanism is inhibition
of ischaemia-induced myocardial lipolysis, in view of the
lack of a detrimental effect of sodium oleate infusion.
However, a synergistic effect of reduced plasma free fatty
acids can not be excluded.
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INTRODUCTION
There is probably no other disease to date, which
more
challenges man in our western society^ than coronary
heart disease. No wonder many physicians and epi¬
demiologists have been and are engaged in studies aimed
to prevent this killer-disease. It is now accepted
that one is not dealing with one particular form of
illness, but more likely with a spectrum of different
aetiologies: atherosclerosis, sudden death, thrombosis
and possibly even coronary arterial spasm. Epidemio¬
logical studies have underlined the importance of a
multitude of genetic, metabolic, dietary and environ¬
mental factors. It is believed that some of these
factors may contribute to the narrowing of the coronary
arteries by formation of atherosclerotic plaques or
thrombi, and thereby ultimately impeding blood supply
to the myocardium. During most of the time these
underlying processes may go unnoticed to the person at
risk and as a result it may be difficult to obtain his
full cooperation in reducing his risk. Also the
apparently constant changing environmental influences
introduced by all kinds of changes (legislation,
economic conditions, availability of raw products, etc)
21
makes it impracticable to examine the effect of one
particular dietary or environmental change on the
incidence of coronary heart disease. The speed of
the development of new scientific methods and concepts
in relation to the length of the primary prevention
studies often make the best possible design and measure¬
ments at the start out-of-date or insufficient in some
essential details on completion of those studies. And
even if the incidence of ischaemic heart disease could
be reduced, can long term treatment of an apparently
healthy population or even those at higher risk, of
whom some would never have suffered a heart attack,
be justified by increasing the risk of inducing other
diseases at the same time? These considerations raise
doubt on the impact, which studies of primary prevention
of ischaemic heart disease will have in the immediate
future. Most likely therefore, patients will present
themselves for treatment of acute myocardial infarct¬
ion. The main challenge remains the early contain¬
ment of the ischaemic changes, which so often lead to
lethal ventricular arrhythmias.
In this thesis the role which myocardial metabolism
of glucose and fatty acids plays in the early phase of
acute myocardial ischaemia is examined using an experi¬
mental model in the dog.
22
AIM OF THE THESIS
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Aim of the thesis
Acute myocardial infarction in man is accompanied
by an increase in the plasma concentration of free
fatty acids (Kurien and Oliver, 1966; Gupta et al,
1969; Rutenberg et al, 1969; Ravens and Jipp, 1972;
Vetter et al, 1974; Christensen and Videbaeck, 1974).
The rise, which may be observed as early as 1 hour
after onset of symptoms (Vetter et al, 1974), is
probably due to stimulated adipose tissue lipolysis
as a result of increased activity of the sympathetic
nervous system (Vetter et al, 1974; Christensen and
Videbaeck, 1974). In support of this view is the
observation that plasma glycerol concentrations were
! f
also raised after acute myocardial infarction (Carlstrom
and Christensson, 1971) and raised plasma glycerol con¬
centration often considered as a better index of adipose
tissue lipolysis (Scow and Chernick, 1970). Those
patients with the highest concentration of plasma free
fatty acids have been reported to be at greater risk
of developing serious ventricular arrhythmias and death
(Oliver et al, 1968; Gupta et al, 1969), although not
all investigations have confirmed this association
(Rutenberg et al, 1969). In another study individual
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free fatty acids were quantitated using gaschroma-
tography and the concentration of plasma free linoleic
acid, rather than the total free fatty acids concentra¬
tion was associated with a bad prognosis (Ravens and
Jipp, 1972)0
A was .advanced J »— «A hypothesisj that acute lipid mobilisation from
adipose tissue may lead to the accumulation of 'unbound'
free fatty acids within the ischaemic myocardium, where
they exert direct detergent effects on the cell membrane,
with cation loss and resultant development of ectopic
pacemaker activity (Kurien and Oliver, 1970). This
hypothesis has been supported by the demonstration that
the incidence of ventricular arrhythmias during the
early phase of acute myocardial infarction was reduced
by effective antilipolytic therapy in the absence of
changes in plasma catecholamine concentrations (Rowe et
al, 1975) and may lead to decreased ischaemic injury
(Kjekshus, 1978).
A toxic effect of FFA on the heart could be mediated
through an alteration of membrane potentials (Wasilewska-
Dziubinska et al, 1975) or an increase in the severity
of the ischaemic injury to the myocardium (Mj^s, 1973).
Marked elevation of the plasma concentration of
free fatty acids was associated with the development
of arrhythmias during experimental coronary occlusion
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in dogs (Kurien et al, 1971). In other experiments
the severity of myocardial ischaemic injury was re¬
duced by the administration of an antilipolytic drug -
(3-pyridy1-carbinol (Kjekshus and Mj^s, 1973), attri¬
buted to decreased oxygen requirements of the ischaemic
tissue, in analogy with the reduced myocardial oxygen
consumption observed in healthy dogs (Mj^s, 1971).
These results support the view that raised plasma
concentrations of free fatty acids may have deleterious
effects on the ischaemic myocardium, and are comple¬
mented by the beneficial effects claimed for the other
major substrate: glucose.
It was suggested that 'raised blood glucose concentra¬
tions might benefit the ischaemic myocardium by in¬
creasing the rate of anaerobic glycolysis, by reversing
ion losses, by a direct membrane effect, by altering
the extracellular volume, and by decreasing the circula¬
ting free fatty acid concentrations' (Opie, 1970).
However it should be pointed out that the formulation
of this hypothesis was largely based on
firstly - the extrapolation of observations made in
anoxic, well perfused preparations,
secondly - on the extrapolation of reciprocal behaviour
of fatty acid and glucose metabolism in well
oxygenated heart muscle preparations (Handle,
1963) to the ischaemic myocardium.
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Due to the complex changes occurring during acute
ischaemia these extrapolations may not be justified.
Therefore detailed studies of the interrelation
between glucose and free fatty acid metabolism in the
ischaemic myocardium are indicated.
27
THE WORKING HYPOTHESIS
Enhancement of glucose availability, or decrease in
fatty acid utilisation might provide the ischaemic
myocardium with greater cellular integrity, and there¬










It is not the intention to review all aspects
of the metabolism of the normal and ischaemic myo¬
cardium. The reader is referred to several review
articles and a monograph (Randle, 1963; Opie, 1968;
Opie, 1969a,b; Neely et al, 1972). However for
sake of clarity a summary of the metabolism of normal
and ischaemic myocardium is given.
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SECTION 1.1:
METABOLISM OF THE NORMAL HEART
31
Metabolism of the normal heart
In order to satisfy the demand for energy required
for the maintenance of contractile and cellular pro¬
cesses, the heart must generate ATP. In the heart
most of the ATP is obtained from mitochondrial oxida¬
tive phosphorylation. Oxygen and substrates are
extracted from the arterial circulation. Although
the heart can use virtually any substrate, under normal
physiological conditions two substrates contribute
most to myocardial oxidative metabolism: plasma free
fatty acids and glucose (85-90% of energy requirements),
while others: lactate, triglycerides and ketonebodies
play a definite but quantitatively less important role.
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Fatty acid metabolism
Plasma free fatty acids utilised by the heart
originate from adipose tissue triglycerides. During
lipolysis fatty acids diffuse into the circulation
where they are bound to albumin, which functions as
the carrier for these water insoluble acids. Plasma
free fatty acids are extracted by the myocardium in
a process which does not require energy (Evans, 1964).
The extraction is related to the arterial concentra¬
tion, the nature of the fatty acids and the degree of
binding to albumin, determined by the free fatty acid
to albumin molar ratio. Within the cell the fatty
acids are thought to be bound by a fatty acid binding
protein (Ockner et al, 1972). Fatty acids can not be
utilised within the cell directly, but must be 'activated'
in the form of their coenzyme A ester (acyl-CoA). This
from
process requires a phosphate transfer j ATP. Only then can
they enter the various pathways: oxidation, incorpor¬
ation into triglycerides or into phospholipids, syn¬
thesis of complex lipids.
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Oxidation of acyl-CoA
Long chain acyl-CoA cannot penetrate directly into
the mitochondrial matrix, where the integrated enzyme
system for fatty acid oxidation is located adjacent
to and functions in a closely-linked fashion with
the respiratory chain. The transport of acyl-CoA into
the mitochondria is achieved by a shuttle mechanism in
which acyl-carnitine, which (in contrast to acyl-CoA )
can cross the mitochondrial membrane, is the intermediate.
Once inside the mitochondrion acyl carnitine is converted
back into acyl-CoA. The stepwise degradation of acyl-CoA
to acetyl-CoA yields reduced flavoprotein and NADH.
Acetyl-CoA is further degraded by the enzymes of the
KrebS cycle, also located in the mitochondrial matrix,
leading to further formation of reduced coenzymes and
1 molecule of GTP. The reduced coenzymes are regenerated
in the presence of oxygen in the respiratory chain under
formation of ATP.
Synthesis of triglycerides
Experiments with radioactive fatty acids have
demonstrated the synthesis of triglycerides. Activated
fatty acids are esterified with ^-glycerophosphate, derived
from the glycolytic pathway. In the normal myocardium net
synthesis of triglycerides is not observed and there must
be a dynamic equilibrium between triglyceride synthesis
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and hydrolysis of triglycerides by hormone-sensitive
lipase and/or intracellular lipoprotein lipase, enzymes
which are under hormonal control,and with activities which
ti
vary with the nutryonal and hormonal status of the
subject.
Control of plasma free fatty acid metabolism by the heart
The main control over the metabolism of plasma free
fatty acids by the heart is exerted on the mobilisation of
fatty acids from adipose tissue, which is the net result
of lipolysis and re-esterification of hydrolysed fatty
acids into adipose tissue triglycerides. Adipose
tissue triglyceride lipase is thought to exist in
enzymically interconvertible forms. The inactive form is
phosphorylated by acyclic-AMP sensitive protein-kinase to
a catalytically active form. Catecholamines, growth
hormone, glucagon all stimulate lipolysis, while insulin
has a direct antilipolytic effect.
The rate of re-ester ification is affected by the
availability of glucose, providing (^.-glycerophosphate.
Addition of fatty acids to isolated adipocyte stimulates
ester if icat ion, but ©".-glycerophosphate levels in adipose
tissue were unchanged. Thus there may be still unidentified
factors which can regulate re-esterification and hence
fatty acid mobilisation.
The cellular control of fatty acid metabolism in the
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heart has not been widely investigated. The fate of
fatty acid is determined by its availability ,
and that of other substrates,
such as glucose. The rate of triglyceride formation
is increased under conditions where fatty acid supply
exceeds the rate of fatty acid oxidation. However much
more work is needed to establish how control over this
and other pathways is exerted. The reader is referred
to a review article by Neely and Morgan (1974).
Myocardial Glucose metabolism
The other major substrate for the myocardium is
glucose. It can provide the heart with 30-60% of its
energy requirements. Transport of glucose across the
cell membrane involves a specific carrier mechanism.
No energy is required for this. Glucose is then, after
phosphorylation to glucose-6-phosphate by ATP in a
reaction catalysed by hexokinase, degraded to pyruvate
in a series of enzymic conversions, which is known as
the glycolytic pathway. It is important to point out
that in addition to the formation of reduced NADH, in
this pathway a net synthesis of 2 molecules of ATP per
molecule of glucose is made. Another important feature is
that a constant supply of NAD is required in order to
maintain the flux of glucose through the pathway.
However glycolytic flux is not dependent on oxidative
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regeneration of NADH in the mitochondrion, as is necessary
to maintain fatty acid oxidation, since NAD+ required for
the dehydrogenation of glyceraldehyde-3-phosphate can be
provided by conversion of pyruvate (+ NADH) to lactate
(+NAD+)o
The fate of pyruvate
Normally pyruvate is further degraded to
acetyl-CoA and C02 with the formation of NADH by
mitochondrial pyruvate dehydrogenase. The fate of the
formed acetyl-CoA is the same as that described for
acetyl-CoA orginating from oxidation of fatty acids.
The dehydrogenation of pyruvate and the metabolism of
acetyl-CoA, which both are dependent on oxygen availability,
constitute the energetically most important part of the
pathway and lead to 95% of the ATP production.
Control of glucose metabolism
Glucose extraction by the heart is related to arterial
glucose concentrations, the availability of insulin, pH
and arterial concentrations of plasma free fatty acids.
(Other factors such as workload are not considered here,
and the effect of hypoxia will be discussed later).
Investigations of the intermediate metabolites and
of the activities of the key enzymes of the glycolytic
pathway suggest that phosphofructokinase is under most
conditions a regulatory enzyme, controlling the overall
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flux through the pathway (Newsholme and Start, 1973;
Neely and Morgan, 1974).
Insulin stimulates glucose uptake by the heart,
by direct enhancement of glucose transport, and intra¬
cellular free glucose accumulates. This is taken as
evidence that under these conditions phosphorylation of
glucose determines essentially the glycolytic flux.
Insulin also stimulates glycogen synthetase, the regulatory
enzyme for glycogen synthesis.
Catecholamines, by stimulating the
formation of cyclic-AMP by adenvlcyclase, affect the
conversion of phosphorylase-b (inactive) to phosphorylase-
a (active) and thereby increase glycogenolysis.
A low pH inhibits and a high pH increases the activity
of phosphofructokinase and thereby infIuencesglycolytic
flux (Mansour, 1972).
The interrelation between fatty acid and glucose
metabolism in the heart has been studied by Randle and
colleagues (Randle, 1963). The glycogen sparing activity
of fatty acids and inhibition of glycolysis was explained
by increased citrate levels, inhibiting phosphofructo¬
kinase. As a result more of the glucose entering the cell
is diverted to glycogen. The reduced glucose uptake seen
under these conditions was related to increased levels of
glucose-6-phosphate, which are inhibitory to hexokinase.
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Glycogen metabolism
The heart stores some of the extracted glucose in
the form of glycogen, serving as a fuel reserve. Three
enzymic steps are involved in the conversion of glucose-
6-phosphate into glycogen. In the first glucose-6-
phosphate is converted into glucose-1-phosphate, a
reaction catalysed by phosphoglucomutase. In the next
step glucose is transferred to part of the
nucleotide uridine-tri-phosphate (UTP). Only glucose
moieties in this activated form (uridine-di-phosphate-
glucose) can be transferred to glycogen by glycogen
synthetase. The incorporation of 1 molecule glucose-
6-phosphate into glycogen requires the hydrolysis of one
high energy phosphate bond for the formation of uridine-
di-phosphate-glucose.
Glycogenolysis is not simply the reversal of glycogen
synthesis. The enzyme phosphorylase catalyses the cleavage
of the glucose moiety from glycogen with the formation
of glucose-1-phosphate, which is converted into glucose-
6-phosphate, prior to entering the glycolytic pathway.
Control of glycogen metabolism
Glycogen synthetase controls the overall flux in the
synthesis of glycogen. It occurs in two forms: I and D.
The activity of the D form is dependent (D) on the
glucose-6-phosphate concentration. This form is strongly
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inhibited by ATP in such a way that under most physiological
conditions it is considered to be inactive. The maximal
activity of the I form is independent (I) of the level
of glucose-6-phosphate, and this form is relatively
insensitive to inhibition by ATP. Control of glycogen-
synthesis depends on a phosphorylation-dephosphorylation
mechanism. The D-form is phosphorylated and can be
dephosphorylated by glycogen synthetase phosphatase, and
as a result glycogen synthetase activity will increase.
However glycogen inhibits the phosphatase, and as more
glycogen accumulates a progressively lower percentage of
glycogen synthase will be in the active I form. The
conversion of the active (I) into 'inactive' (D) form is
catalysed by a cyclic AMP dependent protein kinase.
Glycogenolysis is controlled by the activity of
phosphorylase. This enzyme occurs in two forms,
phosphorylase a and b. These two forms differ in their
sensitivity to the inhibitors ATP and glucose-6-phosphate.
Phosphorylase-b is only active when AMP and Pi levels
are high enough to overcome the inhibitory effects of
ATP and glucose-6-phosphate, while phosphorylase-a is
also active at high levels of these inhibitors. The
conversion to phosphorylase-a is regulated by phosphorylase-
b kinase, which in its turn exists in an active and in¬
active form. A cyclic-AMP dependent protein kinase is
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responsible for the formation of the
active form. Thus stimulation of this protein kinase
by cyclic-AMP will result in stimulation of phosp'norylase-
b-kinase, which will in its turn stimulate the formation
of the active form of phosphorylase, leading to stimulation
of glycogenolysis.
Thus myocardial glycogen synthesis and glycogenolysis
are controlled in a complex but integrated manner,
in which cellular levels of ATP, glucose-6-phosphate,
glycogen, AMP, Pi and cyclic AMP all play a regulatory
role.
Interrelation of glucose and fatty acid metabolism
Ran die and collegues have extrapolated the findings
from their extensive series^in vitro studies of heart,
muscle and adipose tissue to the intact animal and man
This concept is known as the glucose-fatty acid cycle
(Randle, 1963), and gives an explanation for the well-
known inverse relation between glucose and fatty acid
metabolism. When concentrations of plasma free fatty
acids are high, fatty acid utilisation is increased
and glucose uptake by the heart (and muscle) is depressed.
Consequently plasma glucose levels will increase, resulting
in increased glucose uptake and glycolysis by adipose
tissue. The provision of more ^-glycerophosphate due to
enhanced glycolysis will stimulate fatty acid reesterification
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and as a result free fatty acid release will be
diminished. Now glucose uptake by the heart (and
muscle) is no longer inhibited and increased glucose
uptake will result in lowered plasma glucose concentra¬
tion. As a result increased mobilisation of fatty
acids due to low glucose uptake by adipose tissue will
cause plasma concentrations of free fatty acids to rise.
Since this concept was proposed, evidence has been
presented that high plasma concentrations of free fatty
acids stimulate insulin release (Crespin et al, 1972),
explaining the negative feedback of plasma free fatty
acids on adipose tissue lipolysis. Similarly it is
possible that fatty acids and ketone bodies exert an
independent antilipolytic effect on adipose tissue.
This additional information does not invalidate the
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Metabolic events during acute myocardial ischaemia
The heart requires a constant supply of oxygen to
maintain its functional activity. When its activity
is increased the augmented oxygen demand is chiefly
met by increased coronary flow, while the extraction
of oxygen is almost unchanged. In patients with
ischaemic heart disease with severe stenosis or occlusion
of one or more coronary arteries, the heart is no longer
capable of meeting the increased oxygen demand and
acute ischaemia, which may or may not lead to infarct¬
ion, ensues. It is apparent that different degrees
of residual regional myocardial blood flow may occur.
Reduction in flow will not necessarily correlate with
the severity of ischaemia, and has to be considered
against the background of oxygen demand of the heart.
In this section the metabolic consequence of acute
ischaemia, but not those of anoxia will be reviewed.
This distinction, which may seem rather arbitrary is
made to avoid confusion. During anoxia, the heart
compensates for the lack of oxygen supply by maximal
vasodilation. Therefore this hypoxic condition is
characterised by increased coronary flow rates, rather
than a decrease, which is so characteristic for
ischaemia. Marked differences between anoxia and
ischaemia have emerged: the accumulation of 'waste'
products (lactate, H etc) occur in ischaemic, but not
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in anoxic myocardium, which in turn appear to affect
other processes within the cell. On the other hand the
anoxic cell may be loaded with substrates (fatty acids)
it can " not utilise.
These considerations have to be taken into account
when interpreting results obtained from different models
of (experimental) ischaemia. It is conceivable that
the reduction in coronary flow required to induce a given
deficit in oxygen supply may be widely different. This
may lead to differences in intracellular pH and/or accumu¬
lation of metabolites between models, which in turn may
affect enzymic processes, etc. It is extremely difficult,
if not impossible, to predict the ultimate outcome.
Animal experiments have contributed to most of our
present knowledge of the effects of acute ischaemia. In
such experiments localized ischaemia was induced by
)
coronary ligation or global ischaemia was induced by a
reduction in total coronary perfusion. While in the
first model gradients of oxygen deficit and cellular
impairment occur with or without functional impairment
of the heart as a whole, the latter is characterised
by a more homogeneously affected tissue, with impairment
of left ventricular function. There is an increased
tendency to develop differences in arrhythmias of the
former model, which is presumably a reflection of the
difference in metabolism. However since the effects
of ischaemia on myocardial metabolism in these two pre¬
parations have not been studied systematically, they will
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be discussed together.
The onset of myocardial ischaemia is characterised
by a precipitous drop in myocardial oxygen tension in
the area within the distribution of the ligated artery
(Sayen et al, 1958; Gudbjarnason et al, 1970), despite
increased oxygen extraction across this area (Opie et
al, 1973; Opie et al, 1973^; Steenbergen et al, 1977).
The lack of oxygen is reflected in an increase in NADH/NAD
ratio. Contractility in the ischaemic area is depressed
within seconds after occlusion (Puri, 1976; Smith, 1977)
and the myocardium virtually ceases to contract at a time
when the levels of ATP are not, but CP levels are decreased
(Puri, 1976). It remains to be seen if the persistence of
depressed contractile behaviour in the ischaemic area
(Richardson et al, I960) is solely responsible for the
marked decline in ATP and CP immediately afterwards
n
(Wollenberger and Krause, 1968; Kubler and Spieckermann,
1970; Gudbjarnason et al, 1970; Jones et al, 1976).
AMP, ADP and inorganic phosphate levels rise, as well as
those of the degradation products of adenine nucleotides,
hypoxanthine and inosine (De Jong et al, 1977; Jones et
al, 1976; Stam and De Jong, 1977). Cyclic AMP was also
raised soon after induction of ischaemia (Wollenberger
et al, 1972; Podzuweit et al, 1975; Podzuweit et al, 1978)
possibly as a result of adenylcyclase stimulation by
locally released noradrenaline (Shahab et al, 1969), due
to enhanced activity of the myocardial sympathetic nervous
system (Malliani et al, 1969).
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Electrolyte gradients are no longer held and the
+. . . .
lschaemic cell loses K ions, while it gains Na and Ca
(Naylerfl9h; Flear et al, 1976), although this was not
confirmed in another study (Whalen et al, 1974). These
electrolyte changes might be a direct result of lack of
ATP (Trump, 1976), since Na+, K+-ATP-ase might not be
inhibited early on (Schwartz et al, 1973). The
intracellular acidosis (Opie et al, 1975; Williamson
et al, 1977) is probably responsible for the rise in
pCC>2 (Khuri et al, 1975; O'Riordan et al, 1977), since
COp production is decreased during acute ischaemia (Opie
et al, 1973^). All these changes are observed during the
reversible phase of acute ischaemia with little or no
histo-chemically demonstrable changes (Whalen et al,
1974; Jennings and Ganote, 1972).
However if the occlusion was maintained for longer
periods (40-60 min) irreversible damage became apparent
in a large proportion of ischaemic cells: swelling,
disrupted mitochondria, with irregular dense amorphous
matrix densities (Kloner et al, 1974; Jennings and
Ganote, 1972). It is not clear whether the transition
from reversible to irreversible damage is induced by an
increase in permeability of the lysosomal membranes due
to the lowered intracellular pH. However studies appear
to exclude lysosomal involvement during the reversible
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phase of ischaemia.
It should be emphasized that these histochemical observations
of Jenningsand colleagues were made on severely ischaemic
tissue, (posterior papillary muscle) and that the
transition of reversible to irreversible damage may be
delayed in less severely ischaemic myocardium.
Mitochondrial function during ischaemia
Several groups have investigated the function of
mitochondria, isolated from ischaemic myocardium (Jennings
et al, 1969; Schwartz et al, 1973; Lochner et al, 1975).
Mitochondria were almost in all cases isolated from
irreversibly damaged tissue. They were fragile and
yields were only half of those obtained for the isolation
of mitochondria from the non-ischaemic myocardium (Jennings
et al, 1969). When studied in vitro using manometric
or polarographic techniques high oxygen tensions are used.
Under these conditions the mitochondria exhibited a
disturbed function: low phosphorylation/oxidation (P/0)
ratios, low respiratory control by the addition of ADP
and low oxygen consumption (Jennings et al, 1969; Schwartz
et al, 1973; Lochner et al, 1975).
However there are two reasons, why these results
should not be extrapolated to in vivo ischaemic myocardial
mit ochondrion:
1 - The homogenisation medium used during the isolation
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procedure influenced markedly the results. Particularly
the use of fat free albumin and EDTA could nullify the
effect of ischaemia on P/C ratios and oxygen consumption
(Lochner et al, 1975).
2 - With the present techniques (manometric and
polarographic) high oxygen tensions are used. Reperfusion
of ischaemic myocardium 40 min after coronary occlusion
causes explosive cell damage: disrupted mitochondria
intramitochondrial Ca deposits, etc (Kloner et al, 1974).
This exacerbation of ischaemic myocardial damage during
reoxygenation was confirmed with a different end point
(enzyme release) in hypoxic perfused rat hearts
(Hearse et al,1976). Thus it is conceivable that the
exposure of isolated mitochondria from ischaemic
myocardium to high oxygen tensions, necessary for the
in vitro studies, contributes to the mitochondrial
damage.
The effect of albumin and EDTA may tell us more of
the likely causes of the mitochondrial disturbance in
ischaemic tissue. The effect of albumin could be exerted
by binding of fatty acids, formed from mitochondrial
acyl-CoA (Idel1-Wenger and Neely, 1977; Lochner et al,
1978). EDTA may counteract the accumulation of Ca, which
is a known depressant of mitochondrial function. Although
this suggests that fatty acids and Ca might be involved
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in the disruption of mitochondrial function, it is almost
impossible in these studies to be sure that the observations
are not artifacts. A promising approach is the development
of techniques designed to assess mitochondrial (and
cytoplasmic) redox couples, using reflectance fluorescence
NADH (Steenbergen et al, 1977). A first, exciting finding
is that the ischaemic area of isolated rat heart was
heterogeneous, with highly localised anoxic zones. These
anoxic islands developed while the effluent oxygen tension
was significantly greater than zero. Whether these results
can be confirmed in blood perfused hearts remains to be
seen.
However hopefully this technique will continue to contribute
to the desperately needed information of mitochondrial
function in ischaemic myocardium.
Substrate metabolism during acute ischaemia
The effect of acute ischaemia on the extraction and
metabolism of fatty acids, glucose, lactate, pyruvate
and ketone bodies has been investigated. The increase
of glucose extraction across the ischaemic area is well
established (Opie et al, 1973: Van der Vusse and Reneman,
1977; De Jong et al,1977 ), and it appears that glucose
uptake by the ischaemic myocardium is decreased despite
the compensatory increase in extraction (Opie et al, 1973;
Neely et al, 1973). Glycogenolysis leads to a rapid
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decline of the glycogen stores (Braasch et al, 1968;
Opie et al, 1973; Neely et al, 1973; Crass et al, 1976;
Opie et al, 1975), although they do not appear to vanish
completely (Kloner et al, 1974, Opie et al, 1973). The
stimulation of glycogenolysis is thought to be mediated
by raised intracellular levels of cyclic AMP (Wollen-
berger et al, 1967), possibly in combination with the
increased levels of AMP, inorganic phosphate (Neely et al,
1973). Contrary to the widely held view the major fate
of glucose is oxidation and not lactate formation (Opie
et al, 1973; Neely et al, 1975). This is probably best
illustrated in the recalculated data of Neely et al (1975),
presented in Table 1.01. Even under the most severely
ischaemic conditions (residual blood flow 4% of control
values) most of the contribution of glucose to ATP forma¬
tion is derived from its aerobic metabolism.
The effect of acute ischaemia on fatty acid metabolism
has also been examined. Extraction of radioactive fatty
acids may (Scheuer and Brachfeld, 1966) or may not be
decreased (Riemersma et al, 1972). In an extension of
the latter study Opie, Owen and Riemersma (1973) deter¬
mined also the extraction of plasma free fatty acids by
chemical methods. The observed decrease in net extract¬
ion was explained - in view of the unchanged extraction
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Table 1.01
The contribution of aerobic and anaerobic glucose metabolism





Coronary flow* ATP production* Anaerobic Aerobic
Control 100% 100% 5% 95%
ischaemic 34% 73% 13% 87%
8% 37% 19% 81%
4% 16% 19% 81%
♦Results expressed as % from control. Data from Neely et al,
1975.
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of radioactive fatty acids - by increased intramyo-
cardial lipolysis, releasing free fatty acids into the
ischaemic effluent. Oxidation of fatty acids is in¬
hibited (Scheuer and Brachfeld, 1966; Riemersma et al,
1972; Idell-Wenger and Neely, 1977), and as a result
intermediates of this pathway : acyl-CoA, acyl-earnitine,
hydroxy-acy1-CoA all accumulate (Idell-Wenger and Neely,
1977; Bittar et al, 1976; Shug et al, 1978), but it
remains to be seen whether acyl-CoA inhibits adenosine
nucleotide translocase in ischaemic myocardium, which
catalyzes the transport of ADP in and ATP out of the
mitochondria (Shrago and Sul, 1977; Shug et al, 1978).
The same reservations apply as those listed in the para¬
graph 'Mitochondr ial function during ischaemia ' (pp 47).
The synthesis of triglycerides is enhanced (Scheuer
and Brachfeld, 1966; Crass et al, 1976; Riemersma, 1979),
possibly due to increased levels of acyl-CoA and ^-gly¬
cerophosphate, and probably exceeds the rate of lipolysis,
in view of the well documented infiltration of neutral
lipids in ischaemic myocardium (Bryant et al, 1958).
Enhanced triglyceride synthesis in the presence of an
increased rate of lipolysis indicates the operation of
an energy wasting cycle.
53
Control of metabolism during acute myocardial ischaemia
It seems odd to consider control of biochemical
pathways during acute ischaemia in view of the extensive
derangement of the cell. However the reversibly damaged
cell still generates and utilises energy in an attempt to
maintain its integrity. Some enzymes will control the
flux of substrates through the various pathways.
Several studies have recently been made, specifically
designed to define which enzymes limit the utilisation of
glucose and glycolysis in the ischaemic myocardium,
others have looked at competition of substrates. Factors,
which control the glucose utilisation in ischaemic myo¬
cardium are undoubtedly best, but by no means completely,
understood. The early increase in glycolytic flux in the
ischaemic myocardium is mainly due to enhanced glyco-
genolysis, due to stimulation of phosphorylase by in¬
creased levels of cyclic AMP (Wollenberger et al, 1967),
in analogy with the effect of cyclic AMP in well oxygen¬
ated myocardium during catecholamine stimulation. In
addition the increased levels of AMP and inorganic phos¬
phate will enhance the activity of phosphorylase. Within
minutes the rate of glycogenolysis slows down although
it is actually never inhibited, as can be calculated from
the data of Rovetto and Neely (1977). It is not clear,
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which is the rate-limiting step of glycolysis during
ischaemia. Rovetto et al (1973) suggested that either
phosphofructokinase or glyceraldehyde-phosphate dehydro¬
genase limited the flux of glucose through glycolysis.
Later Rovetto and Neely (1977) suggested that glyceralde-
hyde-3-phosphate dehydrogenase was most likely the enzyme
which controlled glycolysis. On the other hand Opie
(1975) suggested that glycolysis was restricted at the
level of phosphofructokinase, like under aerobic con¬
ditions (Newsholme and Start, 1973; Neely and Morgan,
1974). It is acknowledged that studies using the cross¬
over theorem may provide suggestive evidence of exerted
control, due to the fact that an apparent restriction
could be due to an apparent build-up of difficult to
measure product of the reaction.
The effect of pH has also been examined. Incorpor¬
ation of a buffer in the perfusate of the ischaemic heart
could overcome the inhibition of glycolysis (at the level
of glyceraldehyde-3-phosphate dehydrogenase) and the rate
limiting step appeared to be either pyruvate kinase or
pyruvate-dehydrogenase (Rovetto et al, 1975). However
more work is indicated, since modest elevation of H+ con¬
centration only caused inhibition when accompanied by
oxygen deficiency (Rovetto and Neely, 1977), suggesting
that other factors associated with ischaemia such as
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high NADH levels, reduced phosphate potentials, etc.
might inhibit glycolysis.
Control of fatty acid metabolism in ischaemic myocardium
Control of fatty acid metabolism during ischaemia has
hardly been investigated. Apart from the effect of
ischaemia on the passive process of extraction (see above)
little attention has been given to its control of Ji-
oxidation and triglyceride formation in ischaemic myo¬
cardium. Intracellular concentrations of free fatty acids
might be raised (Lochner et al, 1978), however in view of
the major technical difficulties of such measurements,
they can only be considered with some reservations. Acyl-
CoA accumulates, suggesting that activation of fatty acids
might not be limiting for ^-oxidation. In analogy with
the requirements of the glycolytic pathway, the ^3-oxida¬
tion also requires constant supply of oxidised coenzymes
NAD, flavoprotein. Thus the increased redox-state in
the ischaemic mitochondrion (Steenbergen et al, 1977)
might be responsible for the reduced oxidation of fatty
acids (Idell-Wenger and Neely, 1977). As a result acyl-
CoA levels rise, and acetyl-CoA levels fall (Idell-Wenger
and Neely, 1977; Shug et al, 1978). Acyl-CoA accumulates
intramitochondrially, and to a lesser extent in the cyto¬
plasmic compartment (Idell-Wenger and Neely, 1977). It
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is conceivable that raised acyl-CoA together with in¬
creased levels of ^-glycerophosphate stimulate the
formation of triglycerides, by a mass-action effect.
Although the reasons are unclear, it has become evident
that glucose competes more effectively with fatty acids
for the residual oxygen (Opie et al, 1973); and that fatty
acids may no longer be able to inhibit glucose utilisation
(aerobic and anaerobic) in the ischaemic myocardium (Opie
et al, 1973; Neely et al, 1975), however such observations
need urgent confirmation. If true, they will markedly
effect the thinking of the approach of biochemical inter¬
vention aimed to increase glucose and/or decrease fatty








2.1.1. Considerations leading to the experimental design
Studies of myocardial metabolism have often been
made using the isolated perfused 'non-working1 heart
preparation of Langendorff (1895). Its simplicity and
the control of supply of substrates and hormones has
particularly attracted many biochemists. However
some rather striking differences emerge when this
preparation is compared with in situ heart preparations:
- low work performance and hence low oxygen consumption.
- perfusates contain little or no protein (albumin).
- perfusates are usually free of red blood cells -
hence low oxygen carrying capacity.
- extremely high coronary flow rates (retrograde) under
conditions of optimal oxygenation.
The introduction of the working heart preparation
by cannulation and perfusion of the left atrium by
Neely et al (1967) was a noticeable improvement, but
objections to its validity can still be raised on the
basis of the unphysiologically high coronary flow rate.
One interpretation of the observed coronary flow is
that this preparation is hypoxic, despite maximal
oxygenation of the perfusate. This view is supported
by lactate and <*-glycerophosphate release (O'Brien, 1969).
But more convincing to the haemodynamically orientated
investigators might be the observation that when red
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blood cells were added to the perfusate of the isolated
working rat heart, coronary blood flow decreased, while
cardiac output was augmented (Duvelleroy et al, 1976).
Such modifications have increased the sophistication
of the isolated heart preparation, but at the same
time it has reduced its major advantage: simplicity.
In view of this and the limited experience with perfused
heart preparations in our laboratory it was decided
to use an in vivo dog heart preparation, with localised
ischaemia. A similar preparation was extensively used
by Opie et al and others for the study of myocardial
metabolism during the first 2 hours of acute ischaemia
(Owen et al, 1970; Opie et al, 1973; Marshall et al,
1974; Smith, 1977).
The metabolic response of the ischaemic myocardium
was assessed by analysis of the various substrates in
the effluent draining the ischaemic area, and was
compared with the substrate extraction before
coronary artery occlusion using the same cannula, as
well as with the extraction across the whole
myocardium in samples collected simultaneously from
a coronary sinus catheter (draining predominantly the
non-ischaemic myocardium).
This model is characterised by a relatively high
variability of ischaemic injury (ST segment elevation,
lactate release), despite careful standardisation of
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the location of coronary occlusion, depth of anaes¬
thesia, etc. Kjekshus and Mj^s (1973) observed that
the average ST-segment elevation in the epicardial ECG
of 10-15 sites, measured 15 min after coronary occlusion
ranged from 1.5 to 9 mV, mean - SD: 4.6 - 2.8 (n = 12),
showing a coefficient of variation of 60%.
Using their data (mean and SD) the number of ex¬
periments required to demonstrate a statistically
significant reduction of an arbitrarily selected 30%
was calculated (Statistical methods, Documenta Geigy).
For a confidence limit of 1%, 20 experiments are re¬
quired in the control and in the treated group. However
only 14 experiments are needed if a model, which allows
the animals to serve as their own control is used
(paired Students t-test may be applied). The model of
intermittent myocardial ischaemia, induced by occlusion
of a branch of the left anterior descending coronary
artery using a metal releasable clip as described by
Kjekshus and Mjjz^s (1973) has this advantage, and the
effect of treatment can be assessed during a repeat
occlusion, made 30 min after release of the control
occlusion and recovery. By combining this model and
that of Opie and colleagues (1970; 1973) described above,
using a small cannula inserted into the local vein
draining the ischaemic area, substrate extraction across
the ischaemic area should be possible.
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This model should lead to reproducible effects
during the successive occlusions. Irreversible myo¬
cardial injury does not occur within the first 20 min
of myocardial ischaemia and cell death is not observed
if ischaemia is reversed by restoring arterial flow
(Jennings et al, 1969: Kloner et al, 1974). ST-segment
elevation has been shown to be reproducible following
reocclusion of the coronary artery provided a recovery
period of 30 min was allowed (Maroko et al, 1971;
Kjekshus and Mj^s , 1973; Berdeaux et al, 1976), but
despite this was restudied to check whether the metabolic
changes in the ischaemic myocardium were also reproducible.
A depressant effect of induction of anaesthesia with
pentobarbitone on the function and metabolism of plasma
free fatty acids and glucose by the myocardium of the
dog has been reported (Durham et al, 1970). No
preferential effect on either fatty acid or glucose
metabolism was observed. During anaesthesia additional
injections of pentobarbitone had similar effects
(Armstrong et al, 1961; Opie et al, 1973). The effect
of other anaesthetics on particularly free fatty acid
metabolism has apparently not been investigated.
Pentobarbitone was adhered to, since the use of
alternative anaesthetic agents would have required
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a formal study of their effects on myocardial metabolism.
However the acute, depressant activity of pentobarbitone
by bolus injections was eliminated using constant
infusions, inducing therefore a presumably constant
anaesthesia without fluctuations in arterial
concentrations of glucose and free fatty acids.
It is not claimed that this model represents a
true description of the human myocardium during acute
myocardial infarction. Apart from the effect of
anaesthesia, mentioned above, other important differences
are apparent:
- Acute myocardial ischaemia in man is set against
the background of a gradual narrowing of the lumen
of coronary arteries, with previous phases of ischaemia,
glycogen depletion and lipid infiltration of the heart.
- Due to the surgical trauma heart rate and arterial
blood pressure are high (Oliver, 1972).
- During the dissection of the coronary artery the
nervous supply to the ischaemic myocardium might
have been interrupted, leading to loss of nor¬
adrenaline stores (Oliver, 1972).
- Collateral circulation in the healthy myocardium
is more developed in the dog than in man (Schaper,
1971).
However gradual obstruction of coronary flow
during atherosclerosis may in itself lead to collateral
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development, as was observed in dogs (Schaper, 1971).
Two factors largely determined the choice of the model:
1. the necessity to sample ischaemic effluent, excluding
closed-chest preparations
2. the desire to use each animal as its own control.
Permanent occlusion by ameroid constrictors, thrombus
formation, plug embolism can not be used. Balloon
catheters and pump controlled restricted coronary flow
to produce intermittent ischaemia were considered
technically too difficult. Anaesthesia and local venous
sampling is difficult in pig models, and dogs were pre¬
ferred. This model should allow the study of effective¬
ness of treatment, designed to inhibit fatty acid
utilisation or to enhance glucose metabolism by the
ischaemic myocardium.
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2.1.2. Modification of fatty acid utilisation
Myocardial utilisation of plasma free fatty acids
is determined by its arterial concentration and the
free fatty acid to albumin molar ratio (Ballard et al,
1960; Scott et al, 1962; Mj^s, 1971; Lassers et al, 1972;
Miller et al, 1976). Several methods have been suggested
to raise plasma concentrations of free fatty acids:
direct infusion of fatty acids, unbound or partially
bound to albumin (Hoak et al, 1964; Bezman-Tarcher,
1969; Greenough et al, 1969; Riemersma et al, 1974)
induction of intravascular lipolysis by heparin
injection during alimentary lipaemia (Schalch and
Kipnis, 1965; Balasse and Ooms, 1968) or lipaemia
caused by intravenous injection of triglycerides
(Intralipid) (Kurien et al, 1971; M jf>s, 1971 , Opie
et al, 1972)
stimulation of the adrenergic nerves, innervating
adipose tissue (Rosell, 1966)
With the exception of the complicated model of
Greenough et al (1969), direct infusion of fatty acids
or their anions led to profound haemodynamic and
arrhythmic disturbances in normal dogs (Hoak et al,
1972; Riemersma et al, 1974).
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These findings are in sharp contrast with those
obtained from experiments in which Intralipid and
was used
heparin^'as the model, when no adverse (haemodynamic)
side effects were found. However this model was
criticised rightly for the unphysiologically high
concentration of plasma free fatty acids, ranging
from 3 000 to 6 OOO pEq/l (Mj/s, 1971*3; Kurien et al,
1971, Opie et al, 1972). However the actual
concentration of plasma free fatty acids in these
studies were almost certainly overestimated (Riemersma
et al, 1977).
Electrical stimulation in vivo of the sympathetic
nerve, innervating dog subcutaneous fat is too
variable possibly due to the fact that release of
free fatty acids from adipose tissue is counteracted
by the vasoconstriction, induced by the concomittant
release of noradrenaline to be of practical use.
The apparent discrepancy between toxic effects
of free fatty acids, observed during direct infusions
with the well documented lack of adverse side effects
when Intralipid and heparin was used, is most likely
due to circulating unbound plasma free fatty acids
in the former model, which may not occur with Intralipid
heparin since free fatty acids may remain within the tri¬
glyceride particle, once the high affinity sites of
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albumin have been occupied (Goodman and Shafrir, 1959).
In balance, therefore, the toxic effect of fatty acids
during direct infusions are due to unbound and
micellular anions, known detergents, and which are
responsible for massive thrombosis, severe hypotension,
arrhythmias and myocardial ST segment depression in
normoxic animals (Hoak et al, 1972; Riemersma et al,
1974). Such method can't be used with confidence in
normal dogs, but certainly not during acute myocardial
ischaemia/hypoxia, where raised concentrations of
free fatty acids bound to albumin exerted a depressive
effect on myocardial contractility (Henderson et al,
1970; Kjekshus and M j/s , 1972).
Of course concentrations of plasma free fatty
acids are influenced by hormones and drugs (Galli
et al, 1969). Kjekshus and Mj/s (1973) used a combination
amines
of catechol/ (isoprenaline, noradrenaline), to raise
and an ant il ipoly t ic drug ((3-pyr idylcarbinol, Roche)
to reduce the concentration of plasma free fatty acids.
They showed that pretreatment with (3-pyridylcarbinol
did not affect the haemodynamic response of a 15-20
amine
min infusion of the catechol/ but effectively blocked
.amine
the catechoT-induced adipose tissue lipolysis.
This simple model was used to study the role of
fatty acid and glucose metabolism of the ischaemic
myocardium in the determination of the severity of
acute myocardial ischaemia. The effect of the following
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structurally unrelated antilipolytic drugs, alone or
in combination with isoprenaline infusions, was examined:
- the active metabolite of clofibrate (p-
chlorophenoxyisobutyrate, CPIB)
- a naturally occurring antilipolytic substance
prostaglandin (PGE^)
- a ' cardiospecif ic' (3-blocker acebutolol
- nicotinic acid
- sodium salicylate.
It was appreciated that despite the wide range of
structurally unrelated drugs, the drugs could all
theoretically possess an unknown property affecting
ischaemic metabolism or severity of myocardial
ischaemia, in addition to their common antilipolytic
activity. Therefore the effect of raised plasma free
fatty acids concentration on ischaemic myocardial
metabolism and severity of myocardial ischaemic injury
using the complicated, but side-effect free system
of Greenough et al (1969) was considered. This became
more of practical proposition when it was learned
that this system could be built for us by Dr N.McLeod,
Department of Chemical Engineering, University of
Edinburgh. In the original publication of Greenough
et al (1969) haemodynamic parameters were not measured,
and therefore the use of the blood cell separator
required evaluation of haemodynamic effects in relation
69
to fatty acid (sodium oleate) infusions in control
experiments. Both these experiments and those in which
sodium oleate was infused during experimental coronary
occlusion and its effect on ischaemic myocardium are
described in detail in Part 5.
Originally it was not intended to use the model of
Intralipid and heparin to raise plasma concentrations
of free fatty acids. However when it was discovered,
that plasma free fatty acids concentrations were
seriously overestimated in lipaemic samples of
heparinised dogs or men (Riemersma et al, 1977), a
formal study of Intralipid-heparin as a model to raise
plasma free fatty acid in anaesthetized dogs was made.
The results of this study are reported in Part 5.
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2.1.3. Stimulation of glucose utilisation
During experimental acute myocardial ischaemia
the oxidation of plasma free fatty acids by the ischaemic
myocardium is impaired to a greater extent than that of
glucose, and the heart becomes more dependent upon
both aerobic and anaerobic glucose metabolism for
its energy requirements (Opie et al, 1973).
Early experiments, which showed that the perfused heart
became totally reliant on anaerobic glycolysis and
the rate of utilisation of glucose or glycogen could
determine the rate of survival of the anoxic heart
(Cascarano et al, 1968; Weissler et al, 1968; Scheuer
and Stezoski, 1969), led to the now widely-held belief
that measures promoting glucose utilisation by the
ischaemic myocardium should decrease the extent of
ischaemic injury (Opie, 1970). Although the early
observations are undoubtedly valid and have been
extended, serious doubt is raised to the validity of
the extrapolation of the metabolic behaviour of the
anoxic, well-perfused myocardium to situations of
ischaemia (lack of bloodflow). The difference between
these two preparations, with on the one hand in the
anoxic model where coronary flow is increased with
increased glucose supply and increased removal of
lactate and H+ and on the other hand the ischaemic
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model with decreased glucose supply and accumulation
of metabolites (lactate and H+) falls outside the
scope of this thesis. But it suffices that these
reservations have been confirmed recently in comparative
studies (Rovetto and Neely, 1977). Similarly it is not
clear whether measures, which are known to enhance
glucose utilisation of the normoxic heart such as
increased glucose concentrations (Morgan et al, 1961;
Opie et al, 1962; O'Brien, 1969),the addition of
insulin (Morgan et al, 1959; Newsholme and Randle,
1964) will increase glucose utilisation by the ischaemic
myocardium. The lack of effect of raised concentrations
of plasma free fatty acids on glucose extraction by
the ischaemic myocardium (Opie et al, 1973) in contrast
to its effect on normoxic myocardium (Shipp et al, 1961;
Newsholme and Randle, 1964) does support the view that
control of ischaemic myocardial glucose metabolism
has been modified. On the other hand high lactate
concentrations (40 mmole/l) inhibit glucose utilisation
of the ischaemically perfused rat heart (Rovetto et al,
1975). Clearly more work is indicated.
However, despite these theoretical objections animal
studies have supported the hypothesis that raised
glucose concentrations during intravenous infusion
of glucose and insulin reduced myocardial ischaemic
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injury following coronary occlusion (Maroko et al,
1972; Sybers et al, 1973; Haneda et al, 1974; Opie
et al, 1975; Opie and Owen, 1976).
We tested the effect of enhanced glucose utilisation
with another model, which had not previously been
tested in dogs with acute myocardial ischaemia. This
approach stemmed from the observation that di-isopropyl-
ammonium dichloroacetate raised the respiratory quotient
in alloxan-diabetic rats, suggesting an increased
utilisation of glucose relative to that of (free)
fatty acids (Lorini and Ciman, 1962). McAllister et al,
(1973) showed that the active component dichloroacetate
stimulated glucose uptake and oxidation, and inhibited
fatty acid oxidation in the isolated perfused rat
heart and in intact dog heart. It was suggested that
dichloroacetate stimulated both glycolysis and glucose
oxidation by increasing the activities of phospho-
fructokinase and pyruvate dehydrogenase. The activation
of pyruvate dehydrogenase in rat myocardium by
dichloroacetate was confirmed by Whitehouse and Randle
(1973).
Therefore experiments were conducted of the metabolic
and haemodynamic effects of dichloroacetate during
experimental acute myocardial ischaemia in dogs. The
possibility that the stimulation of myocardial glucose
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and inhibition of fatty acid utilisation might limit
the severity of acute myocardial ischaemia was
examined.
The results are presented in Part 4.
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2.1.4. Surgical procedures and animal preparation
Mongrel dogs of either sex, weighing 12-25 kg
were obtained from the Animal Breeding Centre, University
of Edinburgh, The Bush. After overnight fast anaesthesia
was induced by intravenous injection of sodium
pentobarbitone (Sagatal, May and Baker, Dagenham)
approximately 25-30 mg/kg. The depth of anaesthesia
was judged by the presence of corneal and paw reflexes.
The animal was intubated, using a cuffed endotracheal
tube (size 7.5 - 9) and the cuff inflated using
12 - 14 ml air. Respiration using air (15 cycles/min)
was maintained by a positive pressure respirator
(Harvard Apparatus Co., Mass., USA). Stroke volume
was adjusted according to nomogram (made by Kleinman
and Radford for Harvard Apparatus Co., Mass., USA).
Ventilation was monitored using arterial blood gas
determinations kindly analyzed for us by the Blood
Gas Laboratory, Department of Medicine, The Royal
Infirmary, Edinburgh.
The left femoral vein was dissected and cannulated
using a sterile polyethylene cannula (6 FG, 30 cm;
Portex Ltd, Hyphe, Kent) for the continuous infusion
of maintenance sodium pentobarbitone anaesthetic
(dose 4 mg/kg/hr at a rate of 10 ml/hr) using a Harvard
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Infusion pump.
The left and right femoral arteries were cannulated
using polyethylene catheters (8 FG, 30 cm, Portex) for
the measurement of arterial blood pressure and for the
collection of arterial blood samples.
The right femoral vein was cannulated using a
sterile polyethylene catheter (6 FG, 30 cm; Portex)
for the administration of drugs.
The cannulae were filled with saline (0.9%),
except in heparinised dogs where heparinised saline
5 u/ml was used.
If neccessary, the left jugular vein was dissected
and left with a loose ligature around the vessel until
required for the introduction of the coronary sinus
catheter after opening of the chest (see later).
The chest was opened through the 5th intercostal
space for the studies in which myocardial ischaemia
was induced or sham occlusions were made. Pectoral
muscles were tied using 2/0 silk and then transsected.
In studies on heparinised dogs diathermy was adopted,
to avoid bleeding.
A small opening was carefully made in the pleural
space using a finger (no sharp instruments to avoid
damage to the lung). The thorax was then further
opened and the ribs were spread. After thoracotomy
ventilation was increased by 20 ml/stroke to avoid
76
underventilation (empirical adjustment found in early
studies with Dr R.G.Talbot).
The base of the heart was exposed. The pericardium
was opened near the root of the aorta and a transsection
was made parallel to the phrenic nerve, followed by
a diagonal transsection to the apex. Fatty tissue
overlying the pericardium was dissected, tied and cut.
A pericardial cradle was made using four 2/0 silk
stitches tied to the ribspreader. Before the two ties
near the base of the heart were made a small swab,
soaked in saline was inserted between the pericardium
and the lungs to avoid the threads cutting into the
lungs. Care was taken not to obstruct the caval veins
or to lift the cradle too high resulting in reduced
arterial blood pressure.
A cannula (3 FG, 30 cm; Portex) was tied in the
left atrium for injections of radioactive microspheres.
The distal part or a branch of the left anterior
descending coronary artery was dissected free over a
distance of 0.5 - 1.0 cm, using two pairs of curved
forceps (10 cm). A loose ligature was then placed
around the vessel to facilitate later retrieval for
occlusion.
A local vein draining the myocardium perfused by
the dissected coronary artery was cannulated according
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to a method suggested by Dr R.Norris, Auckland, New
Zealand. A white needle (19 gauge, Yale microlance,
was bent through a right angle 10 mm from the tip.
This needle was inserted into the (local) vein,
preferably at a point at least 1-lj cm away from any
confluences, in order to avoid problems in advancing
the cannula past these points. It is important to
make a clean, full puncture with the needle. This is
difficult since the view is partially obscured by a
sudden squirt of blood before a complete puncture
has been made. However the needle will check the
bleeding once inserted, allowing inspection of the
puncture. The needle was then pulled out and the
matching cannula (3 FG, 30 cm; 0D 1.02 mm; Portex)
filled with 1 U/ml heparin inserted guided by the
origin of the bleeding. Generally this caused no
difficulty, except when a hole could only be made
through a fine layer of fatty or connective tissue.
In this case it was helpful to insert first a smaller
cannula (3 FG, 0D 0.75 mm; Portex) which was then
replaced by the matching cannula (see above). The
distal part of cannula is positioned away from curved
sections or branches of the vein. A test collection
of blood is made (under normal myocardial perfusion),
and if found acceptable (more than 3-4 ml/min) the
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cannula secured using the anchoring stitch, made
whenever possible on the right ventricle.
Normally the cannula will stop the bleeding, but
sometimes Sterispon (Allen and Hanburys Ltd, London)
was applied to the punctured vessel to check the bleeding.
Occasionally the local anatomy was unsuitable for
cannulation of a local vein, in this case cannulation
was attempted in the great cardiac vein near the
origin of the left anterior descending coronary artery.
The cannula was then pushed in retrogradely to the
desired site, using gentle finger pressure to guide
it.
In 2 of 29 experiments it was impossible to
obtain a suitable local venous cannulation.
The coronary sinus polyethylene catheter (modified
from a Bourassa-left coronary catheter (7 F; ESCI,
USA)) was inserted using the exposed jugular vein and
positioned under fluoroscopic guidance. When fluoroscopy
was not available, the catheter was placed into the
coronary sinus guided by the tip of a finger positioned
at the orifice.
A schematic representation of the model is given
in Fig 2.01.
The animals were allowed to recover from the surgical
procedures for at least hour.
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Figure 2.01











Not indicated are the coronary sinus
right atrial pacemaker electrodes.
catheter and the
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2.1.5. Induction of acute myocardial ischaemia
The basic model for the induction and assessment
of severity of myocardial ischaemia was taken from the
work of Maroko et al (1971) and Kjekshus and Mj^s (1973).
Ischaemia was induced by occlusion of the distal
part or a branch of the left anterior descending
coronary artery using a Mayfield intracranial clip.
Myocardial ischaemia was characterised by cyanosis,
Q
paradoxyal contraction and ST segment changes in the
epicardial electrocardiogram of the area supplied by
the occluded coronary artery. The site of occlusion
was selected to yield a relatively stable ischaemic
preparation free of major haemodynamic disturbances
and arrhythmias and would lead to an infarct, comprising
10-15% of the free wall of left ventricular myocardium
(Owen et al, 1970). Despite the fact that in this model
the site of occlusion is standardised the severity of
myocardial ischaemia (ST^segment changes, lactate
release) varies considerably from preparation to
preparation. But if after release of occlusion a
recovery period of 30 min is allowed a second occlusion
leads to reproducible changes, provided the occlusion
did not exceed 20 min, allowing each animal to serve
as its own control. However, the exact time of onset
of irreversible ischaemic changes is uncertain and
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may depend on what criteria are used (morphological,
biochemical or functional changes). ST-segment ele¬
vation is virtually constant between 10-20 min. We
preferred to use occlusions of 10-15 min duration and
thereby increase the margin of safety. The model we
have adopted consists of 3 to 4 periods of myocardial
ischaemia of 10-15 min duration, each separated by a
recovery phase of at least 30 min. Usually studies
were made both with and without isoprenaline stimulation.
The reproducibility of our model was demonstrated
in a joint study with the University of Troms^
(Dr. H. Vik-Mo and Prof. O.D. Mj^s). The results are
tabulated in Table 2.01. Due to the slow return of
plasma glycerol concentrations to baseline values after
cessation of an isoprenaline infusion, the interpretation
of glycerol data, obtained during two repeated occlusions
(basal conditions) is complicated, as glycerol extraction
may depend on its arterial concentration. Therefore the
model in this form is not suitable to study myocardial
glycerol metabolism under basal conditions.
This model is versatile and allows randomisation of
myocardial ischaemia with or without pre-treatment,
provided that the half life of the drugs used is short.
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Table 2.01
Experimental acute myocardial ischaemia: The reproducibility of the model
Occlusion I Occlusion II P* Isoprenaline + Isoprenaline + P
occlusion I occlusion II
(A) (C) (B) (D)
1ST (mV) 25.3 + 6.9 27.2 + 7.3 N.S. 57.3 + 10.6 57.6 + 11 .6 N.S.
ST> 2 mV 5.5 + 0.8 6.2 + 0.8 N.S. 9.0 + 0.5 8.7 + 0.4 N.S.
Heart rate (beats/min) 151 + 9 150 + 13 N.S. 189 + 11 184 + 12 N.S.
LVSP (kPa) 16.4 + 1.1 15.8 + 1.1 N.S. 15.8 + 0.7 15.8 + 0.9 N.S.
LV dP/dt max. (kPa/s) 208 + 21 204 + 18 N.S . 418 + 37 395 + 34 N.S.
AP (kPa) 15.1 + 0.9 14.4 + 0.8 N.S. 13.3 + 0.5 13.3 + 0.5 N.S.
Oxygen saturation (%) 98.9 + 0.9 100 + 0.9 N.S. 93.5 + 2.5 95.8 + 2.9 N.S.
Oxygen saturation^ cg 59.2 + 2.3 61 .0 + 3.1 N.S. 58.0 + 2.5 56.5 + 1 .2 N.S.
Oxygen saturation ,a-lv 71.8
+ 2 .4 70.8 + 3.3 N.S. 69.5 + 2.4 68.5 + 3.3 N.S.
Glucose (mmole/l) 8.16 + 0.42 7.55 ± 0.79 N.S. 12 .71 + 0. 98 12 .22 + 1.11 N.S.
Glucose
a-cs
1.15 + 0.67 0.77 + 0.29 N.S. 0.36 + 0.20 0.61 + 0.46 N.S.
Glucose ,
a-lv
2.32 + 0.27 1.75 + 0.35 N.S. 2.65 + 0.22 2.18 + 0.32 N.S.
FFA^ (|umole/l) 205 +
|
29 194 + 26 N.S. 1542 + 258 1640 + 274 N.S.
FFA
a-cs
59 + 20 46 + 7 N.S. 349 + 69 351 + 70 N.S.
FFA .
a-lv
55 + 19 57 + 21 N.S. 52 5 + 117 465 + 71 N.S.
Lactatea(mmole/l) 1 .87 + 0.23 1.93 + 0.29 N.S. 2 .62 + 0.38 2.31 + 0.48 N.S.
Lactate
a-cs
0.64 + 0.05 0.68 + 0.09 N.S . 0.65 + 0.14 0.24 + 0.09 N.S.
Lactate ,
a-lv
-2.41 + 0.69 -1.01 + 0.62 N.S. —2 .86 + 0.54 -2 .39 + 0.68 N.S.
Glycerola(pmole/1) 33.5 + 3.9 73.3 + 13.6 t 276.6 + 32 .8 398.5 + 52 .7 N.S.
Glycerol* a-cs insufficient data
t 23.6 + 8.4 48.7 + 15.5 t
Glycerol^ ^ -43.1 + 16.4 -11.3 + 5.9 t 6.6 + 9.9 3.9 + 14.9 t
The reproducibility of the effects of two intermittent coronary artery occlusions of 12 min duration was studied under basal,.,
conditions and during isoprenaline infusion.in 6 open-chest, anaesthetized dogs. The sequence of occlusions was: Occlusion I*1 '
Isoprenaline+occlusion 1^ Occlusion 11^ ' and Isoprenaline+occlusion II* , each separated by a recovery period of 45 min
after reflow. Myocardial ischaemic injury and haemodynamic parameters were recorded at 12 min of occlusion. Blood samples
were obtained simultaneously from femoral arterial, coronary sinus and local venous cannulae between 6 and 12 min after
occlusion.
Abbreviations :ZST=sum of ischaemia-induced ST-segment elevation, ST>2 number of sites with ST-segment elevation^2 mV, LVSP= syst
left ventricular pressure, LV dP/dt max.= maximum of first derivation of left ventricular pressure, AP=mean aortic blood
pressure. Note: Arterial glycerol concentrations during Occlusion 11(C) have not returned to basal values 45 min after
cessation ~o! the first isoprenaline infusion (Isoprenaline + occlusion I (B) .
* Statistical analysis performed using the Wilcoxon*s test for paired data.
I Statistical analysis not made : number of experiments<5.
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However, when the drug metabolism is slow (such as for
CPIB,acebutololnicotinic acid, DCA) a fixed protocol
of: control occlusion, control occlusion during
isoprenaline infusion, repeated in the same sequence
after the administration of the drug, was followed
(see Fig 2 .02 ) .
In this way systematic factors (time, sequence) may
operate. A check was made in a few studies on this
by reversing the order, the two control occlusions
were made after a delay sufficiently long to metabolise
the drug.
In recent studies continuous monitoring of the
epicardial ECG using a multiplex system (see Section
2.3) was possible. In some of these studies collection
of a blood sample after 5 min of occlusion from the
local vein reduced transiently ST- segment
elevation. (The mechanism of this was not
investigated but it seems likely that the negative
venous pressure during sampling may have affected
blood flow in the ischaemic area). In the same studies
ST segment elevation was almost maximal at 5 min and
were therefore used as the endpoint rather than ST -
segment elevation at 10 or 15 min of occlusion.
In some studies drugs were administered during an
established coronary occlusion, a more real-life
situation. Under these circumstances drug induced
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0 10 20 30
Occl = occlusion; Isopren = isoprer.aline infusion
0.1-0.2 ^ig/kg/min. In some experiments the administra¬
tion of antilipolytic drugs preceded the first
and the second occlusion (during isoprenaline infusion),
and the 2 control occlusions were then made after a period
sufficiently long to metabolise the drug.
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alterations of myocardial metabolism before coronary
occlusion, such as increased glycogen stores, which








Measurements of differences in the concentrations
of metabolites between arterial and coronary sinus
blood have proved to be important in the study of
myocardial metabolism in vivo. But alterations in the
metabolism of small ischaemic areas, such as alterations
in glucose extraction or lactate production, are too small
effectively . to modify the arterio coronary sinus difference
of these metabolites, but are reflected in the arterio¬
venous difference of metabolites determined using blood,
obtained from a cannulated local vein, draining that area.
An immediate implication of this observation is that
preferably only micro(bio)chemical techniques should be
used, because during ischaemia only small blood samples
can be obtained from the local vein with difficulty and
sometimes not at all.
Another condition which must be fulfilled by the
various analytical techniques stems from the fact that it
may not be sufficient to quantify the arterio-venous
difference of a metabolite. It should well be that the
change in arterio-venous difference may be more closely
related to differences in myocardial ischaemic injury under
varying conditions. Therefore methods with high precision,
but not necessarily with a high accuracy are required
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and this is particulary so for measurements of plasma
glucose, where arterio-venous differences are small. It
is obvious that simultaneous, preferably automatic analysis
of all samples of a study will contribute to achievement
of high precision. Therefore the basic condition in all
methods described was the simultaneous analysis of
samples from one experiment. This section is concerned
with methodological aspects of the biochemical techniques.
After a short summary of the principle of each method
a description of the exact technique will be given,
including details of the precision on individual
estimates, the collection and storage of blood samples,
and possible interference of other metabolites and
drugs.
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2.2.2. Estimation of plasma free fatty acid concentration
Introduction
Two methods for the measurement of plasma free
fatty acid concentrations were used. Normally plasma
free fatty acid concentrations were determined by the
titrimetric method of Dole and Meinertz (1960), according
to the modification of Trout et al (1960). Fatty acids
were extracted from plasma aliquots and from standards
(palmitic acid) into heptane and determined titrimetrically
using a Metrohm micro-buret.
However in studies (described in section 5) when plasma
free fatty acid concentrations were raised in vivo by
heparin-induced intravascular lipolysis and by the
administration of Intralipid* as the substrate the
method of Dole is unsuitable, due to the continuation
of lipolysis in vitro. Therefore another method was
developed for those studies in which both Intralipid
and heparin were administered. In vitro lipolysis was
prevented by immediate denaturation of proteins in
blood samples, after which fatty acids were extracted.
Fatty acid concentrations were then determined using
the method of Ho (1970). Its principle is the formation
* Intralipid is fractionated soya bean oil (Kabi Vitrum,
Sweden).
9O
of radioactive Ni-fatty acid salts, which, unlike
2 +
free Ni , are soluble in chloroform-heptane, and can
be estimated by liquid scintillation counting.
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The titrimetric method of Dole
The basic procedure of collection of blood samples
was as follows:
Arterial and coronary sinus catheters and local
venous cannula were cleared by withdrawal of 4-6 ml
and 1 ml blood respectively. Blood samples were then
collected into heparinized disposable plastic syringes
(Becton, Dickinson Co Ltd., Ireland), transferred to
heparinized tubes (Searle, Morpeth, Northumberland),
and immediately cooled on ice. Blood cells and plasma
were separated by centrifugation (10 min at 1 500 g)
in a cooled (4°C) MSE 4L centrifuge within 15-30 min.
Plasma (1 ml) was then transferred in duplicate to a
stoppered thick walled glass tube (capacity 14 ml),
containing 5 ml Dole's extraction mixture: isopropanol:
n-heptane: H2S04 (1 mole/l) 40:10:1 by vol., shaken
vigorously and stored at -20°C until analysed.
Extract ion
Free fatty acids were extracted using the method
of Trout et al (I960), which includes a washing procedure




A Metrohm microtitrator (Metrohm, Switzerland) was
used for the titrimetric step. The titrator, shown in
Fig. 2.03 consists of a micro-syringe (1 ml capacity)
which was filled with NaOH (approximate concentration
O.025 mole/1).
The location of the titrator is important as it is
difficult to judge the end-point accurately under
conditions of variable light intensity. Direct light
into the laboratory was therefore excluded and the
equipment was positioned far away from the windows.
Each extract was titrated in duplicate. Aliquots
(1 ml) were transferred to a glass cuvette (3 ml) using
a bulb pipette (Emil, Gold Line). Freshly redistilled
ethanol (1 ml, J. Burrough, Analar) and 6 drops of
phenol red indicator (0.79 mg/ml ethanol) were added.
The end-point was considered to be reached when the
yellow colour changed to pink.
Figure 2.03. The
The







The equipment used in the microtitration:
The microsyringe, which serves as the titrant
can be removed to be filled using a nut. Fine control
of the titration is ensured by the use of a large dial
moving the plunger attached to a micrometer. Acid free
N^is used to expel CO^ from the titration vessel and
facilitates proper mixing. The pivot mechanism facil¬
itates the insertion/removal of the hypodermic needle in
and from the titration vessel (cuvette).
94
Interference of lactate, phospholipids and other
compounds
Theoretical considerations
The specificity of the method is determined by
two factors: the specificity of the extraction and the
specificity of the titration.
The partition coefficients for lactate, phospholipids
have been determined by Dole and are given in Table 2.02.
The partition coefficients (r) were used to calculate
the % extraction of the various fatty acids, lactate
and lecithin.
The equations used for these calculations are
derived as follows: if the fraction of extracted (fatty)
acids is x, then (1-x) will remain in the water-phase.
By definition r is the ratio between the acid concentration
in the upper Tlu and the lower phase
[ ]u
r = — Equation 1.
[ ] 1
Taking the volume of the upper phase (4 ml) and of the
lower phase (7 ml) of the basic Dole's method into
account, equation 1 can be rewritten as:
x / 4 7 x
r = or
(1-x) / 7 4 (1-x)
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Table 2.02
Factors influencing the specificity of the titrimetric
method. The effect of the Trout wash on lactate
interference.
partition Basic Dole's method Dole's method
coefficient)* + Trout wash
r_ % in % in % in
extract water phase extract
FATTY ACIDS:
C12 :0 5.90 77 23 66
C14:0 8. 50 83 17 74
C16:0 11 .00 86 14 78
C18: 0 13.60 89 11 83
C18:1 10.75 86 14 79
C18:2 10.30 86 14 78
C20: 4 9.30 84 16 76
OTHERS:
lactate 0.021 1.2 98.8 0.025
lecithin 0.07 3.8 96.2 0.25
* partition coefficient r, taken from Dole and Meinertz
(1960).
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Expressing the fraction extracted (x) as a function
of r:
4 2T
Fraction extracted (x) = — Equation 2.
4 r + 7
The volume of the Trout wash is 4 ml instead of
7 ml and as a result it can be shown that the fraction
extracted during the Trout wash will be
x'= Equation 3.
1 + r
The overall extraction including the Trout wash is
of
x.x'. The results of the calculated percentages^fatty
acids lactate and lecithin extracted, using the Dole
method with or without the Trout wash are presented in
Table 2. 02.
A few points emerge:
r
a. The physiologically-occujying fatty acids (C16:0 - C18:2)
are all extracted to the same degree, about 86% (justifying
the use of palmitic acid as a standard)
b. Lactate and lecithin interference is small and is
virtually eliminated using the Trout wash.
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The specificity is also determined by the exact end-
point used during the titration. The pKa values of the
fatty acids, lactic acid, phospholipids etc in heptane-
ethanol are likely to be different. Thus at a specific
end point different degrees of neutralisation will have
been achieved: Acids stronger than fatty acids will be
fully dissociated and will therefore interfere more
severely than weaker acids. However it is important to
realise that the partition coefficients in Table 2. 02
were almost certainly based on titrimetric estimations
of these compounds using thymol blue as the indicator.
Thus differences in interference caused by differences
in pKa have already been taken into account. Nevertheless
the registration of the titration curve (moles of
NaOH vs pH) could reduce interference by weaker acids
(but not by stronger ones). However recording pH
accurately in heptane-ethanol mixtures is exceedingly
difficult. An attempt was made, but unsatisfactory
results (lack of stability of pH reading) were obtained.
This was attributed to interference of static electricity
(no proper earthing could be made) and unsuitable pH
electrodes: electrolytes of the salt bridge were not
soluble in heptane-ethanol, causing a poor continuity
between the sample and pH electrode. Therefore this
approach was abandoned.
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Interference of lactate and phospholipids
The interference of lactate was measured by the
extraction and titration of a lactate standard
(100 mmole/l). The estimated lactic acid concentration
was 0.051 +_ 0.020 mmole/l, thus 99.95% of lactic acid
present is eliminated.
The interference of phospholipids was not measured, due
to the lack of phospholipid standards which would be
fatty acid free.
Stability of stored samples
The stability of plasma samples or Dole extracts
stored at -20°C has been investigated by several
independent groups and plasma free fatty acid concentrations
remain unchanged under these conditions for at least
8 months(Braun, 1971; Broechoven ana Parijs, 1968).
This aspect was not further explored.
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Calibration and precision of the method
A stock standard of palmitic acid (10 mmole/l,
Analar 99%, British Drug Houses,Poole, Dorset) was made
in redistilled n-heptane and stored at 4°C. Working
standards (400-2400 pmole/l) were prepared every 10
days. Standards and blank (redistilled n-heptane) were
simultaneously extracted with the samples in each run.
A typical calibration graph is shown in Fig. 2.04. The
blank reading is 20 titration units, equivalent to
approximately 0.05 pmole/l of acid. The calibration
graph was drawn by hand.
Samples which exceeded the range of the standards
were diluted 1:1 with redistilled n-heptane and re-
estimated.
The precision of the method, determined using 10
individual extracts of a canine pool was (mean - SD):
475 ± 16.5 jdmole/l (CV = 3.5%).
lOO







Palmitic acid standards in heptane were 'extracted'
and titrated with NaQH (about 0.025 moles/l) as de¬
scribed in the text.
Ten titrator units = 1 ^1 titrant.
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2.2.2 . The measurement of free fatty acid concentration
in heparinised animals
Preamble:
Originally the use of Intralipid and heparin to
modify plasma free fatty acid concentrations in dogs
was not planned as a part of the work concerning the
thesis. However we were interested to re-examine the
effect of heparin in patients admitted to the coronary
care unit (CCU) with acute myocardial infarction. The
reason for this was that if the original hypothesis
was true: i.e. that raised plasma free fatty acid
concentrations lead to serious ventricular arrhythmias,
then the routine use of heparin in the CCU should be
avoided in the prophylaxis of deep vein thrombosis.
Indeed this was and is the official policy in the CCU
in the Royal Infirmary for that reason. However heparin
is routinely used in other countries (Holland, Germany
and USA), and it seemed strange thet even incidental
occurrence of serious ventricular arrhythmias after the
administration of heparin would go unnoticed. Obviously
this is not a simple problem, since the time of
administration after the onset of symptoms might be
crucial.
Unfortunately no double-blind trials of the effect of
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heparin on the incidence of serious ventricular arrhythmias
have been made, and therefore the intention was to re¬
examine this problem.
There was concern about the methodology used for the
determination of plasma free fatty acid concentration
in heparinised patients, particularly when it was likely
that at least some samples would be taken during the
night. The release of lipolytic enzymes (lipoprotein
lipase, hepatic lipase and phospholipase) could artificially
raise plasma free fatty acid concentrations, depending
on the length of delay in deproteinising the samples.
Therefore a pilot study was made in a closed-chest
anaesthetised dog to examine the effect of time delay
in deproteinisation of plasma samples on plasma free fatty
acid concentration. The conditions were chosen to increase
in vitro lipolysis, if any. Thus plasma triglycerides
were raised by injection of Intralipid 20% (w/v) (dose 1
ml/kg body weight) and the collection of one blood sample
(160 ml) was made 10 min after the injection of heparin
(2 000 U), at a time of maximal lipolytic activity
(see also Part 5, section 1). The blood was divided into
two sets of heparinised tubes; one set was kept in ice
and the other kept at room temperature. Plasma was
obtained by a short (2 min) centrifugation at 1 500 g in
a cooled centrifuge, and was immediately deproteinised
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using Dole's extraction mixture. Plasma free fatty acid
concentrations were then determined using the titrimetric
procedure, described above.
The results are shown in Fig 2.05. Plasma free fatty
acid concentrations in samples kept at room temperature
rose quickly when the extraction/deproteinisation was
delayed. The approximate rate calculated from the data
is 4%/min of the original plasma free fatty acid
concentrations. This process could be inhibited by
storing the blood samples on ice, but an increase
representing about 1%/min could still be demonstrated.
Similar results were found for ambulant ward
patients given 12 500 U heparin 2 hours after a meal
(Riemersma et al, 1977)
Previously the method of Intralipid/heparin to raise
plasma free fatty acid concentrations in dogs was
criticised amongst other thingsfor the unphysiologically
high concentrations found (up to 6 000 jamole/l).
However the most important observation of the study
of ambulant patients mentioned above, was that plasma
free fatty acid concentrations were still in the
physiological range, even after \ hour delay.
We therefore decided to reinvestigate the problems
of the Intralipid-heparin model in the dog. We were
particularly interested to measure plasma free fatty acid
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Figure 2.05. The estimation of plasma free fatty acids
in lipaemic samples from heparinised dogs:
In vitro lipolysis in samples kept at room
















A blood sample (160 ml) was obtained 10 min after the
intravenous injection of Intralipid/heparin, and divid¬
ed in 14 aliquots, half stored at room temperature and
the other half kept on ice. Plasma was obtained im¬
mediately and at 5-50 min after collection by a short
centrifugation and plasma free fatty acids were extracted
without delay.
For details see text.
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concentrations in vivo and relate these to their turnover.
Before we could do this we had to develop a practicable
method for measuring plasma free fatty acid concentrations
in heparinised subjects (dogs and patients with acute
myocardial infarction).
Considerations leading to the FFA method, suitable
for samples of heparinised dogs
As was demonstrated the in vitro lipolytic activity
in lipaemic samples of heparinised dogs could not be
blocked by cooling the samples on ice, the routine
procedure in our laboratory. Addition of known inhibitors
of heparin lipolytic activity (mainly lipoprotein lipase)
to blood were tried in experiments identical to those
described in the previous section, where storage at 0°C
and at room temperature were compared. EDTA, Triton X 100,
alizuran blue and protamine sulphate were all ineffective
in blocking in vitro lipolysis in samples stored on ice
or at room temperature, and in the case of protamine
sulphate (in presence of EDTA) clotting became a problem.
A more drastic approach was taken. It is well known
that free fatty acids in blood are restricted to the
plasma compartment, where they are bound to albumin.
Only under situations of high FFA/albumin molar ratios
approx. 5
exceeding,/ free fatty acids can be shown to bind with
red cell membranes (Spector, 1969), but in quantitative
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terms this is unimportant (less than 1% of the total).
Thus immediate extraction of blood, with the
appropriate correction for blood cell volume, should be
valid and overcome the artificially high free fatty
acid concentrations caused by lipolysis in vitro.
Fatty acid extraction from blood samples
The extraction of free fatty acids, from different
quantities of blood was checked in a pilot study, using
3
albumin-bound H -palmitate (Radiochemical Centre,
Amersham). The results showed that the volume of blood,
ranging from 0.2 ml to 1.0 ml did not affect the amount
3
of H -palmitate extracted by 5 ml Dole's extract (see
Reagents, titrimetric FFA method). However when more than
0.75 ml blood was extracted the dead space of the cells
aggregated by the procedure was large and it became
difficult to work with the extracts. Therefore 0.75 ml
blood was chosen as the maximum volume of blood to be
extracted.
3
The extraction of H -palmitate from 0.75 ml human
blood was checked. Using 8 different blood samples on
average 100.0 +_ 1.7 (SEM)% was recovered.
Interference by phospholipids
Normally 55% of blood phospholipids are located within
the erythrocytes (Scientific Tables, Diem and Leutner
(Eds), Ciba - Geigy, 7th Ed. pp 600) and the remainder
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essentially in the plasma compartments. The implication
is that if blood extracts are used for the determination
of free fatty acids, phospholipid interference could be
a much more serious problem than when plasma FFA are
estimated by Trout's modification of the titrimetric
method of Dole (see Table 2.02). Thus the required method
should be free of interference by phospholipids.
Required sensitivity of the method
The method must also be more sensitive, since the
extraction of 0.75 ml blood represents 0.3-0.35 ml of
plasma instead of the usual 1 ml plasma used for the
titrimetric procedure. On this basis the titrimetric
procedure was ruled out, because one of its drawbacks
is lack of sensitivity.
A wealth of methods for the determination of plasma
free fatty acids have been described (Mliller and Ulrich
quoted 40 methods in 1966), most of them modifications of
two basic procedures:
- (1) the titrimetric method of Dole
- (2) the colorimetric method of Duncombe (1963);
or a combination of the two.
The colorimetric method of Duncombe (1963) which in
itself was a modification of the method of Ayers (1956)
was introduced as a more sensitive alternative to the
titrimetric procedure. It is based on the principle that
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metal ions (Cu2+, Co2+) form readily water-soluble
soaps when mixed with long c^ain fatty acids (14 C atoms
or more). These metal soaps, unlike the metal ions, are
soluble in chloroform and chloroform-heptane mixtures
and are conveniently quantified as highly-coloured
complexes with diethyIdithiocarbamate (Duncombe, 1963);
1-nitrose-2-naph^ol (Novak, 1965); diphenylcarbazide
(Laurell and Tilbling, 1967); or tetra-ethylthiuram
disulphide (Manasterski et al, 1972).
The method of Duncombe works well when standards are
made up in heptane or if plasma extracts are analysed.
However, the water-phase containing the excess copper
ions forms above the organic phase (extract), and this
gives rise to occasional spurious results. An important
improvement was made by reversing the water and chloroform
phases, by adding salts to the water and heptane to the
chloroform phase (Novak, 1965), because this allowed
direct analysis of the metal ions in the upper phase.
Interference of phospholipids was eliminated by preferential
adsorbtion of extracted phospholipids to silicic acid
(Laurell and Tibling, 1967).
Finally the use of radioactive tracers (Co^, Cu°^ and
6 3
Ni ) led to a further increase in sensitivety (Ho and
Meng, 1969;Ho, 1970). Ho incorporated the modification of
Novak (1965) and of Laurell and Tibling (1967) and his
109
method is practical and highly specific (no phosphopipid
interference). It seemed therefore that this method was
the best available. Ni^, rather than Co~^, Co^ and
6 0
Cu was selected because it was noticed that the Co
reagent spontaneously oxidized. Cu^^ was not considered
due to its hard ^-emitting properties.
The radiochemical analysis of fatty acids in heptane
extracts
The method of Ho
In the method of Ho for estimating plasma free fatty
acids, free fatty acids are extracted using the extraction
procedure of Dole (1955), scaled down to allow extraction
63
of 5 - 10 ^ul plasma samples. Ni soaps are then formed by
shaking the extracts (final mixture chloroform: heptane
8:7) with alkaline Ni-reagent, triethanolamine is added
to form a Ni-complex and thereby prevents the precipitation
of Ni(0H)2 under alkaline conditions used. Phospholipids
are adsorbed to silicic acid, as was suggested by Laurell
and Tibling (1967).
6 3
The development of the Ni " -method
We increased the scale of the method in order to
handle 1 ml of heptane extract, rather than 80 ^il as
was originally used by Ho. The reason for this was that
it became apparent that handling small quantities of
these highly volatile solvents was extremely difficult
no
and was not really necessary as it would be impossible
to extract quickly and accurately correspondingly small
volumes of blood (5-10 pi).
The adsorption of phospholipids
The conditions for the preferential adsorption of
phospholipids was also investigated. A solution of
lecithin in heptane in a concentration about equal to
that of the total phospholipids in blood (2.75 mg/ml)
was extracted using 5 ml of Dole's extract. The extracts
which were diluted with an equal volume of redistilled
chloroform were shaken for 5 min in the presence of
varying quantities (0-500 mg) of activated silicic
acid (heated overnight at 110°C). The supernatant (3 ml)
was evaporated using a stream of N2(60°C) and the residue
was redissolved in 1.5 ml of heptane.
The heptane-soluble acids (phospholipids and free
fatty acids) were then determined by the previously
described titrimetric procedure.
The results (mean of 4 experiments; Fig 2.06) show that
between 50 and 100 mg activated silicic acid are
necessary for the complete adsorption of phospholipids.
(The low amount of titratable acids not removed were
assumed to be free fatty acids contaminating the
phospholipids, about 6% of the titre if allowance is
made for the difference in extraction of phospholipids.
Figure 2.06. The estimation of plasma free fatty acids:
Adsorption of phospholipids (lecithin) to
silicic acid
Phospholipids (lecithin) were adsorbed to varying amounts
of silicic acid. The phospholipids in the silicic acid
treated extract were determined by a titrimetric procedure
and expressed as a % of the value found for the silicic
acid free extract. Results of 4 experiments. For further
details see text.
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Alternatively it could denote incomplete adsorption of
phospholipids, however this may be less likely in view
of the monophasic curve.)
However palmitic acid was also adsorbed (up to
50% with 300 mg silicic acid) but, in agreement with
Laurell and Tibling (1967), this could be prevented by
adding 2% (v/v) methanol. The procedure using 300 mg
silicic acid was therefore adopted.
Interference by lactic acid
In the titrimetric procedure lactic acid interferes
and is removed using a washing procedure (Trout wash).
We wanted to establish whether this step was still
necessary since the soaps of short chain fatty acids
are not soluble in organic solvents. For this a
solution of lactic acid (0.8 mmole/l) dissolved in
chloroform-heptane (8:7 v/v, plus 2% methanol) and
6 3
blanks were mixed with the Ni reagent. Lactate failed
6 3
to solubilise any Ni into the chloroform-heptane
mixture. Therefore the washing procedure of Trout was
omitted.
Preliminary method
The method which was tried for routine use was as
f ollows:
Blood samples (0.75 ml) were extracted using standard
Dole's extraction procedure: 5 ml Dole's extract (see
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above) and the addition of 3 ml heptane and 2 ml double-
distilled water to separate the two phases. The heptane
extract (1.5 ml) was mixed with 3 ml chloroform-heptane-
methanol ^6:6:1 by vol.) and 300 mg activated silicic
acid was added using a scoop. The samples were shaken for
5 min, and silicic acid precipitated by short centrifugation
(5 min, 1 000 g). The supernatant (3 ml) was then shaken
6 3
with the Ni reagent (as described by Ho, see Reagents)
for the formation and extraction of Ni-fatty acid salts
(5 min). After another short centrifugation the radioactive
salts in 1 ml of the organic upper phase was determined
by liquid scintillation spectrometry. For this 9 ml
liquid scintillation solution (NE 260, New England
Nuclear, Winchester, Hants.) was used.
Samples were counted for 10 min or until 10 000 counts
had been accumulated.
Initial experience with the preliminary method
The method was tested (precision, standards) and
most of this work went without problems, except that
suddenly spontaneous inversion of the two phases during
the formation of Ni^ salts was noted in about 60% of
all samples. This was frequently associated with the
presence of white crystals (presumably Na2S04 from the
Ni-reagent) in the test tubes. Reproducible results
could not be obtained.
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At first it was thought that a decrease in the
temperature caused the crystallisation of the salts in
6 3
the Ni reagent and that this process at times was
initiated by the presence of grains of silicic acid.
However it turned out to be a complicated problem:
and although the temperature did play a role it was
obviously not the sole factor.
The most important factor was the methanol which
had been added to the chloroform-heptane mixture to
avoid the adsorption of palmitic acid to the silicic
acid. This final concentration of 2% methanol may
seem low, but it constitutes a volume of 60 jilt which
63
diluted the 200 jul saturated salt solution of the Ni
reagent to such a degree, that its final spec, density
was lower than that of the chloroform-heptane mixture.
Indeed, inversion could be induced by addition of 60 ^ul
methanol to tubes not containing methanol. This
problem was avoided by taking the methanol/chloroform/
heptane mixtures to dryness (the residue was redissolved
in 3 ml chloroform:heptane 8:7 (v/v)); and the cry¬
stallisation problem was overcome by replacing the
saturated Na2S04 solution by an unsaturated solution
of KBr (450 g/l).
It was also noticed that a number of factors
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affected the blank values:
- the amount of radioactive Ni used per test
- the addition of silicic acid
- the batch of silicic acid
- the evaporation of solvents
- the glassware
The most important contributor to the blank was
silicic acid. Blank values of lOOOO cpm were observed
with a particular batch. Washing the silicic acid
with chloroform or methanol reduced the blank by some
20%.
Separate experiments demonstrated the effect of
evaporating and then redissolving the FFA extracts and
of washing the glassware used with chloroform or KOH.
We were unable to reduce the blank to those observed
when redistilled chloroform-heptane (8:7 v/v) was
directly shaken with Ni^ reagent (200-400 cpm) by a
combination of chloroform rinsed glassware; choice of
suitable silicic acid batch and washing silicic acid
with chloroform; distillation of solvents. The blank
was usually 1900-2000 cpm. The top-standard (600 yumole/
gave some 60000 cpm. Although we realised that further
reduction of the blank value might be possible by avoid¬
ing the evaporation step. During the evaporation step
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fatty acids contaminating the redistilled solvents are
concentrated and lead to higher blank values. Thus
avoiding this step, used to eliminate the methanol
should lead to lower blank values. However we were
concerned that spontaneous reversal of the phases would
occur in the presence of methanol (see above). Since
the actual blanks are not excessive and it was exceed¬
ingly difficult to make small improvements, ways of
reducing blanks were not further explored.
The reproducibility of individual estimates was
steadily improved by selecting different pipettes
(Pettor; Alpha Laboratories, London) which were more
suitable for the pipetting of organic solvents than the
previously used Oxford pipettors.
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The procedure finally adopted
Blood (0.75 ml) was extracted using 5 ml Dole's
extraction mixture as described for the titrimetric
method in Section 2.2.2, except that the Trout wash
was omitted (see above). Phospholipids were removed
in a 2 ml aliquot of the heptane extract by preferen¬
tial adsorption to silicic acid after adding 2.5 ml
chloroform-heptane methanol (231:9:9 by vol). Silicic
acid (20O mg) was added using a scoop and the sample
shaken for 5 min. After a short centrifugation
(5 min at 1000 g), 3 ml of the supernatant was removed
using a Pettor and was evaporated under a stream of
nitrogen in a heating block (WTW, Weilheim Obb.,
Germany) set at 60°C. The fatty acids were redissolved
in 3 ml chloroform-heptane 8:7 (v/v) and the tubes were
stoppered. The tubes were left for 30 min, which is
claimed to improve the reproducibility of the results
(Elving and Carlson, personal communication).
6 3
The Ni salts were prepared by addition of 200 jal
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Ni reagent and the samples were mixed for 15-20 s
using a Vortex. After a short centrifugation (5 min,
lOOO g) the radioactive Ni-salts in the chloroform-
heptane phase were analysed in 1 ml sample added to 9 ml
liquid scintillation solution (NE 260, New England,
Nuclear) using a liquid scintillation counter.
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Calibration of the method
The method was calibrated using palmitic acid
standards dissolved in redistilled heptane, of which
3 ml were taken through the extraction procedure. The
concentrations were 0-600 jamole/l.
A representative calibration graph is shown in
Fig 2.07.
Calculations
The fatty acid concentrations of the unknown
samples were read from the hand-drawn calibration line.
Allowance was made for the fact that only 0.75 ml blood
was extracted, and usually the results were converted
to plasma free fatty acid concentration by multiplying
by a factor correcting for the packed cell volume (PCV)
( 100/(100-PCV) ).
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Figure 2.07. The estimation of free fatty acids in
blood extracts: Calibration graph
Free fatty acid concentration
(/i mole /I)
Palmitic acid standards in heptane were 'extracted'
and analysed by the formation of the Ni^-salt.




Nickel nitrate: 2 mmoles of Ni(N02)2
All organic solvents (isopropanol, heptane, chloro¬
form, methanol) were redistilled,, The composition of
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the Ni reagent was modified from the method of Ho
(1970) to increase its specific gravity by replacing
the saturated Na2S04 solution with accurate solution
of KBr (This had no effect on either the blank or the
standards).
The following stock solutions were prepared:
Solution a.
and 0.8 ml of glacial acetic acid were
made up to lOO ml with double-distilled
water.
Solution b. KBr solution: 45 g/lOO ml in double-dis¬
tilled water.
Solution c. Ni (N02)2/KBr solution:
2.5 ml solution a and 7.5 ml triethanol-
amine were added to 90 ml solution b.
6 3
Solution d. Working Ni reagent:
63
To 10 ml of solution c 0.1 ml of Ni Cl2 m 0.1 mole/l
6 3
HC1 were added(20pCiNi , NBS 1, The Radiochemical
Centre, Amersham). This solution is stable for at
63
least 3 months. Two hundred ^il of this working Ni
reagent mixed with 9 ml of scintillant solution NE 260
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gave 350 000-400 OOO cpm.
63
The original Ni reagent (Method of Ho, 1970) was
made by addition of the following stock reagents:
10 ml i" & saturated aqueous solution of sodium
sulphate
8.5 ml saturated aqueous solution of potassium sulphate
1.5 ml triethanolamine.
This solution contained 5 pCi Ni^/ml.
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Stability of the extracts
Stability of free fatty acids in plasma or plasma
extracts has been well documented by other groups,
(Braun, 1971; Broechoven and Parijs, 1968) and this
aspect of the method was not investigated.
Comparison with the titrimetric method
The method was compared with the standard titri¬
metric method of Trout. Blood samples were obtained
from blood donors at the Blood Transfusion Service,
Edinburgh. No heparin was administered to the donors
during this procedure. The samples were collected into
heparinised tubes and stored on ice. Fatty acids in
each whole blood sample were extracted in duplicate and
the remainder was used for the preparation of plasma.
Plasma concentrations of free fatty acids were analysed
in duplicate. A separate sample was collected in a
small EDTA tube (2.5 ml, Stayne Laboratories, London)
for the determination of packed cell volume in quadru¬
plicate, using a Hawksley micro-haematocrit centrifuge.
The concentrations of fatty acids in blood extracts were
expressed in terms of plasma concentrations to allow
direct comparison of the two methods. The results of the
comparison are presented in Fig. 2.08 , and show that the
titrimetric method overestimated plasma free fatty acid
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Figure 2.08. The estimation of free fatty acids in
blood extracts: Comparison with the
titrimetric method of Trout
Plasma concentrations of free fatty acids were estimated
in blood samples from healthy volunteers (40) using the
radio-chemical method and the titrimetric method of Trout.
For the radiochemical method 0.75 ml blood was extracted
and the results were expressed as plasma free fatty acid
concentration by multiplying by a factor correcting for the
packed cell volume. Note the overestimation of plasma
free fatty acid concentration by the method of Trout. For
details see text.
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concentrations by about 300 ^umole/l. This almost
certainly was due to the interference of plasma phospho¬
lipids in that method, whereas in the radiochemical
method phospholipids were removed by silicic acid. In
line with this is the fact that the slope of the re¬
gression is not significantly different from l.OO (line
of identity).
This was further examined by treating plasma extracts
of 7 volunteers with silicic acid in an identical manner
to that described for the whole blood extracts, to remove
interfering phospholipids. The purified extracts were
evaporated under a stream of nitrogen, redissolved in
heptane, and analysed titrimetrically. Both methods give
similar, but not quite identical results (see Fig. 2.09),
the reason for this is not clear, but could be explained
by a more efficient adsorption of phospholipids from the
plasma extracts due to a lower phospholipid content.
Novak found that the colorimetric analysis of plasma FFA
concentrations (which did not use silicic acid to adsorb
phospholipids) gave similar results to the titrimetric
method of Trout et al (1960).
The precision of the individual estimate
The precision of the method was assessed by repeatedly
analysing a palmitic acid standard (400 |umole/l) 10 times
on two occasions. The CV was 6% and 8.5% respectively.
12 5
Figure 2.09. The estimation of free fatty acids in blood
extracts: Comparison with the titrimetric
method of Trout using silicic acid treated
extracts
Blood samples were obtained from healthy volunteers (7).
Phospholipids interfering in the method of Trout were
removed by adsorption with silicic acid ( 300 mg). Note
similarity in results of the two methods. For details
see text.
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2.2.3. The estimation of plasma glucose
At times insufficient thought is given to the
special requirements of plasma glucose methods, suitable
for the determination of glucose extraction by the heart
in vivo. The reason for this may be that glucose methods
are considered to be well characterized. Therefore they
may be accepted without considering what effect metho¬
dological errors have on the determination of arterio¬
venous differences of glucose across the heart. Indeed
it is surprising that this problem appears to have been
ignored, or at least not been published formally.
The effect of methodological errors on the deter¬
mination of arterio-venous differences of plasma glucose
will be considered in some detail, before describing the
actual methods which were adopted with this particular
purpose in mind.
Theoretical consideration on the measurements of arterio-
coronary sinus differences of glucose
The effect of the precision of the estimation of
glucose on that of the determination of its arterio¬
venous difference was studied by computer simulation
using a Hewlett Packard computer Model 9821A and by
theoretical consideration.
At a physiologically normal arterial glucose
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concentration of 5 mmole/l the arterio-coronary sinus
difference of glucose is about 0.3 mmole/l. This was
used as the basis for generation of 20 random arterial
(5.0 mmole/l) and coronary sinus (4.70 mmole/l)
concentrations. The computer programme used (Pseudorandom
numbers, Hewlett Packard Statistics Package 9820A/9821A,
Programme no.0516, written by J.Gabriel) generates
pseudo-numbers with a mean and a standard deviation which
can be declared. Two coefficients of variation were
tested: 3 and 1% (the former is frequently published
for manual methods, and the latter can be achieved
using Autoanalyzers). From the generated "arterial" and
"coronary sinus" glucose concentrations arterio-coronary
sinus differences were computed and were sequentially
put into 4 groups, each comprising 5 replicate
determinations and the mean was determined for each
group. The results (mean _+ SD) are presented in Table 2.03.
The arterio-venous difference of the 4 groups
ranged from 0.15 - 0.43 mmole/l (CV = 3%) or from
0.28 - 0.32 mmole/l (CV = 1%). The means of these
4 average arterio-venous differences, were 0.31 +
0.25 and 0.31 +_ 0.07 mmole/l. The means are not different
from one another, or from the the theoretical value
of 0.3, but the standard deviations are. If we accept the




































































































































































































































doubtful on small numbers), one can predict that the
coefficient of variation of estimating arterio-coronary
sinus differences using a glucose method with a CV = 3%
will be about 80% (§^-§§ x 100%).
A much more acceptable figure for this will be
obtained with a more precise method (CV = 1%): but it
will still be about 20% (q * 3Q x 100%).
Similar results were obtained by calculation of the
standard deviation of the arterio-venous differences
using the equation Sa-cs = 7(Sa)2+(Scs)2 where & a,
Scs, 6 a-cs is the standard deviation of arterial,
coronary sinus and of arterio-coronary sinus difference
respectively (Scientific Tables, Documenta Geigy,
7th Ed.).
The standard deviation of the arterio-coronary
sinus difference estimated using a method with a CV of
3% and 1% is 0.2058 (= V(0.15)2+ (0.141)2) and
0.0686 (= 7(0.05 )"2+ (0 . 047 )2 ) respectively. The CV of
the arterio-coronary sinus difference is thus about
70 or 20% depending on the coefficient of variation
of the glucose estimations.
Using these calculated standard deviations random
arterio-coronary sinus differences can be derived from
tables of random normal deviates (Nixon and Massey, 1969).
These tables provide random, normally distributed data
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with a known mean and standard deviation. The random
numbers were transformed to data with the required
mean arterio-coronary sinus difference of 0.3 and a
standard deviation of 0.2058 or 0.0686.
The average arterio-coronary sinus difference of
5 consecutive estimations was then calculated (Table 2.03).
Like in the simulation experiment the data shows that
although the mean of the calculated arterio-coronary
sinus differences, based on data with a CV = 3%, is
not different, the variability is higher.
It is clear therefore that a method with high
precision is required, since the alternative of analysing
many replicates is not possible due to the limited
amount of blood available.
In establishing the finally adopted method
improvements in CV % of the method have played an
important, at times dominating role.
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At the beginning of this project an automated method
of using glucose oxidase had been established for studies
on glucose turnover in man and glucose utilisation in the
perfused rat heart in collaboration with Drs. Nimmo and
O'Brien, Department of Biochemistry, University of
Edinburgh. It was therefore only natural to adopt their
method as the basic method. The stability of the reagents,
optimal pH and reaction time etc were not only well
known, but had been thoroughly tested over a period of
years. We will quote here the relevant information at
the time available to us. For full details the reader
is referred to the thesis of O'Brien (1969).
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The method of O'Brien and its modifications
O'Brien (1969) developed his method for glucose
utilisation studies of the perfused rat heart. The
principle of the method is the enzymically catalysed
oxidation of (3-glucose using glucose oxidase (EC 1.1.3.4.):
P - D ( + ) glucose + > D - glucono-5-lactone + i^C^
Hydrogen peroxide is quantified by the indicator reaction
catalysed by peroxidase (EC 1.11.1.7), in which a compound
from gum guaiacum is oxidized to a product absorbing
at 625 nm:
gum guaiacum + HgOg * oxidized gum guaiacum + H20
The reaction was carried out using an Autoanalyzer.
The flow diagram of the system is shown in Fig 2. 10.
Standards and unknown samples were analysed in palindromic
sequence, in order to nullify the influence of any regular
change in the baseline (O'Brien, 1969).
Calibration of the method
were prepared according to O'Brien (1969), except that
an aqueous solution saturated with benzoic acid was
used. The justification for the inclusion of the
bacteriostat was shown in an experiment summarised in
Table 2.04.
Glucose standards (concentration 0
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The composition of the reagent is presented in the text.








































Stock gum guaiacum in sodium acetate buffer was
prepared according to O'Brien (1969) <>
The properties of this stock dilution vary with
different batches of the resin. O'Brien found that the
relation of glucose concentration with extinction was
only linear after the stock solution had been left for
1 to 10 days at room temperature. Therefore the stock
solution was always left for 14 days before use.
The enzyme reagent (1 litre), containing 5 ml
Fermcozyme (Hughes and Hughes Ltd., Brentwood, U.K.) and
5 mg horse radish peroxidase (Hughes and Hughes Ltd.,
Brentwood, U.K.) was made the day before use and left
overnight in a fridge. The enzyme concentrations were
modified from the original method in order to obtain
a linear relation between extinction and glucose con¬
centration up to 11.10 mmole/1 (200 mg/lOO ml), equi¬
valent to 25 ug/ml in Autoanalyzer cup.
Preparation of plasma samples
Blood samples were collected as described in
Section 2.2.2. and immediately transferred to plastic
fluoride-oxalate tubes (1 ml), cooled on ice. Blood
cells and plasma were separated by centrifugation
(10 min at 1500 g) in a cooled (4°C) MSE 4L centrifuge
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within 15-30 min. Plasma was then transferred to a
clean plastic tube and stored at -20°C until analysed.
Under these conditions plasma samples are stable for
at least 128 days (Nimmo, personal communication).
Originally plasma samples (25 jul) were deproteinised
with perchloric acid and neutralised with K^CO^ according
to the method of Nimmo (1970). It was noted that this
ultra-micro method consistently overestimated plasma
glucose concentrations by about 10%. The coefficient
of variation was also considered slightly too large
(1.2%). Therefore this approach was abandoned. Plasma
samples (50 pi) were diluted with 4 ml distilled water,
saturated with benzoic acid, acting as a bacteriostat.
Special attention was paid to factors causing
variability of the results. Oxford pipettors can be used
in two ways: dispensing with the 'forward' or with the
'reverse' technique. In the forward technique, which was
originally recommended by the manufacturer, the exact
quantity of a sample is sucked into the pipette tip, and
then expelled using an excess of air to displace it. Thus
in this manner the volume of the sample sucked into the
pipette is equal to the volume of displaced air prior to
sampling.
On the other hand one can suck as much as possible
into the pipette tip by maximal displacement of air. The
required volume can then be dispensed by displacement of
the exact volume of air, leaving some sample in the tip
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behind. Since in this fashion the order of moving the
plunger is reversed to that as originally recommended,
it has been called the 'reverse* technique.
It was found that the method of pipetting protein
free samples was unimportant, both in regard to mean
quantity dispensed and precision of dispensing. However
this did not hold for plasma samples. Pipetting of small
quantities (50 ^ul) was checked using a plasma pool to
which potassium chromate was added. Plasma samples were
then dispensed using the forward or reverse technique
into plain plastic tubes, containing 4.0 ml double-
distilled water. The extinction (320 nm, light path 10 mm)
was measured using a Pye Unicam SP 1800 Ultraviolet
spectrophotometer and the results were recorded on a Pye
Unicam AR 25 linear recorder. Using the forward technique
more plasma was dispensed as indicated by the higher
extinction (see Table 2.05). The precision of the
forward technique was 1.1% and of the reverse technique
0.7% (n= 10) and could be further improved when a fresh
tip was used with the reverse technique CV= 0.5% (n= 10).
Pipetting was also checked by weighing and the
variability was smallest when the 'reverse' technique
with a fresh tip each time was used.
The results are tabulated in Table 2.05.
Therefore in the finally adopted method the reverse
technique with a fresh tip for each pipetting was used.
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Table 2.05
The effect of pipetting on the CV of glucose estimation
Canine plasma pool was repeatedly pipetted using the
•forward', 'reverse' and the 'reverse' technique with
a fresh tip each time and the amount dispensed estimated
by extinction measurement (plasma + chromate) or
weighing. For further details see text (n = 10).
pipetting Ext inct ion Weight
technique mg
'Forward' 1.016 +_ 0.011 CV= 1.1% 49.6 +_ 0.4 CV= 0.9%
'Reverse' 0.951 +_ 0.007 CV= 0.7% 48.6 _+ 0.3 CV= 0.6%
'Reverse + 0.946 +_ 0.005 CV= 0.5% 49.0 +_ 0.1 CV= 0.2%
fresh tip'
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Calculation of plasma glucose concentration
The percentage transmissions of standards and unknown
samples were read from the recorder charts, and were
converted to optical densities. A line y= a + bx was
fitted to the data of the standards, using a least square line
fit computer programme, and the optical densities of
unknown samples were then converted to plasma glucose
concentrations using the coefficients of the calculated
line. All calculations were made using a computer
programme, written by Dr J.O'Brien, Department of
Biochemistry, University of Edinburgh, for a desk top
computer (Advanced Programmable Calculator 700 B, Wang
Laboratories Inc., Mass., USA).
Precision and accuracy of the glucose oxidase method
A canine plasma pool was repeatedly analysed (mean
SD): 6.98 +_ 0.03 mmole/l (CV = 0.4%, n= 20) . Recovery
of added glucose 2.78 mmole/l was 96.5 + 1.5% (n= 4).
Quality control samples (Wellcome Laboratories Ltd.,
Beckenham, Kent), assigned value 5.93 mmole/l were
analysed during each run. In 11 consecutive runs plasma
glucose was (mean +_ SD) : 5.65 + 0.11 mmole/l.
The mean glucose concentration is 5% lower than the
specified value for automated glucose oxidase methods
and is most likely caused by unidentified reducing
agents in the quality control sample or by an error in
the assigned value.
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The measurement of plasma glucose in haemolysed samples
In FFA infusion experiments using the blood cell
separator (Part 5) haemolysis, caused by the blood
cell separator was observed. Using the glucose oxidase
method lowered plasma glucose concentrations were
found. The reason for this is most likely a reduction
in H202 (formed by glucose oxidation) by glutathione,
released from haemolysed red blood cells. Interference
of glutathione can be eliminated by preincubation of
samples with 0.25 mole/l sodium carbonate (Technicon,
Clinical method 02, 1972). However, despite this precaution,
artificially low results were still observed, and may be
due to the oxidation of haemoglobin to methaemoglobin by
H202 (Makarem, 1974). Thus incorporation of a dialysis
step in the manifold for plasma glucose seemed inevitable
for haemolysed samples despite the fact that the
incorporation of a dialyser would certainly lead to more
practical problems and decreased precision. Two
alternatives were considered : purchase of a dialyser
unit for the existing method (glucose oxidase) or
purchase of the newly developed cartridge for the
measurement of glucose using hexokinase and glucose-6-
phosphate dehydrogenase, yielding NADPH as the end point.
The advantage of the latter method would be the increased
specificity due to hexokinase/glucose-6-phosphate
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dehydrogenase. The disadvantage was obviously capital
expenditure and higher running cost. The factor which
pushed the balance towards purchase of the new system
was the improved performance of the new chemical cartridges,
including miniature mixing coils, heating bath and
dialyser unit. This improved performance expresses itself
in diminished sample-to-sample interaction, despite
higher sampling rates. NADFH formed on oxidation of glucose-
6-phosphate is quantified using a double-beam colori¬
meter at 340 nm. The output potential is proportional
to optical density.
Other automated hexokinase methods (Bernt and
Lachenicht, 1970) have used fluorimetry for the
determination of NADPH (CV +_ 2%), but despite the lower
sensitivity of the colorimeter in the present method
calorimetry was prefered for its stability. Manual
methods using hexokinase were really never considered
due to their lack of precision.
Glucose by hexokinase/glucose-6-phosphate dehydrogenase
The principle of the method is as follows:
Glucose is phosphorylated using ATP, a reaction
catalysed by hexokinase (EC 2.7.1.1.):
glucose + ATP 9 glucose-6-phosphate + ADP
and glucose-6-phosphate is oxidized in the presence
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of NADP+by glucose-6-phosphate dehydrogenase (EC 1.1.1.49)
to 6-phosphogluconate and NADPH:
glucose-6-phosphate + NADP ^ 6-phosphogluconate + NADPH+H
The pH is optimal at 7.5 - 7.6. The equilibrium of the
indicator reaction is moved far to the right, and this
reaction drives the phosphorylation of glucose by
continuous removal of glucose-6-phosphate.
Although hexokinase catalyzes also the phosphorylation
of fructose and mannitol, the specificity of the method
is ensured by the specificity of glucose-6-phosphate
dehydrogenase for glucose-6-phosphate (Bergmeyer et al,
1970). This sequence of reactions is achieved using a
manifold as depicted in Fig 2.11.
The sample is added to an air-segemented stream of
distilled water. After mixing it passes through a 12
inch dialyser where some of the glucose is dialysed
into an air-segmented,concurrent recipient stream of
distilled water. The enzyme reagent, containing hexokinase,
glucose-6-phosphate dehydrogenase, ATP and NADP is then
added to the recipient stream and incubated at about
37°C. The absorbance at 340 nm is measured using a
double beam colorimeter.
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Figure 2.11. AAII method for glucose/hexokinase
Modified manifold
Double Coil , „















12.00 ml /min Water
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60/h 6:1
) ml /min From flgy Cell
The official Technicon cartridge (No. 933-0453-01) was
modified to increase the sensitivity of the method by
replacement of the 3 inch dialyser by a 12 inch dialyser.
The composition of the reagents is presented in the text.
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Establishment of an automated glucose method using
hexokinase
The Autoanalyzer system was tried as recommended by
the manufacturer (AA II method for glucose/hexokinase,
Technicon International Div., 1976). Under these conditions
a linear response for glucose concentrations up to
27.75 mmole/l (500 mg/lOO ml) is claimed. We wanted to
check this for our working range (4-8 mmole/l) with
standards ranging from 0 to 10 mmole/l . At this time
the Technicon enzyme reagent was not available. Although
the concentration of hexokinase, glucose-6-phosphate
dehydrogenase, NADP and ATP were known, the nature and
the strength of the buffer and the MgSO^ concentration
were not (classified information). We therefore prepared
our own enzyme reagent on the basis of the available
Technicon information, but the buffer system (0.3 mole/l
triethanolamine with 4 mmole/l MgS04, pH 7.6) was taken
from another automated method (Bernt and Lachenicht,
1970). The change in optical density was very small:
equivalent to 0.090 O.D. units for the 10 mmole/l
standard. Increasing the concentration of ATP, NADP and
the enzymes did not increase the peak height, excluding
the nature of the enzyme mixture as the cause for small
peaks. In the mean time we had learned from the
manufacturer that our response was similar to that
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usually found by others.
Peak height could be electronically enlarged, but
it was felt that this would be compensating for the
bad chemistry and would not lead to high precision.
Only a small amount of glucose is dialysed (+ 3%) and
substitution of the 3 inch dialyser by a 12 inch dialyser
should lead to greater sensitivity, possibly with more
sample to sample interaction.
Replacement of the dialyser resulted in a 3 fold increase
in peak height: A° .D. of 0.270 for 10 mmole/l standard.
The precision of the method was assessed on two occasions
by sequentially analyzing 20 samples of a canine plasma
pool of 5.8 mmole/l glucose. In this way sample to sample
interaction as a source of variability is excluded,
especially since the first peak was ignored. The co¬
efficient of variation was rather high 1.4% and 1.3%
(n= 19).
A continuous aspiration of a glucose standard did
not result in a steady reading, but in a reproducible
oscillating trace with a cycle of about 4 min. The flow
rate through the system was constant, and therefore
variations in flow (surging) could not explain this
phenomenon.
It is known that the dialysis is variable if the
donor and the acceptor fluid segments are travelling
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through the dialyser at slightly different rates. Only
maximal and constant dialysis can be obtained, when the
fluid segments are exactly opposite each other and remain
in phase. The flow in the donor and receptor stream was
matched by calibration and selection of pump tubes. The
phasing of the fluid segments was achieved by shortening
the transmission tube, connecting the mixing coil with
the dialyser. Despite this the oscillating trace remained,
leaving variability of the temperature as its only
possible cause.
The temperature in the heating bath was checked using
a digital thermometer (DU-3, Ellab A/S, Copenhagen,
Denmark). A variation between 37.0 and 37.6°C was found
with a periodicity of _+ 4 min. The stability of a
replacement bath was checked and found to be virtually
constant temperature variations between 35.5 and 35.6°C
(only one decimal point could be recorded). A steady
trace was found during constant aspiration of a sample.
The reproducibility also improved: coefficient of
variation of 0.4% (n= 19). A noticeable drift up was
observed in the peak heights over a period as little
as 20 min ( 0.3%/hour). Sample-to-sample interaction
was examined using standards. Standards were analysed in
palindromic sequence (0, 2, 4, 6, 8, 10, 10, 8, 6, 4, 2,
0 mmole/l). Peak heights obtained during the descending
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part of the palindrome were higher than those measured
in ascending order; normally indicative for carry-over.
Carry-over is less with lower sampling-rates. Therefore
standards were analysed in palindromic sequence with
different sampling rates and sample-to-wash ratios:
60 samples/hour; sampling time 6 parts wash 1 part
(60 6:1), 50 6:1 and 50 8:1. Carry-over expressed as a
percentage of the difference in concentration between
two adjacent peaks was less with 50 6:1 or 50 8:1 than
60 6:1 : 0.7-0.8 vs 0.9% respectively. However during
these experiments we observed that in addition to the
earlier baseline drift the sensitivity of the method
also increased with time. Therefore the observed 'carry¬
over' could partly be explained by the increase in
sensitivity with time. It became apparent that for
highest precision corrections were necessary for baseline
and sensitivity drift, as well as for sample-to-sample
interaction (see Calculations of results, pp 150-154).
We therefore decided to study whether different sampling
rates were associated with different degrees of precision,
in a fashion which eliminated effects of baseline and
sensitivity drift (appropriate corrections were made).
The results are summarized in Table 2. 06 . No major
differences were found. Therefore in the finally adopted




Plasma glucose by hexokinase
The effect of sampling rate and sample-to-wash ratio
on the precision (CV %) of the method. Canine plasma
samples were repeatedly (n= 20) analysed using
different cams used for the timing of the sampler. Two
observations were made using each cam. Results were
corrected for baseline and sensitivity drift.
CAM* Precision %
50 5:1 0.14 , 0.26
50 6:1 0.13 , 0.32
60 6:1 0.23 , 0.24
* Sampling rate per hour; sample-to-wash ratio.
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Reagent mixture
The hexokinase reagent mixture was purchased from
Technicon (Catalogue number T 11-1049-56) and stored
in a fridge until used. The reagent is provided in a
lypophilized form. Immediately before use it was
reconstituted by addition of 80 ml double-distilled
water. The mixture was stored in an ice bath, in which
it is kept during the analysis, during the working
day (Temperature 0 - 0.5°C).
The concentration of the active ingredients were:
NADP 0.67 mmole/l
ATP 0.40 mmole/l
Hexokinase 1 000 U/l
G-6-P DH 1 000 U/l
The nature of the buffer (pH 7.5) is unknown. For some
experiments (interference of glucose-6-phosphate) the
enzyme reagent was made up with or without hexokinase.
The concentrations of the active ingredients were:
NADP 0.67 mmole/l
ATP 0.40 mmole/l
Hexokinase 1 000 u/l (if required)
G-6-P DH 1 000 U/l
The buffer was triethanolamine 0.3 mole/l, 4 mmole/l MgSO^,
pH 7.6. The reagent was immediately used and kept on ice.
A 0c03% (w/v) Brij-35 solution (Technicon Chemicals,
Belgium) was used as the diluent.
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Standards
Standards (0-10 mmole/l) were prepared in a bovine
albumin (fraction V) solution, (55.55 g/l). The
concentration of albumin was selected on the basis of
the average canine plasma albumin concentration and the
albumin/total protein ratio. The reason for inclusion
of albumin is the fact that rate of dialysis is claimed
to be protein dependent (AA II method for glucose/
hexokinase, Technicon International Div., 1976). Batches
of albumin were checked for glucose contamination prior
to use. No glucose was found. Sodium azide (0.1 g/l)
which did not affect peak heights was included as a
bacteriostat. Aliquots were frozen at -20°C.
A typical calibration graph is shown in Fig. 2.12.
Calculation of results
Baseline drift during the run was recorded and
assumed to be constant. Sensitivity drift was assessed
as the difference in slopes of calibration graphs analysed
in the beginning and at the end of the run. The change in
sensitivity was assumed to increase linearly with time.
Carry-over was determined as follows: a drift standard
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Peak heights were converted into their corresponding
optical density readings using a Technicon calibration
chart. The plotted optical density measurements were
corrected for drift and carry-over. Standards made in
bovine albumin (55.55 g/1) .
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was analysed three times in a row. It was assumed that
the sample-to-sample interaction is constant after the
second peak. The height of the 3rd peak (R3; see Fig 2.13)
is the sum of the true peak height h plus the contribution
(c) due to carry-over. The value of c is also equal to
the difference between the observed baseline and the
baseline which would have been observed without carry¬
over (see Fig 2. 13). The factor which characterizes







The magnitude of this factor is considered to be a
constant both with respect to time and to the difference
in peak height between samples.
A computer programme was made for the Hewlett Packard
Computer Model 9821A in which the above 3 corrections were
applied. The effect of carry-over corrections was assessed
by analysis of two drift standards 4 and 6 mmole/l
respectively inserted after every 10 samples in a normal
run with unknown samples. The coefficient of variation,
without correction was 1.8 and 2.0% respectively. Much
153
Figure 2.13. AAII method for glucose/hexokinase:
Carry-over corrections
100
This is a hypothetical trace to illustrate the method
used for the calculation of the sample-to-sample inter¬
action (carry-over). True peak height = h; contribution
in peak height due to carry-over = c, ^i_4 are the un¬
corrected chart readings. During repeated aspirations
of the same sample c is assumed to be constant after the
first two peaks and is equal to R4—baseline. The mathe¬
matical equation expressing the carry-over factor is pre¬
sented in the text.
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more acceptable results were obtained after correction:
0.35 and 0.50%.
Interference in haemolysed samples
Haemolysis can theoretically cause interference in
the glucose by hexokinase method by releasing
- compounds which yield NADPH, directly or after conversion
of an endogenous substrate
- compounds which oxidize the formed NADPH
- compounds which absorb light at 340 nm.
The most obvious compound in the first category is
glucose-6-phosphate. However it was doubtful whether
glucose-6-phosphate could be dialysed, due to the net
charge of the molecule. Nevertheless interference of
glucose-6-phosphate was checked. A solution of glucose-
6-phosphate (5 mmole/l) was analysed using an enzyme
reagent with glucose-6-phosphate dehydrogenase, but
without hexokinase. Under these conditions glucose
standards can not be used, since in the absence of
hexokinase glucose is not converted to glucose-6-P
and no peaks are observed. Therefore the response was
related to glucose standards analysed after the addition
of hexokinase to the reagent. On this basis only 0.46 mmole/l
glucose-6-phosphate was found (9.2% of theoretical value
of 5 mmole/l). This taken together with published
glucose-6-phosphate concentrations of (human) whole
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blood (Scientific Tables, Documenta Geigy, 1970) it
is impossible for glucose-6-phosphate to interfere
with glucose measurements.
It is conceivable that there are substrates which
would be able to dialyse. However most substrate
concentrations in red blood cells would be too low to
cause serious interference, even if the enzyme reagent
is contaminated with the relevant NADP utilising enzyme.
One of compounds which might utilize the formed
NADPH is oxidized glutathione (Bergmeyer, 1970). However
the enzyme reagent did not contain glutathione reductase,
and therefore even if oxidized glutathione could dialyse
no interference can be expected. Haemolysed blood
showed no significant absorption at 340 nm.
156
2.2.4. Plasma glycerol estimation
Principle
The concentration of plasma glycerol was estimated
using a modification of the fluorimetric enzymic method
of Chernick (1969). The principle of the method is the
phosphorylation and then dehydrogenation of glycerol.
The first reaction is catalysed by glycerokinase
(EC 2.7.1.30):
glycerol + ATP > L-glycerol-3-phosphate + ADP
(o<-glycer ophosphate )
The indicator reaction is catalysed by glycerophosphate
dehydrogenase (EC 1.1.1.8):
L-glycerol-3-phosphate + NAD > dihydroxyacetone-
phosphate + NADH + H+
The equilibrium of the indicator reaction lies to the
left, but by removal of dihydroxyacetone-phosphate and
H+ by hydrazine and alkaline conditions (pH 9.25)
respectively,the reaction is shifted far to the right.
NADH is quantified by fluorimetry.
This method was introduced by the late Dr B.W.Lassers in
our laboratory for the measurement of glycerol in perfusates
of isolated rat hearts and in plasma ultrafiltrates.
The basic validation of it will not be presented, except
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where modifications were introduced.
Sample preparation
Blood samples were collected and processed as described
in Section 2.2.2.
Deproteinisation of plasma
In the original method glycerol was estimated in
samples deproteinised by ultrafiltration. Ultrafiltrates
were prepared by centrifugation of 2 ml plasma in Amicon
filter cones (Amicon Ltd., High Wycombe) for 40 min at
1 400 g in a refrigerated centrifuge. The ultrafiltrates
were stored at 4°C and analysed the next day.
As this method does not lend itself to the analysis
of glycerol in small blood samples alternative techniques
were examined. Acid deproteinisation (perchloric acid,
trichloroacetic acid) was unsatisfactory, due to occasional
inactivation of the assay enzymes, which could not be
prevented by the inclusion of 0.02% (w/v) bovine albumin
in the assay buffer.
Heat denaturation of plasma proteins proved to be
satisfactory, provided plasma was first diluted and
subsequently frozen. Both the effect of time and
temperature on this process were examined.
In the method that was finally adopted canine plasma
(250 yul) was diluted with 350 yul double-distilled water
and heated for 15 min at 138°C in a stoppered tube
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(nitric acid washed, bacteriological tube 50 x 6 mm,
McKay and Lynn, Edinburgh). The tubes were stored over¬
night at - 20°C. The denatured proteins were precipitated
by centrifugation for 30 min at 1 300 g.
The clear supernatant (100 ill) was used for the analysis
that day.
It was possible to use smaller plasma samples (50 ^ul).
However the procedure was tedious and only with difficulty
could one single analysis be made. Therefore the methods
described above using 250 jil plasma was preferred, despite
its requiring more plasma.
I am grateful for the cooperation of Mr J.Simpson M.Phil.,
who developed the deproteinisation procedures.
Reagents
Glycerokinase, from Candida mycoderma, specific
activity 85 u/mg and glycerol-3-phosphate dehydrogenase
from rabbit muscle, specific activity 170 U/mg were
obtained from Boehringer Corporation London Ltd.
The following stock solutions in double-distilled
water were prepared using nitric acid washed glassware:
-glycine 0.2 mole/l
-MgS04 0.3 mole/l
-hydrazine hydrate 1 mole/l
-EOTA 0.1 mole/l
159
Bulk buffer was prepared weekly by mixing 100, 6.06,
100 and 3.03 ml of the above stock solutions respectively.
The pH was adjusted to 9.25 with NaOH (1 mole/l prepared
fresh fortnightly). The bulk buffer was stored at 4°C.
Working buffer was made daily by addition of NAD (Grade
I, Boehringer Corporation London Ltd.) and glycerol-3-
phosphate dehydrogenase to bulk buffer. Final concentrations
in the cuvette were:
- glycine 70 mmole/l
- NAD+ 0.4 mmole/l
- glycerol-3-phosphate dehydrogenase 1 000 u/l
- hydrazine hydrate 340 mmole/l
- MgSO^ 6 mmole/l
- EDTA 1 mmole/l
The glycerokinase/ATP reagent was prepared daily using
working buffer.
Final concentrations in the cuvettes were:
- glycerokinase 50 u/l
- ATP 0.6 mmole/l
Enzymic conversion
The enzymic conversion of glycerol was directly
carried out in the fluorimetry cuvettes. To each cuvette,
containing 100 jj.1 standard or deproteinised sample, was
added 900 jj.1 glycine buffer (containing NAD+ and glycerol-
3-phosphate dehydrogenase, see Reagents). Cuvettes, sealed
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with Parafilm, were incubated for 25 min at 36 - 38°C in
a bacteriological incubator (Townson and Mercer, Edinburgh).
The fluorescence due to oxidation of endogenous glycerol-3-
phosphate was determined. Phosphorylation and oxidation
of glycerol was then initiated by addition of 25 yul
glycerokinase/ATP (see Reagents). After a second incubation
for 25 min the final fluorescence was determined.
Calibration of the method
An aqueous stock standard (10 mmole/l) was prepared
from glycerol (Analar, British Drug Houses, Poole).
The purity of glycerol was determined by measuring its
specific gravity at 20°C (Handbook of Chemistry and
Physics, pp D-181, 51st Edition).
Working standards (7 concentrations, ranging from
5-180 yumole/l) were prepared from this stock standard,
divided into quantities sufficient for one analytical
run and stored at -20°C. Under these conditions glycerol
solutions are stable for at least 1 year. On the day
of the analysis the working standards were thawed out,
100 jj.1 was analysed directly in the cuvette and the
remainder discarded. Standards and blanks were analysed
in duplicate.
A representative calibration graph (increase in
fluorescence after the addition of glycerokinase vs
glycerol concentration) is shown in Fig 2.14.
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The line (y = a + bx + cx ) was calculated using a poly¬
nomial computer program.
Ordinate : Increase in fluorescence (A) at 415 nm after the
addition of glycerokinase.
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Calculation of plasma glycerol concentration
2
A line (y= a+b x+ c x ) was fitted to the data of the
calibration graph using a least squares line fit-computer
programme, wpitten by Dr JP'B rien, Department of
Biochemistry, University of Edinburgh. A desk top computer
(Advanced Programmable Calculator 700B, Wang Laboratories,
Inc., Mass., USA) was used.
The increase in fluorescence after the addition of
glycerokinase to plasma samples was not directly converted
into corresponding glycerol concentration. The reason
for this is that initial fluorescence readings for de-
proteinised plasma samples were invariably higher than
those for standards. Therefore for a given glycerol
concentration the increment in fluorescence would be less
for samples than for standards, due to the tailing off of
the calibration graph at higher glycerol concentrations
and direct conversion would lead to underestimation of
plasma glycerol concentration. This is avoided if
fluorescence readings (initial and final) are both
expressed as 'glycerol' using the calibration graph.
Plasma glycerol concentration is then taken as the
difference between the two 'glycerol' concentrations.
Validation of the method
A main obstacle in the validation of the modified
plasma glycerol method was the lack of a suitable plasma
quality control sample, containing in addition to free
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glycerol physiological levels of esterified glycerol.
Plasma lipids are not stable and may hydrolyse slowly
to free fatty acids and glycerol (Lindlar, 1969).
Therefore our main concern was that this process might be
heat-catalysed during the deproteinisation procedure.
On the other hand albumin, which acts as the binding
protein for the water-^soluble part of the lipids (the
fatty acids), will be denatured and it is conceivable that
it would therefore lose its binding capacity and hence
its property to facilitate the lipolytic formation of
glycerol.
The validity of the method was checked by two different
and independent series of experiments. First of all the
results obtained using heat-denatured, deproteinised plasma
samples were compared with those obtained from plasma
ultrafiltrates prepared at 4°C (Reference method). The
results were similar, provided corrections were made
for the loss of glycerol in the preparation of the
ultrafiltrates (see Table 2.07). These data, however,
should be interpreted with caution, because the recovery of
glycerol using the reference method could vary considerably.
A more direct approach checking the occurrence of
the hydrolysis of esterified glycerol (^glycerophosphate,
p-glycerophosphate,lecithin and triolein, all from Sigma
Ltd., London)was made. Both glycerophosphate, (3-glycero-
164
Table 2.07












* The pools were analysed in triplicate, using ultra-
filtrates (Reference method) and heat-denatured
deproteinised samples. Recovery of glycerol, presented
in brackets, was determined on separate aliquots. The
glycerol results were corrected for recovery:
observed value x (100/recovery).
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phosphate,lecithin and triglycerides were stable during
the heat-denaturation procedure.
The recovery of 50 nmoles glycerol added to 1 ml
canine plasma was 104% (mean.+_ SD: 52.0 +_ 1.0 nmoles;
n=7). The recovery was slightly, but significantly higher
than 100% ( p <0.01, Student's t-test).
On the basis of these findings on accuracy, lack of
hydrolysis of esterified glycerol and glycerol recovery,
the heat-denaturation deproteinisation procedure was
adopted for the analysis of plasma glycerol concentrations.
The recovery was a marked improvement upon the
original method (ultrafiltration). In that technique
varying amounts of distilled water adhering to the
Amicon cones caused dilution of the ultrafiltrates
('loss' of glycerol). Even with much care the mean recovery
was 89.5 +_ 12.3%, giving a CV of 14%.
Quality control of the plasma glycerol methods
Both in the original method, using ultrafiltrates,
and in the modified method (heat-denatured samples) the
performance of the enzymic conversion was always checked.
For this glycerol quality control samples at a concentration
of 10 and 100 |imoles/l, made in double-distilled water
and stored in aliquots at -20°C, were analysed during
each run. The increase in fluorescence after the addition
of glycerokinase was remarkably constant over long
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periods. The results obtained from one set of quality
control samples analysed over a 9 month period are
summarised in Table 2.08. The mean glycerol concentration
(_+ SD) of the low quality control sample was not
statistically significantly different from the theoretical
values, but the high quality control sample gave results
which were slightly, but significantly too low (p<^0.01,
Student's t-test).
For the monitoring of glycerol-3-phosphate dehydrogenase
a quality control sample was prepared using L-glycerol-
3-phosphate in double-distilled water and stored at
- 20°C.
The results are presented in Table 2.08.
Recovery of plasma glycerol
The recovery of glycerol added to plasma samples
prior to deproteinisation was determined on some
randomly selected samples during each run. The mean +_
SD recovery recorded over a 9 month period (same as above)
was
98.7 _+ 3.9% (n=31 ) , CV= 4.0% (see Table 2 £>8 )
The precision of the individual estimate
The precision of the individual estimate was analysed
by repeated analysis of a canine pool,
mean + SD : 92.1 + 1.3 (n=7) jimole/l, CV= 1.4%.
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Table 2.08
Quality control of plasma glycerol method
Value
Sample Theory Observed (mean +. SD) CV
glycerol(jamole/l) 10 10.1 +_ 0.4 (n=40) 4.0%
100 97.9 _+ 2.5 (n =32) 2.6%
Recovery*(%) 100 98.7 _+ 3.9 (n=31) 4.0%
L-glycerol-3-
phosphate (|imole/l) - 126.9 +_ 5.1 (n=23) 3.0%
* Samples were deproteinised by heat denaturation.
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2.2.5. The estimation of plasma lactate concentration
Principle:
Plasma lactate concentrations were determined using
an enzymic fluorimetric method (Passonneau, 1970).
Lactate dehydrogenase (L-lactate: NAD oxidoreductase,
EC 1.1.1.27) is used to catalyze the reaction:
L-lactate + NAD+ — > pyruvate + NADH + H+.
The equilibrium lies to the left; however, the reaction
can proceed quantitatively to the right provided the end
products of the reaction are removed: pyruvate as pyruvate
hydrazone, and H+ by selection of a pH of 10 of the
reaction mixture. The NADH formed is measured
fluorimetrically.
Sample preparation
Initially, blood was collected into a heparinised
tuberculin syringe (1 ml) and immediately transferred
into 4 micro haematocrit capillary tubes. The tubes were
quickly sealed and centrifuged for 1 min in a micro-
haematocrit centrifuge (Hawksley, London) at room
temperature. The plasma freed from red blood cells
was recovered by breaking the tube, and transferred to
a small plastic conical tube (Beckman, Glenrothes, Fife),
frozen and stored at -20°C until analyzed (within one
week of collection). More recently, blood was centrifuged
in the small conical tubes described above in a Jobling
micro centrifuge Model 320 (Townson and Mercer, Edinburgh)
until full speed (10 000 rpm, 9 000 g) was reached (10 s).
Plasma was then immediately transferred to another tube,
frozen and stored at -20°C (as above). The procedure
(i.e. sampling until plasma was separated) normally
took f min and during this time a small change in lactate
concentration was found. This was also checked by
delaying the processing of blood samples (Table 2.09).
On the day of the analysis, plasma samples were
allowed to thaw on the bench. Plasma samples (50 pi)
were diluted with 2.45 ml fresh double distilled water
using Oxford pipettes, mixed and 100 pi of the diluted
sample was used for the analysis. A higher dilution was
used (50 pi plasma plus 4.95 ml double distilled water)
when plasma samples with high lactate concentrations
were processed.
The enzymic conversion of lactate
The enzymic conversion of lactate to pyruvate and
NADH was carried out directly in the fluorimetric cuvettes.
To 1 ml incubation buffer 100 pi of diluted samples (un¬
known and standards) were added, and the initial fluo¬
rescence was determined. The fluorimetric equipment and
procedures wereAdentical to those described in
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Table 2.09
Plasma lactate estimation: The effect of time delay in
processing pfblood samples on the plasma lactate concentration
A canine blood sample (10 ml) was collected and plasma was
obtained by short centrifugation with a delay as indicated.
Delay Plasma Lactate % of
(min) (mmole/1) 'initial'value
0.45 1 .90 100.0
0.95 1 .89 99.5
1 .17 1 .95 102 .6
1.75 2 .07 108.9
2.42 2.11 111.1
3.08 2 .03 106.8
3.75 2 .12 111.6
4.62 2 .24 117.9
5.28 2 .25 118.4
6 .00 2 .29 120.5
6.67 2 .28 120.0
171
Section 2.2.4. (fluorimetric analysis of glycerol).
The enzymic conversion was then initiated by the addition
of 20 U lactate dehydrogenase. The cuvettes were sealed
with Parafilm and incubated for 60 min in a bacteriological
incubator set at 37°C.
In the original method (Passonneau, 1970) the
necessary incubation time for complete conversion of
lactate to pyruvate was given as 20-30 min (temperature
unspecified). We were unable to reproduce this. At least
90 to 105 min was necessary to reach steady fluorescence
reading when the samples were incubated at room temperature
(Fig 2.15). Increasing the incubation temperature to 37°C
and/or doubling the amount of enzyme did not change the
time course of the reaction. Passonneau had suggested
that the enzyme is not very stable at high pH, and
theoretically this could cause the decline in reaction
rate with time as more and more enzyme would be in¬
activated. However even if this possibility were
operational, it could not have been the major factor,
since the addition of lactate to lactate dehydrogenase
(incubated in buffer of pH 10 for 60 min) resulted in
a marked increase in fluorescence. Increasing the
hydrazine concentration resulted in increased conversion
of lactate during a 45 min incubation period (37°C)(Fig 2.16).
As a result, the concentration of hydrazine in the
1 /z
Figure 2.15. Plasma lactate method: Timecourse of the
enzymic conversion of lactate (Original
Passonneau method)
The enzymic conversion of 10 nmoles lactate was followed
fluorimetrically. Cuvettes were incubated for times vary¬
ing from 5-120 min at 25 C. Appropriate blanks were also
carried through. Each point represents the mean of 4 ob¬
servations .
Ordinate : increase in fluorescence (A) at 415 nm after
the addition of LDH.
X X blank
• • lactate standard (10 nmoles/cuvette).
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Figure 2.16. Plasma lactate method: The effect of
hydrazine on lactate conversion
100
Hydrazine (mmol/1)
The effect of hydrazine (final concentration 0-200 mmoles/l)
on the enzymic conversion of 10 nmoles lactate was analysed.
The increase in fluorescence (A) after the addition of LDH
and incubation of the cuvettes for 45 min at 37 C was deter¬
mined (Ordinate). Each point is the average of 4 cuvettes.
The appropriate blanks were also carried through.
• • blank
0 0 lactate standard (10 nmoles/cuvette).
Note: Optimal hydrazine concentration of 125 mmol/l.
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incubation mixture was increased from 50 to 125 mmole/l.
Increasing the concentration of NAD was considered but
in view of its price not explored.
Calibration of the method
Standards were prepared freshly from a commercial
stock solution (1.00 mmole/l), Boehringer Corporation,
London). A working stock solution of 1 mmole/l was
prepared by diluting 100 jal of the stock solution with
100 ml double distilled water. The secondary standard
was then further diluted to obtain standards with 2, 4,
6, 8, and 10 nmoles per 100 j.il respectively.
A representative calibration graph is shown in Fig 2.17.
The curve was calculated using the same programme as
described in detail in Section 2.2.4.
The precision of the individual estimate
Aliquots of a frozen canine plasma pool were repeatedly
analysed. The mean + SD concentration of plasma lactate
was 4.58 + 0.11 mmole/l; the coefficient of variation
ranged from 1-3.1%, mean 2.5% (see Table 2.10).
The accuracy of the individual estimate
The specificity of lactate dehydrogense ensures that
only lactate is converted (Bergmeyer, 1970). The enzyme
used was of the highest purity available.
A source of inaccurate results which is more difficult
to assess is related to the method of collection of blood
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Figure 2.17. Plasma lactate method: Calibration graph
2 4 6 8 io
Lactate concentration
(n moles/cuvette)
The line (y = a + bx + cx") was calculated using a
polynomial computer programme.
Ordinate : increase in fluorescence (A) at 415 nm
after addition of lactate dehydrogenase.
Blank set at 1.0.
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samples and the preparation of plasma. The increase
in lactate concentrations in vitro is due to glycolysis,
which takes place in the cells. Quick separation of
cells from plasma is essential. Using the finally
adopted method we found a small significant increase in
plasma lactate concentrations of about 3%/min, since
delaying the processing up to 7 min did increase lactate
concentrations (see Table 2.09). However separate blood
samples were collected over a short period, usually about
30 s, simultaneously from the arterial, coronary sinus and
local venous catheters. Therefore the estimation of
arterio-venous differences of lactate concentration should
be correct.
Stability of lactate in stored canine plasma (at -2Q°C)
A canine plasma pool was analysed on the day of
collection and the remainder was divided inj°aliquots and
stored at -20°C. There was no deterioration within 10
days (Table 2.10).
Reagent s
Buffer: 2-amino-2 methyl-l-propanol (1 mole/1,
9.5 ml/100 ml double-distilled water; Sigma, London),
pH adjusted to 10 with 4.2 ml HC1 concentration.
Hydrazine hydrate (2 mole/1) was prepared by 1:10
dilution of 20 mole/l stock (B.D.H., Poole).
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Table 2.10
Plasma lactate method: Stability of plasma lactate samples
A canine plasma pool was collected and analysed on day 0.
The remainder was divided into aliquots and stored at
-20°C for later analysis.
On each day samples were analysed in 5 fold. The results
+ SD are presented (n= number of replicates).
Day of analysis Plasma lactate CV %
(mmole/l)
0 4.54 + 0.14 3.1
1 4.45 + 0.06 1 .2
2 4.66 + 0.08 1.8
3 4.66 + 0.06 1.2
4 4.52 + 0.05 1.1
8 4.57 + 0.04 1.0
10 4.66 + 0.10 2.1
Grand mean (n= 35) 4.58 + 0.11 2.5
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Nicotinamide adenine dinucleotide (NAD) 0.1 mole/1,
70 mg/ml double-distilled water (Boehringer Corporation,
London) stored in 100 js 1 aliquots at -20°C.
The reaction mixture finally adopted:
10 ml buffer plus 6.25 ml hydrazine hydrate and 50 jdl
NAD in lOO ml double-distilled water, prepared immediately
before use.
Lactate dehydrogenase (Boehringer Corporation, London,
pig heart, cat. no 107 042) suspension in ammonium
sulphate solution, 5 mg protein/ml.
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2.2.6. The estimation of plasma albumin concentration
Principle:
Plasma albumin concentrations were determined using
a manual colorimetrie method, based on the method of
Northam and Widdowson (1967). When a solution containing
albumin is added to a buffered solution of bromocresol
green (3, 3', 5, 5' ,-tetrabromo-m-cresolsulfonphljklein ,
Fig 2.18) an increase in optical density at 637 nm is
observed, which is proportional to the concentration of
albumin.
Sample preparation
Heparinised plasma samples were prepared as described
for the determination of plasma free fatty acid concentrations
(Section 2.2.2.) and stored at -20°C until analysed.
Reagent
Working bromocresol green solution was prepared by
addition of:
8.0 ml stock bromocresol green solution (50 mmole/l,
BDH, clinical reagent)
5.08 g sodium citrate dihydrate (BDH, Analar)
6.85 g citric acid (BDH,Analar)
0.1 g sodium azide (BDH, Analar)
1 ml 30% Brij-35 (Technicon Chemicals, Belgium).
The pH was adjusted to 3.80 using sodium citrate or citric
acid (but not NaOH or HC1), and the volume made up to
1 litre using double distilled water. Final concentration
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Figure 2.18. The chemical structure of bromocresol green
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of bromocresol green is 0.40 mmole/l, the strength of the
citric acid buffer about 50 mmole/l.
Procedure
Bromocresol green reagent (5.0 ml), dispensed using
an Oxford Pipettor (Boehringer Corporation, London) was
mixed with 50 P1 of double distilled water (blank),
albumin standard (Bovine albumin Cohn's fraction V,
Sigma, London) or samples. Optical density measurements
are made using an Unicam SP 1800 ultraviolet spectro¬
photometer (Pye Unicam, Cambridge) and recorded on an
Unicam AR 25 linear recorder (Pye Unicam, Cambridge).
Spectra obtained from a blank and from a canine
plasma sample are shown in Fig 2.19. It was found that
albumin not only increased the optical density in the
region of 580 to 680 nm, but also shifted the wave length
of the absorption maximum from 620 to 630 nm. The maximal
difference in optical density between samples and blanks
was at 637 nm. This was the wavelength used in the
finally adopted method.
The stability of the developed colour was examined
and found to be stable after 5 min. Therefore optical
densities were measured 5 min after albumin samples were
mixed with bromocresol green reagent. Optical densities
were measured using disposable plastic cuvettes (optical
path 10 mm). The slitwidth was 0.2 nm.
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Figure 2.19. Plasma albumin method: The spectrum of
bromocresol green - albumin complex
Blank and plasma were mixed with bromocresol green
reagent (for details see text) and their sjectrum deter
mined 5 min later (scanning speed 1 nm/s, 'path length
10 mm, reference double distilled water).
Spectrum 1: blank; 2: canine plasma (albumin concentra
tion, 33.8 g/l). The difference between plasma and
blank (in reference position) is presented as spectrum
note maximal difference is observed at 637-638 nm.
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Calibration of the method
There are considerable difficulties in obtaining
absolute albumin standards due to varying water content
and electrophoretic homogeneity (Doumas et al, 1971).
Standards could only be made with great difficulty of
canine albumin (Cohn's fraction V, Sigma, London),
quite unlike our experience with bovine albumin (Cohn's
fraction V, Sigma, London). The resultant solution was
more viscous and had a gelatinous character. No stable
optical density readings could be obtained due to
floating flocculent material in the cuvettes. We never
encountered similar experiences with bovine albumin.
The physiological role and chemical structure of
albumin in different species is similar. E.g. we are not
aware of difference in binding affinity of bromocresol
green to albumin of different species. Therefore despite
the theoretical advantage of standardizing against
canine albumin, plasma albumin measurements were
standardized against bovine albumin in view of the
mentioned problems. A calibration graph is shown in Fig 2.20.
The precision of the individual estimate
The precision of the method was determined using a
canine plasma pool: mean +_ SD 32.0 +_ 0.8 g/l (n = 10)
(CV = 2.5%).
184
Figure 2.20. Plasma albumin method: Calibration graph
Albumin concentration (g/1)
Standards were made of crystallised bovine albumin.
The graph was drawn by hand.
For details of the method see text.
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Interference by free fatty acids
Uptake of plasma free fatty acids (FFA) by the heart
is dependent on the FFA/albumin molar ratio rather than
on the FFA concentration (Spector et al, 1965; Evans et
al, 1963). Meaningful FFA/albumin molar ratios can only be
obtained, if plasma FFA don't interfere with the bromocresol
green albumin method. Generally speaking dye binding
albumin methods are subject to interference by compounds
competing for albumin binding sites (Watson, 1969). E.g.
it has been suggested that the low albumin values (using
eosin as the dye) were caused by a FFA induced reduction
in eosin binding to plasma albumin.
Therefore the effect of raised plasma FFA concentrations
on the estimation of albumin using bromocresol green was
examined. Appr. 4% (w/v) albumin solution (Bovine albumin,
Cohn's fraction V, essentially fatty acid free, Sigma,
London) in 0.9% w/v saline was prepared. The FFA
concentration was 275 pmole/l. To one part potassium
linoleate (99% pure, Sigma, London) was added, final
concentration 1815 pmole/l. Albumin concentrations were 6%
lower: 48.3 - 0.1 and 44.8 - O.l g/l respectively.
The effect of haemolysis on albumin determination
In experiments using the blood cell separator
haemolysis was at times observed (see Part 5). Therefore
the effect of haemolysis on albumin estimations was studied.
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Dog red blood cells (one volume) were washed 7 times
with one volume of 0.9% w/v sodium chloride, after which
the cells were haemolysed by addition of one volume
double distilled water. The haemoglobin concentration
of the haemolysate was kindly measured by Mr. P.Newman,
Department of Haematology, The Royal Infirmary, Edinburgh.
The effect of different degrees of haemolysis expressed
as haemoglobin g/l, on the bovine albumin calibration
curve is shown in Fig 2.21. (Haemolysis of 1% of
circulating red blood cells would result in free
haemoglobin concentration of about 2 g/l)
The interference of haemoglobin is related to the
haemoglobin/albumin ratio, rather than the absolute amount
of haemoglobin. A hyperbolic relation between the error
in albumin measurement and haemoglobin/albumin ratio
(w/v) was found (not shown): for a given haemoglobin
concentration a marked interference at low and no
interference at high albumin concentrations. The nature
of the interference is therefore almost certainly binding
of bromocresol green by haemoglobin.
Haemoglobin did not absorb light at 637 nm (not shown).
Our experimental animals usually have albumin
concentrations ranging from 25 - 35 g/l, and as a result
the problem is more serious than it would have been for
human samples range 50 - 65 g/l. However the high free
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Figure 2.21. Plasma albumin method: The effect of
haemolysis
Albumin concentration (g/1)
The effect of haemolysis (haemoglobin) on the deter¬
mination of plasma albumin concentration was studied
by addition of albumin free haemolysed red blood cells.
The amount of haemoglobin added was determined separ¬
ately.
0 0 albumin standards (control)
A—'—-——A albumin standards plus 4 g/1 haemoglobin
X • X albumin standards plus 20 g/1 haemoglobin
High haemoglobin concentrations were selected to demon¬
strate its effect. For further details and implications
see text.
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haemoglobin concentrations used were chosen to demonstrate
an effect, and they are much higher than observed in our
experiments: 1.0 - 3.0g/l. At this level of haemolysis
errors in plasma albumin concentrations were estimated
in the order of 1.5- 2.0g/l, which could represent
an error of 4-8% depending on the actual albumin
concentration.
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2.2.7. The estimation of lipolytic activity
in canine plasma
Normal blood does not contain appreciable lipolytic
activity, but after the injection of heparin the
activity is markedly increased, as evidenced by the
clearing of any lipaemia. It is now clear that a
number of lipolytic enzymes are released by heparin
from various organs: including lipoprotein lipase and
other triglyceride- and phospho I ipases (Jansen and
Hlilsmann, 1974; Vogel and Bierman, 1965).
This post-heparin lipolytic activity in the presence
of lipaemia (Intralipid infusion) was used to raise
the concentration of plasma FFA in vivo. The lipolytic
activity in plasma samples was estimated to relate
this on a semi-quantitative basis to changing plasma
FFA concentrations after heparin administration. The
conditions employed to assay the lipolytic activity
were optimal (but not specific) for the expression of
lipoprotein lipase (EC 3.1.1.3) activity (Riley and
Robinson, 1974).
Principle:
Plasma lipolytic activity was estimated using a
triglyceride emulsion, Intralipid, preincubated with
canine serum apolipoprotein lipase activators, as the
is.
substrate. Thisiin contrast to the conditions in vivo,
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when Intralipid does not require pre-activation. This
is due to the presence of circulating apolipoprotein-
lipase activators (La Rosa, 1970).
The activity was expressed as free fatty acids
released during incubation for 60 min at 37°C, in
Tris buffer of pH 8.31 (1 Unit= umole/ml/60 min). The
enzymic reaction was initiated by adding the plasma
sample to the reaction mixture and terminated by
deproteinisation/extraction of an aliquot into Dole's
extraction mixture. Free fatty acid concentrations were
analysed as described in Section 2.2.2. using the
titrimetric method of Dole. This lipoprotein lipase
method, established in our laboratory by Mr James
Simpson, M.Phil., is essentially the same as described
by Riley and Robinson (1974).
Preparation of plasma samples
Blood samples were collected in EDTA tubes(Stayne Lab¬
oratories, London ), and stored on ice. Plasma and red
blood cells were separated by centrifugation at 4°C
(10 min, 150 g) and the plasma was transferred to
another tube kept on ice. The assay was started
immediately after the end of the experiment (less than
2 hours after the first samples had been collected.
The incubation
The lipolytic activity was assayed in Tris buffer,
pH 8.31 with 5.7% (w/v) bovine albumin (Cohn's fraction
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V, Sigma, London). The substrate Intralipid (20% (w/v),
Kabi-Vitrum, Ealing, UK) was preincubated with canine
serum. For this fresh blood (25 ml) was collected
from the non-heparinised dog early during the experiment
and mixed with 0.380% (w/v) trisodium citrate. Citrate
plasma was obtained by centrifugation (15 min, 1 500 g)
in a cooled MSE 4L centrifuge at 4°C. The plasma (1 ml)
was recalcified by adding 25 jil of 1 mole/l CaC^
and left to clot for 30 min at 37°C. The clear re-
calcified serum, containing apolipoprotein lipase-
activators (La Rosa et al, 1970), was stored at 4°C
until used later that day for the activation of
Intralipid. For this Intralipid, double-distilled
water and the recalcified serum (1:3:4 by vol) were
mixed and incubated at 37°C for 30 min.
Immediately before lipolytic activity was estimated
1 ml activated substrate was added to the buffer (5.8 ml)
dispensed in incubating flasks (glass liquid
scintillation vials). The flasks were then transferred
to a shaking waterbath set at 37°C (Grants Instruments
Ltd., Cambridge), and allowed to equilibrate for 5 min.
The enzymic reaction was initiated by addition of
0.2 ml plasma, mixed and immediately three 1 ml aliquots
were taken and transferred to tubes each containing 5 ml
Dole's extraction mixture for the estimation of free
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fatty acid concentration at time zero.
The incubation was terminated by transferring
another three 1 ml aliquots of the reaction mixture
after exactly 60 min to tubes containing Dole's
extraction mixture. The extracts were then stored at
-20°C until analysed.
Results are expressed as FFA released (pmole ml "*"h .
The amount of free fatty acids released is
said to be linear with time (Robinson, 1963) and no
extensive tests were made to confirm this. However,
during each run one post-heparin sample was also
incubated for 30 min. The results were similar in
4 experiments (mean +_ SEM) : 28 +_ 5 and 26 _+ 2 u for
30 min and 60 min incubations respectively.
The effect of heparin
Samples were analysed from dogs before and after
the intravenous injection of 2 000U heparin. Therefore
the effect of additional heparin (10 u/7 ml reaction
mixture) was investigated. On average there was a
small, but insignificant increase (mean +_ S.E.M.):
11 _+ 14%(n=4) in post-heparin lipolytic activity.
The effect of serum activation
The addition of extra serum activator (+ 75%)
increased in3 out of 4 experiments the post-heparin
lipolytic activity:8 _+ 5% (mean +_ S.E.M.; n=4)„
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Discuss ion
The lipolytic activity is strongly influenced by the
substrate used in the assay (Riley and Robinson, 1974).
We have not used the physiological substrates chylomicrons
or VLDL triglycerides, but a stabilised triglyceride
emulsion (Intralipid). On the other hand it was exactly
the same Intralipid and not chylomicrons or VLDL tri¬
glycerides which was infused to serve as the substrate
of heparin-induced lipolytic activity.
Heparin also releases phospholipase activity (Vogel
and Bierman, 1965) and as Intralipid contains 1.2% (w/v)
lecithin, it is not clear to what extent lecithin and
plasma phospholipids were hydrolysed in vitro.
It is of course quite impossible to extrapolate from
the in vitro activity to the intact animal:
1. The activity was estimated at pH 8.31.
2. Incubations in vitro were carried out with excess
albumin to bind fatty acids released.
Dog plasma albumin concentrations are much lower than
observed in man, ranging from 25-35 g/1 (2.5-3.5%).
Thus in vivo, the fate of fatty acids originating from
hydrolysed triglycerides might be expected to play
(indirectly) a role in determining the overall enzyme
activity too. However the in vitro activity will indicate
the relative activities in vivo in a qualitative manner.
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2.2.7. The estimation of plasma triglyceride
concentrations
Principle;
Plasma triglyceride concentrations were determined
on plasma extracts in isopropanol using an automated
fluorimetric technique (Kessler and Lederer, 1966).
All chemical reactions were carried out using an
Autoanalyzer system (depicted in Fig 2.22), the
hydrolysis to free glycerol:
Triglycerides + KOH >free glycerol + K+ soaps
the oxidation of free glycerol:
glycerol + 2 NalO^ > 2 formaldehyde + formic acid + 2 NalO^
the condensation of formaldehyde to 3,5-diacety1-1,
4-dihydrolutidine (see Fig 2.23) using pentane-2,
4-dione 3, 5-diacety1-1, 4-dihydrolutidine is quantified
fluorimetrically.
The oxidation is specific for 2 cis hydroxyl
groups, as a result most carbohydrates will yield
formaldehyde. Therefore the extract must be purified
prior to analysis: carbohydrates (free glycerol,
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The sample line was changed each day.
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The CH2~group in the ring, opposite the =group
originates from formaldehyde.
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glucose etc) are removed by adsorption to CuSO^ and
phospholipids are adsorbed by zeolite (sodium
aluminium silicate).
Preparation of lipaemic plasma samples
Samples were collected in heparinised syringes as
described in Section 2.2.2. Plasma was obtained by
centrifugation in a cooled centrifuge for 10 min at
150 g. In hyperlipaemic samples part of the tri¬
glycerides were floating on the surface and were then
resuspended, using a glass rod and plasma was then
transferred, immediately extracted (see below).
Extraction and treatment with zeolite
A plasma sample (0.5 ml) was extracted into 9.5 ml
redistilled isopropanol using glass stoppered Quick
fit tubes. Zeolite (about 2 g, Harleco, Didcot, Berks.)
was added using a scoop, the tubes thoroughly mixed
on a Vortex and left overnight at 4°C. Zeolite was
then packed into a pellet by centrifugation (10 min
at 1 000 g) and the clear supernatant transferred to
another stoppered tube. Extracts were allowed to reach
room temperature before analysis using the Autoanalyzer.
Reagents
Isopropanol (Analar, British Drug Houses, Poole)
was redistilled prior to use. Pentane-2,4-dione obtained
from the same manufacturer was redistilled and the
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clear distillate was stored in a brown bottle at 4°C.
Even under these conditions it would slowly turn
yellow and then high baseline fluorescence was
observed. Therefore it was kept for about 1 month,
after which it was discarded.
The isopropanol/KOH mixture was prepared fresh:
5 g KOH in aqueous isopropanol, 75% (v/v).
For the analysis of blanks the KOH was omitted from
the KOH/isopropanol reagent. This did not influence
the final pH of the reaction mixture(flowcell effluent).
The sodium periodate reagent:
5.4 g sodium periodate,
115 ml glacial acetic acid (Analar, B.D.H.), made up
to 1 litre with double-distilled water.
Ammonium acetate 154 g/l adjusted with approx.
200 ml 2 moles/l HC1 to pH 6.0(stable for at least
1 month).
The pentanedione in ammonium acetate reagent
was prepared fresh daily: 65 ml of a mixture of
pentane-2,4-dione/isopropanol 15:50 (v/v) was added
to 1 litre ammonium acetate reagent.
Analysis of extracts using the Autoanalyzer
Under laboratory conditions a noticp.ble evaporation
of isopropanol was observed. Therefore samples were
loaded on sampling plates in small batches of 5 extracts
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(in duplicate), separated by drift standards. Standards
were analysed after every 40 extracts. They were loaded
in palindromic sequence to check on carry-over between
samples. Usually no carry-over was observed, but if
present the manifold was checked for bad connections
and/or bubble pattern,and changed. Provided the
precautions mentioned above were adhered to, no
corrections for drift were necessary.
Samples which exceeded the range of the standards
were diluted 1:1 with 95% isopropanol and reanalysed.
Analysis of blanks
For the analysis of blank values of unknown samples
the same extracts used for triglyceride analysis, were
reanalysed in an identical manner, except that the
KOH necessary for the hydrolysis step was omitted.
Calibration of the method
Standards made of triolein(99%+, Sigma, London)
in redistilled isopropanol were made and stored at
4°C.
The standards were 'extracted' and treated with
Zeolite after the addition of 0.5 ml double-distilled
water (in stead of plasma) in an identical manner as
was used for unknowns.
A representative graph is shown in Fig 2.24.
The graph was drawn on a transparent plastic comparator
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(Technicon, Basingstoke), which was then used to
convert peak heights of unknowns directly into
triglyceride concentrations.
The precision of the individual estimate
Precision of the method was determined using 7
individual extracts of a human quality control sample
(Technicon): mean +_ SD was 2.40 _+ 0.20 mmole/l
(CV=8.2%). These pools have a considerable amount of
free glycerol. Corrections were made for this, by
omitting the plasma triglyceride hydrolysis step.
The mean (+_ SD) plasma triglyceride concentration was
then: 1.82 +_ 0.03 mmole/l (CV =1.7%).
Specificity of the method
Despite the use of zeolite blank readings were
observed for certain quality control samples (with
unphysiologically high free glycerol concentrations)
and some dog samples, obtained after the injection of
Intralipid (stabilised with glycerol). However, if
results were corrected for blank readings, comparison
with an automated enzymic method(SMAC, Department of
Clinical Chemistry, The Royal Infirmary, Edinburgh)
were good, and the precision was also better. The
results suggest that in situations with high free
glycerol or glucose concentrations (Intralipid-heparin
studies, injection of glucose etc) zeolite adsorbs
in an irreproducible manner interfering carbohydrates
and individual corrections have to be made.
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SECTION 2.3:
ELECTROCARDIOGRAPHIC AND HAEMODYNAMIC MEASUREMENTS
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2.3.1. The recording of epicardial electrocardiograms (ECG)
Since the publication of Maroko et al (1971) ST -
segment elevation in epicardial ECG's has been widely
used as an index of ischaemic injury. The methods used
vary, mainly in the use of different exploring electrodes:
a looped metal wire (Opie et al, 1975); a steel ball
electrode (Smith, 1977) or cotton-wick electrodes
(Maroko et al, 1971; Kjekshus and Mj^s, 1973). More¬
over the different techniques appear not to have been
compared systematically. The same pragmatic approach
as other workers before us was adopted. The
acceptance criteria were that ECG's should be reproduc¬
ible and the technique did not irritate the myocardium:
e.g. induced ST-segment elevation in normal myocardium
or caused arrhythmias.
The cotton-wick fulfilled these criteria. Re¬
producible tracings were obtained if the electrode was
loosely held and allowed to move with the moist
surface of the heart. However ECG complexes were always
inspected immediately and recordings were repeated if
necessary.
The actual technique
The epicardial ECG was recorded using a cotton-wick
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electrode, according to the method of Maroko et al.
(1971). The cotton-wick electrode was constructed
using a piece of Autoanalyzer tube (length 5-7 cm,
diameter 2 mm). A U shaped thread of cotton was twisted
around the exposed metal of an insulated wire and pulled
through the tube. Only the cotton loop (wick) was
allowed to emerge. Good contact between the exposed
wick and the wire was ensured by storing the electrode
immersed in saline (0.9% w/v) until used.
The combined limb leads served as the reference
electrode (see Appendix A, Fig 1).
Location of epicardial sites: Ten-15 anatomically
well defined sites were selected within the area supplied
the
byycoronary artery to be occluded as well as in areas
remote from the occlusion (see Fig 2.25).Sites were at
least 1 cm away from the anterior descending coronary
artery where ECG changes due to conduction delay are
common. For each experiment a map was drawn showing
the selected sites in relation to the site of occlusion
and anatomical features.
The epicardial ECG's were recorded on a Devices M8
recorder with a sensitivity of 10 mV/cm and a paper
speed of 25 mm/s. Recording of all 10-15 sites took
about 1 min. Unless otherwise specified, recordings
were made immediately before the start of infusion of
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Figure 2.25. Monitoring of epicardial electrocardiogram:
Selected sites in relation to local anatomy
A schematic representation of the selected sites used
for the recording of epicardial electrocardiograms.
The ischaemic myocardium is indicated by the hatched
area. The numbers relate to the sites in the sequence
which was used during the epicardial ECG mapping.
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drugs, and prior to, and at 5, 10 and 15 min of coronary
occlusion.
ST-segment elevation was determined at mid ST-
segment and the exact point was marked on each complex
using a divider. The average of 4-6 ECG complexes
recorded from each site was calculated. The results
were expressed as ischaemia induced st-segment elevation
and the values for all sites were summed (Est ). £st
was used as an estimate of the severity of myocardial
ischaemia (Maroko et al, 1971).
The evaluation of the results was time consuming,
and because of its nature observer bias could possibly
affect the results. Added to this was the relatively
long time required to make the recordings (1 min) during
a period of ischaemia of not more than 15 min. Al¬
ternative methods devoid of these problems were con¬
sidered. The solution was found in a 10-16 lead
epicardial grid and an electronic averaging device (see
Appendix A, Figure 2 ), which allowed continuous monit¬
oring of mean ST-segment elevation.
The epicardial grid was made of thin latex rubber
with a suture ring made of gauze. Silver electrodes
(diameter 4 mm) soldered to 36 Swg insulated copper wire,
were glued to the grid using latex rubber. The grid
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is positioned loosely over the area within the dis¬
tribution of the coronary artery to be occluded. It
is secured with 3-4 stitches (4-0 silk) well outside
the area of interest.
The leads are connected to a 16 lead selection box.
The right leg electrode served as the earth lead and
the combined right and left front leg (RA, LA) and the
left hind leg (LL) were used as the reference electrode
(see Appendix A, Figure 2 ). During the experiment
only those leads, showing ST segment elevation during
S "t
the 1 coronary occlusion, were selected for the com¬
putation of mean ST segment elevation. During the rest
of the experiment the validity of this assumption was
regularly checked for all selected leads. Correction
was made for ST-segment depression, if necessary.
This system proved adequate and superior to the
above described manual technique since it offered con¬
tinuous information, less time required for evaluation
of results, and elimination of observer bias. However,
the basic information of a particular individual lead
was lost. Transient changes in some of the leads might
have gone undiscovered. Only continuous sampling of
all leads would overcome this problem and was thought to
lead to the insight required to decide whether recording
of averaged ECG would always give the right answer.
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This led to the development of a multiplexer system.
In the multiplexer each of the fifteen epicardial
signals is amplified and then they are arranged into
three groups of five, i.e. channels 1-5, 6-10, 11-15,
The five channels in each group are then sequentially
sampled at a rate of 300 samples/second/channel. The
three time division multiplexed data channels along with
the synchronizing pulse channel are recorded on a four
channel F.M. tape recorder running at 15"/second, the
bandwidth and track configuration of this recorder
dictating to a large extent the design of the complete
system. The magnetic tape was replayed and decoded.
ST-segment elevation was computed using a purpose built
ST-segment computer (Neilson et al, 1968) and recorded
on a Devices M4 recorder with a sensitivity of 1 or 2
mV/cm. ST-segment elevation was calculated at
70 ms after the onset of the QRS complex (Appendix A, Fig 3).
The early method of recording epicardial ECG's
(Phase 1) should be considered essentially relative to
one another within a particular experiment. The reason
for this is the lack of input resistors for the limb
leads. (Appendix A, Fig 1A) . Thus the exact signal
obtained would be dependent on the resistance of the
individual limb leads, which might have varied from
experiment to experiment, depending on the actual contacts
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made. However as the limb electrodes were intra¬
muscular, variations in input resistance of the limb
leads within an experiment seem unlikely.
This problem was rectified by a modification to the
attenuator box (Phase 2).
Epicardial ST-segment elevation reflects the severity
of experimentally induced myocardial ischaemia (Wegria et
al, 1949; Kjekshus et al, 1972; Smith, 1977) and correlates
with the local reduction in myocardial oxygen tension
produced by coronary artery occlusion (Angell et al,
1975).
However ST-segment elevation is an index of myocardial
ischaemic injury, and its limitations, particularly when
precordial mapping in man is used have been reviewed
(Ross, 1976). The technique cannot be used when marked
conduction delay is present (Muller et al, 1975), as




Arterial blood pressure was measured from a catheter
introduced into a femoral artery. A Statham pressure
transducer (P23Db) calibrated using a mercury manometer
was used. Airbubbles were carefully excluded. The
cannula was kept patent by intermittent flushing with
saline. Heparin was not used, except in heparinised
animals when the cannula was filled with heparinised
saline 5 U/ml.
The signal from the transducer was amplified using
a Devices direct-coupled DC2 amplifier and recorded on
a Devices M 8 recorder, with a sensitivity of 5 mm Hg/mm.
The overall frequency response of the system was
flat within 5% at 40 Hz and is mainly determined by the
response of the heated stylus, which was determined
using a sinusoidal wave form of fixed amplitude,
generated by a wave generator (Wavetek, Model 112).
In the colaborative studies with Dr. H. Vik-Mo and
Prof. O.D. M j/>s , University of Troms/, as well as in
those with Dr. A. Ungar, Department of Pharmacology,
University of Edinburgh, it was also possible to measure
left ventricular pressure and its first derivative
(dP/dt). A short cannula was inserted into the left
ventricle through the dimple of the apex and directly
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connected to the pressure transducer (a Statham P23Gb
in Troms/; a L223 (Consolidated Electro dynamics,
England) in Edinburgh). The left ventricular pressure
and its first derivative were recorded in Troms/ on
a Dynograph recorder and Edinburgh on a UV-recorder
(Honeywell Ltd, Holytown). In Edinburgh the frequency
response of the overall system was also flat within
5% at 40 Hz.
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SECTION 2.4:
THE MEASUREMENT OF REGIONAL MYOCARDIAL BLOOD FLOW
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2.4. The measurement of regional myocardial blood flow
Introduction
Accurate knowledge of regional myocardial blood flow
in the non-ischaemic and ischaemic area is a keystone
in the interpretation of the effect which enhanced
glucose availability, or decreased fatty acid utilisation
has on the severity of myocardial ischaemia.
Essentially two methods are most frequently used
for the determination of regional (myocardial) blood flow.
In the first, the initial uptake of a diffusible, flow-
limited tracer is followed after a bolus injection,
and measured before the onset of the wash-out phase.
Without going into details of the problems of this method,
it can be said that this method has a limited range of
applications, due to the fact that the heart has to be
excised shortly after the injection during the wash-
in phase. This restricts the method to one observation
per experiment.
The principle of the microsphere method is not all
that different: the distribution of a non-diffusible
tracer (microsphere) in a region or an organ after an
arterial injection is determined by flow. However there
is one essential difference and that is that unlike the
diffusible tracer the microsphere with a diameter of
15 ll becomes lodged during its first transit in the
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precapillary bed. It is therefore not necessary to
excise the heart immediately and provided different
labels for microspheres are used for successive
injections several determinations can be made.




The adopted procedure is based on the method of
Utley et al (1974) .
The characteristics of the microspheres used are
summarised in Table 2.11.
6
Prior to injection 1.5 - 3.0 x 10 microspheres
were subjected to ultrasound in 10% dextran for 5-10 min
to dispel aggregates (Dawe Sonicleaner, type 6441A),
and drawn into a syringe containing 0.1 mg 5% (v/v)
Tween-80 in saline (9 g/l) to prevent reaggregation.
The suspension was diluted with 10% dextran to give a
final concentration of Tween-80 of less than 0.5% (v/v).
A small air bubble was taken into the syringe, allowing
continuous agitation until injected.
Ten seconds prior to the injection of the micro¬
spheres withdrawal of femoral arterial blood for the
estimation of reference blood flow (RBF) was commenced.
Reference blood was collected into a weighed heparinized
syringe at a constant rate (approximate 9 ml/min) for




Characteristics of the radioactive microspheres
Manufacturers: 3M; NE|\|
General properties Carbonized microspheres;
Nominal diameter 15 +_ 3 p(Mean +_ SD)
Nominal specific activity: 10 mCi/g

























































* contained free Co++, washed before use.
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The microspheres were injected through a left atrial
cannula over a period of about 10 sec, and flushed with
5 ml 10% Dextran.
It was observed that despite the Dextran flush, some
microspheres were left behind in the tap and/or the Luer-
lock connection of the cannula. Therefore the tap was
replaced after microspheres had been removed from the
connector. Not more than 4 injections were made per
experiment.
Between 5 and 30 min after the last injection the dog
was sacrificed with sodium pentobarbitone. The heart was
excised, the free wall of the left ventricle dissected
out, and visual fat and large vessels removed.
Full thickness biopsies (10-20) were made and divided
into epicardial and endocardial layers by mid-line
transsection. (This was easier if the heart was allowed
to go into rigor mortis overnight and this was adopted
generally. The heart was stored in a closed, moist
chamber at 4°C to prevent dehydration.)
The epicardial and endocardial layers were transferred
to a plastic tube (18 x 63 mm, Ravens, Haverhill,
Suffolk, when the Gamma Guard; and 15 x 950 mm when the
Wallac gamma counter was used). The layers were divided
into 10-20 blocks to produce relatively constant
geometrical factors for the measurement of radioactivity.
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2.4.2-, The measurement of radioactivity
The radioactivity was originally measured using a
three channel gamma counter (Gamma Guard, Tracerlab Inc.,
USA), equipped with a three inch Nal crystal. The
counting times ranged from 100 - 600 sec and were
approximated to yield 10 000 counts in samples with
low counting rates. The windows were selected so that no
isotope contributed in a significant degree (less than
0.1%) to an energy window, selected for an isotope with
(Table2.12)
a higher energy/ This was an essential condition to
allow the calculation of the results (see Calculations).
The contribution of the isotopes was determined at
the start of each counting procedure using the reference
blood samples as standards in a similar geometrical
setting. The underlying assumption of this is that only
the one isotope, injected during the collection of the
reference blood sample is present, and that no microspheres
from the previous injection recirculate.
This was checked on a few occasions by placing a
shielded counter over the withdrawal line before and
during a 5 min collection of arterial blood in an
otherwise identical manner as for the collection of
reference blood. The results showed that most microspheres
had been removed from the arterial blood l\ min after
injection, and possibly very few were circulating for
219
Table 2 .12
Selected energy windows (Gamma Guard)
Relative contribution to channel
Isotope Window (keV) t125 Ce141 Yb169 c 85Sr
I125 25 47.5 • oo 0.001 0.001 0.001
Ce141 122.5 - 152 .5 0.03 1.00 0.001 0.001
Yb169 180 310 N.D. 0.20 • Oo 0.001
Sr85 480 620 0.09 0.27 0.35 1 .00
N.D. Not determined, combination not used.
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another •§•-§ min.
It has also been checked by bleeding and collection
of blood into a donor bag at least 30 min after the
last injection of microspheres. Using the whole body
counter (Department of Medical Physics, The Royal In¬
firmary, Edinburgh), only background counts were ob¬
tained .
Later the Gamma Guard could no longer be used due
to mechanical fault in the sample changer. Radio¬
activity was then analysed using a two channel gamma
counter (Wallac, 80 OOO Gamma sample counter, LKB-Wallac,
Finland), equipped with a two inch Nal crystal. Samples
were counted in 2 cycles if necessary. The results
were printed on a paper tape. For selected windows
see Table 2.13.
Electronic stability of the gamma counters
The gamma counters were checked for stability over
periods similar to those used for the counting of
samples. For this a mixed source containing 3 isotopes:
113 85 95
Sn , Sr and Nb was repeatedly (46 times) counted.
The variability of the count rates was almost identical
to the theoretically predicted values. Thus the stability
of the counters has a small effect on the accuracy of
the count rates, if anything.
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Table 2.13
Selected energy windows (Wallac)
Relative contribution to channel*













Ru 470-560 0.21 0.10 1.00 0.00
GroupIV:
Nb 670-850 0.13 0.23 0.22 1.00
Sc46 650-1200
*Approximate values for groups I, III and IV.
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2.4.3. Calculation of regional myocardial blood flow
In the early experiments, using the Gamma Guard,
windows were selected to avoid contributions of an
isotope with a low energy to a channel selected for
an isotope with a higher energy. Thus the channel
of the isotope with the highest energy was free from
interference by other isotopes. The net count rate
of the lower energy channels was obtained after
stepwise correction for the contributing counts,
originating from isotopes with a higher energy. When
the Wallac was used the contribution of isotopes to
a higher channel was not zero and the stepwise correction
could not be applied. The net count rates of the 4
channels were computed by solving 4 simultaneous
equations, each describing the respective contributions
of the 4 isotopes to a particular channel.
These equations were solved using
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a computer programme (Gelg, I.B.M.-mathematical package).
Regional myocardial blood flow (MBF) was calculated for
each biopsy using the formula:
CM
MBF = x RBF, where MBF is expressed in ml blood
g . min-"'". CM is the biopsy radioactivity in cpm/g
wet weight, CR is the total cpm in the reference blood
sample. Reference blood flow (RBF) was calculated from
the weight and timing of the reference blood collection,
using an assumed blood specific gravity of 1.05 g/ml.
Correct ions
Corrections for decay during counting procedures
were not made. It can be theoretically shown that even
141 95
for Ce and Nb (with the shortest half lives of
32 and 35 days) inaccuracies in counting rate due to
decay do not exceed 0.7%; for other isotopes Sr^^, Sc4^,
this is <0.4% (total counting time 10 hours).
The errors in the calculation of contributing factors
of one isotope to other channels due to decay are of the
same order of magnitude.
The influence of geometrical factors on the estimation
of radioactivity was explored by Dr P.Tothill, Department
of Medical Physics, The Royal Infirmary, Edinburgh.
Using the same counter (Wallac) and sample tube, he studied
the height corrections for the counting of two isotopes
(in the extremes of the energy range we were using
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_ 57 , _ 46,
Co and Sc ).
- It was found that the counting efficiency was height
dependent.
- The relation between height and efficiency was dependent
46
on the selection of the enery windows. E.g. Sc
counting was more sensitive to variations in height in
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its own window than in the window selected for Co
(see Appendix B-l ). In view of the complexity of this
problem it is not possible to use simple height correction
factors. Besides it was found that the corrections were
small in our working range 1-3 cm and therefore corrections
were not made.
The calculations described above were made using a
computer programme written by Dr J.O'Brien for a desk¬
top computer (Advanced programmable calculator 700B,
Wang Laboratories Inc., Mass.) or a Fortran programme
(see Appendix B-^ written by Dr K.Boardman for the
PDP-12. The former was used for the data obtained using
the Gamma Guard and the latter using the data on a paper
tape from the Wallac.
2.4.4. The reproducibility of the method
The reproducibility oT the method was checked in
4 experiments. Physiological variation in coronary blood
flow as a cause of variability in regional myocardial
blood flow was excluded by a simultaneous injection of
1.5 x 10 microspheres labelled with 3 different isotopes
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z„ 57 103 46. T . . , .(Co , Ru , Sc ). In one experiment a 4th isotope
113
(Sn ) could be injected as well. The left atrial
injection was made 5 min after coronary artery occlusion,
made to reproduce the conditions under which microspheres
are normally injected. In addition this would ensure
that the reproducibility of the method could be checked
over a range of regional myocardial blood flows. The
influence of the reference blood flow determination
was studied by two simultaneous collections of reference
blood from the left and the right femoral artery
using the same Harvard withdrawal pump (9 ml/min).
The myocardial biopsies (endocardial and epicardial)
were taken as described above. Three sets of (4) artificial
standards containing one isotope only were made and the
breakthrough of the isotopes into other energy windows
determined. The net radioactivity (per isotope) of the
real reference blood samples collected during the
experiment was then calculated using the Fortran
programme (described above), and they were used to
calculate the regional myocardial blood flow.
The mean results (+_ SEM) obtained from epicardial and
endocardial layers of the normal border and ischaemic
area as determined by Co~^ (Sn^^ 1 experiment), Ru^^
46
and Sc labelled microspheres are tabulated in Appendix B-3.
The reference sample which was used for the calculation
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is referred to as A and B.
The data of one particular experiment (1A, IB,
2A, etc) was analysed using paired analysis. Highly
significant differences between the determinations with
two isotopes were found in most cases (19 out of 24
possible combinations). Only in 1 experiment (4B) was
there no significant difference between the measurements
obtained with the three isotopes. However there was no
systematic difference between blood flow determination
made with the different isotopes .
Thus as an example in experiment 1A the highest flow was
46
determined with Sc ~ microspheres and using the same
tissue but a different reference blood sample (B) the
highest flow was estimated with microspheres labelled
. .. _ 103
with Ru
The average of the mean data of the 4 experiments
, . . , , _ 57 103 , „ 46 . ,
as determined by Co , Ru and Sc microspheres are
the same: 0.918; 0.890 and 0.888 ml g ^ min-"'". (p^0.05,
paired t - test). The individual results obtained with
the various microspheres were inspected graphically and
a representative example is given in Fig 2.26 A/b,
„ 57 _ 103 .
Co vs Ru microspheres.
These graphs underline the importance of the reference
blood sample in the determination of regional myocardial
blood flow. E.g. when the results were calculated on the
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Figure 2.26 A. Determination of myocardial blood flow (MBF):
The reproducibility of the method
.ft
0.00 .25 .50 ,7«
\'S
1.50 1.75 2.00 2.25
MBF (ml mln'M
The reproducibility of the determination of regional
myocardial blood flow in epi- and endocardial layers
of the ischaemic and non-ischaemic area of the left
ventricle was determined 5 min after coronary occlusion
using a simultaneous injection of different micros¬
pheres (Co57, Ru-^3 and Sc45) in 4 experiments.
Results based on reference blood sample A.
On the abscissa: MBF determined with Co57 microspheres.
On the ordinate: MBF determined with Ru3*33 microspheres.
The calculated, dotted line is:
y = 0.065 + 0.872 x (r = 0.992, n = 144, P < 0.001)
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Figure 2.26 B. Determination of myocardial blood flow (MBF):
The reproducibility of the method
y;
I.on .25 .50 • .75 1.25 1.50 1.75
MBF (ml f mln" )
Details as in Figure 2.26 A.
Results based on reference blood sample B.
The calculated, dotted line is:
y = -O.042 + 1.038 x (r = 0.993, n = 144, P < O.OOl)
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basis of reference blood sample A regional myocardial
57
blood was underestimated with Co microspheres (Fig 2.26
A), but not if reference blood sample B was used (Fig 2.26
B).On close inspection of the data it was observed that
this error was mainly due to the results of experiment
1, in which myocardial blood flow in the non-ischaemic
myocardium was high. Nevertheless it is worrying that
the discrepancy between the relative amount of different
microspheres in simultaneously withdrawn reference blood
samples can (occasionally) be as large as was observed.
A separate statistical analysis was made of the blood
flow obtained from epi-and endocardial samples taken
from the border and ischaemic zone. (In experiment 4
myocardial blood flow was low and the effect of coronary
artery occlusion was hardly detectable. For this reason
it was excluded for this analysis.) The mean results
_+ SEM are tabulated in Appendix B-4 and show in agreement
with the overall data that no systematic effects were
operative. The results were also graphically examined
and an example (Co~^ vs Ru^^ microspheres) is presented
in Fig 2.27.
Finally the endocardial/epicardial ratios of regional
myocardial blood flow were also analysed using paired
t-tests. (Only one estimate per experiment is obtained,
since in this ratio the radioactivity and the weight of
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Figure 2.27 .Determination of myocardial blood flow (MBF):
The reproducibility of the method, applied to
ischaemic and border zone
MBF
0.00 .20 .40 .60 .80 1.00 1.20 1.40 1.60 1.80
MBF (ml g"1 mln*1)
The reproducibility of the determination of regional myo¬
cardial blood flow in epi- and endocardial layers of the
ischaemic and border zone was determined 5 min after
coronary occlusion using a simultaneous injection of differ¬
ent microspheres (Co^7j pu103 and Sc46 ) in 4 experiments.
On the abscissa- : MBF determined with Co*^ microspheres.
On the ordinate : MBF determined with Ru^0^ microspheres.
The calculated, dotted line is :
y = -0.020 + 1.009 x (r = 0.983, n = 88, P < 0.001).
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the reference blood sample drop out as can be seen in
the MFB equation on page 223).
The results of the overall data (normal plus ischaemic
tissues) are tabulated in Appendix B-5and an example
of a typical correlation is presented in Fig 2.23.
The results of the ischaemic and border zone biopsies
are similar (Appendix B-6 and Fig 2.29).
In one study (experiment 3 ) the difference in
duplicate estimation of regional myocardial blood flow
(expressed as a percentage of the mean result) was
analysed and related to the weight of the biopsy.
Comparing the data from all tissues (ischaemic plus
non-ischaemic) as well as those of non-ischaemic biopsies
only no significant correlation was found (see Fig 2.30).
This and the above data show that there is no
systematic error in the method of blood flow determination
with differently labelled microspheres (Co~^, Ru^^,Sc4^)
or their endo-epicardial distribution; as could be
operative due to differences in geometrical factors
and/or decay during counting. There was a wide range
of isotope \ lives and energies of the gamma rays,
suggesting that within these boundaries with similar
isotopes these results may be considered as universal.
The biggest source of variability is the composition
of the reference blood sample. We used left atrial
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Figure2 .28.Determination of endo-/epicardial ratio of
regional myocardial blood flow (MBF):
Reproducibility of the method
Vi




The reproducibility of the method was checked in 4 experi¬
ments. The ratio of regional myocardial blood flow in epi-
and endocardial biopsies of the ischaemic and non-ischaemic
areas of the left ventricle was determined 5 min after
coronary occlusion with a simultaneous injection of differ¬
ent microspheres (Co57, Ru1<55, Sc45) .
On the abscissa : Endo-/epi ratio of MBF measured with Coj7
microspheres; on the ordinate determined with Ru103 labelled
spheres.
The calculated, dotted line is : y = 0.0264 + 0.962 x
(r = 0.976, n = 71, P < O.OOl)
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Figure 2.29. Determination of endo-/epicardial ratio of
regional myocardial blood flow (MBF): The
reproducibility of the method, applied to
the ischaemic and border zone
MBF
Endo/epl RATIO
.60 .80 1.0i 1.20 1.40 1.60 1.80
MBF Eado/«pl RATIO
Ischaemic and border zone biopsies only.
Details as in Figure 2.28.
The calculated dotted line is:
y = 0.049 + 0.890 x (r = 0.987, n = 20, P < 0.001)
Note that some endo-/epicardial ratios of MBF > 1
due to a reduction in epicardial, but not endocardial
MBF (border zone).
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Figure 2.30. Determination of myocardial blood flow:
Relative error between duplicate deter¬
mination with different microspheres








Regional myocardial blood flow was estimated using a
simultaneous injection of different microspheres (Co57,
Rul03, Sc46 ).
The error between duplicate determina¬
tion of regional blood flow in non-i§chaemic myocardium
was calculated from the Co^ and Sc4° microsphere data,
selected to obtain the maximal difference in gamma energy
used in our experiments. No significant correlation
was found between the relative error between duplicate
estimation, expressed relative to the mean and the weight
of the biopsy. (r = 0.345, dotted line, n = 20, NS).
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injections as suggested by Kaihara et al (1968) to
ensure adequate mixing, but despite this streaming
of microspheres in the aorta must have occurred
(Phibbs et al, 1967).
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SECTION 2 .5 :
THE USE OF ENZYME RELEASE IN THE ASSESSMENT OF
SEVERITY OF MYOCARDIAL ISCHAEMIA
237
2.5.1. Biochemical assessment of severity of myocardial
ischaemia
It is well established that myocardial proteins and
enzymes (myoglobin, creatine kinase, lactate dehydrogenase
etc) are released from the infarcting myocardium into
the circulation during acute myocardial infarction.
The plasma activity ofcreatine kinase (CK) and its
MB isoenzyme (CK-MB), which is more cardiospecific,
are the first to increase significantly at about 4-6
hours after the onset of symptoms. These enzyme tests
are therefore commonly used for the confirmation of
a clinical diagnosis of myocardial infarction. Plasma
CK-MB activity seems to be a particularly sensitive
and specific index of myocardial infarction (Varat
et al, 1975; Galen et al, 1975; Smith et al, 1976).
Therefore the use of CK release, in addition to
electrocardiographic evidence, as an index of severity
of myocardial ischaemia was considered. In a model of
intermittent coronary artery occlusion this could be
done by measurement of myocardial CK activity in
successive biopsies or alternatively by estimation
of the CK release into the venous effluent of the
ischaemic myocardium (by measurement of the arterio¬
venous difference of plasma CK).
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There were likely to be difficulties with the first
procedures since it is conceivable that repeated
biopsies might have deleterious effects on the model,
It would also be difficult to quantify CK loss against
the high background of myocardial CK activity. On the
other hand, local venous catheters draining the ischaemic
area were used and therefore estimation of CK activity
in the effluent from the ischaemic area seemed to be
the better approach. However plasma CK activity might
become raised in the open-chest model due to release
from skeletal muscle cut during the operation, rather
than from the myocardium. We had no data on this,
although it is recognised that surgical operations
are associated with a rise in plasma CK activity
(Schmidt and Schmidt, 1976). Since skeletal muscle
contains predominantly CK-MM, with little or no CK-MB,
it was hoped to overcome this problem by the use of
isoenzyme studies.
While setting up the electrophoretic method for the
separation and quantification of CK isoenzymes, it
was reported that dog myocardium had little or no
CK-MB (Yasmineh et al, 1975; Ahmed et al, 1976). The
following experiments were performed in order to
verify these findings.
Samples of myocardium were obtained from 5 dogs.
A 10% (w/v)myocardial homogenate in 10% (w/v) sucrose
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plus 2 mmole/l glutathione was prepared using a Douce-
Potter homogeniser (Unicorn, Hemel-Hempstead). The
heart and homogenates were kept on ice throughout.
The CK isoenzymes were quantitated by electro¬
phoresis on agarose films (Corning Eel, Halstead,
Essex) followed by visualisation of the separated
isoenzymes (Wong and Smith, 1975). A fresh 1:50 dilution
of the homogenates was made, and 1 jal applied to the
film. After electrophoresis, the CK isoenzymes were
visualised by the following reaction sequence:
ADP + creatine phosphate ^ >ATP + creatine
ATP + glucose * ADP + glucose-6-phosphate
glucose-6-phosphate + NADP+ -^NADPH + H + + 6-phosphogluconate
NADPH fluorescence was used for the visualisation and
quantification of the isoenzyme bands with a Vitatron
TLD 100 densitometer (Fisons Scientific Apparatus,
Loughborough).
In agreement with the reports mentioned above,
a small percentage ranging from 0-1.2% of CK-MB was
found. A representative photograph taken of the
fluorescent bands is shown in Fig 2.31. The photograph
was deliberately over-exposed to show up the faint
MB isoenzyme bands present. A similar photograph
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Figure 2.31. The occurrence of creatine kinase iso-
enzymes in canine myocardium
CANINE MYOCARDIUM HUMAN CK
Creatine kinase isoenzymes from dog myocardium were
separated electrophoretically using agarose sheets.
A homogenate sample, equivalent to 10 pg tissue was
applied. The isoenzyme bands were visualised using
an enzymatic staining procedure yielding NADPH.
Top: Anode Bot|om: Cathode
The isoenzyme bands of three homogenates, prepared
from 2 hearts 554 and 555 (biopsy A and B) are shown.
For comparison a similar photograph of purified human
CK-MB and CK-MM (at the origin) after electrophoresis
is mounted to the right. Note a barely detectable
CK-MB band in the canine samples (photo deliberately
overexposed).
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(kindly made available by Dr A.F.Smith, Department of
Clinical Chemistry, The Royal Infirmary, Edinburgh)
mounted to the right shows the fluorescent bands of
purified human CK-MM (on the origin) and CK-MB.
In view of small amounts of CK-MB in dog myocardium
it was decided to measure total plasma CK activity.
Creatine kinase activity was determined using the method
of Rosalki (1967). Measurements were made in the
Department of Clinical Chemistry, The Royal Infirmary,
by arrangement with Dr A.F.Smith. The coefficient of
variation of this method is 6-7% for samples with
plasma CK activity in the range 100-1 000 iu/l.
The effect of surgery on femoral arterial plasma
CK activity was studied in 8 anaesthetized dogs.
Samples were collected at frequent intervals (at least
\ hourly) throughout the experiment. Arterial plasma
CK activity rose continuously from 311 +_ 91 I.U./l at
about 30 min after completion of the surgical procedures
to 600— 1 500 I.U./l 3-| to 4-| hours later.
In the same experiments the effect of the first
coronary artery occlusion on myocardial CK release
was studied. Arterial, coronary sinus and local venous
blood samples were taken simultaneously immediately
before and at 6-10 min after occlusion. No sham occlusion
was made. The results are expressed as the difference
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between arterial and coronary sinus (draining pre¬
dominantly non-ischaemic myocardium) or arterial and
local venous (draining ischaemic myocardium) plasma
CK activities.
Prior to coronary artery occlusion no CK release
could be demonstrated: both the arterio-coronary sinus
and the arterio-local venous difference of plasma CK
activity were positive and undistinguishable from each
other using a Wilcoxon paired ranktest Table 2.14, (P> 0.05).
However during the occlusion the plasma CK activity
in the effluent from ischaemic myocardium did exceed
the arterial CK activity: resulting in a negative
ar ter io-venous difference of -57 _+ 16 I«U./l. This
gradient across the ischaemic area was significantly
different from the one observed before the occlusion
(p<0.01) (Wilcoxon paired-rank test). Although the
arterio-coronary sinus difference of plasma CK activity
also became negative (-28 +_ 13 I.U./l), it was not
significantly different from the arterio-coronary
sinus difference measured prior to the occlusion
(control).
These results suggest that CK may be released
from ischaemic myocardial cells, before irreversible
damage can be demonstrated histochemically - usually
after 20-30 min of occlusion (Jennings et al, 1969).
Table2.14 Theeffectofxperimentalcoro ryocclusion(6-10mi )nart rio-v ous differencesofc atinekinasac vity(M _+S.E.M.) Differenceinplasma creatinekinasac vity(I.U./l)= arterio-localv nous arterio-coronarysinusControl 10+_ 31+24
Occlusion -57 _+16* -28+13
Pvaluefrom Control** <0.01 N.S.
to
UJ
**ApairedWilcoxonr nktestwasus(onilv lue). *p=0.025vsarterio-coronarysinusdifference(Occlusion).
244
Alternatively it is possible to explain the negative
arterio-venous difference of CK activity in^terms of
transfer of plasma water into damaged cells.
Whatever the explanation may be, it was evident
that a precise estimation of CK release could not be
obtained in this model, and this approach was abandoned.
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Part 3
THE EFFECTS OP REDUCTION OF PLASMA CONCENTRATIONS OP
FREE PATTY ACIDS ON MYOCARDIAL METABOLISM AND ST-




In order to test the hypothesis, which is the basis
of this thesis, that fatty acid and glucose metabolism
affect the severity of myocardial ischaemic injury,
the effects of altering myocardial metabolism are ex¬
amined. This part of the thesis is confined to the
effect of reducing plasma free fatty acid concentrations
on ischaemic myocardial metabolism, and will be related
to changes in ischaemia-induced ST-segment elevation in
epicardial electrocardiograms. As a tool to lower
plasma concentrations of free fatty acids, a series of
drugs were used. Their effect was studied under basal
conditions and during stimulation of adipose tissue
lipolysis using isoprenaline infusion. The effect of







The selection of each drug was not solely based on
their ability to lower plasma concentrations of free
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fatty acids, and the reasons will be given in each







Substantial reductions in plasma concentrations of
free fatty acids have been reported in animals treated with
the active metabolite of clofibrate: p-chlorophenoxyiso¬
butyrate (Barrett and Thorp, 1968; Cenedella et al, 1968),
although it is not known whether this is accompanied by a
reduction in the utilisation of free fatty acids by the
myocardium (Thorp, 1973).
The effect of p-chlorophenoxyisobutyrate on the ex¬
traction of plasma free fatty acids by the heart and
magnitude of epicardial ST-segment elevation during experi¬
mental coronary artery occlusion in dogs was examined. The
effect of this antilipolytic drug on regional myocardial
blood flow during coronary artery occlusion was also in¬
vestigated, with the aid of microspheres.
We were interested in the effect of this active metabolite
of clofibrate, since it might be relevant to the acute phase





Experiments were carried out in 23 mongrel dogs
of both sexes (15-20 kg body weight), fasted for 12-15
hours, as described in Part 2 (Section 2.1) of this
thesis.
Regional Myocardial Blood Flow
Regional myocardial blood flow was measured by
means of radioactive microspheres as described in
Section 2.4.
Biochemical analyses
Blood samples were collected 15 min after each occlusion
and processed as described in Section 2.2.2.
Plasma concentrations of p-chlorophenoxyisobutyrate
were kindly analysed by Dr. Thorp, ICI Pharmaceuticals Div.,
Alderley Edge, Manchester, using a spectrophotometric method
(Barrett and Thorp, 1968). Plasma concentrations of free
fatty acids were assayed in duplicate by the titrimetric
method of Trout et al (1960), as described in Section 2.2.2.
Corrections for the presence of p-chlorophenoxyisobutyrate,
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which interferes in the titrimetric method, were made
according to Barrett and Thorp (1968). Plasma free glycerol
were determined in duplicate on deproteinised samples,
prepared by ultrafiltration ,using the fluorimetric enzymic
method described in Section 2.2.4.
3.1.2. Experimental design
Effects of pretreatment with p-chlorophenoxyisobutyrate
on subsequent coronary artery occlusion
The effect of pretreatment with p-chlorophenoxyiso¬
butyrate on plasma free fatty acid concentrations and on
the ST-segment elevation during subsequent coronary artery
occlusion was studied in 10 dogs. In 7 animals the basic
procedure of 4 intermittent periods of ischaemia (each of
15 min duration), separated by a recovery period of at
least 30 min was used (see Fig. 2 .02). After the recovery
period of the second control occlusion (in the presence
of isoprenaline (0.2-0.3 pg/kg/min)) p-chlorophenoxyiso¬
butyrate was administered as the sodium salt by slow
intravenous injection in 0.9% (w/v) saline at the dose of
20 mg/kg body weight. Thirty minutes later the two test
occlusions were made at first in the absence and then in
the presence of isoprenaline.
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In the remaining 3 dogs (307, 309 and 313) studies
were carried out either in the absence or presence of
isoprenaline only.
In five additional dogs the effect of p-chlorophenoxy-
isobutyrate on regional myocardial blood flow during
coronary artery occlusion was assessed. Measurements were
made during an initial control occlusion (in 3 dogs only),
during a second occlusion in the presence of isoprenaline
and during a third occlusion performed in the presence of
isoprenaline 30 min after the intravenous injection of
p-chlorophenoxyisobutyrate. The effect of p-chlorophenoxy-
isobutyrate on myocardial blood flow was assessed in the
presence of isoprenaline, rather than under basal con¬
ditions, since it had previously been found that the re¬
duction in epicardial ST-segment elevation by p-chloro-
phenoxyisobutyrate was more marked in the former situation.
Effects of p-chlorophenoxyisobutyrate administration during
established coronary artery occlusion
In six dogs an i.v. infusion of isoprenaline (0.2-
0.3 jj.g/kg/min) was maintained for the duration of the study.
Five minutes after its commencement a branch of the left
anterior descending coronary artery was permanently occluded.
Five and ten minutes later recordings were made of epi¬
cardial electrocardiograms, aortic blood pressure and heart
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rate. p-Chlorophenoxyisobutyrate was then administer¬
ed as previously described, and the recordings repeated
after further intervals of 5 and 10 minutes. Simulta¬
neously with each recording, arterial blood was sampled
for the measurement of plasma free fatty acids, drug levels
and free glycerol concentrations. In five of these dogs,
and in an additional two animals, coronary sinus blood was
also sampled immediately before and ten minutes after
p-chlorophenoxyisobutyrate administration for the deter¬
mination of the arterial-coronary sinus concentration
differences of plasma free fatty acids.
Statistics
Each dog served as its own control. Student's t-test
for paired data was used to calculate probability values.
P>0.05 was regarded as not statistically significant.
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3.1.3. Results
Effects of pretreatment with p-chlorophenoxyisobutyrate
The effects of p-chlorophenoxyisobutyrate on the response
to subsequent coronary occlusion are summarised in Tables
3.01 and 3.02. Occlusion of a branch of the left anterior
descending coronary artery was followed by marked changes
in epicardial ST-segments. After 15 minutes of occlusion
ZST averaged 26i 6 mV (mean - SEM). After p-chlorophenoxy¬
isobutyrate administration re-occlusion of the artery re¬
sulted in a much smaller ZST, averaging 14 ± 3 mV (P < 0.03).
p-Chlorophenoxyisobutyrate also reduced the number of sites
with evidence of ischaemic injury (ST > 2 mV) from an
average of 4.9 ^ 1.1 to 2.9 - 1.0 (P < 0.05). These
effects of p-chlorophenoxyisobutyrate occurred in the ab¬
sence of any changes in mean aortic blood pressure and heart
rate, or blood glucose concentration (Table 3.01). However,
arterial concentrations of plasma free fatty acids were re¬
duced from 466 - 41 to 221 - 44 )umol/l (P < O.OOl; Table
3.01).
Prior to p-chlorophenoxyisobutyrate the infusion of
isoprenaline increased occlusion-induced ZTST from 26 : 6 to
74 t 11 mV (P < O.OOl), and the number of sites with is¬
chaemic injury from 4.9 - 1.1 to 9.0 - 0.9 (P = 0.02;
Tables 3.01 and 3.02). After p-chlorophenoxyisobutyrate
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£ST associated with subsequent coronary occlusion and
isoprenaline infusion was markedly reduced to 40 t 7 mV
(P < 0,005), while the number of sites with ischaemic
injury was reduced to 7.6 - 1.3 (P < 0.05). Intravenous
infusion of isoprenaline before p-chlorophenocyisobutyrate
reduced mean aortic blood pressure from 97 i 5 to 91 t 3
mm Hg (P < 0.05), and increased heart rate from 134 t 7 to
176 t 6 beats/min (P < 0.001), blood glucose concentration
from 60 1 4 to 80 ± 12 mg/lOO ml (P< 0.02) and
arterial concentrations of plasma free fatty acids from
466 t 41 to 1966 ± 183 pmole/l (P < O.OOl). These effects
of isoprenaline (reduction in mean aortic blood pressure,
increase in heart rate and increase in blood glucose con¬
centration) were not altered by the administration of p-
chlorophenoxyisobutyrate, except that isoprenaline's lipo¬
lytic effect was reduced, evidenced by reduced arterial
plasma free fatty acid concentrations (now 1429 ^ 209 ^umole/l,
P < O.OOl).
Myocardial blood flow during coronary artery occlusion
When the tissue of the free wall of the left ventricle
distant from the occluded artery was taken to represent
normal myocardium, blood flow to the ischaemic zone was
reduced by about 40% at 10-13 min after occlusion. The
reduction in blood flow was greater in the endocardial than
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in the epicardial layers, resulting in a significant in¬
crease in the epicardial/endocardial blood flow ratio
(P < 0.01 ; Table 3.03).
The effect of isoprenaline on myocardial blood flow
Isoprenaline significantly increased the blood flow
to the non-ischaemic left ventricle, but had no effect on
that to the ischaemic areas (Table 3.03).
The effect of p-chlorophenoxyisobutyrate on myocardial
blood flow during isoprenaline infusion
It was of interest to note that pretreatment with p-
chlorophenoxyisobutyrate did not alter blood flow to the
ischaemic and non-ischaemic layers of the free wall of the
left ventricle.
Effects of p-chlorophenoxyisobutyrate administration
during established coronary artery occlusion
The acute effects of p-chlorophenoxyisobutyrate when
given during an established coronary artery occlusion and
isoprenaline infusion are summarised in Table 3.04. Five
and ten minutes after giving (i.e. 15 and 20 minutes follow¬
ing coronary artery occlusion) values for EST and arterial
concentration of plasma free fatty acids were both signi¬
ficantly reduced relative to those recorded immediately
before treatment, while mean aortic blood pressure and
heart rate remained unchanged. EST has previously been
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found to increase or remain unchanged between 10 and 20
min following coronary occlusion during isoprenaline in¬
fusion in the absence of treatment (Mj/^s, unpublished
results). The reduction in arterial concentration of
plasma free fatty acids was associated with a proportion¬
ate decrease in the arterial-coronary sinus difference
(Table 3.05). No significant uptake of p-chlorophenoxy-
isobutyrate by the myocardium could be detected: mean
arterial and coronary sinus p-chlorophenoxyisobutyrate
concentrations were 225 t 18 and 218 t 21 pg/ml respect¬
ively: p-chlorophenoxyisobutyrate reduced the arterial
free glycerol concentration from 254 1 31 to 185 i 21
^umole/l (P < 0.01) .
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Table 3.05
Effects of p-chlorophenoxyisobutyrate (CPIB) on arterial
concentration of plasma free fatty acids (FFA) and myocardial

























323 760 365 360 50 47 14





321 3020 1125 750 155 25 14
323 2 800 2155 450 400 16 19
324 1210 920 360 300 30 33
325 1070 730 120 105 11 14
326 2250 1780 300 180 13 10
327 1850 950 420 375 23 41
328 1890 850 420 315 22 37
Mean 1701 1022 260 212 22 21
SEM 297 199 67 46 3.8 4.2
P <0 .01 <0.01 NS
*Extraction ratio=
arterial concentration-coronary sinus concentration .'
arterial concentration ' 0
**Values obtained 10 minutes after intravenous CPIR (20 mg/kg)
263
3.1.4. Discussion
The present observations demonstrate that pretreat-
ment with p-chlorophenoxyisobutyrate substantially reduced
the extent and magnitude of epicardial ST-segment elevation
after experimental coronary artery occlusion in dogs, and
reduces the increase in ischaemia-induced ST-segment eleva¬
tion by isoprenaline infusion. The reduction in ST-
segment elevation, achieved by pretreatment with p-chloro-
phenoxyisobutyrate was related to the initial magnitude of
ST-segments during the control occlusions. This was ob¬
served both in the absence and in the presence of iso¬
prenaline (see Fig. 3.01). The absolute reduction in ST-
segment elevation during isoprenaline infusion was thus
greater than that recorded during occlusion in its ab¬
sence. This difference was also observed when p-chloro¬
phenoxy isobutyrate was given during an occlusion establish¬
ed 10 min earlier.
These findings probably indicate a limitation of the
acute myocardial ischaemic injury by p-chlorophenoxyiso-
butyrate.
The severity of acute myocardial ischaemic injury has
been shown to be influenced by factors, which alter the
oxygen requirements of the heart, relative to oxygen
supply (Maroko et al, 1971). The major determinants of
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Figure 3.01. The relation between initial ST-segment
elevation and the effect of p-chlorophen-
oxyisobutyrate (CPIB) on ST-segment elevation
during experimental myocardial ischaemia






Panel A: Basal state.
The effect of p-chlorophenoxyisobutyrate on ST-segment
elevation expressed as the difference between
2ST(control occ lusion )-SST , . . = A (ZaST) __TOx ' (CPIB + occlusion) v 'CPIB,
was plotted against ST determined during the control
occlusion. One experiment did not adhere to the general
trend. Data from Table 3.01.
Panel B: Isoprenaline stimulated state.
The effect of p-chlorophenoxyisobutyrate on ST-segment
elevation ^(22ST)Cp + was plotted against SST
determined during the occlusion, preceded by a continuous
isoprenaline (IP) infusion. Data from Table 3.02.
Occ = occlusion.
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myocardial oxygen requirements include the mechanical
factors of contractility, heart rate and wall tension
(Sonnenblick et al, 1968). However, the lack of any effect
of p-chlorophenoxyisobutyrate on mean aortic blood pressure
or heart rate in this investigation renders it unlikely
that there was a reduction in ischaemic injury due to
altered mechanical activity, but the fact is acknowledged
that necessary sophisticated haemodynamic measurements to
prove this could not be made. An effect of p-chlorophen-
oxyisobutyrate on coronary collateral circulation can be
excluded from the results of the microsphere studies,
which demonstrated that blood flow to both the ischaemic
and non-ischaemic areas of the left ventricular free wall
during isoprenaline infusion was unaltered by treatment.
Furthermore the failure of p-chlorophenoxyisobutyrate to
alter regional ischaemic myocardial blood flow might suggest
that the reduction in ST-segment elevation was also un¬
related to its known effects on platelet aggregation, blood
clotting mechanisms and blood viscosity. This is supported
by the observation that platelet aggregation in the ischaemic
myocardium after coronary artery occlusion does not impair
coronary circulation (Vik-Mo, 1978).
iso
p-Chlorophenox^butyrate reduced the arterial concentra¬
tion of plasma free fatty acids by some 40%, and this was
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associated with a proportionate decrease in the arterial-
coronary sinus difference of plasma free fatty acid con¬
centration. Myocardial uptake of radiolabelled palmitate
was also reduced by p-chlorophenoxyisobutyrate (Miller and
Mj^s, unpublished observations). It could not have been
predicted that fatty acid extraction would still relate
to arterial fatty acid concentrations after the adminis¬
tration of p-chlorophenoxyisobutyrate, in view of reports
that it may displace fatty acids to weaker binding sites
on the albumin molecule (Thorp, 1973). The fact that
plasma free glycerol concentrations were already reduced
after 10 min post p-chlorophenoxyisobutyrate suggests that
the effect of the drug stemmed at least in part from an
inhibition of lipolysis, in accordance with in vitro studies
of adipose tissue metabolism (Speake, 1967; Curtis-Prior,
1974).
It is also possible that ischaemia induced myocardial
lipolysis may have been inhibited by p-chlorophenoxyisobu¬
tyrate. However in absence of arterio-venous difference
of glycerol concentrations across the ischaemic myocardium
this study cannot confirm or deny this possibility. Nor
can it elucidate whether the effect of p-chlorophenoxyisobu¬
tyrate on ST-segment elevation was associated with increased
glucose utilisation in the ischaemic area. In this context
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it is of interest that in one study where the effect
of p-chlorophenoxyisobutyrate on ST-segment elevation




reduced ischaemia-induced ST segment elevation both
in the basal state and during infusion of isoprenaline.
p-Chlorophenoxyisobutyrate was also effective, when
administered during an established coronary artery
occlusion.
This beneficial effect of p-chlorophenoxyisobutyrate
was not related to changes in heart rate, blood pressure
or regional myocardial blood flow, but was associated with
a reduction in arterial concentrations and myocardial
extraction of plasma free fatty acids. These observations
support the view that the severity of myocardial ischaemic








Prostaglandins are naturally occurring substances
with wide-ranging haemodynamic (Horton and Ungar, 1975)
and metabolic effects (Bergstrom et al, 1968). Prosta¬
glandins E and A increase coronary blood flow in normal
dogs (Horton and Ungar, 1975) and it has been suggested
that they might be used clinically to increase blood flow
to the ischaemic myocardium (Bloor et al, 1973).
In addition to increasing coronary blood flow prosta¬
glandin E^ also reduces adipose tissue mobilisation of
free fatty acids. As was discussed in Part 1 of this
thesis, this might be desirable. Prostaglandin E^ has
also been claimed to be anti-arrhythmogenic (Vergroesen
et al, 1972), presumably by controlling the equilibrium
between sympathetic and parasympathetic nervous system.
It is also possible that prostaglandin-E^ could inhibit
platelet aggregation during acute myocardial ischaemia.
These beneficial effects of prostaglandin-E^ stimulat¬
ed us to study its role on plasma free fatty acid con¬
centration, myocardial blood flow and ST-segment elevation
in dogs with experimental myocardial infarction, since it
was realised that all possible beneficial effects could
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not be investigated. Prostaglandin-E^ in low con¬
centrations however actually may increase plasma con¬
centrations of free fatty acids, and therefore a dose
which has been shown to be consistently antilipolytic




Experiments were carried out in 21 mongrel dogs of
both sexes (12-25 kg body weight), using in 17 experi¬
ments the procedures described in Part 2 (Section 2.1)
of this thesis.
A different preparation was used in four dogs
whereby heart rate, left ventricular end diastolic
pressure and mean aortic pressure could be kept constant
(Kane and Ungar, 1976). The heart was exposed by a
mid-sternal split. The left atrium was cannulated and
connected to a reservoir after heparinisation of the
dogs (2000 U). Left ventricular end diastolic pressure
was computed on-line using an analogue computer and
maintained constant by varying the height of the fluid
column in the left atrial reservoir. Mean aortic blood
pressure was kept constant using a pressurised flask
connected to both femoral arteries.
If changes in peripheral resistance occurred, equi¬
librium between two reservoirs was maintained by pumping
blood from one to the other with a Watson-Mar low MHRE
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roller pump. A water jacket and a heated, siliconised
glass coil in the reservoir were used to maintain the
o
fluid in the system near 37 C. The system was primed
with a solution of 2.5% (w/v) dextran, which was allowed
to mix with the blood in the dog in order to minimise
later changes in haematocrit during the observation
periods. Right atrial pacing was used to keep the heart
rate constant. Arterial pressure was measured through
a carotid arterial cannula. Left ventricular pressure
was measured using a metal cannula inserted through the
dimple of the apex and directly connected to the pressure
transducer (L223, Consolidated Electrodynamics, England).
The frequency response of the overall system was flat
within 5% at 40 Hz. dP/dt max. was derived by the ana¬
logue computer. The initial values of heart rate, mean
aortic blood pressure and left ventricular end diastolic
pressure were chosen close to those observed prior to the
first infusion and then maintained constant during the
observation periods. After release of the occlusion
heart rate, left ventricular end diastolic pressure and
mean aortic blood pressure were no longer controlled.
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Measurements
Electrocardiographic recordings were performed
with a mobile cotton wick electrode at 10-15 anatomically
well defined sites on the epicardial surface as described
in Section 2.3.1.
Regional myocardial blood flow was measured using
radioactive microspheres, as described in Section 2.4.
Biochemical analyses
Plasma concentrations of free fatty acids (Section
2.2.2), glucose (Section 2.2.3) and free glycerol
(Section 2.2.4) were determined according to the standard
procedures.
In the 4 heparinised dog studies the blood samples
were centrifuged immediately after collection and fatty
acids were extracted without delay, to prevent in vitro
lipolysis. This precaution was taken despite the fact,
that plasma triglyceride levels are too low to cause




The basic design was to induce two or three discrete
periods of myocardial ischaemia each of 10-14 min dura¬
tion, separated by a recovery period of 30 min, as de¬
scribed in Section 2.1.3. Three series of experiments
were performed.
In the first series (Procedure 1, Fig 3.02)the effect
of prostaglandin-E^ was studied on ST segment elevation
during lipolysis stimulated by a continuous infusion of
isoprenaline in nine dogs (dogs 1-9). Intravenous iso-
prenaline 0.1-0.2 yug kg "'"min "*" was commenced 5 min prior
to the control occlusion and maintained throughout. At
10 min of ischaemia the epicardial electrocardiogram,
heart rate and mean aortic blood pressure were recorded
and microspheres injected into the left atrium for measure¬
ment of regional myocardial blood flow. An arterial
blood sample was taken for the determination of plasma
concentration of free fatty acids. The occlusion was
released and the isoprenaline infusion stopped. After
a 30 min recovery period an intravenous infusion of
prostaglandin-E^ 0.6 p.g kg "'"min was given, followed
5 min later by an isoprenaline infusion. Both infusions
were maintained during this occlusion. All measure¬
ments: epicardial ECG (ZST), heart rate, mean aortic
blood pressure and regional myocardial blood flow were
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Figure 3.02 Protocol for the study of the effect of
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The basic experimental design consisted of two or three
intermittent occlusions (Occl). Prior to release, re¬
cordings of epicardial electrocardiograms were made, and
an arterial blood sample was obtained for biochemical
parameters (arrows). Regional myocardial blood flow was
determined by injection of 1.5-3.0 x lO^ microspheres
into the left atrium immediately before the release of the
occlusion.
Further details see text.
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repeated (Fig 3.02).
In two experiments (dogs 7 and 9) the sequence was
reversed, isoprenaline and prostaglandin-E^ being in¬
fused during the first occlusion period. After release
and recovery, isoprenaline alone was infused for the
second occlusion period. This was done in order to
check whether the effects of prostaglandin-E were related
to the time of administration.
In the second series (Procedure 2, Fig 3.02 ) the effect
of prostaglandin-E^ administered intravenously (0.6 pg
kg~^"min~^) or intra-atrially (0.03 pg kg "'"min "*") was
studied in eight dogs (dogs 10-17). Three occlusions
of approximately 10 min duration were made as described
above. The first occlusion served as a control. The
other occlusions were made 5 min after the start of
either a continuous prostaglandin-E^ infusion into the
femoral vein or into the left atrium. The infusion of
prostaglandin-E^ into the left atrium was made in order
to check whether prostaglandin-E^ or its metabolites were
the active components. Normally up to 90% of prosta¬
glandin^^ is removed on a single passage through the
lungs. The order in which the prostaglandin-E infusions
were administered was randomised. E.ST segment elevation,
heart rate and mean aortic blood pressure were measured
immediately prior to the release of the occlusion. In
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five dogs, microspheres were injected for measurement
of regional myocardial blood flow after 10 min of
occlusion during each of the three experimental occlusions
described above. Isoprenaline was not given to dogs in
the second series.
In the third series the effect of intravenous prosta-
glandin-E^ (0.6 jug kg'^min-"'") was studied in four dogs
(dogs 18-21), whilst heart rate, mean aortic blood
pressure and left ventricular-end diastolic pressure
were maintained constant.
Two occlusions of approximately 10 min duration
were made as described above (Procedure 2, Fig 3.02), each
5 min after the start of a continuous infusion of either
prostaglandin-E^ or saline. The order of these in¬
fusions was randomised. Epicardial ECG (ZST-segment
elevation) heart rate, mean aortic blood pressure,
left ventricular end diastolic pressure and left ventri¬
cular dP/dt max were measured immediately before and at
5 min intervals during the occlusion. Arterial (carotid
artery) blood samples were obtained for the estimation
of plasma free fatty acids .
Stat is tics
Each dog served as its own control. Student's




The effects of prostaglandin-E^ during isoprenaline
infusions
After the occlusion of a distal branch of the left
anterior descending coronary artery, the onset of acute
myocardial ischaemia was characterised by localised
cyanosis, contractile asynergy and ST-segment elevation
in the distribution of the ligated artery.
When the induction of myocardial ischaemia was made
in the presence of isoprenaline ZST segment elevation
averaged 46 t 6 mV (mean t SEM) after 10 min of occlusion
(Table 3.06). When the isoprenaline infusion was pre¬
ceded by a continuous infusion of prostaglandin-E^ ZlST
averaged 34 t 6 mV (P < O.OOl). This effect of prosta¬
glandin^^ was independent of the sequence of administra¬
tion. The data from all dogs were pooled.
The lipolytic activity of isoprenaline was apparent
from the high plasma free fatty acids concentrations
(1925 - 150 jumole/l). This was partly inhibited when
prostaglandin-E^ was simultaneously administered
(1320 t 220 jumole/l: P < 0.005) (Table 3.06).
The intravenous administration of prostaglandin-E^
did not significantly alter mean aortic blood pressure
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during isoprenaline infusions, but a small and signific¬
ant decrease in heart rate was observed (Table 3.06).
Prostaglandin-E^ administration had no effect on regional
myocardial blood flow in the endocardial and epicardial
layers of the ischaemic and non-ischaemic part of the
left ventricle during the isoprenaline infusions (Table
3.07).
Effects of prostaglandin-E^ infusions alone
In the absence of isoprenaline, prostaglandin-E^
did not reduce plasma free fatty acid concentrations
(Table 3.08), or alter plasma free glycerol and glucose
concentrations.
The haemodynamic effects of prostaglandin-E^ alone,
were also different from those observed during isoprena¬
line infusions. Prostaglandin-E^ alone did not change
heart rate. Prostaglandin-E^ reduced mean aortic blood
pressure significantly, irrespective of which route was
used (Table 3.08). This drop in mean aortic blood
pressure was associated with a marked reduction in
regional myocardial blood flow in epicardial and endo¬
cardial layers of the non-ischaemic myocardium (Table
3.09. The reduction was slightly more marked in the
endocardial layers of the non-ischaemic myocardium,
giving rise to a significant decrease in the endocardial-
Table3.07 Theeffectofintrav nouspr staglandin-E^(PGE^)onregio almyocardialblo dflowinon-ischaemica dce t lplus peripheralischaemicleftv ntricleduringcontinuousisoprenali einfusifo rd gwithexperimentalac t myocardialischaemiaof10millduration won-ischaemic
Ischaemic
EndocardiumEpicardiumEndocardial/epicar ialEndoca iumEpicardiumEndoc.ar ial/epicardial (mlg~*min-1)(mlg~l in_1)ratio(mlg-1min-1)( lg-1min1)ratio
00
ucclusion+ isoprenaline1.29+_Q 061.450.0.89 _+O 3 (24)(24)
(24)
0.82+_u.081.080 9.76+_0 04 (20)(20)
Occlusion+ isoprenaline+ PGE1i.v.
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epicardial blood flow ratio (P < 0.005). Prostaglandin¬
s' (both administered intravenously or intra-atrially)
also reduced myocardial blood flow in the ischaemic epi-
and endocardial layers (P < 0.005), and the reduction was
possibly more pronounced in the endocardial layers.
However, no change was observed in ST-segment elevation
after 10 min of occlusion (Table 3.08). Therefore the
studies were extended to another series in which the
blood pressure as well as heart rate and left ventricular
end diastolic pressure were controlled. Under these con¬
ditions intravenous prostaglandin-E^ reduced EST in three
out of four experiments. This effect was not related to
plasma free fatty acid concentrations, which tended to
increase (Table 3.10).
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3.2.4. Discussion
The effect of prostaglandin-E^ during isoprenaiine
infusions
During experimental myocardial ischaemia under con¬
ditions of high adrenergic drive (isoprenaline infusions),
prostaglandin-E^ reduced ST-segment elevation, which is
thought to reflect the severity of acute myocardial is¬
chaemia (Wegria et al, 1949).
Arterial concentrations of plasma free fatty acids
were lowered by prostaglandin-E^ due presumably to its
inhibitory effect on the lipolytic activity of isoprenal¬
ine. This is likely to have led to reduced myocardial
extraction of free fatty acids. Arterial-coronary sinus
differences were not measured but proportionality be¬
tween arterial concentration and myocardial extraction
has been found (see Part 1). This applies also to the
extraction of free fatty acids by the ischaemic myocard¬
ium (Riemersma et al, 1972). In the presence of acute
myocardial ischaemia, such reduction in plasma concentra¬
tions of free fatty acids after the administration of
antilipolytic drugs was also associated with reduced signs
of ischaemia, such as H.ST (Kjekshus and MjVs, 1973;
Lekven et al, 1973: Mj^s et al, 1974; Ilebekk and Mjrfs,
1974).
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Factors changing myocardial oxygen requirements
relative to oxygen supply, such as heart rate and blood
pressure, also influence the extent of ST-segment ele¬
vation (Maroko et al, 1971; Redwood et al, 1972). In
this study during isoprenaline infusions, prostaglandin-
did not change mean aortic blood pressure, and the
small reduction in heart rate which was observed seems
too small to account for the reduction in ST-segment
elevation.
Direct effects of prostaglandin-E^ have also to be
considered. ST-segment elevation can occur when rest¬
ing membrane potential is reduced (Prinzmetal et al,
1961). Prostaglandin-E had no effect on resting mem¬
brane potential in mammalian, well oxygenated myocardial
cells and, when used in very high concentrations, caused
a decrease (Kecsmeti et al, 1974). This would tend to
increase ST-segment elevation. Since prostaglandin-E^
reduced ZST, it seems unlikely that an effect on the
resting membrane potential could explain our findings.
Prostaglandin-E^ could have exerted its effect by in¬
hibiting platelet aggregation in the ischaemic myo¬
cardium. Although platelet aggregation at 15 min of
occlusion in this model was demonstrated (Vik-Mo, 1978),
it is of insufficient magnitude to cause severe impair-
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merit of blood flow to the ischaemic myocardium (Vik-Mo,
1978). The fact that in our experiments during iso-
prenaline infusion prostaglandin-E^ did not change
myocardial blood flow, supports the view that inhibition
of platelet aggregation was not its mode of action.
The effects of prostaglandin-E^ in the absence of
isoprenaline
During experimental myocardial ischaemia, but in the
absence of isoprenaline, the effect of prostaglandin-E^
on occlusion-induced ST-segment elevation was dependent
on the experimental conditions. In the main series of
experiments during basal lipolysis, prostaglandin-E^
effected no change in occlusion-induced ST-segment
elevation. But a marked reduction was observed in mean
aortic blood pressure and regional myocardial blood flow
both in the ischaemic and non-ischaemic areas of the myo¬
cardium. Similar haemodynamic effects have been report¬
ed, when prostaglandin-E^ was given to cats with acute
myocardial ischaemia (Hutton et al, 1973), but ST-segment
measurements were not made. Since hypotension has been
shown to increase occlusion-induced ST-segment elevation
(Maroko et al, 1971; Redwood et al, 1972), the observa¬
tion of unaltered ST-segments by prostaglandin-E^ needs
comment. It cannot be explained by increased myocardial
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uptake of free fatty acids, since plasma concentra¬
tions of fatty acida were unaltered by prostaglandin-E^.
A possible explanation was that the expected increase
in EST due to hypotension was counteracted by some oppos¬
ing influence. To test this hypothesis further studies
were made. In these studies, conducted with controlled
mean aortic blood pressure and left ventricular end dia¬
stolic pressure, prostaglandin-E^ reduced ST-segment
elevation. While these studies do not explain the
nature of this opposite action, they appear to exclude
mechanisms based on changes in metabolism of plasma free
fatty acids, but ischaemia-induced myocardial lipolysis,
thought to be mediated by noradrenaline release, may have
been inhibited.
Patients with acute myocardial infarction have in¬
creased adrenergic drive. During nervous stimulation
(Wennmalm and Stjarne, 1971) and hypoxia (Wennmalm et al, 1974)
endogenous prostaglandins are released from the sympath¬
etically innervated heart and prevent excessive stimula¬
tion of the myocardium by noradrenaline. Indomethacin,
which inhibits prostaglandin synthesis, increased infarct
size after experimental coronary artery occlusion in
conscious dogs (Jugdutt et al, 1978). Their and our
findings suggest that prostaglandins play a role in de-
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termining the viability of the ischaemic myocardium.
It needs to be stressed that the effect of intra¬
venous prostaglandin infusions may be quite different
from that of locally released prostaglandin from the
ischaemic myocardium. In the latter situation this may
be devoid of an effect on adipose tissue lipolysis.
In the present study pharmacological doses of
prostaglandin-E were used and due to its side effects
(Bergstrom et al, 1959) may not be useful to reduce




myocardial ischaemia, through its antilipolytic
action, without affecting regional myocardial blood
flow. However in the absence of catecholamine
stimulation the main effect is to reduce blood pressure,
resulting in reduced regional myocardial blood flow,
and thereby counterbalancing any potential beneficial





Effects of a 'cardioselective' p-blocker: acebutolol
Introduction
Patients with acute myocardial infarction have in¬
creased activity of the sympathetic nervous system, as
evidenced by increased plasma concentrations of cate¬
cholamines (Gazes et al, 1959; Valori et al, 1967;
McDonald et al, 1969; Christensen and Videbaeck, 1974;
Vetter et al, 1974) or by increased urinary catechol
excretion (Jewitt et al, 1969; Prakash et al, 1972).
The origin of raised catecholamines is complex, but
appears to stem from the adrenals (Ceremuzynski et al,
1969) and from the ischaemic myocardium (Shahab et al,
1969). Raised catecholamines are commonly considered
to be detrimental to the acutely ischaemic heart and
thus prevention of their (haemodynamic and electro¬
physiological) effects should be beneficial. This has
stimulated the search for drugs which by their haemo¬
dynamic and vascular action would specifically reduce
the consumption of oxygen by the ischaemic heart;
•cardioselective' ^-blocker (e.g. practolol, acebutolol).
It was of interest whether the beneficial effect
of ^-blockade was due to their heart rate lowering
property, or whether non-'cardioselective' effects on
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fat and glucose metabolism were also contributory.
Therefore the effects of acebutolol on the severity of
myocardial ischaemia, arterial concentrations of free
fatty acids and glucose and on myocardial metabolism





Experiments were carried out in 11 mongrel dogs of
both sexes (11-21 kg body weight), fasted for 12-15
hours, as described in Part 2 (Section 2.1) of this thesis.
Electrocardiographic monitoring
In this study electrocardiograms were recorded using
an epicardial grid with 10-15 silver electrodes. In¬
itially the mathematical mean electrocardiogram was
computed by an electronic averaging device, and more
recently (experiments without pacing) using a multi¬
plexer system, as described in Section 2.3.1.
Acebutolol hydrochloride (May and Baker) was a gift
from Dr. Khambatta, was administered in slow intravenous
injection over 5 min (dose 0.3 mg/kg).
Biochemical analyses
Standard procedures were used for the processing of
blood samples and analyses of plasma free fatty acids
(Section 2.2.2), plasma glucose (Section 2.2.3) and
plasma glycerol (Section 2.2.4). Insulin was measured
by a radio-immunoassay in the laboratory of Dr. E.
Cameron, Regional Hormone Laboratory, Department of
Clinical Chemistry, The Royal Infirmary, Edinburgh.
Dog insulin (Novo, Denmark) was used as the standard.
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3.3.2. Experimental procedures
The basic experimental design was two to four dis¬
crete periods of ischaemia of 5-7 min duration, se¬
parated by a recovery period of 30 min, as described
in Section 2.1.3. The protocol used is presented in Fig 3
Two series of experiments were performed. In the
first the effects of acebutolol was examined in dogs,
whilst heart rate was maintained constant by right atrial
pacing. Pacing frequencies were 10 above basal heart
rate for both the control occlusion and the occlusion
after acebutolol. For the occlusions during iso-
prenaline infusions (control and acebutolol) the heart
rate was kept at 10 above the heart rate after 5 min
isoprenaline infusion in the absence of acebutolol. ST
segment elevation was recorded before and at 5 min of
coronary artery occlusion. Blood samples for the bio¬
chemical analyses was obtained between 5-7 min of occlu¬
sion, at the same relative time during control and
sectral occlusions.
In three dogs, two in the presence of and one in
the absence of isoprenaline, the experimental design was
modified to check on the effect of the sequence of ad¬
ministration. In these experiments a first occlusion
(control) and a second occlusion (acebutolol) were made,
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Figure 3.03. Experimental procedures for assessing the
effect of acebutolol on the response to sub-
















Four identical occlusions of 5-7 min duration were
performed in each animal, two in the absence of acebutolol
(0.3 mg/kg) and two in its presence. One pair of occl¬
usions was performed during a continuous infusion of iso-
prenaline (0.1 jug/kg/min), started 5 min before the occl¬
usion. Heart rate was maintained constant by right atrial
pacing. Recovery periods of 30 min were allowed between
successive occlusions. Immediately before the release of
each occlusion (indicated by vertical arrows) haemodynamic
measurements were recorded and blood samples were collected.
Sectral = acebutolol.
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followed by a period sufficiently long for the effects of
acebutolol on heart rate to wear off (2-§ to 3-§ hours).
At this time a second control occlusion was made. The
results of the first and second control occlusion were
the same and the effects of acebutolol in these experiments
were similar to those performed according to the basic
procedure. Therefore the effects of acebutolol were assess¬
ed by paired analysis of all data from the 9 experiments.
In the second series the effects of acebutolol were
examined in 5 dogs, without pacing. Two occlusions
(5 dogs) were made 5 min after commencement of an intra¬
venous infusion of isoprenaline (0.1 jjg/kg/min), the
first was the control and the second was made 30 min
after acebutolol.In one of these another control occlusion
was made (during isoprenaline) after a period sufficiently
long for the effect of acebutolol on heart rate to wear off.
The results of this study were similar and all results
were pooled.
Statistics
Kach dog served as its own control. Student's
t-test for paired data was used to calculate probabilit¬




The effects of acebutolol in dogs with constant heart rate
When myocardial ischaemia was induced in dogs in which
heart rate was maintained at a constant level by right
atrial pacing, acebutolol did not affect ST-segment ele¬
vation in the absence or in the presence of isoprenaline
infusion (Table 3.11). Mean aortic blood pressure was also
not significantly different.
The effects of acebutolol on isoprenaline induced tachy-
cardia and ST-segment elevation in unpaced dogs
Acebutolol inhibited the increase in heart rate in all
but one experiment, on average by some 45 t 8%. In the
4 experiments, in which heart rate was not maintained at
a constant level, a marked reduction in ST-segment elevation
was observed : isoprenaline + occlusion : 8.9 - 2.0 and
acebutolol + isoprenaline + occlusion 5.3 - 1.8 mV(P < 0.05).
Mean aortic blood pressure was not significantly changed but
heart rate was (Table 3.12).
The metabolic effects of acebutolol (Table 3.13)
The effects of acebutolol in paced and unpaced experi¬
ments were similar and the data was pooled. Acebutolol
reduced arterial concentrations of plasma free fatty acids,
but not glycerol during basal and isoprenaline stimulated
conditions. Arterial glucose concentrations were also re¬



















































































The effect of acebutolol on ischaemia-induced ST-segment
elevation, mean aortic blood pressure (AP) and heart rate
(HR) during isoprenaline infusion (UNPACED experiments)
ST*(mV) AP (mmHg) HR (beats/min)
Dog control acebutolol control acebutolol control acebutolol
699 6.5 3.5 94 94 154 105
702 14.5 10.7 121 103 183 151
705 9.2 3.7 122 120 176 119
706 5.4 3.3 111 122 168 136
ST = average ST-segment elevation.
Table3.13
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in extraction of plasma free fatty acids and glucose across
the non-ischaemic myocardium (arterio-coronary sinus differ¬
ence). Arterial insulin levels tended to decrease, however
this effect did not reach a level of statistical significance.
The effects of acebutolol on substrate extraction by the
ischaemic myocardium
The extraction of metabolites across the ischaemic
myocardium was studied by analysis of the effluent from the
area supplied by the occluded artery. In this study however,
difficulties were experienced in obtaining a complete set of
blood samples (control and after acebutolol), particularly
when isoprenaline infusions were used. As a result the
interpretation of the data is restricted to the observations
made in the basal state. The reduction in arterial plasma
free fatty acid concentration by acebutolol was associated
with a decrease in fatty acid extraction by the ischaemic
myocardium. The ischaemia-induced increase in glucose ex¬
traction (compare control occlusion:glucose a-cs 0.51 - 0.07 vs.
glucose a-lv: 0.91 - 0.10 mmole/l) was reduced by the ad¬
ministration of acebutolol. However during isoprenaline
this effect may not be observed (no statistical test performed).
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3.3.4. Discussion
These studies show that acebutolol reduced evidence
of myocardial ischaemic injury in dogs, which were not
electrically paced. This observation is in agreement
with those of others using other ^-blockers such as
propranolol (Maroko et al, 1971; Serrano et al, 1971;
Becker et al, 1975) and using the 'cardioselective1 drug
practolol (Libby et al, 1973^). The" mechanism of this
beneficial effect appears to be complex. A reduction
in heart rate limits the extent of myocardial ischaemia
per se (Maroko et al, 1971). However propranolol can
not be equated with the 'cardioselective' p-blockers.
In an elegant study Marshall and Parratt (1976) showed
that, although propranolol and practolol both depressed
myocardial function and oxygen demand, practolol unlike
propranolol, did not reduce myocardial blood flow to
the ischaemic area. This was explained by an increase
in left ventricular end diastolic pressure after
propranolol, which was much less after practolol. The
reduction in coronary perfusion pressure after practolol
was balanced by an increase in the period, during which
the coronary perfusion pressure exceeds the trans-
ventricular pressure leading to myocardial perfusion
(effective perfusion period). As a result oxygen supply
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to the ischaemic myocardium was not depressed and was
apparently sufficient to meet the oxygen demand in
view or the ceased lactate production.
On the other hand, they showed that practolol caused
a pronounced deterioration of cardiac function in 2
experiments in wnich heart rates were maintained con¬
stant by electrical pacing. In our studies acebutolol
did not effect a beneficial(nor an overt detrimental)
effect, despite the fact that the reduced extraction of plasma
free fatty acids was not modified by pacing.
Therefore the contribution of reduced fatty acid
metabolism to the development of ischaemic injury may super¬
ficially appear insignificant. However acebutolol also
reduced myocardial extraction (Aarterio-local vein) of
glucose by the ischaemic myocardium (in the absence of
isoprenaline)and therefore the relative contrioutions
of each suostrate to total myocardial metabolism was un¬
altered. The effect of acebutolol on glucose extraction
Dy the ischaemic myocardium was not apparent during
isoprenaline infusion. However, due to technical
difficulties insufficient observations were obtained.
The reduced glucose extraction is possibly due to
the reduction of arterial glucose and insulin concentra¬
tions. Similarly the decreased arterio-venous differ¬
ence ox free fatty acids across the ischaemic myocardium
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is likely to be caused by reduced plasma concentrations
of free fatty acids due to inhibition of catecholamine-
induced lipolysis.
The effects are similar to those of propranolol (Opie
and Thomas, 1976). They showed reduced arterial con¬
centrations of glucose and free fatty acids. However
despite the reduction in glucose concentration, propranolol
increased the extraction of glucose by the ischaemic
myocardium. The discrepancy between their and our re¬
sults can not be explained. Neither they nor we measured
regional myocardial blood flow in the ischaemic area
and it may well be the residual blood flow which deter¬
mines glucose uptake by the ischaemic myocardium, as
demonstrated using an ischaemically perfused rat heart
preparation (Neely et al, 1975) could have been an im¬
portant difference.
If the results of our experiments of experimental
myocardial ischaemia in anaesthetised dogs can be extra¬
polated to patients with acute myocardial infarction at
all, then it appears that the predominant effect ofacebutolol
is reduction of heart rate. Although metabolic effectscan
not be excluded, their contribution to the severity of
ischaemic injury may be of lesser importance.
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3.3.5. Summary
In experiments with controlled heart rate, acebutolol
did not reduce the severity of acute myocardial ischaemic
injury, despite the fact that the extraction of plasma free
fatty acids by the ischaemic myocardium was reduced. However
glucose extraction was also diminished, and the relative con¬
tribution of glucose and free fatty acids to myocardial
metabolism was unaltered. However when heart rate was
allowed to decline, a marked reduction in ST-segment ele¬
vation and a similar reduction in plasma free fatty acid
concentrations was observed. Thus the beneficial effect
of acebutolol appears to be due predominantly to the re¬
duction in heart rate.
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SECTION 3.4:
EFFECTS OF SODIUM SALICYLATE
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INTRODUCTION
bodium salicylate has been shown to reduce the
extent of myocardial ischaemic injury in experimental
studies (Vik-Mo, 1977; Vik-Mo and Mj^s, 1977). This
was related to its plasma free fatty acids lowering
effect. However extraction of free fatty acids and of
glucose by the ischaemic myocardium could not be de¬
termined in these studies. Therefore the effect of





Studies were performed in 7 overnight-fas ted mongrel
dogs of either sex, with an average weight of 22 kg, as de¬
scribed in Part 2 (Section 2.1) of this thesis. The coronary
sinus was catheterised without fluoroscopic control as de¬
scribed in Section 2.1.4.
Haemodynamic measurements
Mean aortic blood pressure (AP) and left ventricular
pressure were recorded on A Dynograph recorder (Type 411,
Beckman Instruments Inc., Schiller Park, 111., USA), as de¬
scribed in Appendix E.
Metabolic measurements
Plasma concentrations of free fatty acids were analysed
using the radiochemical method of Ho (1970) and plasma glucose
was estimated by a manual glucose oxidase method using a
commercial kit (Boehringer Mannheim Gmbh, Mannheim, Germany)
in Troms/. Frozen plasma samples for the analyses of lactate
were shipped by air in dry-cold (-56°C) to Edinburgh, where
they were estimated using the enzymic fluorimetric method de¬
scribed in Section 2.2.5.
Packed cell volumes were determined by a micro-haematocrit
centrifuge, and oxygen saturations were measured spectrophoto-
metrically (The Oxygen Saturation Meter, type OSM 1, Radiometer,
Copenhagen, Denmark).
In Troms^ all analyses were performed in triplicate. The
coefficients of variations for the plasma free fatty acid
method and glucose method were 3% and 2% respectively.
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3.4.2. Experimental procedure
experiments were carried cut both under basal con¬
ditions and during continuous intravenous infusion of
isoprenaline at a rate of O.IO - 0.20 pg/min/kg.
Generally four intermittent occlusions were performed
in each animal (see Section 2.1.5). This allowed each
animal to serve as its own control for the assessment of
the effect of treatment during basal and isoprenaline
stimulated conditions. Haemodynamic measurements were
performed immediately before and 12 min following the
occlusion of the coronary artery. Blood samples were
obtained from 6 to 12 min after induction of myocardial
ischaemia. The coronary artery occlusion was released
after 12 min and a recovery period of 45 min was allowed.
A second occlusion was performed after 10 min of iso¬
prenaline infusion when the haemodynamic variables had
stabilised. All measurements were repeated. After re¬
lease and recovery, sodium salicylate (60 mg/kg as a
slow injection followed by a continuous infusion at a
dose of 0.15 mg/min/kg dissolved in 0.9% (w/v) saline,
pH 7.4) was started. After 30 min a third occlusion was
made, followed after release and recovery by a fourth
occlusion during isoprenaline. Care was taken that the
haemodynamic and electrocardiographic measurements were
always done and blood samples were always obtained in the
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same order, and at the same time after occlusion.
In two of the seven dogs given sodium salicylate
only experiments without infusion of isoprenaline were
conducted.
Statistics
Each dog served as its own control. Wilcoxon's
non-parametric test (two-tailed) for paired data was
used to calculate probabilities. Statistical com¬
parisons are not performed between samples of 5 or less.
P> 0.05 was regarded as not statistically significant.
Standard error of the methods was calculated from tri¬
plicate analyses of 4 randomly selected experiments, and




Metabolic and haemodynamic effects of sodium salicylate
In the basal state sodium salicylate administration
reduced arterial concentrations of plasma free fatty
acids (P < 0.05, n = 7), whereas no changes in arterial
oxygen saturation or plasma concentrations of glucose and
lactate were observed. The reduced arterial concentra¬
tion of plasma free fatty acids was associated with a re¬
duction of fatty acids across the ischaemic and non-
ischaemic myocardium (P < 0.05, n = 7, Table 3.14).
Sodium salicylate did not modify the haemodynamic
state: no significant differences were observed in heart
rate, left ventricular systolic pressure or the maximum
of its first derivative.
During isoprenaline infusion sodium salicylate re¬
duced arterial concentrations of plasma free fatty acids
in all 5 experiments, and the free fatty acid extraction
(a-lv) was consistently reduced. Arterial plasma lactate
concentrations were not affected by sodium salicylate
(5 experiments), and although an average lactate release
by the ischaemic myocardium increased after sodium
salicylate it actually was reduced in 2 out of 3 experi¬
ments. However these observations were very limited
due to difficulties in obtaining complete sets of blood
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samples in the experiments. The utilisation of oxygen
and glucose did not appear to be modified by sodium




The administration of sodium salicylate before the
induction of experimental acute myocardial ischaemia
reduced the magnitude and the extent of myocardial is-
chaemic injury in dogs (Vik-Mo, 1977; Vik-Mo and M j0s ,
1977). The effect of sodium salicylate was assumed to
be due to its antilipolytic property, since blood flow
to the ischaemic myocardium was not affected (Vik-Mo,
1977). In the present study we have demonstrated that
the extraction of plasma free fatty acids by the is¬
chaemic myocardium is indeed substantially reduced by
sodium salicylate. This was not associated with re¬
duced lactate release. It should be noted that these
findings occurred without significant change in glucose
extraction by the ischaemic heart, although glucose
extraction tended to increase. Glucose extraction by
the non-ischaemic myocardium followed a similar pattern.
This raises the possibility that the manual glucose
method might not have been precise enough to pick-up
a small increase in glucose extraction by the ischaemic
heart after sodium salicylate, although the results did
demonstrate the well-known increase in glucose extraction
across the ischaemic heart (a-lv) in comparison to that
by the non-ischaemic myocardium (a-cs).
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This most probably means that during myocardial
ischaemia salicylate lowers fatty acid supply to the
ischaemic cell, and thereby reduces the ot -glycerophos-
phate (and ATP) requirements for triglyceride synthesis
and more glucose may be available for immediate energy
purposes.
However a direct inhibition of ischaemia-induced
myocardial lipolysis (Opie et al, 1973; Hough and Gevers,
1975) by sodium salicylate cannot be excluded.
It could be argued that sodium salicylate could have
effected the observed reduction in severity of myocard¬
ial ischaemic injury by inhibiting prostaglandin synthesis
(Vane, 1971). This is unlikely, however, since prosta¬
glandins prevent excessive stimulation of adrenergic re¬
ceptors by noradrenaline release (Wennmalm, 1976), and
therefore inhibition of prostaglandin synthesis by sodium
salicylate would lead to unopposed stimulation of the
myocardium by noradrenaline, released from the ischaemic
myocardium (Shahab et al, 1969). Indomethacin, which
also inhibits prostaglandin synthesis, has been shown to
increase myocardial ischaemic injury (Jugdutt et al, 1978).
In high doses salicylates increase total body oxygen
consumption in dogs and man (Tenney and Miller, 1955) and
may uncouple oxidative metabolism in vitro (Brody, 1956).
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However in this study and in a recent study using a
similar dose, myocardial oxygen consumption was not
raised (Vik-Mo and M j^s , 1976).
The results of experimental models should only be
extrapolated to the clinical situation in patients with
acute myocardial infarction with great caution. The
biochemical effects of this study and the evidence of
reduced myocardial ischaemic injury in a previous study
(Vik-Mo and Mj/>s, 1-977), support the view that ischaemic




Sodium salicylate reduced arterial concentrations of
plasma free fatty acids and their extraction by the ischaemic
and non-ischaemic myocardium, during basal and isoprenaline
stimulated lipolysis. The extraction of glucose and oxygen
and the production of lactate were not affected. Nor was
the haemodynamic state altered.
These results and the evidence of reduced myocardial
ischaemic injury in a previous study, support the view that




EFFECTS OF NICOTINIC ACID
321
INTRODUCTION
Nicotinic acid is known to have
antilipolytic activity. Catecholamine-induced lipolysis
can completely be abolished (Kjekshus and Mj/s , 1973),
which was not observed with the other drugs used to
lower plasma concentrations of free fatty acids. Thus
the impression is that nicotinic acid is most effective,
although admittedly, a formal comparative study has not
been made.
Nicotinic acid and its derivative p-pyridylcarbinol
reduced myocardial ischaemic injury during experimental
coronary occlusion in dogs (Vik-Mo, 1977; Kj'ekshus and
Mj^s, 1973) and in patients with acute myocardial in¬
farction (Russell and Oliver, 1978; Kj'ekshus,
1978). Reduction in myocardial oxygen requirements, due
to reduced plasma concentrations and uptake of free fatty
acids, was assumed to be the mode of action. However,
the metabolism of the ischaemic myocardium could not be
assessed. Therefore the effect of nicotinic acid on the
metabolism of plasma free fatty acids, glucose and lactate
by the ischaemic myocardium was examined. This was
accomplished by measurement of arterio-venous differences
of plasma concentrations of free fatty acids, glucose and
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lactate across the ischaemic and non-ischaemic myo¬
cardium during basal and isoprenaline-stimulated
lipolysis, preceding and after administration of nicotinic
acid.
Furthermore, since glycerol is not utilised in the
myocardium to any significant amount (Robinson and
Newsholme, 1967), the effect of nicotinic acid on myo¬





Studies were performed on 7 overnight-fas ted mongrel
dogs of either sex, weighing on average 22 kg as described
in Part 2 (Section 2.1) of this thesis.
Haemodynamic measurements
Mean aortic blood pressure (AP), left ventricular
pressure, dP/dt were recorded on a Dynograph recorder
(Type 411, Beckman Instruments Inc., Schiller Park, 111.,
USA) as described in Appendix E.
Metabolic measurements
The biochemical procedures were identical to those
described in Section 3.4.1., except that plasma glycerol
was also analysed in Edinburgh, using the fluorimetric
enzymic method presented in Section 2.2.4.
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3.5.2. Experimental procedure
Experiments were carried out both under basal con¬
ditions and during continuous intravenous infusion of
isoprenaline at a rate of 0.10 - 0.20 ^ug/min/kg.
Generally four intermittent occlusions were performed
in each animal (see Section 2.1.3). This allowed each
animal to serve as its own control for the assessment of
the effect of treatment during basal and isoprenaline
stimulated conditions. Haemodynamic measurements were
performed immediately before and 12 min following the
occlusion of the coronary artery. Blood samples were
obtained from 6 to 12 min after induction of myocardial
ischaemia. The coronary artery occlusion was released
after 12 min and a recovery period of 45 min was allowed.
A second occlusion was performed after 10 min of iso¬
prenaline infusion when the haemodynamic variables had
stabilised. All measurements were repeated. After re¬
lease and recovery, the infusion of nicotinic acid dis¬
solved in 0.9% (w/v) saline at a dose of 0.3 mg/kg/min
was started. After 30 min a third occlusion was made,
followed after release and recovery by a fourth occlusion
during isoprenaline. Care was taken that the haemodynamic
and electrocardiographic measurements were always done and
blood samples were always obtained in the same order, and
32 5
at the same time after occlusion.
Saline (0.9%, w/v) , at a rate of 10 ml/kg/hr was
given throughout the experimental procedure.
Glycerol measurements were made in 5 experiments
without and in 6 experiments with isoprenaline infusion.
Statistics
Each dog served as its own control. Wilcoxon's
non-parametric test (two-tailed) for paired data was
used to calculate probabilities. Statistical com¬
parisons are not performed between samples of 5 or less.
P > 0.05 was regarded as not statistically significant.
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3.5.3. Results
Effects of nicotinic acid during basal lipolysis
Nicotinic acid significantly reduced the arterial
concentrations of plasma free fatty acids during basal
lipolysis (i.e. in the absence of isoprenaline); P < 0.05,
n = 7, whereas no other significant changes in arterial
levels of oxygen, glucose or lactate were observed. The
extraction of free fatty acids by the ischaemic and non-
ischaemic myocardium were both reduced by nicotinic acid
in all experiments, but no change in arterio-local venous
(across the ischaemic myocardium) or arterio-coronary
sinus difference (draining mainly non-ischaemic myocardium)
for oxygen, glucose and lactate was observed. Arterial
plasma glycerol concentrations were reduced after admin¬
istration of nicotinic acid in only 2 out of the 5 experi¬
ments, where glycerol was measured. In 4 out of 5
experiments coronary occlusion induced glycerol release
into the local venous effluent. After administration of
nicotinic acid this was observed in 3 experiments. Due
to the preceding isoprenaline infusion (see Fig 2.02)
arterial glycerol levels were still falling. Therefore,
in order to cancel the effect of the increased arterial
glycerol concentrations, the exchange of glycerol was
also calculated from arterio-local venous differences
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measured immediately before (not shown in Table 3.15)
and during coronary artery occlusion. The change in
arterio-local venous differences in glycerol concentra¬
tions induced by myocardial ischaemia were then
-30.9 - 12.9 and -6.5 t 10.2 pmole/l, measured before and
after the administration of nicotinic acid respectively.
Nicotinic acid did not alter the haemodynamic para¬
meters measured in this study.
The effects of nicotinic acid during isoprenaline infusion
During isoprenaline infusion the arterial concentra¬
tions of plasma free fatty acids (P <0.05, n = 7) and
glycerol (P < 0.05, n= 7), measured at 6-12 min of
coronary artery occlusion, were substantially reduced
by nicotinic acid, whereas those of the other substrates
and oxygen were unaltered. Extraction of plasma free
fatty acids and oxygen by the ischaemic myocardium were
markedly reduced (both P <f 0.05, n = 7). The arterio-
coronary sinus difference of plasma free fatty acids was
also significantly reduced, but this change in free fatty
acid metabolism by the predominantly normal myocardium
was not expressed in a reduction in oxygen extraction.
Nicotinic acid appeared to unmask glycerol release by
the ischaemic myocardium, however this change in arterio-
local venous difference of glycerol was not significant,
32 9
nor could it be distinguished from zero or from pre-
occlusion values, which were 4.7 * 4.6 jrmole/l (n = 6).
Nicotinic acid did not modify the heart rate, left
ventricular pressure and left ventricular dP/dt max




Nicotinic acid substantially reduced the plasma con¬
centrations and extractions of free fatty acids by the
ischaemic myocardium, and thus almost certainly net uptake
of free fatty acids, since regional myocardial blood flow
in the ischaemic area is not effected by the drug (Vik-Mo,
1977). It should be noted that these changes in fatty acid
metabolism occurred without significant changes in arterio-
local venous difference of glucose and lactate, although a
tendency of reduced lactate release was noticed.
Therefore the well established beneficial effect of
treatment with nicotinic acid or its analogues in experi¬
mental acute myocardial ischaemia (Kjekshus and Mj^s , 1973;
Vik-Mo, 1977); in patients with acute myocardial infarction
(Rowe et al, 1975; Russell and Oliver, 1978; Kjekshus,
1978) or with angina pectoris (Luxton et al, 1976)
may indeed have a metabolic basis. It needs to be stressed
that the actual demonstration of reduced ischaemic myocardial
metabolism of fatty acids is crucial, since one cannot
reasonably extrapolate from the normal to the ischaemic
tis sue.
The possibility that inhibition of ischaemia-induced
myocardial lipolysis by nicotinic acid partly or entirely
accounts for its beneficial effect should be considered. In
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the absence of isoprenaline, occlusion of the left anterior
descending coronary artery induced glycerol efflux from the
ischaemic myocardium in all experiments (5), where glycerol
was measured and was observed after nicotinic acid in 4 out
of 5 experiments. Mean arterio-local venous difference of
glycerol increased from -20.9 - 8.0 to -13.7 - 13.4 ^umole/l
(n = 5). It is therefore tempting to interpret this as an
inhibition of ischaemia-induced myocardial lipolysis by
nicotinic acid. However such interpretation is hampered
by the fact that
a trend of reduced glycerol release was observed during
repeated (control) occlusions in our model (results
reported in Table 2.01).
arterial concentrations of glycerol were higher during
nicotinic acid infusion*, and may be associated with
increased extraction of glycerol, in analogy with similar,
well-documented relations between arterial concentrations
and arterio-venous differences observed for other sub-
s trates .
*The reason for the apparent failure of nicotinic acid to
reduce arterial glycerol concentrations, while plasma free
fatty acids were lowered, is most likely an effect of the
preceding isoprenaline infusion (see Section 2.1.5 ).
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Therefore in view of these problems our results can not
substantiate whether nicotinic acid inhibited ischaemia-
induced lipolysis or not^ but it has been shown to inhibit
glycerol release from the ischaemically perfused rat heart
(Brownsey and Brundt, 1977). However it may be that this
study cannot be compared directly, due to the absence of
free fatty acids in the perfusate of the isolated rat heart
study, since fatty acids themselves affect lipolysis. Further
studies are needed to establish firmly whether nicotinic acid,
apart from its effect on fatty acid extraction, also inhibits
ischaemia-induced lipolysis, and thereby prevent the energy-
wasting recycling of myocardial triglycerides on account of
these two effects. The reduced oxygen requirements by the
ischaemic, but not by the non-ischaemic myocardium, could be
explained by such a mechanism (Observations during isoprenaline
infusion). It is of interest to note that this was not ob¬
served with sodium salicylate, which had less marked anti-
lipolytic effects (Section 3.4).
These results support the view that ischaemic myocardial
metabolism may influence the viability of the compromised
heart, but a distinction between the effects of inhibition
of ischaemia-induced myocardial lipolysis and adipose tissue
lipolysis can not as yet be made.
*The extrapolation of the antilipolytic effect of nicotinic
acid on catecholamine induced lipolysis in normoxic tissue
to the ischaemic myocardium is deliberately not made.
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3.5.5. Summary
The mechanism of nicotinic acid's beneficial effect
during acute myocardial ischaemia was examined. A marked
reduction in fatty acid extraction by the ischaemic myo¬
cardium was found. It is not clear whether the reduction
in severity of acute myocardial ischaemic injury is also
due to an inhibition of ischaemia-induced myocardial lipolysis.
Nicotinic acid did not affect glucose extraction by the
ischaemic heart, but reduced that of oxygen, suggesting that
ischaemic myocardial metabolism became more efficient.
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Part 4
THE EFFECTS OF ENHANCED GLUCOSE UTILISATION ON MYOCARDIAL
METABOLISM AND ST-SEGMENT ELEVATION DUPING EXPERIMENTAL
MYOCARDIAL ISCHAEMIA IN DOGS
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SECTION 4.1:
DICHLOROACETATE, MYOCARDIAL METABOLISM AND ISCHAEMIA
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Introduction
The hypothesis that fatty acid and glucose metabolism
of the ischaemic myocardium influences the severity of acute
myocardial ischaemic injury was also tested by enhancing
glucose utilisation.
The effect of glucose, often in combination with insulin
and potassium, on the severity of myocardial ischaemic injury
has been demonstrated by others (Maroko et al, 1972; Sybers
et al, 1973; Haneda et al,1974;0pie and Owen, 1976). Di-
chloroacetate which increases the consumption of glucose by
the normal heart, by stimulating phosphofructokinase and
pyruvate-dehydrogenase was used (McAllister et ai, 1973).
Its use during acute ischaemia might have an advantage over
glucose infusions, in that it could theoretically prevent at
the same time the intracellular acidosis (lactate accumulation),




Experiments were performed on 29 healthy mongrel dogs
of both sexes (12-19 kg body weight) as described in Part 2
(Section 2.1) of this thesis. Coronary sinus blood was
sampled through a catheter inserted under fluoroscopic
guidance. In 10 experiments the local vein draining the
ischaemic area was cannulated for the assessment of metabolic
changes in the ischaemic myocardium.
Measurement s
Epicardial ST-segment mapping
The severity of acute myocardial ischaemic injury was
assessed by epicardial ST-segment mapping using a mobile
cotton wick electrode, as described in Section 2.3.1 of this
thesis.
Regional myocardial blood flow
141
Regional myocardial blood flow was measured with Ce
85
and Sr -labelled microspheres (nominal diameter 15 u), as
described in Section 2.4.
Biochemical analyses
Standard procedures for the collection and processing of
blood samples and for the estimation of plasma free fatty
acids (Section 2.2.2) and plasma glucose (Section 2.2.3) were
used. Blood lactate was measured in duplicate according to
338
the method of Hohorst (1970), or when local venous plasma
lactate concentrations were estimated as described in
Section 2.2„5. Plasma lipids were extracted in duplicate
and radioactive free fatty acids isolated by thin layer
chromatography as described by Boberg (1966). Radioactivity
was measured using a Packard Liquid Scintillation spectrometer
Model 3390. Internal standards were used to correct for
quenching.
4.1.2. Experimental design
Effects of dichloroacetate (DCA) on the response to
subsequent coronary occlusion
Experiments were carried out both under basal conditions
and during a continuous intravenous infusion of isoprenaline.
In six animals the experimental design conformed to procedure
1 of Fig 4.01. In one animal a similar sequence of occlusions
was performed without the use of isoprenaline in another animal
isoprenaline was given during all four occlusions. In three
animals the experimental design was reversed in accordance
with procedure 2 of Fig 4.01. In these experiments sodium
dichloroacetate was given before the first and second occlusions,
and a period of 95 min was then allowed for the metabolic
effects of dichloroacetate to diminish before repeating the
occlusion. The effects of dichloroacetate were assessed by
paired analysis of the data for all 11 experiments.
In five separate animals the effect of dichloroacetate
(120 mg/kg) on the metabolic pattern across the ischaemic zone
was studied during basal lipolysis. A constant infusion of
Figure 4.01 Experimental procedure for assessing the
effect of dichloroacetate on the response
subsequent coronary artery occlusion
to



























occlusions of 15 min duration were performed
two in the absence of dichloroacetate (DCA)
presence. Immediately before the release
of each occlusion (indicated by vertical arrows) epicardial
Four identical
in each animal,




Note in procedure 2
(+ dichloroacetate)
Occln = coronary artery occlusion.
Isopren = isoprenaline infusion.
mean aortic pressure and heart rate were
was sampled from a femoral artery and the




albumin-bound H -oleate (Radiochemical Centre, Amersham),
prepared as described by .Opie et al (1973) was commenced
at least 90 min before blood samples were collected and
maintained throughout the experiment. Between 5 and 15
min after the occlusion of the branch of the LAD coronary
artery, arterial, local venous, and coronary sinus blood
3
samples were taken for measurements of FFA, H -FFA, glucose
and lactate. After release and recovery DCA was administered
and the occlusion repeated 10 min later. Care was taken that
blood samples were obtained at the same relative times during
the two occlusions. In another five animals the identical
procedure was repeated except that now the occlusions were
preceded by a continuous isoprenaline infusion (0.1-0.15 /ag
i -1 • -1\kg mm ) •
In four additional animals the effects of DCA on regional
myocardial blood flow 15 min after coronary occlusion
were assessed by means of radioactive microspheres.
Measurements were made during an initial control occlusion,
and then during a second occlusion performed 10 min after
administration of sodium dichloroacetate (120 mg/kg). The
order of injection of the differently labelled microspheres
was varied to avoid systematic errors due to possible
differences in their behaviour.
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Effects of dichloroacetate admin¬
istration during established coronary occlusion
In another four animals iv infusion of isoprenaline
(0.2-0,3 pg .kg" "'"minwas maintained for the duration of
the study. Five minutes after its commencement control
recordings of the epicardial electrocardiogram,
arterial blood pressure and heart rate were made before
a branch of the left anterior descending coronary artery
was permanently occluded. Further electrocardiographic
and haemodynamic measurements were made 5, 10, and 15 min
following coronary occlusion. Sodium dichloroacetate
(120 mg/kg iv) was then infused over 2 min and the electro¬
cardiographic and haemodynamic recordings repeated 5, 10,
15, and 20 min later. Arterial and coronary sinus blood
was sampled immediately before and 20 min after the in¬
jection of dichloroacetate for measurement of plasma free
fatty acids and glucose concentrations.
In the same animals the effect of dichloroacetate on
the total (a-cs) myocardial extraction of radiolabelled
palmitate was also examined. For this purpose a con-
3
tmuous intravenous infusion of albumin-bound (9,10(n)- H)
palmitate (Radiochemical Centre, Amersham) was commenced
at least 90 min before blood samples were collected.
Arterial and coronary sinus blood for measurement of plasma
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free fatty acid radioactivity was sampled immediately
before and 20 min after dichloroacetate injection,,
Statistics
Each dog served as its own control. Student's t-test
for paired data was used to calculate probabilities.
P>0.05 was regarded as not statistically significant.
4.1.3. Results
Effects of dichloroacetate on the response to subsequent
coronary occlusion
The effects of dichloroacetate on the response to sub¬
sequent coronary occlusion under basal conditions are
summarised in Table 4.01. Coronary occlusion raised epi-
cardial ST segments in all experiments. In the absence
of dichloroacetate, EST averaged 18 t 3 mV (mean t SEM)
15 min after coronary occlusion. Values for EST were
significantly less when coronary occlusion was performed
after the administration of dichloroacetate (EST 6 t 2 mV;
P<0.005). Heart rate was decreased from 136 - 8 to
127 - 8 beats/min (P < 0.05), while AP was unchanged.
Arterial blood lactate concentration was reduced by
dichloroacetate from 1.10 1 0.24 to 0.28 t 0.03 mmole/l
(P < 0.01). The arterial-coronary sinus difference
(Lactate ) in lactate concentration was reduced froma-cs'
0.32 t 0.07 to 0.08 ± 0.02 mmole/l (P < 0.02), while that
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Table 4.01
Effects of pretreatment with sodium dichloroacetate (120 mg/
kg) on epicardial ST-segment elevation and haemodynamic and
biochemical measurements 15 min after coronary occlusion
under basal conditions
Measurements n* Mean _+ SEM p**
Control Dichloroacetate
ZST(mV) 10 18+_3 6+_2 <0.005
HR(beats/min) 10 136+_8 127+_8 <0.05
AP(kPa) 10 15.3+0.8 15.3+0.8 NS
FFA
a
10 0 .4 5+0.05 0.46+0.06 NS
FFA
a-cs
10 0.09+0.03 0.06+0.02 NS
Glucose
a
9 5.22+0.22 5.22+0.28 NS
Glucose
a-cs
9 0.2 5+0.08 0.55+^0.06 CO.005
Lactate ****
a
7 1.10+0.24 0.28+0.03 CO.01
Lactate ****
a-cs
7 0.32+0.07 0.08+0.02 <0.02
Series II***
FFAa(umole/litre)








6 .11_+0 . 72








4 0.99+0.46 1 .12_+0 . 50 NS
Lactate
a
4 0.78+0.13 0.50+0.11 NS
Lactate ,
a-lv
4 -2 .38+0 .71 -1 .72^0.44 NS
Z'ST = sum of ST-seqment elevation at 10-15 epicardial sites;
HR=heart rate; AP=mean aortic pressure; -FFA=radioactive
FFA.The subscripts indicate:a=arterial concentration; a-cs =
arteriocoronary sinus concentration difference; a-lv=arterio-
local venous concentration difference (local vein, draining
the ischaemic area);(a-lv)/a=extraction in the ischaemic area.
Concentrations and arterio-venous differences in mmole/l.
*Number of dog studies.
**P values were obtained by the paired t test; NS=not
statistically significant(P> 0.05).
***Separate study, observations were made between 5-15 min
after coronary occlusion.
****Blood lactate concentrations.
Conversion: SI to traditional units: 1 kPacf7.5 mmHg.
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in glucose concentration (Glucose ) was increased3. — C S
from 0.25 t 0.08 to 0.55 t 0.06 mmole/l (P <0.005). Other
metabolic measurements were unchanged.
The effect of dichloroacetate on the a-v differences in
concentration of metabolites across the ischaemic zone is
tabulated in Table 4.01 (series II). There was a tendency
for arterial-local venous difference in plasma glucose con¬
centration (Glucose ) to increase (three out of fourv a-lv' v
experiments), although arterial glucose concentration
tended to decrease and the decrease in glucose a-lv actually
occurred when arterial glucose concentration decreased as
much as 18%. In three out of four experiments lactate
release was diminished. No marked effect of dichloro-
acetate on the extraction of radioactive free fatty acids
in the ischaemic area was found.
In the absence of dichloroacetate, isoprenaline infusion
increased 2IST from 18 t 3 to 62 t 8 mV (Table 4.01 and
4.02; control occlusions;P <O.OOl). This was associated
with a reduction in AP (P< 0.005), and increase in heart
rate (P < O.OOl), and increases in the arterial concentra¬
tions of free fatty acids (P<0.001), glucose (P<0.01) and
lactate (P< 0.025).
The effects of dichloroacetate on the response to sub¬
sequent coronary occlusion during isoprenaline infusion
appear in Table 4.02.
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Table 4.02
Effect of pretreatment with sodium dichloroacetate (60 mg/kg)
on epicardial ST-segment elevation and haemodynamic and bio¬
chemical measurements 15 min after coronary occlusion during
a continuous intravenous infusion of isoprenaline (0.2-0.3
pg/kg/min)
Measurements n Isoprenaline( mean+SEM) P
Control Dichloroacetate
1ST(mV) 10 62 + 8 45 + 7 <0.001
HR(beats/min 10 162 + 8 155+6 <0.05
AP(kPa) 10 11.7+0.93 12 .2+0.80 <0.02
FFA
a
9 1.72+0.18 1 . 72+0.17 NS
FFA
a-cs
9 0.31+0.40 0 .19+0 . 02 <0.005
Glucose
a
9 6 .7 8+0 . 61 6.67+0.56 NS
Glucose
a-cs
9 0 . 3 9+_0 .11 0.68+0.14 0.02
Lactate **
a
7 1 .67^0.35 0.6 9 +0.10 0.02
Lactate
a-cs















5 6.39+0.4 8 5.83+0.59 NS
Glucose
a-lv
5 1.28+0.21 1.66^0.39 NS
Lactate
a
4 1 . 32 +0.15 0 . 80+0 .19 <0.01
Lactate .
a-lv
4 -2.67+0.63 -1.88+0.51 <0.05
All abbreviations as in Table 4.01. Concentrations and arterio'
venous differences in mmole/1 #
*Separate study:dose of sodium dichloroacetate 120 mg/kg; dose
of isoprenaline 0.1-0.15 (ug.kg 1. min; observations were made
between 5-15 min after coronary occlusion.
**Blood lactate concentrations.
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Pretreatment with dichloroacetate reduced isoprenaline-
induced increase in rST from 62 ± 8 to 45 ± 7 mV (P<0.001).
Heart rate was reduced from 162 t 6 to 155 t 6 beats/min
(P<0„05), while AP was increased from 11.7 t 0.93 to
12.3 t 0.80 kPa (88 1 7 to 92 1 6 mmHg) (P<0.02). The
effects of dichloroacetate on lactate and glucose meta¬
bolism during isoprenaline resembled those observed under
basal conditions: i.e. decreases in arterial lactate con¬
centration (P<0.02) and a decrease in the arterio-venous
difference of lactate concentration (P<0.10), and an in¬
crease in the glucose of 0.29 t 0.09 mmole/l (P<0.02).SL "™C S
In addition, the arterio-venous difference in free fatty
acid concentration was decreased from 0.31 ± 0.04 to
0.19 ± 0.02 mmole/l (P <0.005) in the absence of change
in arterial free fatty acid concentration.
The effects of dichloroacetate on the a-v differences
of substrates across the ischaemic area during iso¬
prenaline infusion are summarised in Table 4.02 (series
II). Dichloroacetate had a consistent and significant
lowering effect on lactate release from the ischaemic
left ventricle. The arterio-venous difference of glucose
increased in four out of five experiments, and arterial
plasma glucose concentrations tended to decrease; when
arterial glucose concentrations decreased by as much as
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25%, glucose extraction by the ischaemic area actually
decreased after dichloroacetate (one experiment). The
3
extraction of ( H) free fatty acid appeared to be un¬
changed by dichloroacetate.
The results of the radioactive microsphere studies are
summarised in Table 4.03. Non-ischaemic tissue of the
free wall of the left ventricle distant from the occluded
artery was taken to represent normal myocardium. On this
basis coronary occlusion produced an average decrease of
approximately 75% in blood flow to the ischaemic zone, the
reduction in flow being greater in the endocardial (mean
reduction, 0.95 ml .g"^ .min'^-^han in the epicardial (0.87
ml.g ^ .minelayers. Dichloroacetete increased blood flow
to both the epicardial (+0.19 ml.g ^ min or 16%; P < 0.005)
and endocardial (+0.16 ml .g-"^ .min ^or 13%; P< 0.025) layers
of the non-ischaemic myocardium, but had no effect on that
to the ischaemic zone.
Effects of dichloroacetate administration during establish¬
ed coronary occlusion
The effects of dichloroacetate administration during
established coronary occlusion and isoprenaline infusion
are presented in Table 4.04 and the changes in epicardial
ST segments in one experiment are illustrated in Fig 4.02.
Ten, 15, and 20 min after dichloroacetate values for ST
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Table 4„03
Effects of sodium dichloroacetate, 120 mg/kg, on regional
myocardial blood flow in ischaemic and non-ischaemic free
left ventricular wall 15 min after coronary occlusion in
four dogs






Epicardial 1 .16 +0.05 1.35^0.06 <0.005
(25) (25)
Endocardial 1 .25+0.05 1 .41+0.06 <0.025
(25) (25)
Ischaemic myocardium***
Epicardial 0.29+0.07 0.34+0.07 NS
(11) (11)
Endocardial 0.30+0.08 0.35+0.10 NS
(11) (11)
Results are expressed as means + SEM. The figures in parentheses
indicate the number of biopsies.
*Paired t test. NS: P>0.05.
**Myocardium distant from the occluded artery.
***Myocardium within the area of distribution of the occluded
artery.
























































AllabbreviationsresinTable4.01.Concentrationsandarterio-venousdiff r cem ole/l,x ptrII-KFA( d-cs) whichareexpressedindpm/ml. 3 H-FFA^-arterialF Aradioactivitys(9,10(n)-H)p lmitate;H-FFAc"arterial-coronarysinusconcentrationiffer nce inFFAradioactivity. Statisticalcomparisonswereperfo medbyp ir tag insth sere ultsbtainedI m iatelyb forDCA(ti e20ln). *p<0.05;®P<0. 1;""P<0.005;**P .001. ®®Onedogonly.Isoprenalineinfusion(0.2-3pg.kg/mi ) Coronaryarterocclusion Dlchloroacetate(12Qmg.kg"^iv)
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Figure 4.02. The effect of dichloroacetate during an
established coronary artery occlusion on
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Epicardial electrocardiographic recordings from four of
11 sites in one experiment. Five minutes after the
commencement of an intravenous infusion of isoprenaline
(0.2-0.3 pg.kg-l/min) a branch of the left anterior de¬
scending coronary artery was permanently occluded. Fif¬
teen min later sodium dichloroacetate was given by intra¬
venous injection at the dose of 120 mg/kg. Epicardial
electrocardiograms were recorded immediately before coronary
occlusion (time, 5 min), and subsequently at 5 min intervals
until 20 min after the administration of dichloroacetate.
LV = left ventricle; LAD = left anterior descending coronary
artery; Occln = coronary occlusion.
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were significantly lower than those observed immediately
before treatment (P<0.05). Mean aortic pressure and
heart rate at these times were similar to those recorded
before treatment, with the exception that heart rate had
decreased by 8 t 2 beats/min (P<0.01) after 20 min. The
arterio-venous difference, \ in glucose concentration(a-cs) ^
was increased from 0.11 to 0.61 mmole/l (one experiment),
while that in free fatty acid concentration was decreased
(P < 0.05) in the presence of unchanged arterial con¬
centrations. Dichloroacetate also reduced the arterio¬
venous difference in free fatty acid radioactivity in
these experiments (P<0.05).
4.1.4. Discussion
The most notable finding of the present study was
that dichloroacetate reduced the degree of epicardial
ST-segment elevation following acute coronary occlusion
in dogs, and reduced also the augmentation of ST-segment
elevation induced by isoprenaline. This latter effect
was observed both when dichloroacetate preceded subsequent
reocclusion of the artery and when given during an occlus¬
ion established 15 min earlier.
Epicardial ST-segment elevation has been shown to re¬
flect the severity of myocardial ischaemia (Wegria et al,
1949), and to correlate with the local changes in tissue
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oxygen tension (Sayen et al, 1958) and cellular membrane
potential( Prinzmetal et al, 196l) during coronary occlus¬
ion. The degree of ST-segment elevation 15 min after
coronary occlusion has been correlated with the subsequent
depletion of myocardial creatine kinase activity (Maroko
et al, 1971; 1972; Kjekshus and Mj^s, 1973) and the de¬
velopment of histological, histochemical, and ultrastruct-
ural evidence of cellular necrosis (Maroko et al, 1972;
Libby et al, 1973) after 24 h of sustained occlusion. It
is likely, therefore, that the reduction in ST-segment ele¬
vation produced by dichloroacetate in the present study
reflected a limitation of the acute myocardial ischaemic
injury.
The severity of myocardial ischaemic injury is in¬
fluenced by factors which alter myocardial oxygen require¬
ment relative to oxygen supply. The major determinants
of myocardial oxygen requirement are heart rate, wall
tension, and contractility (Sonnenblick et al, 1968), and
the possibility must be considered that the reduction of
ST-segment elevation by dichloroacetate may have been
secondary to a change in one of these parameters. Al¬
though dichloroacetate reduced mean heart rate in all
experiments, this effect averaged only 5%, and was
probably insufficient to account for the mean reduction
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in ST-segment elevation of 44% (Maroko et al, 1971;
Wendt et al, 1974). Furthermore, in six instances di-
chloroacetate administration was associated with an un¬
changed or increased heart rate, but nevertheless ZST
was significantly reduced. Changes in AP, when present,
were also insufficient to explain the reduction in ST
segment elevation. An effect of dichloroacetate on
myocardial oxygen supply is unlikely as the results of the
ch
microsphere studies showed that blood flow to the i^aemic
zone was unchanged by dichloroacetate.
The effect of dichloroacetate on non-ischaemic myocardial
metabolism
The use of arterial-coronary sinus differences has been
shown to be justified for the study of non-ischaemic myo¬
cardial metabolism when small ischaemic lesions are produ¬
ced (Owen et al, 1970; Opie et al, 1973). Changes in
arterial-coronary sinus concentration differences have
indicated that dichloroacetate had marked effects on the
pattern of substrate utilisation by the non-ischaemic left
ventricle. In all experiments dichloroacetate raised the
total myocardial extraction of glucose relative to that
of free fatty acid. In most instances this reflected
both an increase in the arterio-venous difference in
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glucose concentration and a decrease in that of free
fatty acid, although the latter reached statistical
significance only in the presence of isoprenaline. In
all but one of seven animals dichloroacetate also reduced
the arterial lactate concentrations and the arterio-venous
difference in lactate concentrations. The decrease in
3
arterio-venous difference in free fatty acid ( H-palmitate
experiments and free fatty acid during isoprenaline) can
be interpreted either as a decrease in the extraction of
free fatty acid or an increase in intramyocardial lipoly-
sis. The latter does not seem likely, since dichloro-
acetate exerted an antilipolytic effect in rats (Black-
shear et al, 1974). Another possibility could be that
dichloroacetate behaves in a similar fashion as a non-
readily oxidisable acid, such as hypoglycin or 4-pentenoic
acid (Bressler, 1970). These acids lower tissue levels
of free coenzyme A, and thereby leading to a situation in
which extracted fatty acids cannot be readily activated
and may diffuse back into the plasma free fatty acid pool.
The stimulation of glucose metabolism by dichloro-
acetate is in agreement with the observations of McAllister
et al. (1973) who studied alloxan-diabetic dogs and
healthy dogs in which free fatty acid concentrations had
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been raised by infusions of a triglyceride emulsion and
heparin. The increase in myocardial glucose utilisation
was attributed by these workers to a stimulation of
phosphofructokinase and to the activation of pyruvate
dehydrogenase. The reduction in arterial lactate con¬
centrations is also in agreement with earlier studies in
dogs and rats (McAllister et al, 1973; Blackshear et al,
1974). In functionally hepatectomised rats it was shown
that the decrease in arterial lactate concentrations is
due to a reduced release of lactate from extrahepatic
tissues (Blackshear et al, 1974). This and the observa¬
tion that dichloroacetate increases pyruvate dehydrogenase
activity in muscle (Whitehouse and Randle, 1973) may ex¬
plain the decrease in arterial lactate concentration. The
decrease in total lactate extraction by the heart accords
with its known arterial concentration-extraction relation¬
ship (Kaijser et al, 1972).
The effect of dichloroacetate on ischaemic myocardial
metabolism
These metabolic findings cannot be extrapolated to
the metabolism in the ischaemic area and therefore should
not be directly related to the electrocardiographic changes
recorded over that area. It is necessary therefore to
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make comparable measurements using local vein sampling
techniques, thereby deriving arterial-local vein con¬
centration differences which mostly reflect metabolic
changes in the ischaemic tissue (Owen et al, 1970; Opie et
al 1973). Dichloroacetate increased a-lv concentrations
of glucose, even when arterial glucose concentrations fell.
Lactate release was decreased in the isoprenaline stimula¬
ted situation.
It is possible that apparent changes in local venous
concentrations of metabolites are entirely due to a change
in the relative proportions of blood originating from non-
ischaemic and ischaemic myocardium. However, having
acknowledged the existence of this problem, there are no
methods to our knowledge which would define the particular
admixture of blood sampled from the local vein.
With this reservation in mind, it appears that the local
metabolic effects; increased arterio-venous difference in
glucose concentration and reduced lactate release could be
related to the reduction in £ST in the ischaemic area.
This interpretation is supported by the observation
that dichloroacetate reduced ischaemia induced enzyme
release from the isolated perfused rat heart (Burges ,
personal communication). However the effect of dichloro¬
acetate on myocardial metabolism could not be assessed in
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those studies. On the other hand our findings have not
been confirmed by another study of coronary artery occlu¬
sion induced ischaemia in an anaesthetized dog preparation
(Burges , personal communication). He used however l/10
of the dose, which was used in this study and did not
measure the effect on myocardial metabolism.
Mechanism of dichloroacetate
The metabolism of the acutely ischaemic myocardium has
been reviewed (Opie, 1970; Oliver, 1972; Opie, 1972; Opie,
1975; Rovetto and Nealy, 1977; this thesis). The oxida¬
tion of glucose, free fatty acids and lactate is immediate¬
ly impaired. However, for unexplained reasons glucose
competes better with fatty acids for the residual oxygen
than it normally does. There is evidence that catechol¬
amines are locally released, and this may explain the early
rise in cyclic AMP levels in the ischaemic myocardium,
which are thought to stimulate glycogenolysis. Other
factors which may play a role are the enhanced breakdown
of ATP and the accumulation of AMP and inorganic phosphate
under these conditions. However within minutes glycolysis
is inhibited, presumably due to inhibition of glyceralde-
hyde-3-phosphate dehydrogenase or of phosphofructokinase,
which are both sensitive to the intracellular acidosis
caused by lactate accumulation.
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It is now clear that a considerable degree of glucose
oxidation persists in the ischaemic myocardium (Opie et
al, 1973; Neely et al, 1975) . It is possible that di-
chloroacetate in our experiments might have prevented the
intracellular acidosis, by enhancing the activity of
pyruvate dehydrogenase. This could possibly then have
prevented the inhibition of phosphofructokinase and/or
glyceraldehyde-3-phosphate dehydrogenase. A similar
mechanism appeared to operate in ischaemic perfused rat
hearts, in which acidosis was counteracted by the use of
buffers. Control of glycolysis in ischaemic myocardium
under these conditions was shifted to pyruvate kinase or
pyruvate dehydrogenase (Rovetto et al, 1975). Thhs di-
chloroacetate might have reduced ischaemic injury by
increasing the capacity of the ischaemic cells to meta¬
bolise glucose aerobically, and its effectiveness may be
dependent on the presence of residual oxygen supply.
Other mechanisms whereby dichloroacetate may have re¬
duced ischaemic injury include the inhibition of free
fatty acid metabolism and an enhancement of lactate removal
from the ischaemic cell secondary to the reduction in
arterial lactate concentration.
However, this latter possibility seems remote in view
of the high gradient of lactate across the is¬
chaemic membrane (Rovetto and Neely, 1977). Therefore,
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no certain conclusions concerning the precise mechanisms
whereby dichloroacetate reduces ST-segment elevation can
be drawn at this stage.
Application of dichloroacetate in the clinical setting of
acute myocardial infarction
Dichloroacetate has not been used in the early treat¬
ment of acute myocardial infarction. Although it has been
used alone or in combination with buformin in maturity-
onset of diabetics (Stacpc^Le et al, 1978; Standi et al,
1977).Other workers have suggested that dichloroacetate
could lead to oxalate (derived from dichloroacetate)
nephrotoxicity and that 2-chloropropionate, which also
activates pyruvate dehydrogenase may be devoid of this
severe side effect (Crabb and Harris, 1978)f It is often
said that increased myocardial glycogen stores enhance the
chances of survival during ischaemia. If this is true, then
depletion of glycogen stores after the administration
(Hulsmann, personal communication) could have serious
repercussion for patients with acute myocardial infarct¬
ion, treated with these compounds which have an extension
of their infarct. Therefore, alternative combinations
such as PDH activators plus pyruvate or glucose could
offer potential advantages. Clearly more work with non-toxic
drugs is indicated.
*Note in print: Dichloroacetate has been withdrawn after
neurological disorders were observed in patients during




Acute administration of or pretreatment with di-
chloroacetate reduced ischaemia induced ST-segment
elevation. This effect could not be explained by changes
in mean aortic blood pressure, heart rate or regional
myocardial blood flow. Increased glucose and decreased
free fatty acid extraction by the non-ischaemic myo¬
cardium was observed. Lactate release by the ischaemic
zone was reduced and glucose extraction tended to increase.
These results support that ischaemic myocardial metabolism
influences the cellular viability.
However the use of pyruvate dehydrogenase activators
can not yet be recommended for the treatment of patients
with acute myocardial infarction, since they may deplete
myocardial glycogen stores and dichloroacetate can certain¬
ly not be used due to its recently discovered toxicity.
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Part 5
THE EFFECTS OF RAISED PLASMA CONCENTRATIONS OF FREE
FATTY ACIDS ON NORMAL AND ISCHAEMIC MYOCARDIAL METABOLISM
362
INTRODUCTION
In this section we will examine the effects of raised
plasma concentrations of free fatty acids on metabolism
of the normal and ischaemic myocardium. The considera¬
tions leading to the choice and development of the two
models used is given in Section 2.1. In the first model,
for sake of convenience referred to as Intralipid/heparin,
plasma free fatty acids are raised by intravascular lipo-
lysis of triglycerides (Intralipid), induced by heparin.
In the second model plasma concentrations of free fatty
acids were raised using a blood cell separator. This
centrifuge separates blood into a stream of blood cells
and cell free plasma. Sodium salts of fatty acids can
then be infused and bound directly to the plasma albumin
of the dog, which is then returned to the animal recon¬
stituted with the blood cells.
The validity of the former model was queried due to its very
high arterial plasma concentrations of free fatty acids,
reported by our group and others, using Intralipid/heparin
as the model (Mj/s, 1971 ; Kurien et al, 1971; Opie et al,
1972). Therefore a formal study of the effect of Intra¬
lipid/hepar in as a model was undertaken in closed-chest
anaesthetised dogs (Section 5.1 ).
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The effects of raised plasma free fatty acids, using
the blood cell separator, was also examined in normal dogs
(control studies) and in dogs with coronary artery occlus¬
ion. The results are reported in Section 5.3. and 5.4.
respectively, after the development of the blood cell
separator is first described in Section 5.2.
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SECTION 5.1:
THE EFFECTS OF RAISED PLASMA CONCENTRATION OF FREE FATTY
ACIDS ON MYOCARDIAL METABOLISM AND FUNCTION, USING INTRA-
LIPID/HEPARIN AS A MODEL
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The effects of Intralipid/heparin
Introduction
Heparin has been widely used in studies of the effects
of raised plasma concentrations of free fatty acids on
various aspects of general metabolism in man or in animals.
In some studies heparin was used to induce intravascular
lipolysis during alimentary lipaemia (Schalch and Kipnis,
1965; Greenough et al, 1967; Balasse and Ooms , 1968;
Crespin et al, 1969). In other studies the complicating
effects associated with alimentation were avoided by in¬
jection of Intralipid (Meng and Edgren, 1963; Kurien and
Oliver, 1970; Mj/s, 1971^; Opie et al, 1972).
There can be no doubt that this is the most convenient
system, available to those who aim to raise plasma con¬
centrations of free fatty acids and who can not or do not
want to use lipolytic drugs, with their cardiovascular
and haemodynamic effects. Despite this we did not intend
to use Intralipid/heparin as a model, mainly due to our
concern over the unphysiologically high plasma free fatty
acid concentrations.
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Nor were we unduly concerned about the use of heparin,
since this drug could be administered as a continuous
infusion and thereby be a presumably constant factor
common to the control and observation periods. However,
it is acknowledged that heparin may have effects which
change the background conditions, under which the ex¬
periments were made.
When it was learned that in vitro lipolysis in
lipaemic samples of heparinised dogs or patients could
be as high as 1-4%/min, a formal study of Intralipid/





Seven mongrel dogs of either sex, weighing between
13 and 18 kg, were anaesthetised after overnight fasting
by an intravenous injection of sodium pentobarbitone
(about 25 mg/kg). Anaesthesia was maintained using a
constant infusion of pentobarbitone at a dose of 3-4 mg/
kg/hr. Ventilation was maintained through a cuffed
endotracheal tube with a positive pressure respirator
(Harvard Apparatus Co, Mass., USA). Both femoral veins
were cannulated as a route of infusion, and the left
femoral artery was cannulated for the monitoring of aortic
blood pressure with a Statham P23Db transducer.
A catheter was introduced via the left jugular vein
into the coronary sinus under fluoroscopic guidance as
described in Section 2.1.4 , and kept patent using a slow
drip of 0.9% (w/v) saline.
Biochemical analyses
Blood samples were collected simultaneously from the
arterial and coronary sinus catheter. In addition to
our standard procedure of keeping samples on ice, special
care was taken with the processing in this study to avoid
flotation of triglycerides during centrifugation and to
avoid artifacts due to in vitro lipolysis.
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Free fatty acid concentrations were estimated on
blood samples, immediately extracted, as described in
Section 2.2.2^. The results were expressed in terms
of plasma concentrations by correcting for the dead space
occupied by the packed cells, which were measured in
quadruplicate using a Hawksley microhaematocrit centri¬
fuge. Plasma triglycerides were immediately extracted
after centrifugation (usually within 15 min) and their
concentration was determined using the automated fluori-
metric method with blank corrections, as described in
Section 2.2.7. Radioactive free fatty acid concentra¬
tions were determined in duplicate by liquid scintillation
counting after immediate extraction and later purification
by thin layer chromatography according to the method of
Boberg (1966). Free fatty acid turnover was calculated
from the arterial plasma specific activity and the in-
14
fusion rate of C-palmitate,(bound to bovine albumin—
Fatty acid poor Cohn's fraction V - prepared accord¬
ing to Opie et al (1973). Final FFA/albumin molar
ratio 0.20). Plasma albumin was measured according to
the method, described in Section 2.2.6.
5.1.2. Experimental procedure (Fig 5.01).
Two series of experiments were performed. In the
first group comprising 4 dogs, a bolus injection of
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Figure 5.01. Experimental procedure for the study of
myocardial metabolism and whole body
turnover of free fatty acids using Intra-
lipid/heparin as the model
Protocol
C14 - PALMITATE INFUSION
INTRALIPID
HEPARIN
1 1 1 1111 I i i_
60 80 110 150 min
Arterial and coronary sinus blood samples for the estimation
of plasma FFA, plasma ^4C-FFA, TG, LPLA.
Abbreviations: FFA = plasma free fatty acid concentra¬
tion; 14C-FFA = 14C-radioactivity in free fatty acids




1- C-palmitate, sufficient to raise arterial plasma
14 .
C- fatty acids at the required level of 2000 dpm/ml
was given (about 0.3 pCi/kg), followed by a continuous
14
infusion of C-palmitate, calculated to maintain this
level of radioactive fatty acids (about 1.2 pCi/kg/hr).
The bolus injection was given to ensure that a steady
state was quickly reached (Dr. G.L. Atkins, personal
communication). The infusion was maintained throughout
the experiment. The first blood sample for the analysis
of arterial and coronary sinus concentration of plasma
14
free fatty acids, triglycerides, C-free fatty acids and
lipolytic activity was taken at 70 min of infusion and
at 80 min of infusion (control observations). An intra¬
venous bolus injection of Intralipid 20% (w/v), (Kabi-
Vitrum, Ealing) at a dose of l.O ml/kg, followed by a
continuous infusion of 30 ml/hr was given throughout the
rest of the experiment. Blood samples were taken 10, 20
and 30 min later (Intralipid observations). After the
collection of the last samples heparin was administered
as an intravenous bolus injection (100 U/kg), followed
by a continuous infusion at a dose of 50 U/kg/hr, and
another set of blood samples were taken at 10 min intervals.
The second series (3 dogs), was identical to the first
except that plasma albumin levels were raised (from
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average 31.5 to 42.7 g/l) 70 min after the start of the
14
C-palmitate infusion. Blood samples were collected
10, 20 and 30 min later (control samples), after which
the Intralipid bolus injection and infusion were commenced.
From this moment the procedure was identical to that of
the first series.
5.1.3. Results
In series I, initially plasma free fatty acid and
triglyceride concentrations were low, averaging 0.35 1 0.05
and 0.85 - 0.07 mmole/l respectively (Table 5.01, Fig 5.02).
14
A steady state of arterial C-free fatty acid concentra¬
tion had been reached (not shown) and the turnover of
plasma free fatty acids was on average 138 t 10 pmole/min.
No lipolytic activity could be detected in plasma samples.
The infusion of Intralipid increased arterial tri¬
glyceride levels in all experiments (mean t SEM)
2.52 - 0.27 mmole/l. No systematic effect of Intralipid
alone on arterial plasma concentrations of free fatty acids
and their turnover was observed, but both tended to in¬
crease slightly. Lipolytic activity in plasma remained
virtually undetected. Ten min after the administration of
heparin plasma concentration of free fatty acids were in¬
creased and remained elevated during the rest of the 40
14
mm observation period. The concentrations of C-free
Table 5.01
The effect of Intralipid and heparin on plasma concentrations of free fatty acids and triglycerides, lipolytic activity
and whole-body free fatty acid (FFA) turnover in anaesthetized dogs






































605 345 560 1230 112 174 398 0.76 2.03 h-1 00o
0.2 27.2
606 270 250 975 147 117 396 0.97 2.52 1,65
0.9 26.3—
609 485 575 1030 137 176 329 0.95 3.29 4.44
O.O 21 .00.8
612 340 560 1250 137 205 446 0.71 2.26 2.94
6.6 21.9-1.3
Mean+SEM 350+50 490+80 1120+70 138+10 168+18 395+22 0.85+0.07 2.52+0 .27 2.70+0.65
-0.2 2+2 24+_3——■ —
Dog
Seriesll:
644 605 880 1180 1855 218 277 342 483 1.19 1 .20 3.63 4.00 0.2 12.5
647 1545 1845 1925 2370 426 561 534 575 1 .67 1.55 3.26 4.35 -2.1 1.1 19.0
64 9* 1010 1245 1255 1450 386 408 432 437 1 .36 1.20 3.44 5.17 4.4 0.4 3.3
Mean+SEM 1055+270 1325+280 1455+235 1890+265 343+64 415+82 436+55 419+41 1.41+0.14 1.32+0.12 3.44+0 .11 4. 51+0.35 1.2 0.6+0.3 11.6+4.5
For conditions see text. *Note in dog 649, heparin did not release lipolytic activity.
Concentrations were determined in arterial plasma. Average results of observation periods(3-4 measurements/period).
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Figure 5.02. The effect of Intralipid and Intralipid/
heparin on plasma free fatty acid con¬
centration, triglycerides, (lipoprotein)
lipase activity and free fatty acid turn¬


















□ Intralipid + heparin
Effects of Intralipid and Intralipid/heparin on arterial
plasma free fatty acids (panel 1); plasma triglycerides
(panel 2) on plasma lipolytic activity (panel 3) and on
free fatty acid turnover (panel 4).
Abbreviations as in Figure 5.01.
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fatty acids remained constant throughout the heparin-
period. Thus within 10 min a new steady state was
obtained, and the increase in free fatty acid turnover
is valid. The lipolytic activity of plasma was also
increased after heparin and remained constant during the
rest of the observation period. The results of all ob¬
servations during heparin were pooled. No systematic
effect of triglycerides was observed:in experiments 609/612
levels were rising, whilst in the other 2 concentrations
fell, but not below the initial values.
The increase in plasma fatty acid turnover was always
related to its arterial concentration and the results of
a representative study is shown in Fig 5.03.
The increase in arterial plasma free fatty acid con¬
centration was associated with an increased arterial-
coronary sinus difference of free fatty acids, and the
results of all dogs are shown in Fig 5.04.
In series II the effects of Intralipid/heparin was
examined in 3 anaesthetised dogs, after their plasma
albumin concentrations were increased from a mean of
31.5 to 42.7 g/l. The results are summarised in
Table 5.01.
Plasma free fatty acid concentrations in this sub¬
group were higher than those of series I. As a result
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FFA nM/1
Figure 5.03. The relation between arterial concentra¬
tions of plasma free fatty acids and their
turnover. Intralipid/heparin study (Dog 605)
500 _
Fatty acid turnover was measured before, during Intra-
lipid and during Intralipid/heparin (Combined results).
A similar relation was found between arterial free fatty
acid concentration and turnover in all dogs.
Abbreviations: Turnover = free fatty acid turnover in
jumole/min; FFA = arterial concentration of plasma free
fatty acids in umole/l.
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Figure 5.04. The effects of Intralipid and Intralipid/
heparin on arterial and coronary sinus
concentrations of plasma free fatty acids
in 4 anaesthetised dogs
HEPARIN
INTRALIPID
Abbreviations as in Fig 5.01.
Note: increase in difference between arterial and
coronary sinus concentration of free fatty acids
during Intralipid/heparin.
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whole-body turnover rates of free fatty acids were also
higher. Albumin increased plasma concentrations of
free fatty acids in all three dogs, and despite the in¬
crease in albumin concentration free fatty acid/albumin
molar ratio also increased (but less marked than the
concentration of fatty acids) from an average of 2.36 to
2.65.
The effects of Intralipid and heparin were similar
but less marked in 2 out of the 3 experiments as in the
experiments of Series I, except that in dog 649 heparin
did not release lipolytic enzymes and did not change the
free fatty acid turnover. The reasons for this ab¬
normal behaviour could not be revealed.
Intralipid/heparin did not affect heart rate and mean
aortic blood pressure.
5.1.4. Discussion
This study was undertaken to check the validity of
the Intralipid/heparin model, to raise plasma free fatty
acid concentrations. If in vitro lipolysis was prevent¬
ed by immediate extraction of whole blood samples, plasma
concentrations of free fatty acids increased after the
administration of Intralipid and heparin, but remained
well within the physiological range. Those results are
in sharp contrast with those of others, who reported
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plasma free fatty acid concentrations ranging from
3000-6000 jumole/l (Mj/4s , 1971 ; Kurien et al, 1971; Opie
et al, 1972). This difference is almost certainly due
to the in vitro lipolysis in blood samples taken from
lipaemic, heparinised dogs. Of course it is difficult
to reconstruct later the exact conditions used in the
processing of laboratory samples. However, Mj^s (1971^)
appeared to take more precautions and extracted fatty
acids quicker than Kurien et al (1970); and it is there¬
fore of interest that he found much lower values than
Kurien in Edinburgh.
It is not clear whether the raised free fatty acids were
solely bound to albumin or whether a substantial amount
was still associated with the triglyceride particles.
However even if they were they appear to be utilised in
the usual way. This conclusion is based on the fact that
no discontinuity in the relation between arterial free fatty
acid concentration and the turnover (Fig 5.03) was ob¬
served. (In this context it is important to note that
the measurements for this graph were made with wide rang¬
ing triglyceride and free fatty acid concentrations).
Secondly the extraction of plasma free fatty acids by the
heart increased, with increasing arterial concentrations
(Fig 5.04).
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Therefore the model of Intralipid/heparin is sound
from the point of view of its effect on plasma free fatty
acids and their turnover. These results eliminate a
severe criticism against the work of Mj^s (1971^), Kurien
et al (1971) and Opie et al (1972) which was the apparent
unphysiologically high plasma free fatty acid concentra¬
tion. Thus the increase in serious ventricular arrhyth¬
mias in dogs with experimental coronary occlusion, occurr¬
ed most likely during plasma free fatty acid concentrations
in the high physiological range (ro 1200yumole/l). It is
of interest that these workers suggested from clinical ex¬
perience that raised plasma concentrations of this order
or higher were detrimental. It also means, that the
depressant effect of Intralipid/heparin on the ischaemic
dog heart was probably due to a physiological increase in
fatty acid metabolism (Kjekshus and Mj^s, 1972). Our ob¬
servations add to the strength of their argument, that
raised plasma concentrations of free fatty acids may be
detrimental to the electrical stability and funtion of the
ischaemic heart.
However another point, concerning Intralipid/heparin
as a model to study the effects of raised concentrations
of plasma free fatty acids, has emerged. It has been
reported that lysolecithin levels in ischaemic myocardium
are raised (Sobel et al, 1978), and that perfusion of
Purkinje fibers with lysolecithin predisposed them to
arrhythmias. During Intralipid/heparin plasma lyso¬
lecithin is raised, due to the effect of heparin-released
phospholipase activity (Vogel and Bierman, 1965; Jansen
and Hulsmann, 1974) on plasma phospholipids or lecithin,
originating from Intralipid*. However the concentra¬
tions of lysolecithin, observed in effluents of anoxic
hearts were much lower (2 j^mole/l) than the high concentra¬
tions used in the perfusion studies (1-3 mmole/l). Thus,
although there is ground for some doubt as to whether
raised plasma free fatty acids or lysolecithin may be
detrimental to the ischaemic heart, either alone or in
combination with one another, at present evidence seems
to point at free fatty acids rather than lysolecithin.
Until this question is satisfactorily solved, no definite
conclusions of the mechanism involved can be drawn from
results obtained in studies of experimental myocardial
ischaemia, employing Intralipid/heparin as a model.
*Intralipid contains egg lecithin (1.2 g/lOO ml).
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5 . 1. 5, Summary
Heparin releases lipolytic enzymes in vivo and these
enzymes continue to degrade triglycerides in vitro, lead¬
ing to serious overestimation of plasma concentrations of
free fatty acids. Immediate deproteinisation of blood
overcomes this problem, and a new method for the measure¬
ment of free fatty acids on whole blood extracts was
developed (Section 2.2.2^). Using the improved methodo¬
logy, the use of Intralipid/heparin as a model to raise
plasma free fatty acids was reinvestigated in 7 anaes¬
thetised dogs. Arterial plasma free fatty acid concentra¬
tions were raised during Intralipid/heparin well within
the physiological range : 1120 - 7O jumole/l (n = 4). The
increase in arterial plasma free fatty acids was associated
with increased extraction by the heart and whole-body FFA-
turnover. The results show that Intralipid/heparin may
be a convenient model to raise plasma free fatty acids, but
previously insufficient attention has been paid to the
technical problems of measuring plasma free fatty acids in
studies, using Intralipid/heparin as a model.
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SECTION 5.2:
THE DEVELOPMENT OF THE BLOOD CELL SEPARATOR FOR
DIRECT INFUSION OF SODIUM OLEATE IN DOGS
383
The blood cell separator
Introduction
The direct infusion of free fatty acids to
raise plasma concentrations, has an advantage over the
use of drugs, and this has been discussed in Section 2.1.2.
However desirable this approach may be it has been severely
hampered by the fact that it can only successfully be done
with the complicated system of the blood cell separator
(Greenough et al, 1969). Briefly, the principle is as
follows: Blood is continuously separated by a centrifuge
into a stream of cell free plasma and another, containing
all blood cells (packed cell volume of about 70%). Fatty
acids, dissolved as their sodium salt in distilled water
(pHtolO) are infused directly into the plasma line, where
they bind instantaneously to the dogs own albumin. The
fatty acid enriched plasma is then returned to the animal
together with the blood cells. Although this system was
published as early as 1969, we have been hesitant to use
it for a long time, due to its complexity. However, it
became increasingly apparent that direct infusions of
fatty acid anions, even when 'stabilised' with albumin*
were toxic to normal dogs (Hoak et al, 1972; Riemersma
*Final fatty acid/albumin molar ratio was 55.
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et al, 1974). On the other hand these problems were
not encountered when fatty acid anions were infused
using the blood cell separator. Fortunately a simplified
version of the blood cell separator could be built for us
by Dr. N. McLeod, Department of Chemical Engineering,
Kings Buildings, University of Edinburgh, at little expense.
In this section of the thesis some of the problems en¬
countered in the introduction of this technique of raising
plasma concentrations of free fatty acids are presented.
But, first a detailed description of the design and the
functioning of the blood cell separator is presented.
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5.2.1. The blood cell separator
The blood cell separator consists of 4 essential
components:
- the centrifuge bowl
- the face seal
- the pumps and tubing connections
- the centrifuge
The centrifuge bowl
The bowl consists of 3 separate parts, all made of
perspex (Fig. 5.05-5.06):
- a transparent top containing the entrance port for
whole blood, and the exit ports for the separated
components
- a solid inner core with the entrance channel for
whole blood through its centre
- the bowl
The effective radius is 2.5 inches and the depth of the
bowl is 4 inches. The inner core is screwed to the top
and the distance between it and the sides and the bottom
of the bowl is 0.04 inches.
The face seal
The most important part of the blood cell separator
is the face seal (see Fig 5.05) through which whole
blood and the separated components must pass. It is
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Figure 5.05. The blood cell separator; Schematic
representation of the centrifuge bowl
A diagonal view through the centrifuge bowl. The
perspex bowl consists of 5 parts: the bowl; the inner
core, filling the dead space; the transparent top and
the rotating and stationary part of the face seal.
Blood enters through the face seal and is separated
into its components while travelling up through the
channel between the inner core and the outer shell of
the bowl.




Figure 5.06. The blood cell separator: The centrifuge bowl
The face seal, which rests on the





composed of 2 matching parts:
- the upper part is a stainless steel adaptor (stationary)
- the lower part made of ceramic, rotates with the centri¬
fuge bowl
The upper part contains the connections for the input
and output ports: whole blood input, plasma and red blood
cell output; and 3 ancillary ports one to lubricate the
seal and two connecting to the irrigation channel (see
later). (On the actual face seal there is another port
for the collection of the buffy coat, but as it is never
used in our experiments, it is not shown for the sake of
simplicity in Fig 5.05 nor is it referred to in the text).
The seal is designed to keep the components separated as
they travel through it. This is achieved by concentric
islands of pressurised saline, between all channels. The
outer channel is irrigated with saline to cool the seal.
It also prevents air entering it, as there is a negative
pressure in the bowl due to the action of the plasma and
red blood cell pumps.
Pumps and tubing
The separated components (plasma and (red) blood cells)
are pumped from the centrifuge bowl using two identical
roller-type blood pumps (5M 1154, Travenol Laboratories,
Inc., Deerfield, 111., USA). Their action generates a
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small negative pressure within the centrifuge bowl,
which causes the whole blood to enter. Silicone tubing
( 0 2.0 mm) is used for the pumps, whilst all other
tubing is pyrogen-free polyethylene tubing. The tubing
manifold is sterilised by ethylene oxide.
The centrifuge
The centrifuge of the blood cell separator was made
from a simple laboratory centrifuge (MSE Minor, MSE, London).
The original bowl of the centrifuge was covered with a
basement plate (see Fig 5.07) with a central opening
for the spindle. A flywheel was mounted on the emerg¬
ing spindle. Lateral movement greater than O.OOl inch
was prevented by stabilising the shaft using a ball bear¬
ing around it.
5.2.2. Operation and functioning of the blood cell separator
The centrifuge bowl is stored in a sterilising solu¬
tion ( Cidex). On the day of the experiment the cidex
is removed, and the bowl flushed 6-9 times with sterile
saline. The bowl is then primed with heparinised saline
(5 U/ml) and mounted on the centrifuge flywheel. The
venous withdrawal line is primed with heparinised donor
blood ( 1 U/ml) and connected to the face seal port. The
centrifuge bowl is primed with donor blood from a blood
donor set, using the blood cell pump at a rate of 5-10
ml/min. All air is removed. The venous withdrawal
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Figure 5.07. The blood cell separator: close up photograph
The centrifuge was covered with a basement plate.
The upper face seal is held in position by a brass
pivot mechanism, which allows the seal to find the
position of least friction. The interface between
cell free plasma and packed cells is indicated by
the arrow (Simulated run).
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cannula is inserted into the left femoral vein and the
primed return cannula is inserted into the left jugular
vein. The dog is heparinised by an intravenous in¬
jection of 2000 U heparin, followed by a slow drip of
heparinised saline (80 U/ml at a rate of about 1 ml/min)
into the withdrawal line is started. The centrifuge
is switched on and slowly taken to the desired speed
(1500 rpm, 160 g). Blood cell pump is started and
whole blood enters the machine via the upper stainless
steel face seal, and passes through the seal and down¬
ward through the center of the solid inner core. Centri¬
fugal force is exerted on the blood as it travels across
the bottom and up the sides of the bowl. The red blood
cells are collected at the top from 4 ports near the
wall of the bowl. When the separation is achieved the
plasma pump is started and plasma is pumped away from
4 centrally located ports. The separated components
then travel through the rotating and stationary parts of
the face seal.
After plasma has gone through the pump
it passes through a mixing chamber, positioned immediately
behind an infusion port. It is then recombined with the
red blood cells in an air bubble trap, before it is re¬
turned to the dog. The total flow rate was about 90-100
ml/min: plasma flow 30-40 ml/min and packed red cells
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60-70 ml/min.
All tube lines, except the silastic tubes in the
pumps, are water-jacketed (temperature 39°C) to prevent
heat loss. The total volume in the bowl and tubing is
about 220 ml. A photograph of the complete
system is presented in Fig 5.08.
5.2.3. Early developmental experiments
Many technical problems were encountered during
the early blood cell separator runs, performed in 23
anaesthetised dogs (surgical procedures as described in
Section 2.1.4). Blood withdrawal from the arterial side,
as advocated by Greenough et al (1969), resulted in wild
blood pressure oscillations. Therefore blood was with¬
drawn from a venous cannula, and arterial blood pressure
was stable, provided the level of blood in the bubble trap
remained constant. The problems met in the pilot studies
were all technical by nature and were solved in due time.
The main problem was air entering the system, causing a
high initial failure rate of about 50% in the first dozen
pilot studies. This problem was traced to the fine ad¬
justment of the face-seal and of the fitting of the centri¬
fuge bowl on the turntable of the centrifuge, necessary to
ensure that the upper and lower part of the face-seal were
dead opposite each other, while spinning. The tolerance
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Figure 5.Q8. The blood cell separator: overview
Note: the thermostated polyethylene tubes around the
withdrawal and return lines. The bubble trap is bare
visible at the top. The polyethylene tube in front of
the centrifuge drains the irrigation, coolant-saline t
waste.
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allowed is extremely small.
Heat loss
Another problem related to heat loss, which was initially
0
overcome by using pediatric extracorporal heat exchangers.
But these proved to be cumbersome and difficult to clean.
The tubes were therefore thermostated using water-jackets
made of heavy polyethylene tubes. This had the addition-
al advantage of reducing the extracorporal volume, which
was determined to a large extent by the heat exchangers.
Inadequate blood cell separation and pumps
Adjustment to the degree of separation of blood cells
and plasma proved to be difficult, due to interaction of
several factors. Intuitively centrifugal force is in¬
creased to obtain better separation. However paradoxical¬
ly the effectiveness of separation became worse under
these conditions, due to the fact that the increased
spinning speed of the centrifuge increased the flow rate
of the system and hence the transit time of blood in the
bowl was reduced. Therefore the speed of the centrifuge
was always kept constant (1450-1550 rpm), and the degree
of separation was adjusted in the first instance by the
relative flow rates of plasma and packed red cells; and
failing this by reducing total flow rate (increase in
transit time). This was very much an empirical affair
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and was extremely difficult when initially two different
peristaltic pumps (with different calibrations) were used.
However, with the two roller-type blood pumps this problem
is less, but improvements could be made by electrically
linking the two pumps. The advantage of 2 linked pumps
is that although the relative flow rates of the pumps can
be varied at will, total flow remains constant.
Haemolysis during centrifugation
Haemolysis during the centrifugational procedure was
observed, particularly when the centrifuge speeds exceeded
1700 rpm. However, when the speed was well controlled
below 1550 rpm, only a slight degree of haemolysis was
noticeable. Donor blood was occasionally haemolysed.
Mixing of sodium oleate with plasma
Problems were also encountered during the infusion of
sodium oleate. The specific gravity of the infusate was
greater than plasma, and as a result the infusate flowed
through the tube without proper mixing. Centrifugal
pumps are ideal for instantaneous mixing of liquids, since
the fluid is forced at high speed from the center of the
pump to its perimeter. However a pilot study showed that
plasma proteins underwent denaturation. A much better
and simple solution was found. The plasma and the in¬
fusate were forced to flow through the fine network of
a plastic filter holder (Millipore-Filter unit 0 1 cm)
resulting in adequate mixing.
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Acute septicaemia
During the design of the centrifuge bowl a choice of
plastics had to be made. The commercial bowl was made
of polycarbonate, which can be heat sterilised. However,
a block of polycarbonate of high quality to make the bowl,
was not available. More experience with machining of
perspex, which was necessary to fabricate the bowl, had
been obtained in the workshop of the Department of Chemical
Engineering. Therefore the fact that perspex can not be
heat sterilised seemed irrelevant, since if necessary ,gas
sterilisation could be used. But this was not considered
seriously, due to the long, necessary delay of 7 days,
which this process requires. However when it became
apparent that acute septicaemia did - unpredictably, but
sporadically occur (and was confirmed in one case by
bacterial growth examination kindly performed for us by
Dr.R.Tonkin, Department of Bacteriology, The Royal In¬
firmary). The following preventative measures were
taken:
the complete plastic tube manifold was gas sterilised
the centrifuge bowl and face seals were sterilised
using Cidex
an antibiotic (Keflin, 1 g) was administered intra¬
venously before the procedure
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all plastic tubes were disposed of at the end of
each experiment
Since these steps were taken no adverse side effects,
due to the actual blood cell separating procedure have
been observed.
5.2.4. Discussion
Many technical problems were encountered during the
introduction of the blood cell separator technique. In
13 out of 23 pilot experiments complete data could not
be obtained, often due to combinations of technical
problems. Similar difficulties were also experienced
by other workers, while developing the blood cell separat¬
ing technique in dogs (Buckner et al, 1968). Their
initial failure rate in a series of 140 experiments was
40%. After that, they still experienced technical
problems in 3% of the final studies. Five dogs died
during their experiments: one each of infection, haemorrhage,
carotid artery thrombosis, pulmonary oedema and unknown
cause.
In our pilot studies 4 dogs died due to embolism.
Blood cultures could not routinely be made, but early
signs of septicaemia were encountered. These findings
illustrate the difficulty of the technique, but in the
recent - definite experiments such problems were not
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encountered, due to experience in the operation of the
machine and also due to improvements in equipment. Despite
this, further improvements could be made: (1) introduction
of electronic control of blood return to eliminate the
risk of air embolism (2) a modification of the speed con¬
trol of the centrifuge, which will make it independent of
the flow rate through the system (3) electric linking of
the two peristaltic pumps which will allow fine regulation
of the blood cell separation without affecting the total
flow rate through the system.
5.2.5. Summary
A procedure has been developed, which allows infusion
and binding of fatty acid anions to plasma albumin. Many
technical problems were encountered and incomplete data
was obtained in many studies. Four animals died and
others may have suffered from mild to severe septicaemic
shock. However all these problems could be solved and
the technique in its present form should allow the in¬
fusion of fatty acid anions into dogs.
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SECTION 5.3:
DIRECT INFUSION OF SODIUM OLEATE AND ITS EFFECTS ON
ARTERIAL PLASMA CONCENTRATIONS OF FATTY ACIDS, MYO-
CARDIAL METABOLISM AND FUNCTION IN NORMAL DOGS
40Q
The infusion of sodium oleate in normal dogs
Introduction
The effects of elevated plasma concentrations, of
free fatty acids, raised by direct infusion of sodium
oleate were studied in normal dogs. These studies were
designed as a control series for those, in which the
effects of raised plasma free fatty acids were examined




Mongrel dogs of both sexes, were anaesthetised after
overnight fast by an intravenous injection of sodium
pentobarbitone (about 25 mg/kg), followed by a continuous
infusion of pentobarbitone at a dose of 4 mg/kg/hr. Ventila¬
tion was maintained through a cuffed endotracheal tube with
a positive pressure respirator (Harvard Apparatus Co, Mass.,
USA). Thoracotomy was performed through an incision in
the left fifth intercostal space using diathermy, and the
heart was suspended in a pericardial cradle. The left
anterior descending coronary was dissected free for a
distance of 0.5-1.0 cm. distally to the first diagonal
branch and a ligature placed loosely around it. However
in this series of experiments, which served as controls
for those in which the effects of sodium oleate were ex¬
amined during coronary occlusion (Section 5.4.), the
coronary artery was not occluded.
The right femoral vein was cannulated as a route for
infusion. The right femoral artery was cannulated for
measurement of mean aortic blood pressure (AP), monitored
with a Statham P23 Db transducer. The left femoral
artery was cannulated for collection of arterial blood
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samples. The jugular vein was dissected high in the
left neck immediately below the mandible, at which point
there is a bifurcation. The superior branch was used
t
for the insertion and placement of the coronary sinus cathe¬
ter as described in Section 2.1.4. (without fluoroscopic
to the blood cell separator
guidance). The connection of the dog/was initiated after
the intravenous administration of heparin (2000 U) and
Keflin (1 g), as described in Section 5.2.2.
Biochemical procedures
Arterial and coronary sinus blood samples were ob¬
tained simultaneously, for the measurement of plasma con¬
centrations of free fatty acids, glycerol, blood gases
albumin and haemoglobin. Plasma free fatty acids were
analysed by the titrimetric method, described in Section
2.2.2. Glycerol was determined using an enzymic fluori-
metric method (Section 2.2.4.) and plasma albumin was
measured with a manual colorimetric technique (Section 2.2.6.).
Blood gas analyses were kindly performed for us by the
Blood Gas Laboratory, Department of Medicine, The Royal
Infirmary, using an IL313 blood gas analyser (Instrumenta¬
tion Laboratory) and oxygen contents were determined using
a Lex02con (Lexington Instr. Corp., Waltham, Mass., USA).
Plasma haemoglobin was measured spectrophotometrically at
a wavelength of 540 nm, using a Unicam SP1800 ultraviolet
40 3
spectrophotometer (Pye Unicam, Cambridge). Haemoglobin
concentrations were calculated from the observed ex¬
tinctions using the molecular extinction coefficient for
2
haemoglobin of HOOO Mole/cm.
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5.3.2. Experimental procedure(Fig 5.09)
After the surgical procedures were completed the dog
was connected to the blood cell separator. A surface
electrocardiogram (lead III) and arterial blood pressure
were continuously recorded on electromagnetic tape, for
later arrhythmia analysis. Thirty min after steady blood
cell separation was achieved, arterial and coronary sinus
blood samples were collected; and blood pressure and heart
rate were recorded. Sodium hydroxide (O.lll mole/l) was
then infused for 15 min at a rate of 4.5 ml/min. Arterial
blood samples were collected at 5 and 10 min of infusion,
and arterial and coronary sinus blood at 15 min. Arterial
plasma free fatty acid concentrations were also measured
4 and 8 min post-infusion.
Thirty min after the end of this infusion, this
procedure of blood sampling, recording of heart rate and
blood pressure was repeated in an identical manner this
time during a 15 min infusion of sodium oleate (0.106 mole/l
in 0.111 mole/l NaOH) at the same rate. Another infusion
of sodium hydroxide (second control infusion) was made
again in an identical manner 30 min after cessation of the
2nd infusion in 5 dogs. In one dog the sequence of in¬
fusion of NaOH and sodium oleate was reversed: 1st in¬
fusion sodium oleate, 2nd infusion NaOH. The results were
similar and the data of the experiments were pooled.
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Figure 5.09. Experimental procedure for assessing the effect
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Three infusions were made; NaOH (0.111 mole/l) was infused
during the first and the third period, and sodium oleate
(0.106 mole/l in 0.111 mole/l NaOH) during the second. Blood
samples were collected immediately before, and at 5, 10 and
15 min during the infusion. Arterial plasma free fatty acids
were measured also 4 and 8 min post infusion.
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In a subgroup of 3 experiments the effect of sodium
oleate on myocardial blood flow was examined. Radioactive
microspheres were injected at 15 min of the first (control)
and second (sodium oleate) infusion.
The effect of blood sampling on total blood volume
was annulled by transfusing an identical volume of heparin-
ised blood (1 U/ml), each time after collection.
Statistical analysis
Each dog served as its own control. Probability values
were calculated using a Student's t-test for paired data.
The observations during the two control infusions were
similar and the data was pooled. P ^ 0.05 = not significant.




During the infusion of sodium oleate, arterial con¬
centrations of plasma free fatty acids rose quickly from
a baseline value of 544 - 46 to 1530 - 141 pmole/l
(mean - SEM, n = 8) at 5 min of infusion. In all but
one experiment arterial concentrations of plasma free
fatty acids peaked at 10 or 15 min of infusion: with
values of 1710 - 154 and 1561 - 190 pmole/l, respectively,
and returned quickly to pre-infusion levels (Fig 5.10;
Table 5.02 ). In contrast, during NaOH infusion (control)
plasma concentrations of free fatty acids remained steady.
The increase in arterial concentration of plasma free fatty
acids was reflected in an increased myocardial extraction.
Also, since arterial plasma albumin levels did not change
during the control and oleate infusions, the increase in
arterio-venous difference of plasma free fatty acids across
the myocardium was related to an increased ratio in the
molar concentrations of free fatty acids and albumin
(Fig 5.11 ). Arterial glycerol levels were measured
in 7 experiments, no effect of NaOH or of sodium oleate
was found (Table 5.02 ). Complete data of myocardial
glycerol extraction was obtained in 4 experiments and
was reduced in 3 (Data not shown). The infusion of
sodium oleate did not effect arterial blood gases when
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Figure 5.10. The effect of sodium oleate on arterial plasma










# sodium oleate infusion
o combined NaOH infusions
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Table 5.02
The haemodynamic and biochemical effects of sodium oleate infusion in 10 dogs
control control infusion control sodium oleate
Heart rate (beats/min) 152+6 153 + 6 157_+8 140 + 7* *
Mean aortic blood pressure
(mmHg)
130+6 116 + 6 122_+7 103 + 7
Free fatty acids (umole/l)SL ' 511+23 483 + 40 544+46 1561 + 190**
Free fatty acids'
a-cs
42+21 -28 + 51 54+58 260 + 56**
Free fatty acid/alb.ratio 1.38+0.09 1.43 + 0.12 1.62+0.14 4.72 + 0.75*
Glycerol (umole/l)cL ' 67+7 71 + 7 66+9 68 + 8
Glycerola_cs — 0 + 6 — 15 + 8
Albumin./g/1) 26.5_+0.7 25.6 + 0.6 24.5 _+ 0.8 24.4 + 1.0
Probability values were calculated using a Student's t-test for paired data,
* P < 0.05; ** P < 0.01
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Figure 5.11. The effect of sodium oleate on arterial plasma
free fatty acid to albumin molar ratio (FFAa/alb)
and arterio-venous difference of free fatty acids
(FFA A-V) across the normal myocardium
The standard
Lower point:
errors of the mean are indicated by the bars,
during NaOH infusion.
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measured at 15 min of infusion (Table 5.03 ). Complete
data for oxygen extraction (arterio-coronary sinus
difference) was obtained in 3 experiments (yielding 6
pairs) and no difference between control and infusion of
sodium oleate was observed: control 11.2 ± 0.6 and sodium
oleate 11.4 - 0.6 ml 02/lOO ml (P> 0.05).
The effect of sodium oleate on arterial blood pressure }
heart rate and blood flow
During the blood cell separation procedure heart rate
and mean aortic blood pressure remained constant (not
shown). The infusion of sodium hydroxide (control) did
not affect mean aortic blood pressure (Fig 5.12 ) nor
heart rate (Fig 5.13 ). The infusion of sodium oleate
reduced heart rate at 15 min, but not at 10 min of in¬
fusion in 4 dogs, and mean heart rate*of all dogs was re¬
duced (P < 0.01; Fig 5.13 ). This phenomenon was un¬
related to the molar ratio of fatty acids to albumin (not
shown). Mean arterial blood pressure fell during sodium
oleate in 3 experiments, but the average mean arterial
blood pressure of all experiments was unchanged. The re¬
ductions in heart rate and blood pressure (when observed)
were transient and returned to preinfusion levels on
termination of the infusion. Sodium oleate increased
myocardial blood flow, particularly to the epicardial
layers (Table 5.04).
*at 15 min of infusion
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Table 5.03
The effect of sodium oleate infusion on arterial pH, PC02




pH 7.40 _+ 0.02 7.39 _+ 0.01
pC02(mmHg) 35 + 2 34 _+ 4
02(ml/l00 ml) 14.6 _+ 1.2 14.7 _+ 0.3
Measurements at 15 min of control or sodium oleate infusion.
For details of composition of the infusates see text.
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Figure 5.12. The effect of sodium oleate on mean aortic
blood pressure (AP) in 8 open chest, anaesthetised
dogs (control experiments)
i 1 1 1 i i
0 5 10 15 +4 +8 min
>■ sodium oleate infusion
combined NaOH infusions
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Figure 5.13. The effect of sodium oleate on heart rate in










# O sodium oleate infusion.
Q O combined NaOH infusions.
Note significant reduction in heart rate after sodium oleate.
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Table 5.04
The effect of sodium oleate infusion on regional












N= number of biopsies.




The effect of sodium oleate on serious ventricular
arrhythmias
In all (10) experiments the electrocardiogram was
recorded on magnetic tape for later analysis of arrhythmias.
In one case the recording had failed and the record was of
poor quality in another. Of the remaining 8 experiments
no arrhythmias were found in 5 and occasional ectopics in
3. Ectopic beats were not associated with the infusion
of sodium oleate, and their rate never exceeded 2 min .
5.3.3. Discussion
Direct infusion of sodium oleate, with the aid of the
blood cell separator, resulted in raised arterial con¬
centrations of plasma free fatty acids. The increments
attained were in the same order of magnitude as those in
the study of Greenough et al (1969). In the present study
we have extended their observations and showed that - as
expected - the increased arterial concentrations were re¬
flected in increased arterio-venous difference of fatty
acid concentration across the myocardium. Their observa¬
tions of unchanged arterial blood gas results have been
confirmed. However, it may be that the infusion of
sodium oleate also affected heart rate and blood pressure
in their studies. The reason for this effect of sodium
oleate could be due to the high free fatty acid to albumin
molar ratio attained both in their and in the
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present study. The most likely explanation for the
high ratios is the low albumin concentration, ranging from
20-30 g/1 in these dogs, much lower than in well-fed grey¬
hounds (Opie et al, 1973). But this can not be the complete
explanation since the reduction in heart rate in our studies
was not related to the attained free fatty acid to albumin
molar ratio. Nor could it be explained by other factors:
pH, haemolysis etc. The response to infusions of fatty
acid emulsions was also variable and unpredictable in
normal dogs (Riemersma et al,1974). It is of interest
that heparin increased the sensitivity of rabbits to direct
injection of arachidonic acid (Debye et al, 1978), although
it is not clear whether this effect of heparin is specific
for the response to this particular fatty acid. More
work is indicated and at present it is difficult to say
with confidence, whether mild haemodynamic effects ob¬
served are not artifacts.
The high concentrations of plasma free fatty acids
were not associated with the development of serious
ventricular arrhythmias. These findings do not agree
with those of Hoak et al (1972), who claimed arrhythmias*.
However, it should be pointed out that the occurrence of
arrhythmias in normal dogs after infusions of free fatty
acids is not well documented. The effects of infusion
*after infusion of 'unbound' fatty acids
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of fatty acid anions on arterial blood pressure for
instance, are not presented. This lack of information
is serious, since the crucial distinction between a
primary onset of arrhythmias and a hypotension, followed
by arrhythmias can not be made. In a previous study
arrhythmias were in most instances seen after hypotension
(Riemersma et al, 1974). And it may well be that the
same applies for the studies of Hoak et al (1972).
The limitation in raising arterial levels of plasma
free fatty acids was mainly determined by the plasma line
flow rate, which in turn is dictated by the haematocrit.
Obviously with higher flow rates more fatty acids can be
infused, while they remain properly bound. It has been
suggested that the volume load might be another limiting
factor in reaching higher arterial concentrations.
However the sodium oleate infusate prepared by our method
was much more stable, since saline was replaced by
distilled water, and the infusate could have been more
concentrated. We have also attempted direct injection
of oleic acid through a fine hypodermic needle directly
into the plasma line (30 times as concentrated as the
present infusate). However the quality of our pumps was
insufficient to control the infusion rate under the high
pressures required for this. This approach would have
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had the additional advantage that it can be used for
the infusion of polyunsaturated fatty acids, which are
prone to isomerisation and autooxidation under alkali¬
ne conditions. Our vein to vein procedure might be
expected to be less efficient than an artery to vein
procedure (Greenough et al, 1969). Some of the fatty
acid enriched blood might have been recirculating in the
blood cell separator. Although we cannot exclude this
in our experiments, the withdrawal cannula is position¬
ed far from the cannula used for the return of fatty acid
enriched blood, and recirculation seems unlikely.
The blood cell separator requires full anticoagula¬
tion of the blood to prevent blockage of the narrow
channels in the face seal. Heparin was used, despite
its well-known effects on lipid-metabolism (releasing
lipoprotein lipase, phospholipase and hepatic lipase (Vogel
IT
and Bierman, 1965; Jansen and Hulsmann, 1974). However
fasting triglyceride concentrations in dogs are low, and
as a result the effect of heparin on plasma free fatty
acids might be expected to be transient. Initial con¬
centrations of free fatty acids measured 30 min after
heparinisation could not be distinguished from those of
our previous non-heparinised studies. The effect of
heparin on myocardial triglyceride utilisation may not be
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transient due to the presumed heparin-induced depletion
of myocardial endothelial lipoprotein lipase. However
it is difficult, if not impossible, to predict the over¬
all effect of heparin on myocardial fat metabolism (free
fatty acids and triglycerides), since the presumed re¬
duction in triglyceride metabolism may be balanced by
increased utilisation of free fatty acids. Furthermore
alternative drugs such as coumarin, with its uncoupling
activity on oxidative phosphorylation, provide other
problems, particularly when used during ischaemia. However
the fact is and should be acknowledged that the use of
heparin (as any other anticoagulant for that matter) is
not ideal. Particularly, since it made the prevention
of bleeding from the chest wounds extremely difficult,
and in some experiments we had to take refuge to use of
blood donation (up to lOO ml) to maintain constant arterial
pressure. Possibly, the use of chemically-bonded heparin
in the extracorporea^system may provide the best
alternative.
Plasma concentrations of glycerol are a good index
of adipose tissue lipolysis (Scow and Chernick, 1970).
High concentrations of free fatty acids inhibited glycerol
release from adipose tissue (Scow and Chernick, 1970).
There is also some evidence that free fatty acids may
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inhibit adipose tissue lipolysis in vivo (Bezman-
Tarcher, 1969). Also the release of insulin by raised
plasma free fatty acids (Greenough et al, 1969) would be
expected to inhibit adipose tissue lipolysis mainly by the
effect of insulin on reesterification (Scow and Chernick, 1970).
In our experiments, which were not designed especially to
study adipose tissue lipolysis, the infusion of sodium
oleate did not reduce arterial glycerol concentrations.
Thus it appears that adipose tissue lipolysis was not
inhibited. However it should be pointed out that glycerol
was measured 15 min after the infusion of oleate, and in
view of the slow turnover of glycerol, this might have been
too early to notice any effect. Another explanation may
be that adipose tissue lipolysis was not stimulated in the
present experiments by catecholamines, and that raised
free fatty acid concentrations inhibit only stimulated
adipose tissue lipolysis. The data on myocardial glycerol
release was incomplete, a rather unfortunate fact ,
particularly since more knowledge of the effects of free
fatty acids on myocardial lipolysis is urgently required.
Clearly more studies designed to examine the possible
modulating effect of free fatty acids on myocardial and/or
adipose tissue lipolysis are indicated. The blood cell
separator may provide us with a useful tool for these studies.
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5.3.4. Summary
Plasma free fatty acids were raised in anaesthetised
dogs using a blood cell separator. This machine allowed
the binding of free fatty acids to the dog's own albumin
prior to recombination and infusion into the dog. Plasma
levels rose from 544 ± 46 pmole/l to 1530 ± 141 pinole/1
within 5 min of infusion. Increased arterial free fatty
acid concentrations, resulted in increased extraction by
the heart. Arterial blood gas values and plasma glycerol
concentrations remained unchanged. Haemodynamic effects
were observed in some dogs, but were not related to arterial
free fatty acid to albumin molar ratios. No arrhythmias
were observed. These results show that the blood cell
separator may be a useful, although technically complicated
tool in metabolic studies in dogs.
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SECTION 5.4:
THE EFFECTS OF SODIUM OLEATE ON MYOCARDIAL METABOLISM





Mongrel dogs of both sexes, weighing 11.0-19.5 kg
were anaesthetised after overnight fast with sodium pento¬
barbitone (about 25 mg/kg). Anaesthesia was maintained
by continuous infusion of pentobarbitone, at the dose of
4 mg/kg/hr. Ventilation was maintained through a cuffed
endotracheal tube with a positive pressure respirator
(Harvard Apparatus Co, Mass). All surgical procedures:
dissection and cannulation of veins and arteries, thora¬
cotomy, suspension of the heart and dissection of the left
anterior descending coronary artery at a point immediately
behind the first diagonal branch, were identical to those
of the control series (normal dogs; see Section 5.3 ).
In addition to this, a small cannula was inserted into the
local vein, draining the myocardium perfused by the dis¬
sected coronary artery. A cannula was inserted into the
left atrium for the injection of microspheres to estimate
regional myocardial blood flow. A 15 electrode epi-
cardial grid was positioned over the area supplied by
the dissected coronary artery, and secured by 3-4 small
stitches (4/0 silk) outside the area of interest.
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Induction of myocardial ischaemia
Intermittent myocardial ischaemia of 10-15 min
duration was induced by occlusion of the dissected coronary
artery using a metal, releasable clip, as described in
Section 2.1.5. The first was a sham occlusion of 10 min
duration made at the end of the surgical procedures. A
recovery period of 30 min was allowed between successive
coronary artery occlusions.
Electrocardiographic and haemodynamic monitoring
Three of the 15 epicardial electrodes were selected
for continuous monitoring. The signals were pre-
amplified* (see Section 2.3.1.), and recorded on a 3
channel magnetic tape recorder (speed; ^ in/s), for later
analysis of ST-segment elevation and arrhythmias. The
proximal occlusion used in these studies caused marked
conduction delay, and measurements of ST-segment elevation
could not be made with confidence. The use of the epi¬
cardial rather than surface leads (for the measurement
of ST-segment elevation) made the analysis of arrhythmias
*The multiplexer was used as a three channel ECG amplifier,
by inhibiting electronically its multiplexing function.
426
with the arrhythmia computer impracticable, due to
constant changing configuration of the electrocardiogram.
Therefore the tapes were frequently replayed to scan
visually whether arrhythmias occurred. Arrhythmias
were inspected by replaying the concerned section of the
magnetic tape on a chart recorder. Mean aortic blood
pressure was monitored from the right femoral arterial
cannula with a Statham P23 Db pressure transducer and
recorded on a Devices M8 recorder.
Regional myocardial blood flow
Regional myocardial blood flow was measured by means
of radioactive microspheres (nominal diameter 15 p.), as
described in detail in Section 2.4. Regional myo¬
cardial blood flow was calculated for each biopsy by
relating its radioactivity to that of a reference arterial
blood sample, withdrawn at a known fixed rate (reference
flow). The calculations were made using a computer
programme written by Dr. Boardman for a PDP-12 computer
(Appendix B).
Biochemical analyses
Arterial and local venous blood samples were collected
simultaneously immediately before, at 5 min and at 12-15 min
of the successive infusions (= 7-10 min of occlusion).
Plasma free fatty acids were estimated using a titrimetric
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method, described in Section 2,2.2. Plasma glucose
was determined using the automated hexokinase method
(Section 2.2.3 ). Plasma glycerol was analysed by the
manual enzymic fluorimetric method of Passonneau (Section
2.2.4 ). Plasma albumin was determined by a dye-bind¬
ing technique (Section 2.2.6 ). K+ was estimated by
flamephotometry in the Medical Renal Unit, The Royal In¬
firmary, Edinburgh. Haemoglobin was estimated spectro-
photometrically as described in Section 5.3.1.
5.4.2. Experimental design
The design was the same as thAt used for the normal
(control) dogs, described in Section 5.3 , except that
after an initial sham occlusion 3 intermittent occlusions
of 10 min duration, each separated by a recovery period
of 30 min, were superimposed on the basic protocol (see
Fig 5.14. Note that the sham occlusion is not indicated).
Haemodynamic measurements were recorded pre-infus ion,
5 min post-infusion and at 5 min of occlusion. Regional
myocardial blood flow was determined 5 min after coronary
artery occlusion. Heart rate was controlled during infusions.
The frequency of the blood sampling procedure was
reduced, in view of the expected difficulties in collect¬
ing local venous samples during ischaemia. Thus arterio
venous differences in concentrations of fatty acids,
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Figure 5.14. Experimental procedure for assessing the
effect of sodium oleate on the response













A sham occlusion ( lO min ) was made at the end of the
surgical procedures. Thirty min after attaining steady
blood cell separation and collection of blood samples, an
infusion of NaOH (0,111 mole/l) was commenced (Control I).
Myocardial ischaemia was induced 5 min later after collect¬
ion of pre-occlusion blood samples. Regional myocardial
blood flow (5 min of occlusion) and arterio-local venous
differences (7-10 min of occlusion) were then assessed.
After release and recovery (30 min) the procedure was re¬
peated except that sodium oleate 0.106 mole/l in 0.111 mole/
1 NaOH was infused. A second control infusion followed by
occlusion was made 30 min post sodium oleate. Occl. =
occlusion.
Note: during all infusion periods the heart rate was main¬
tained constant by right atrial pacing.
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glycerol and glucose were estimated: (1) immediately
before infusion; (2) 5 min later, just before occlusion
and (3) at 7-10 min of occlusion during the sustained
infusion. Total blood volume taken over the course of
the experiment was 240 ml. The influence of this was
annulled by transfusing an identical volume of heparinised
donor blood, each time after collection.
Statistical analysis
Each dog served as its own control. Probability
values were calculated using a Student's t-test for
paired data. The observations made immediately before
and during the first and the second infusions of NaOH
(control periods) and coronary occlusion were not statisti¬
cally significantly different and all control data were
pooled. Probability values of 0.05 were not regarded
as statistically significant (N.S.).
Statistical calculations for 5 or less pairs were not
performed.
5.4.2. Results
The effects of sodium oleate in the absence of ischaemia
During the control infusion of NaOH (0.111 mole/l)
mean aortic blood pressure was stable. When plasma
free fatty acids were raised by sodium oleate infusion,
mean aortic blood pressure fell slightly, but significantly:
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control: 106 t 8 miriHg; sodium oleate: 100 - 8 mmHg
(P <" 0.01, n = 7, Table 5.0 5 )„ The increase in arterial
concentrations of free fatty acids from 575 - 43 to
1531 t 111 pmole/l (P < 0.01 , n = 6), was reflected in
an increase in the molar ratio of free fatty acids to
albumin. Myocardial extraction of free fatty acids was
also increased. Arterial plasma glucose concentrations
tended to fall during the experiment, but this effect
did not reach a level of significance. During sodium
oleate infusion glucose extraction (arterio-local venous
difference) was 0.48 t 0.09 mmole/l. This value was not
significantly different from that obtained immediately
before the sodium oleate infusion (0.55 i 0.05 mmole/l).
It could also not be distinguished from myocardial glucose
extraction measured during the NaOH infusion (Comparison
vs combined data of NaOH Infusion I + II).
Arterial glycerol concentrations tended to increase
throughout the experiment, the pre-infusion observations
were: 38 i 9; 58 -12 and 68 - 14 pmole/l. (No statistical
analysis was performed: only 5 observations during the
second NaOH infusion). There was insufficient data
for the statistical analysis of the effect of sodium
oleate on arterial glycerol concentrations, but in the
4 experiments with complete data no effect was observed:
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Table 5.05
The haemodynamic and biochemical effects of sodium oleate infusion in 7 dogs with experimental coronary artery occlusion
Control infusion (I) Sodium oleate Control infusion (II)
control pre.occl. occlusion control pre.occl. occlusion control pre.occl. occlusion
Mean aortic
blood pressure (mm Hg) 109+8 110 + 8 107+8 106+8 100+8 t 93+7* 111 + 9 111+10 103+12
Free fatty acidsa(jimole/l) 448+_33
Free fatty acidsa-lv 65+15
469+_36 523_+93 575_+48 1531+111 1786jfl57* 717^57 587^102 662 +40
21+49 92+30 158+29 558+29^ 603+69* 208+66 170+62 198
*
Free fatty acid/alb.ratio 1.92+0.39 1.53+0.12 1.76+0.27 2.12+0.21 5.26+0.39 6.57+0.60* 2.71+0.28 2.59+0.21 2.61+0.27






5.36+0.11 5.33+0.16 5.39+0.23 5.20+0.23 5.07+0.16 5.47+0.28 5.27+0.41 4.96+0.33 4.76+0.38



























Haemoglobin (mg/lOOml)3 194+29 187+37 190+52 263+63 245+70 272+86 415+120 397+134 422+137
Heart rates were kept constant by right atrial pacing.
* P< O.Ol vs combined control occlusion.
^ P < O.Ol vs control of the same infusion (preinfusion data).
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control 58 i 12 vs 60 ± 5 pmole/l.
Plasma K+ concentrations remained constant throughout
the procedure.
The effects of sodium oleate and coronary artery occlusion
During the infusion of NaOH (control) occlusion of
the coronary artery did not reduce mean aortic blood
pressure. However, when sodium oleate was infused the
decline in mean aortic blood pressure before coronary
occlusion was continued. Mean aortic blood pressure
during sodium oleate pre- and during occlusion were
100-8 and 93±7 mmHg respectively (P < O.Ol, n = 12).
During -ischaemia arterial concentrations of plasma
free fatty acids remained high (1786 - 157 jumole/l), while
those of glucose, glycerol and potassium were unaltered.
The increased arterial fatty acid concentration resulted
in an increased myocardial extraction.
Coronary occlusion (during NaOH infusion) increased
extraction of glucose across the ischaemic myocardium.
Arterio-local venous difference of glucose , pre-
occlusion: 0.79 t 0.25; during occlusion 1.19 1 0.30 mmole/l.
This effect of ischaemia was not changed by the high
arterial plasma concentrations and ischaemic myocardial
utilisation of free fatty acids: arterio-local venous
difference of glucose pre-occlusion: 0.48 - 0.09; during
occlusion 1.14 i 0.22 mmole/l.
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The effect of sodium oleate on regional myocardial
blood flow
When the myocardium distant from the ischaemic area
was taken to represent normal myocardium, then sodium
oleate tended to decrease myocardial blood flow in the
endocardial and increase it in the epicardial layers
(Both effects not statistically significant). However
the distribution of blood flow was significantly changed:
control endo/epi MBF ratio 1.17 - 0.02 and sodium oleate
1.08 - 0.02 (P< O.OOl, n = 77). Sodium oleate did not
alter ischaemic myocardial blood flow, nor did it change
the blood flow distribution (Table 5.06).
The effect of sodium oleate on arrhythmias
During coronary artery occlusion ectopic beats, often
coupled were seen in all but one experiment (Table 5.07/8).
Spontaneous ventricular fibrillation was observed on 5
occasions, and all were during the NaOH infusion (control).
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Table 5.06
The effect of sodium oleate infusion on regional myocardial
blood flow in non-ischaemic and ischaemic free ventricular
wall 5 min after coronary occlusion in 7 dogs
control sodium oleate
Non-ischaemic area (N=77):
MBF endocardium 0.73 +_ 0.03 0.69 _+_ 0.02
MBF epicardium 0.63 +_ 0.03 0.67 _+ 0.02
endo/epicardium ratio 1.17 + 0.02 1.08 + 0.02*
Ischaemic area (N=39)
MBF endocardium 0.27 +_ 0.03 0.24 +_ 0.03
MBF epicardium 0.36 _+ 0.04 0.34 +_ 0.03
endo/epicardium ratio 0.80 +_ 0.09 0.83 _+ 0.12
N= number of biopsies. MBF = myocardial blood flow.
Probability values were calculated using a student's t-test
for paired data.




The effect of sodium oleate on the occurrence of
arrhythmias during experimental coronary artery occlusion
Coronary artery occlusion
Exp. Control infusion Sodium oleate Control infusion
1 Ectopics none' Ectopics











—^ VF (5-§ min)
Ectopics Ectopics
7 Ectopics none Ectopics
For details see text.
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Table 5.08
The effect of sodium oleate on the occurrence of ectopic
beats and ventricular fibrillation (VF) during experimental
coronary occlusion in 7 dogs
Ectopic beats VF
Control infusion (N=13) 11 5
Sodium oleate infusion (N=7) 4 0
N= number of observations.
Probability values calculated using Fisher's exact test
were ^0.05.
For details see text.
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5.4.3. Discussion
Direct infusion of sodium oleate in order to raise
plasma free fatty acid concentrations, was associated with
increased extraction of plasma free fatty acids across the
ischaemic myocardium. Since regional myocardial blood
flow was not changed, nor its distribution in the ischaemic
area, fatty acid uptake by the ischaemic myocardium was
also increased. Another notable finding was that increased
utilisation of free fatty acids did not reduce glucose
extraction by the ischaemic myocardium, in agreement with
the findings of Opie et al (1973). They measured glucose
extraction by the ischaemic myocardium 20 min after in¬
jection of heparin to induce plasma lipolysis and Intra-
lipid as the substrate. Although their plasma free fatty
acid concentrations during Intralipid/heparin were over¬
estimated, their glucose data should be valid. Results
of anoxic perfused rat hearts can not readily be extra¬
polated to the ischaemically perfused - in vivo - dog heart.
However it is certainly of interest that raised con¬
centrations of palmitate did not inhibit glucose uptake
by the anoxic perfused rat heart (Randle et al, 1964).
It should be pointed out that raised plasma free fatty
acids also did not inhibit glucose extraction before
coronary artery occlusion, against what is usually accepted.
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Indeed palmitate and oleate inhibit glucose utilisation
by the well perfused rat heart (Randle et al, 1964); but
the actual decrease is small: 34 and 27% respectively.
We observed a non-significant reduction of about 13%.
It may be that our failure to demonstrate any (significant)
effect is purely methodological. Errors in quantifying
arterio-venous differences are large (Section 2.2.3.), but
with our method, with a coefficient of variation 0.2-0.5%,
we should have observed a 30% reduction. A more likely
explanation is therefore, that insulin release by sodium
oleate (Crespin et al, 1969) counteracted partially its
inhibition of glucose extraction.
Arrhythmia analysis was hampered by the fact that
two modifications in our techniques were introduced. An
epicardial rather than a surface lead was used, in order
to obtain information both on ST-segment elevation and
arrhythmias. Another difference was the more proximal
site of occlusion, this to enhance the yield of arrhyth¬
mias. The epicardial lead was not compatible with the
Neilson arrhythmia computer, due to rapid changes in the
configuration of the epicardial electrocardiogram. Un¬
fortunately a separate triggering channel was not used,
and could have solved the problem. Therefore the tapes
were frequently scanned and the occurrence of arrhythmias
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was checked by write-out of the relevant sections of the
recording.
The more proximal site of occlusion caused marked
conduction delay and ST-segment mapping would have been
meaningless. However, despite these problems, the results
are of interest. On occasions ventricular fibrillation
was observed and all were during the infusion of NaOH.
Although this effect was not statistically significant,
these findings clearly show that raised plasma free fatty
acids per se are not arrhythmogenic.
These results contrast to earlier studies of our unit,
employing other methods of raising plasma concentrations
of free fatty acids (Oliver and Yates, 1972). In the
present study experiments were designed to allow each dog
to serve as its own control. Myocardial ischaemia is
reversible up to 20 min and leads to reproducible ST-
segment elevation (Maroko et al, 1971; Berdeaux et al,
1976; this thesis Section 2.1.5) and disturbance of
ischaemic myocardial metabolism (Section 2.1.5), provided
a recovery period of 30-45 min is allowed. The price to
pay for superior control of the study had to be a reduction
in the observation period (10 min of occlusion). However
VF was frequently observed. Furthermore myocardial
extraction was fully stimulated before coronary occlusion.
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This would favour the observation of a detrimental
effect of fatty acids. The difference between the present
and the early fatty acid infusion studies (Oliver and
Yates, 1972) may never be explained, but reduced tendency
to develop arrhythmias of open-chest dog preparation
(Oliver and Yates, 1972), does not appear to be the ex¬
planation, in view of the incidence of ventricular
fibrillation and coupled ectopic beats in the present
studies. Nor was the heart rate different. The same source
of dogs was still used, and potassium and albumin levels
were similar. Therefore the results of the present study
raise doubt to the validity of the early observations, as
has arisen before (Riemersma et al, 1974).
Other studies during experimental coronary occlusion
have also provided evidence that raised plasma free fatty
acids - per se - may not be arrhythmogenic (Opie et al,
1971, Opie and Lubbe 1974), or reduce the ventricular
fibrillation threshold in dogs with acute myocardial
ischaemia (Kostis et al, 1973). In contrast, antilipo-
lytic drugs have been associated with reduced incidence
of arrhythmias in dogs (Smith and Duce, 1974) and in
patients with acute myocardial infarction (Rowe et al,
1975). These and our findings tend to favour the
possibility that increased myocardial lipolysis might
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enhance, and its inhibition might decrease, the incidence
of ventricular arrhythmias. The mechanism of this hyp-
thesized, deleterious effect of myocardial lipolysis
could be due to the fact that it appears to control the
overall rate of the triglyceride fatty acid energy
wasting cycle (Fig 6.02). Increased myocardial fat
mobilisation has been linked with increased contractility
(Stam and Hulsmann, 1978). This effect of myocardial
lipolysis was explained by the Ca++-ionophoric properties
of intracellular fatty acids. If the reverse is also
true and can be applied to ischaemic tissue, then in¬
hibition of lipolysis would lead to reduced contractile
behaviour and thereby reducing the oxygen requirements
of the ischaemic cell. It is clear that more attention
should be paid to myocardial lipolysis.
One question springs to mind: 'would raised con¬
centrations of plasma free fatty acids increase the
incidence of arrhythmias when local ischaemic myocardial
lipolysis is stimulated by sympathetic nerve stimulation?'
Studies, along this line of investigation should provide
an important area of future research.
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5.4.4. Summary
Concentrations of plasma free fatty acids were raised
in dogs with experimental acute myocardial ischaemia, by
infusion of sodium oleate. Arterial free fatty acids
levels rose from 575 t 48 to 1786 t 157 pmole/l. Ex¬
traction of plasma free fatty acid by the ischaemic area
was also increased, but glucose extraction was unchanged.
Sodium oleate did not change significantly regional myo¬
cardial blood flow in the non-ischaemic and ischaemic
layers, but did increase the distribution of normal blood
flow. Mean aortic blood pressure fell from 106 t 8 to
93 ± 7 mm Hg. Ventricular arrhythmias tended to occur
during control occlusions and infusions, and no ventricular
fibrillation was observed during sodium oleate. These
results and those of others support the view that myo¬
cardial lipolysis, rather than raised concentrations of






The outcome of acute myocardial infarction is not
predetermined from its onset, but can be influenced
when the balance between oxygen supply and demand is
modified*. Oxygen consumption is increased when fatty
acid metabolism is stimulated (Mj^s, 1973). Thus
alteration of myocardial metabolism should be beneficial.
Two metabolically orientated hypotheses have been proposed,
one claims that raised plasma free fatty acids have a
detrimental (Kurien and Oliver, 1970) and the other that
glucose has a beneficial effect to the ischaemic heart
(Opie, 1970). Both hypotheses are critically dependent
on the assumption that ischaemic myocardial metabolism
can be influenced by its environment. This is well es¬
tablished for the normoxic heart, but extrapolations to
the ischaemic myocardium should not be made.
*For a recent review of haemodynamic interventions, see
Hillis and Braunwald, 1977.
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Extraction and utilisation of fatty acids by the
ischaemic myocardium
Normally myocardial fatty acid metabolism is
positively related to the arterial fatty acid concentrations
or more correctly FFA/alb ratio (Ballard et al, 1960;
Scott et al, 1962; Evans et al, 1963; Spector et al, 1968).
This relation is also observed in all studies where
arterio-venous differences across the ischaemic myocardium
were measured and arterial fatty acid concentrations were
altered using lipolytic and antilipolytic drugs (Sections
3.3, 3.4 and 3.5), infusion of glucose (Russell et al,
1979, Haneda et al, 1974) or when raised directly by
sodium oleate infusion (Section 5.4).
Evidence is accumulating that ischaemia induces myo¬
cardial lipolysis (Opie et al, 1973; Brownsey and Brundt,
1977, Appendix E). The stimulus is presumably cyclic-
AMP, formed by adenylcyclase, stimulated by locally re¬
leased noradrenaline (Shahab et al, 1969). The normal
regulatory mechanisms appear to apply: since ischaemia-
induced lipolysis was inhibited by an antilipolytic drug
(Brownsey and Brundt, 1977).
Glucose metabolism in the ischaemic myocardium
The increased glucose extraction by the ischaemic
myocardium has been well established (Opie et al, 1973;
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De Jong et al, 1977; Jageneau et al, 1975; Vik-Mo
et al, Appendix E, Russell et al, 1979)= This
observation fits well with the observation that glucose
transport is accelerated in the anoxic, well perfused
heart (Morgan et al, 1961), but no explanation can be
given for the finding of Rovetto et al, (1973) that
glucose transport of the ischaemic perfused rat heart
was not accelerated. Glucose and insulin can stimulate
the glucose uptake by the ischaemic heart (Rovetto et al,
1973), and both could be responsible for increased glucose
extraction, after glucose infusions in dogs (Russell et
al, 1979). An important finding is that raised plasma
free fatty acids do not inhibit glucose uptake during
ischaemia (Neely et al, 1975; this thesis, Section 5.4).
This is to the contrary of what was generally assumed
from observations on normoxic myocardium (Kurien and
Oliver, 1970; Opie, 1970), underlining that extrapolation
from the normoxic myocardial metabolism to ischaemic
tissue can not be made.
Increased glycolysis and glycogenolysis ceases early
during ischaemia and the actual glycolytic flux becomes
even inhibited, at the level of phosphofructokinase
(Opie, 1975) or glyceraldehyde-phosphate dehydrogenase
(Rovetto et al, 1975) due to a decrease in cellular pH
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and phosphate potential (ATP/ADP) and/or an increase in
NADH/NAD+ ratioo And when the intracellular acidosis
is prevented, pyruvate dehydrogenase may become rate-
limiting (Rovetto et al, 1975). This together with the
fact that the major fate of glucose in the ischaemic heart
(Opie et al, 1973; Neely et al, 1975) is oxidation and
not lactate formation underlines the importance of the
residual oxidative phosphorylation for the survival of
the ischaemic cell.
Metabolic intervention and severity of myocardial
ischaemic injury
It is now well established that effective antilipolytic
therapy reduces the extent and magnitude of ST-segment
elevation after experimental coronary artery occlusion.
Reduction in epicardial ST-segment elevation after anti-
lipolytic treatment has been correlated with preservation
of myocardial creatine kinase during a sustained occlusion.
Alternatively stimulation of lipolysis with i^prenaline
or nicotine increases the severity of myocardial ischaemia.
The results of 20 independent experiments using a wide
range of anti-lipolytic or lipolytic drugs are summarised
in Fig 6.01*.
*For details: Appendix G.
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Figure 6.01 Effect of changing free fatty acid to albumin
molar ratio ( FFA/alb) on alteration of ischaemia
induced ST-segment elevation (AST) using lipo-
lytic and anti-lipolytic drugs







+50 +200 +250 AFFA /Alb %
O CHANGES IN BASAL LIPOLYSIS
• CHANGES IN STIMULATED LIPOLYSIS
The effect of lipolytic or anti-lipolytic treatment
during basal and isoprenaline stimulated lipolysis
on plasma free fatty acid to albumin molar ratio and
on ST-segment elevation, were both expressed as a
percentage of the initial value.
For further details, see text.
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Decreased fatty acid extraction by the ischaemic
myocardium after anti-lipolytic treatment was associated
with a reduction in ST-segment elevation, but glucose
extraction was not changed. The beneficial effect of
anti-lipolytic treatment could not be explained by changes
in haemodynamic state or regional myocardial blood flow.
Antilipolytic treatment also reduced ST-segment
elevation in patients with acute myocardial infarction
(Russell and Oliver, 1978; Kjekshus, 1978).
During experimental myocardial ischaemia ST-segment
elevation was reduced after the administration of glucose
(Maroko et al, 1972, Ueno et al, 1976); glucose-insulin-
potassium (GIK) (Maroko et al, 1972; Sybers et al, 1973;
Haneda et al, 1974, Opie and Owen, 1976: Ueno et al, 1976).
It is of interest that this decrease in ST-segment ele¬
vation was associated with increased glucose and decreased
free fatty acid utilisation across the ischaemic myocardium
(Haneda et al, 1974). Similar effects have been observed
in patients with coronary artery disease (Chiong et al,
1976) and may also be related to a change in metabolism
(Stanley et al, 1975).
When glucose uptake by the ischaemic myocardium was
stimulated by a variety of drugs: dichloroacetate
(Section 4.1), a similar compound UK 25842 (Surges, 1977),
and propranolol (Opie and Thomas, 1976) or by infusion
of pyruvate and a buffer (Liedtke et al, 1976^) ST-
segment elevation was also reduced. The beneficial
effect of enhanced glucose utilisation was reflected in
reduced enzyme loss (Maroko et al, 1972; De Leiris and
Opie, 1978) and preservation of mitochondrial function
(Calva et al, 1965), reduction in histochemical evidence
of necrosis (Sybers et al, 1973). During severe
ischaemia glucose may be ineffective (Opie et al, 1975;
Liedtke et al, 1976).
Metabolic intervention and arrhythmias
Intravascular lipolysis of triglyceride emulsion
(Intralipid) induced by heparin increased the incidence
of ventricular arrhythmias (Kurien et al, 1971), presumably
due to a lowering of ventricular fibrillation threshold
(Takano, 1976). Other workers were unable to reproduce
these results (Opie et al, 1972; Kostis et al, 1973;
Mg'^s and Kjekshus, 1972; Opie and Lubbe, 1975; Mbuyama,
1976). The significance of raised plasma free fatty
acids for the induction of arrhythmias after administration
of heparin to patients with acute myocardial infarction
is also doubtful (Nelson, 1970; Russo et al, 1970;
Riemersma et al, 1977 ), although arrhythmias have been
reported in another study (Reimann and Schwandt, 1971).
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Raised plasma free fatty acid concentrations by
direct infusion of fatty acids also did not precipitate
arrhythmias during the early phase of ischaemia (Section
5.4). Earlier preliminary reports (Oliver and Yates,
1971) were probably due to toxic effects of such in-
also seen
fusions/in normal dogs (Riemersma et al, 1974). Arrhythmias
can be reduced by anti-lipolytic treatment in patients
with acute myocardial infarction (Rowe et al, 1975). The
difference between the results of heparin or Intralipid/
heparin and antilipolytic treatment could be explained by
inhibition of myocardial lipolysis in the latter situation,
either alone or in conjunction with lowering of plasma
free fatty acids.
The effect of raised glucose concentrations on the
incidence of arrhythmias
A reduction in arrhythmias after glucose infusion was
only observed during the early period of ischaemia (Russell
and Oliver, 1979), and a similar transient increase in
glucose extraction by the ischaemic myocardium was noted.
Ventricular fibrillation was reduced in dogs with coronary
artery occlusion after infusion of glucose-insulin-
potassium (Ueno et al, 1976), however in the baboon,
which has more severe ischaemia after coronary occlusion
no effect was observed (Opxe et al, 1975). Thus the
severity of myocardial ischaemia may be a critical factor
in determining the efficacy of glucose treatment. This
view is supported by electrophysiological (Russell et al,
1979) and clinical studies (Rogers et al, 1976),
Mechanism of metabolic effects
Myocardial oxygen consumption is raised during en¬
hanced fatty acid utilisation, and has been suggested
as a mechanism for the detrimental effect of free fatty
acids (Mj/^s, 1973). Indeed ischaemic myocardial oxygen
consumption was increased after the administration of
Intralipid/heparin (Liedtke et al, 1978), and could be
reduced by nicotinic acid (Section 3.5). Free fatty
acids and acyl-CoA uncouple oxidative phosphorylation in
vitro, but these studies may bear no relation to the in
vivo situation, due to the absence of fatty acid binding
proteins in vitro assays,(Ockner et al, 1972).
Oxygen wasting could also be explained by the operation
of an energy-wasting cycle (Schematically depicted in
Fig 6.02). On entry into the cell free fatty acids are
immediately esterified as their co-enzyme-A ester under
hydrolysis of ATP, and since they cannot readily be
(Scheuer and Brachfeld,
oxidised during acute ischaemia j 1966; Rieme'rsma et al,
1972; Opie et al, 1973; Neely et al, 1975), they accumulate
(Shug et al, 1975; Idell-Wenger and Neely, 1977; Liedtke
et al, 1978). The formation of triglycerides is enhanced
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Figure 6.02
Proposed FFA-TG energy wasting cycle
)
The metabolism of the normal and ischaemic myocardium is
represented in a schematic form in panels A and B respectively.
The flux through a pathway is indicated by the width of the
arrows. The energy wasted in the provision of <x-glycero-
phosphate is not indicated. One full cycle would consume
4 molecules ATP (3 for the activation of FFA and 1 for
glycerol).
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possibly due to a mass-action effect and increased
availability of «-glycero-phosphate, and a net accumulation
of triglycerides (neutral fat) is observed (Bryant et al,
1958; Scheuer and Brachfeld, 1966), despite the fact that
myocardial lipolysis is stimulated (Opie et al, 1973;
Brownsey and Brundt, 1977; Appendix E). Thus lipolysis
appears to be the rate limiting step in the cycle (since
both acyl-CoA and triglycerides accumulate). The
completion of one full turn of the cycle (the synthesis
and degradation of 1 molecule of triglyceride) requires
4 molecules of ATP, and will be directly related to the
lipolytic activity. Controlling the entry of fatty acids
(by reducing plasma free fatty acid concentrations) may
have little effect on the energy wasted, since the activity
of the lipolysis is rate-limiting. Stimulation of myo¬
cardial lipolysis by enhanced activity of the myocardial
sympathetic nervous system will initiate a further decline
in ATP, and thus initiate a vicious circle. This hypo¬
thesized mechanism could also explain the observation
that raised levels of cyclic AMP relate to the incidence
of ventricular fibrillation (Podzuweit et al, 1978),
since cyclic AMP, local noradrenaline release (Shahab
et al, 1969) and ischaemia-induced lipolysis are most
likely closely related.
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When plasma free fatty acids are raised, the level
of acyl-CoA in the ischaemic myocardium is further
stimulated (Liedtke et al, 1978), and may inhibit
adenine nucleotide translocase and thereby impeding the
transport of ADP into and ATP from the ischaemic mito¬
chondrion, leading to an immediate interruption of energy
production (Bittar et al, 1976; Shrago and Sul, 1977).
Acyl-carnitine does not inhibit adenine nucleotide trans¬
locase, and provision of L-carnitine could theoretically
lower acyl-CoA levels. Intracoronary L-carnitine
(hyperosmolar) has been reported to reduce the severity
of ischaemic injury (Shrago and Sul, 1977). There is
serious doubt about the interpretation of the results: hyper¬
osmolar solutions can reduce infarct size by reducing cell
swelling (Opie, 1975). No in vivo evidence of carnitine
uptake was presented, and extraction of L-carnitine by
the ischaemic myocardium could not be demonstrated
(Riemersma, unpublished results). Thus it is not clear
whether inhibition of adenine nucleotide translocase is
involved in the detrimental effects of fatty acids.
Non-specific effects of fatty acids or their derivatives
on (cytoplasmic) enzymes have been proposed (Kurien and
Oliver, 1970). Fatty acids inhibit Na', K+-ATP-ase in
TT
vitro (Lamers and Hulsmann, 1977), but it remains to be
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seen whether these studies have a physiological meaning
in view of the high free fatty acid to albumin molar
ratios used. An interesting observation was made by
Stam and Hulsmann (1978^) who showed that free fatty
acids might lead to noradrenaline release due to their
Ca++ ionophoric properties. If this were to hold during
ischaemia, a self-perpetuating stimulation of noradrenaline
could be initiated. That ionophoric properties of fatty
acids do play a role follows from the observations that
the accumulation of intra-mitochondrial calcium is
associated with lipolytic material of unidentified nature
(Jennings, personal communication).
Anaerobic glycolysis can not contribute significantly
to the energy production of the ischaemic heart (Opie et
al, 1973; Neely et al, 1975), thus it is more likely that
the apparent beneficial effect of glucose is mediated or
associated with a change in its relative contribution to
oxidative metabolism, leading to more efficient oxygen
utilisation possibly due to the higher P/0 ratio of glucose
in comparison to fatty acids. Glycolytic flux is in¬
hibited by the early accumulation of H+ ions, and the
residual ischaemic blood flow is an important regulator
of glycolytic flux (Rovetto et al, 1975). Acidosis can
reduce further impeded coronary flow, while oxygen is
still available and thereby aggravate the compromised
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situation further (Steenbergen et al, 1977). This may
help to explain why the effects of glucose are de¬
pendent on the severity of myocardial ischaemia in
experimental (Opie et al, 1976; Russell et al, 1979)
and clinical settings (Rogers et al, 1976), since
residual flow will determine both oxygen supply and
removal of H+ ions.
Direct beneficial effects of glucose, such as a re¬
duction of potassium loss from the ischaemic myocardium
have been suggested (Opie, 1970). However enhanced
glucose utilisation by the ischaemic myocardium was not
associated with reduced potassium loss, while spontaneous
arrhythmias were less frequent (Russell and Oliver, 1979).
On the other hand K+ loss may not be related to sub¬
sequent development of arrhythmias (Thomas et al, 1970).
Glycolytically produced ATP might be essential for
the maintenance of the transmembrane potential in anoxic
preparations (see Opie, 1970), but data on ischaemic
myocardium is lacking. It would be surprising, that
during ischaemia the small amount of glycolytically
produced ATP could not be furbished. Provision of glucose
reduced plasma free fatty acids and hence indirectly
ischaemic myocardial free fatty acid utilisation.
Whether increased glycolytic flux within the ischaemic
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myocardium reduces the accumulation of intracellular
free fatty acids or their acyl-CoA esters by stimulating
ester ification has not been studied. However, even if
it did the use of antilipolytic drugs may have the
additional advantage of inhibiting ischaemia-induced
lipolysis, and thereby preventing the initiation of an
energy-wasting cycle depicted in Fig 6.02. A precise
mechanism of the detrimental effects of enhanced myo¬
cardial lipolysis and raised plasma concentrations of
free fatty acids, and of the beneficial properties of
increased glucose utilisation by the ischaemic myo¬
cardium can not be given and more basic research in the
controlling factors of ischaemia-induced lipolysis is
indicated.
The acquired knowledge on control of ischaemic
metabolism will then help to define new therapeutic
approaches to the management of acute myocardial infarction.
Tne use of pyruvate and buffer infusion to reduce the
severity of myocardial ischaemic injury is a direct result
of the increased knowledge of ischaemic-myocardial
metabolism. Pyruvate serves a dual purpose: to act as
an intracellular H+ scavenger and to provide the cell
with an alternative substrate. Glycolysis and pyruvate
oxidation were both stimulated and a reduction in the
severity of ischaemic injury was observed (Liedtke et
al, 1976: Liedtke and Nellis, 1978).
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Main conclusions
Effective antilipolytic treatment reduces the severity
of myocardial ischaemic injury (Part 3).
The reduction of evidence of ischaemic injury after
antilipolytic treatment is associated with a reduction
in free fatty acid extraction, but glucose and lactate
exchange are not affected (Part 3).
The reduction in ST-segment elevation is associated
with a reduction in oxygen extraction across the
ischaemic myocardium (Section 3.5).
The extraction of plasma free fatty acids across the
ischaemic myocardium is related to the arterial con¬
centration (Section 5.4).
Increased arterial concentrations of plasma free fatty
acids (oleic acid) do not precipitate ventricular
fibrillation (Section 5.4).
Raised concentrations of plasma free fatty acids do
not inhibit glucose utilisation by the ischaemic
heart (Section 5.4).
Enhanced glucose utilisation by the ischaemic myo¬
cardium limits the degree of ST-segment elevation.
This effect may be dependent on residual blood flow
(Section 4.1).
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During acute myocardial ischaemia the enhanced
triglyceride formation and degradation, establishes
an energy-wasting cycle. The rate limiting step is
the lipolytic activity (Part 6).
Local metabolic and hormonal changes in the ischaemic
myocardium deserve more attention, since they may be
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Appendix A
THE RECORDING OF EPICARDIAL ELECTROCARDIOGRAMS
APPENDIX A. The recording of epicardial electrocardio¬
grams. Electronic equipment and block diagrams
Manual recording of epicardial electrocardiograms:
Phase 1 The original attenuator box/cotton wick
electrode.
Phase 2 Improved attenuator box.
Continuous monitoring:
Phase 3 Recording of average epicardial electro¬
cardiogram .
Phase 4 Continuous monitoring of 15 electrocardio¬
grams, using a multiplexer system.
Figure 1: Phase 1-2 Manual recording of epicardial








PHASE 2 INPUT OUTPUT
SOCKET SOCKET
The epicardial electrocardiogram was recorded using a
cotton-wick electrode. The combined limb leads served
as the reference electrode. The epicardial signal was too
large for the Devices AC amplifier and was first suitably
attenuated using the attenuator box. The equipment was
calibrated prior to each experiment. RA = right arm,
LA = left arm; LL = left leg and RL = right leg.
The attenuator box was improved (Phase 2) by the insert¬
ion of input resistors for the limb leads. Attenuation
x 10.




The electrocardiogram of 16 epicardial electrodes,
attached to a thin latex grid, were continuously
monitored. Electrocardiograms could be monitored
either individually or as the average of a number of
selected sites using a 16 lead selection box. The
resulting complex was suitably attenuated using the
attenuator box (Mark II) and recorded on a Devices
M8 recorder.
Figure 3 : Phase 4 Continuous monitoring of epicardial




























Multiplexer block diagram (Panel A and B). Electrocardio¬
grams, obtained from 15 electrodes on an epicardial grid
vere continuously monitored. After suitable amplification
asing 15 identical amplifiers, the multiplexer sampled the
signals in three groups; group A: electrode 1-5, group B:
b-lO and group C: 11-15. The sampling rate for each com¬
plex was 300 samples/sec. The 3 resultant multiplexed
signals (Groups A, B and C) were recorded on a tape re¬
order. The individual signals could be retrieved using
i signal decoder (Panel C), and the selected epicardial
electrocardiogram was analysed using a purpose built ST-
segment computer (Neilson et al, 1968). For further de-
;ails see text.











THE MEASUREMENT OF REGIONAL MYOCARDIAL BLOOD FLOW









Sc 46 in Co57 channel
Sc46 in Sc46 channel








The effects of geometrical factors on the counting
efficiency of two isotopes Co^? and Sc4^, with the
maximal difference in gamma energy used in our ex¬
periments was examined by Dr. P. Tothill, Department
of Medical Physics, The Royal Infirmary, Edinburgh.
Water soluble standards of Co^7 and Sc4" were re¬
peatedly counted in both channels, each time after
the addition of water to increase the sample height,
while the amount of radioactivity was kept constant.
The efficiency of each isotope was always expressed
relative to the maximal count rate in its own channel
(height O).
The relative efficiency of Co-3' and Sc decreases
slightly in our working range (2-4 cm).
Note that the decrease in Sc4^ efficiency in its own
channel is not identical to that observed in the Co^




























































































IF(IERR.NE.0) GO TO 999
WRITE(4,5)
FORMAT(1H ,'WALLAC FILE .2 '
READ(INDEV,4) FILE2
CALL USR(7,FIL£2,2,IERR)
IF(IERR.NE.0) GO TO 999
WRITE(4,6)
FORMAT(1H ,'WEIGHTS FILE '
READ(INDEV,4) FILES
CALL USR(S«FILE3,2,IERR)
























FORTRAN IV 4BAAA 28-MAR-79 PAGE TWO'
C








C AVERAGE BACKGROUNDS FOR EACH ENERGY
C
DO 17 ENERGY31.4
17 BGD (ENERGY. 1)=(BGD(ENERGY. i )-i-BGD (ENERGY, 2) )/2„
C
C TEMPORARY DUMP OF BACKGROUND MATRIX
C • '
C WRITE(OUTDEV,18)
C 18 FORMATUH0, 'AVERAGE BACKGROUNDS FOR EACH ENERGY'/)
C WR I TE (OUTDEV,44) (BGD(ENERGY, 1) ,ENERGY31.4)
C
C FIND IN WHICH CHANNEL THE MAXIMUM OCCURS FOR EACH SET.OF DATA.


















„ • . •
C THE ARRAY SETNO CONTAINS THE CHANNELS IN WHICH MAXIMUM COUNTS OCCUR.
C USING THIS INFORMATION RESHUFFLE THE DATA INTO STAND SO THATs
C SET 1 HAS MAX ENERGY 1










C TEMP DUMP OF DATA.
C






































































42 FORMAT(1H0,'SET *,II,5X,*SPECIMENS 1 -> 4'/)
DO 40 SPEC®1,4

























WRITE OUT FACTOR MATRIX
I 1/)
DO 55 SET=1,4
LJRITE (OUTDEV, 53) SET
FORMAT(1H0,'CONTRIBUTION FACTORS FOR STANDARD *.
IJRI TE (OUTDEV, 58) (FACT(SET,ENERGY).ENERGY®1,4)
FORMATdH .4F10.4)
IJR ITE (OUTDEV, 59) ISOTOP
FORMAT(1H0,II," ISOTOPES IN THIS STUDY'/)

























FORTRAN IV 4BAAA 2B--MAR~79 PAGE - FOUR
4
C 77 FORMAT(IH0,'ENERGY ',!!/)
C DO 70 R0U=i,5
C 70 URITE(OUTDEV,44) (DOG(ROU,COL,ENERGY,ENDEPI) ,CQL=1,4)
t • r
c
C FOR EACH TISSUE SAMPLE CORRECT THE-COUNTS FOR CROSS CONTRIBUTIONS USING
C THE FACT MATRIX DEVELOPED FROM THE STANDARDS.
C
IF(ISOTOP.EQ.1) GO TO 82












IF(ISOTOP.EQ.3) CALL GELG(GELGB.GELGA3,3,l.EPS,IER) -
IF(ISOTOP.EQ.4) CALL GELG(GELGB,GELGA4.4.l.EPS,IER)
IF(IER.NE.0) URITE(OUTDEV,87) IER,ROU,COL,ENDEPI
87 FORMAT(1H0,' H«UUARN ING . 11,' - POSSIBLE.LOSS OF SIGNIFICANCE AT





C DUMP THE CORRECTED TISSUE DATA.
C
82 URITE(OUTDEV,88) '
88 FORMAT(1H0//T10,'ENDOCARDIUM CORRECTED COUNTS





92 F0RMAT(1H ,4110,10X.4110) • 1
93 FORMAT(1H0,T21.'ENERGY '.I1.T71.'ENERGY '.II/)
C





















IF (DOG(ROW.COL,ENERGY,2) .EQ.0.0) GO TO 144























• DO 170 COL=1,4
IF(DOG(ROW,COL,ENERGY,ENDEPI).GT.TOP)


















190 FORMAT(1H0.'TV DISPLAY (Y/N) ? '-,0)
READ(4,4) ANS
IF(ANS.EQ.NO) STOP
































































FORMAT(' ENERGY (1,2,3,4) ? ',S)
READ <4, 196). ENERGY
FORMAT<II)





FORMAT(' ABSOLUTE OR RELATIVE BLOOD FLOW (A/R)1 ? ',S)
READ(4,4) ANS
IF(ANS.EQ.AB) GO TO 200
IF(ANS.EQ.RE) GO TO 300
GO TO 198
DISPLAY ABSOLUTE BLOOD FLOWS
«
WRITE(4,205)













































FORTRAN IV 4BAAA 28-MAR-79 PAGE EIGHT
400 URITE<4,401)
401 FORHATUH0,'DISPLAY MORE (Y/N) ? ",S)
READ(4,4) ANS












APPENDIX B 3/6 The measurement of regional myocardial blood
flow: The reproducibility of the method (Tables)
I





AppendixB4 Regionalmyocardialblofl w( l^mi*)inschaemicanorderz ne,determi eds ult n ouslyith differentmicrospheres Regionalmyocardialblofl ww sdeterminedinthesc aemicb rd rz e5inftco onaryclusion. Combinedresults(mean+SEM)ofpi-aendocardiallayer .D t ilabbreviat onsiApp n ixB3 ExperimentRBS^ A Br-57•uComicrospheres (n=8)0.484+.077(100%) (n=8)0.535+_.085(100%)o103.Rumicrospheres 0.437 _+.0 5(90. %) 0.568+_.097(106.2%)„46.Scmicrospheres O.538+_0.085(111.2%) 0.492+.077(92.0%)
o113•iSnmicrospheres
2. 3.
A(n=6)0.618+_.053(100%) B(n-6)0.725+_.06 (100%) A(n=8)0.370+•.078(100%) B(n=8)0.388+_.082(100%)
0.573 _+052(92. %) 0.657 _+069(9 . %) 0.384+_.081(103.8%) 0.389 _+0.082(100.3%)
0.586+_.050(94. %) 0.677+_.058(93.4%) 0.322+_.066(87.0%) 0.330 _+.068(85.1%)












*Theeffectofcoronaryocclusionisc aemicbl dfl wwash r ldetect b e.R ultsxclud d. RBS**Ref.loodSample
AppendixB5 Thedeterminationofendocardial/epicardialr tiofegion lmy c rdialblofl wtermineds u t neously withdifferentmicrospheres Regionalmy cardialbloofl ww sdeterminedi epicardialae docardiallay sfisch micndon-ischaemic
57103
myocardium5inaftercoronarycclusion,usingsimultaneousinje t nfdiff tmicrospheres(CR Sc4<^ andinexperiment2Sn^3).Theffectoft re rencebloodsamplc celsutithd t inationf ratio(seeT xt).Inviewofthumberobservations(4)af r altatisticalanalysistm de. ConditionsandbbreviationsaiAppe dixB3 ExperimentCo57microspheresRu103 icrospheresSc46microspheresSn113microspheres 1.0.9100 084(100%).883+_0.077(97.0%)69 _+. 83(5.5 ) 3.1.079 _+0.133(100%)1.075 _+0.126(99.6%)122+.107(104.0%) 2.1.136 _+0.088(100%)1.1 6+_0.0 4(98.2%)124.0 3(98.9 )31+0. 8 (99.6%) 4.1.185+_0 051(100%)1. 790.055(99.5%)241+_.062(1 .7 ) Mean(Exp1-4).078̂0.060(100%)1. 63+_.06 (98.6%1.0 90.078(100.8%)
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Effects of p-Chlorophenoxyisobutyrate
on Myocardial Free Fatty Acid Extraction,
Ventricular Blood Flow, and Epicardial
ST-segment Elevation During Coronary Occlusion in Dogs
O. D. Mj<?s, m.d., N. E. Miller, m.b., ph.d.. R. A. Riemersma, d. biochem,
and M. F. Oliver, m.d., f.r.c.p.
SUMMARY The effect of p-chlorophenoxyisobutyrate (CPIB) on
ST-$egment elevation in epicardial electrocardiographic recordings
was studied during coronary artery occlusion in dogs. Occlusion
alone raised the sum of ST-segment elevations (2ST) to 26 ± 6 mV
(mean ±sem). Intravenous (i.v.) administration of CPIB 30 min
before re-occlusion reduced 2ST to 14 ± 3 mV IP < 0.03). A con¬
tinuous i.v. infusion of isoproterenol increased 2ST to 74 ± 11 mV.
Pretreatment with CPIB reduced 2ST during isoproterenol infusion
to 40 ± 7 mV (P < 0.005). CPIB had no effect on mean aortic blood
pressure, heart rate, or regional myocardial blood flow, as measured
by radioactive microspheres. Arterial free fatty acid (FFA) concen¬
trations were reduced by CPIB from 466 ± 41 to 221 ± 44 ;uEq/L
(P < 0.001) in the basal state, and from 1966 ± 183 to 1429 ± 209
/uEq/L (P < 0.001) during isoproterenol infusion. The reduction in
arterial FFA concentration was associated with a proportionate
decrease in the myocardial extraction of FFA. Similar changes were
observed when CPIB was administered during an occlusion which had
been established 10 min earlier. These observations support other
evidence that the severity of acute myocardial ischemic injury in dogs
is positively correlated with the myocardial extraction of FFA, and
that the severity of the ischemic injury can be reduced by effective an-
tilipolvtic therapy.
ACUTE MYOCARDIAL INFARCTION (AMI) in man
is accompanied within one hour by an increase in the plasma
concentration of free fatty acids (FFA), probably due to in¬
creased adipose tissue lipolysis as a result of enhanced
sympatho-adrenal activity.1"3 Those patients with the highest
plasma FFA concentrations have been reported to be at the
greatest risk of developing serious ventricular arrhythmias
and death,4-5 although not all investigations have confirmed
this association.6 The hypothesis that this might reflect a
toxic effect of FFA on the ischemic myocardium,7 rather
than a direct consequence of increased catecholamine ac¬
tivity, has been supported by the recent demonstration that
the incidence of ventricular arrhythmias during the early
phase of AMI in man can be reduced by effective antilip-
olytic therapy in the absence of changes in plasma catechola¬
mine concentration.8 A toxic effect of FFA on the heart
could be mediated through an alteration of membrane
potentials or an increase in the severity of the ischemic in¬
jury to the myocardium.
Increases in plasma FFA concentration similar to those
observed in clinical studies have been reported to increase
the frequency of ventricular arrhythmias9 and the severity of
myocardial ischemic injury10 during experimental coronary
occlusion in dogs. In healthy dogs, elevated plasma FFA
enhance myocardial oxygen consumption (MV02) without
improving the mechanical activity of the heart,11-12 sug¬
gesting that the deleterious effect of FFA during coronary
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occlusion may reflect an increase in the oxygen requirement
of the ischemic tissue.
Such observations have raised the possibility that the sur¬
vival of the ischemic cells following acute coronary occlu¬
sion may be enhanced by measures which decrease the
delivery of FFA to the ischemic cells. Substantial reductions
in plasma FFA concentrations have been reported in ani¬
mals treated with p-chlorophenoxyisobutyrate (CPIB),13-14
although it is not known whether this is accompanied by a
reduction in the utilization of FFA by the myocardium,15 as
has been demonstrated with /3-pyridyl-carbinol and its active
metabolite, nicotinic acid.12-16
We have studied the effect of CPIB on the extraction of
FFA by the heart and the extent and magnitude of epicardial
ST-segment elevation during experimental coronary artery
occlusion in dogs. The effect of antilipolytic therapy on
regional myocardial blood flow during coronary occlusion
was also examined, with the aid of radioactive microspheres.
Methods
Surgical Techniques
Experiments were carried out in 23 mongrel dogs of both
sexes (15-20 kg body weight), fasted for 12-15 hours. The
dogs were anesthetized with sodium pentobarbital, 25
mg/kg body weight, followed by maintenance doses of
30-40 mg. Ventilation was maintained through a cuffed en¬
dotracheal tube with a positive pressure respirator (Harvard
Apparatus Co. Inc., Mass.). Thoracotomy was performed
through an incision in the left Fifth intercostal space, and the
heart suspended in a pericardial cradle. A branch of the left
anterior descending (LAD) coronary artery was dissected
free for a distance of 0.5 cm and a ligature placed loosely
around it. Subsequent occlusions of the artery were per¬
formed with a releasable metal clip. The left femoral artery
was cannulated for measurement of mean aortic blood
pressure (AP), and the left femoral vein as a route of in¬
fusion. AP was monitored with a Statham P23Db trans¬
ducer and recorded on a 4-channel recorder (Devices Ltd.,
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Herts, U.K.). Arterial blood was sampled through a cathe¬
ter inserted into the right femoral artery. In seven experi¬
ments coronary sinus blood was withdrawn simultaneously
through a catheter introduced via the left jugular vein
under fluoroscopic guidance. Arterial oxygen saturation
was monitored with a Kipp type M01 Hemoreflector, and
pH and pC02 with a Type AME lc Astrup Micro Equip¬
ment (Radiometer, Copenhagen).
Epicardial ST-segment Mapping
Epicardial electrocardiographic (ECG) measurements
were performed with a mobile cotton-wick electrode, as
described by Maroko et al.,17 from 10-15 anatomically
recognizable sites supplied by the dissected coronary artery
and from the surrounding left ventricular tissue. Mea¬
surements were recorded, together with the standard limb
leads, on a Devices 4-channel recorder at a paper speed of 25
mm/sec. The sensitivity of the epicardial recordings was set
at lmV/mm deflection. Those sites at which ST-segment
elevation exceeded 2 mV were considered to be ischemic.17
Results were expressed as the sum of ST-segment elevations
recorded from all sites (2ST), and as the number of sites at
which ST elevation exceeded 2 mV10,17
It should be noted that the values obtained with this
technique are related not only to the severity of the ischemic
injury, but also to the number and location of the recording
sites, and cannot therefore be used to compare the results of
different experiments. For such a purpose it would have been
necessary to use a standardized grid system, which has dis¬
advantages because of anatomical variations from dog to
dog. In the present study, however, such a system was not
required since each animal served as its own control, the
electrode sites remaining constant throughout a given study
and the effect of CPIB being assessed by paired analysis.
Regional Myocardial Blood Flow
Regional myocardial blood flow was measured by means
of radioactive microspheres labelled with 126I, 141Ce, or 85Sr
(3M Riker Laboratories, Loughborough, U.K.: nominal
diameter, 15/x).18'19 Prior to injection 2.0-2.5 X 106 micro¬
spheres were subjected to ultrasound in 10% dextrose for 10
or more min to dispel aggregates (Dawe Sonicleaner, type
6441 A), and drawn into a syringe containing 0.1 ml 5%
Tween 80 to prevent reaggregation. The suspension was
diluted with 10% dextrose to give a final concentration of
Tween 80 of less than 0.5% and then continuously agitated
until injected. Ten to 13 min after each coronary occlusion
blood for the estimation of reference blood flow (RBF) was
withdrawn from a femoral artery into a weighed heparinized
syringe at a constant rate (approx. 9 ml/min) for a period of
2 min using a Harvard infusion/withdrawal pump.
Immediately after the commencement of blood withdrawal,
the microspheres were injected through a left atrial cannula
over a period of about 10 sec. Between 5 and 30 min after the
last injection the dog was sacrificed with sodium pento¬
barbital. The heart was excised, the free wall of the left ven¬
tricle dissected out, and visual fat and large vessels removed.
Between 10 and 14 full thickness biopsies were made and
divided into epicardial and endocardial layers of wet weight
1.5-4.0 g. The method was designed to give a minimum of
1000 microspheres/g wet weight of ischemic myocardium.
Each layer was then divided into 10-20 blocks to produce
relatively constant geometrical factors for the measurement
of radioactivity in a three channel gamma counter (Gamma-
Guard, Tracerlab Ltd.). Approximately 27% and 9% of 86Sr
radioactivity was counted in the 141Ce and 126I channels
respectively, while 3% of 141Ce radioactivity was counted in
the 125I channel. These factors were determined during each
counting procedure using the reference blood samples (con¬
taining only one isotope) as standards in a similar
geometrical setting. Regional blood flow was estimated by
weighing, using an assumed blood specific gravity of 1.05
g/ml. Regional myocardial blood flow (MBF) was
calculated for each biopsy using the formula:
CM
MBF ="qj^X RBF, where MBF is expressed in ml g1,
min-1. CM is the biopsy radioactivity in cpm/g wet weight,
CR is the total cpm in the reference blood sample, and RBF
is expressed in ml/min.18'19
Laboratory Procedures
Plasma CPIB concentrations were measured by a spectro-
photometric method.13 Plasma FFA concentrations were
assayed in duplicate by the method of Dole20 as modified by
Trout et al.,21 and were corrected for the presence of CPIB
as described by Barrett and Thorp.13 Plasma free glycerol
was estimated in duplicate according to Chernick.22 Blood
glucose was measured in duplicate by an automated
method.23
Design ofExperiments
Effects of Pretreatment with CPIB on Subsequent
Coronary Occlusion. The effects of pretreatment with CPIB
on the response to subsequent coronary occlusion were
studied in ten dogs. In seven animals the following ex¬
perimental design was employed. Epicardial electro¬
cardiograms were recorded before and 5, 10, and 15 min
after an initial control occlusion. The clip was then removed
and a recovery period of 30 min allowed. The arterial FFA
concentration was then raised by a continuous intravenous
(i.v.) infusion or isoproterenol (0.2-0.3 /^g/kg/min).
Coronary occlusion alone does not alter plasma FFA con¬
centrations in anesthetized dogs.9-10 This was confirmed in
five of the present experiments, in which arterial FFA con¬
centrations 15 minutes after occlusion (414 ± 16 pEq/L,
mean ±sem) were not significantly different from those im¬
mediately before occlusion (406 ± 23 ^Eq/L). Five minutes
after the start of the infusion (by which time a stable hemo¬
dynamic response had been attained) the artery was re-
occluded. Epicardial ECG recordings were again made at 5
min intervals for 15 min, after which time the clip was
released and the isoproterenol infusion discontinued. After
another recovery period of 30 min CPIB was administered
as the sodium salt by slow i.v. injection in 0.9% saline at the
dose of 20 mg/kg body weight. Thirty minutes later the
foregoing sequence was repeated, identical occlusions of the
artery being induced at first in the absence and then in the
presence of isoproterenol, and ST-segment elevation being
mapped immediately before and 5, 10, and 15 min after each
occlusion. In the remaining three dogs (307, 309, 313)
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studies were carried out either in the absence or presence of
isoproterenol only.
The reproducibility of the ST-segment mapping pro¬
cedure was checked in the same experiments by performing
repeated occlusions under identical conditions. In ten com¬
parisons, values for 2ST measured 15 min after coronary
occlusion agreed consistently within ± 7% (first occlusion:
2ST 46 ± 12 mV, mean ± sem: second occlusion: 47 ± 12
mV [paired r-test: P > 0.30]).
Measurements of AP and HR were made simultaneously
with each ECG recording. Arterial blood was collected 15
min after each occlusion into a heparinized tube, and plasma
for FFA and CPIB estimations separated immediately by
centrifugation at 4°C. In nine dogs arterial blood was also
collected for blood glucose determination.
In five additional dogs the effect of CPIB on regional
myocardial blood flow during coronary occlusion was
assessed by means of radioactive microspheres. Measure¬
ments were made during an initial control occlusion (three
dogs), during second occlusion performed in the presence of
isoproterenol (five dogs), and during a third occlusion per¬
formed in the presence of isoproterenol 30 min after i.v.
CPIB (five dogs), the order of injection of the differently
labeled microspheres being randomized in order to avoid
systematic errors due to possible differences in their
behavior. (The effect of CPIB on myocardial blood flow was
assessed in the presence of isoproterenol, rather than under
basal conditions, since it had previously been found that the
reduction of epicardial ST-segment elevation by CPIB was
more marked in the former situation.)
Effects of CPIB Administration during Established
Coronary Occlusion. In six dogs an i.v. infusion of
isoproterenol (0.2-0.3 /ug/kg/min) was maintained for the
duration of the study. Five minutes after its commencement
a branch of the LAD coronary artery was permanently
occluded. Five and ten minutes later recordings were made
of epicardial ECG, AP and HR. CPIB was then ad¬
ministered as previously described, and the recordings
repeated after further intervals of 5 and 10 minutes.
Simultaneously with each recording, arterial blood was
sampled for the measurement of plasma FFA, CPIB, and
free glycerol concentrations. In five of these dogs, and in an
additional two animals, coronary sinus blood was also
sampled immediately before and ten minutes after CPIB ad¬
ministration for the determination of the arterial-coronary
sinus concentration differences of FFA and CPIB.
Statistics
Each dog served as its own control. Student's r-test for
paired data was used to calculate probability values.
P > 0.05 was regarded as not statistically significant.
Results
Effects ofPretreatment with CPIB
The effects of CPIB on the response to subsequent
coronary occlusion are summarized in tables 1 and 2. Occlu¬
sion of a branch of the LAD coronary artery was followed
by marked changes in epicardial ST segments. After 15
minutes of occlusion 2ST averaged 26 ± 6 mV (mean
±sem). After CPIB administration re-occlusion of the
artery resulted in a much smaller 2ST, averaging 14 ± 3
mV (P < 0.03). CPIB also reduced the number of sites with
evidence of ischemic injury (ST > 2mV) from an average of
4.9 ± 1.1 to 2.9 ± 1.0 (P < 0.05). These effects ofCPIB oc¬
curred in the absence of any changes in AP, HR, or blood
glucose concentration (table 1). However, arterial FFA con¬
centrations were reduced from 466 ± 41 pEq/L to 221 ± 44
/uEq/L (P < 0.001) (table 1).
Prior to CPIB the infusion of isoproterenol increased
occlusion-induced 2ST from 26 ± 6 mV to 74 ± II mV
(P < 0.001), and the number of sites with ischemic injury
from 4.9 ± 1.1 to 9.0 ± 0.9 (P = 0.02) (tables 1 and 2).
After CPIB 2ST associated with subsequent coronary
occlusion and isoproterenol infusion was markedly reduced
to 40 ± 7 mV (P < 0.005), while the number of sites with
ischemic injury was reduced to 7.6 ± 1.3 (P < 0.05). In¬
travenous infusion of isoproterenol before CPIB reduced AP
from 97 ± 5 to 91 ± 3 mm Hg (P < 0.05), and increased
HR from 134 ± 7 to 176 ± 6 beats/min (P < 0.001), blood
Table 1. Effects of Pretreatment with CPIB on Epicardial ST-segment Elevation, Arterial FFA Concentration (FFA), AP, HR,
and Blood Glucose Concentration of 15 Minutes after Coronary Occlusion
2ST*
(mV)




























303 8 5 1 1 340 105 98 90 143 138 — — 139
304 33 32 7 7 440 130 82 92 133 139 61 47 129
305 17 10 4 1 510 105 100 107 145 147 52 60 148
306 5 3 0 0 320 150 102 104 143 142 66 65 125
307 20 17 3 2 460 245 103 97 156 142 66 53 159
308 26 10 5 0 420 340 112 105 162 164 65 64 194
309 31 18 7 4 390 150 75 75 111 109 58 58 166
312 62 19 8 8 630 265 86 92 111 104 75 71 208
315 34 12 9 3 680 500 117 116 100 95 34 46 166
Mean 26 14 4.9 2.9 466 221 97 98 134 131 60 58 159
sem 6 3 1.1 1.0 41 44 5 4 7 8 4 3 9
P <0.03 <0.05 <0.001 NS NS NS —
*Sum of ST-segment elevations at 10-15 sites.
fNumber of sites at which ST-segment elevation exceeded 2 mV.
NS = P > 0.05.
.
Abbreviations: Occ = occlusion; IP = isoproterenol; FFA = free fatty acid; AP = mean arterial pressure; HR = heart rate; Bd glue = blood glucose.
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Table 2. Effects of Prctrcatment with CPIB on Epicardial ST-seqme,nl Elevation, Arterial FFA Concentration (FFA), AP, IIR and
Blood Glucose Concentration 15 Minutes after Coronary Occlusion Performed during a Continuous i.v. Infusion of Isoproterenol
SST*
(mV)








































303 19 5 4 1 1300 975 82 83 185 180 — — 116
304 71 43 11 11 1930 1275 90 92 185 185 81 60 111
305 92 65 9 6 1560 945 93 97 132 185 80 70 122
306 58 40 10 9 2820 2315 82 82 175 176 95 82 127
308 64 17 7 4 1880 1160 98 90 175 170 77 75 166
312 124 54 9 9 1880 1360 83 80 154 149 136 141 185
313 79 34 12 11 2640 2400 102 105 200 198 52 60 139
315 87 58 10 10 1720 1000 95 90 155 148 42 54 166
Mean 74 40 9.0 7.6 1966 1429 91 90 176 174 80 77 142
SEM 11 7 0.9 1.3 183 209 3 3 6 6 12 11 10
P <0.005 <0.05 <0.001 NS NS NS —
♦Sum of ST-segment elevations at 10-15 sites.
fNumber of sites at which ST-segment elevation exceeded 2 mV.
NS = P > 0.05.
For abbreviations see table 1.
glucose concentration from 60 ± 4 to 80 ± 12 mg/100 ml
(P < 0.02) and arterial FFA concentration from 466 ± 41
to 1966 ± 183 /uEq/L (P < 0.001). None of these effects of
isoproterenol was altered by CPIB other than the increase in
arterial FFA concentration, which was reduced to
1429 ± 209 /uEq/L (P < 0.001).
The results of the studies with radioactive microspheres
are summarized in table 3. Nonischemic tissue of the free
wall of the left ventricle distant from the occluded artery was
taken to represent normal myocardium. On this basis cor¬
onary occlusion produced an average decrease of ap¬
proximately 40% in blood flow to the ischemic zone. As
reported by other investigators,24 the reduction in flow was
greater in the endocardial than in the epicardial layers,
resulting in a significant increase in the epicardial/endocar-
dial blood flow ratio (P < 0.01). Isoproterenol significantly
increased the blood flow to the nonischemic left ventricle, as
previously reported,25 but had no effect on that to the
ischemic zone. Values for regional myocardial blood flow in
both the ischemic and nonischemic zones were unchanged by
treatment with CPIB.
Effects ofCPIB Administration During
Established Coronary Occlusion
The acute effects of CPIB when given during an
established coronary occlusion and isoproterenol infusion
are summarized in table 4. Five and ten minutes after giving
CPIB (i.e., 15 and 20 minutes following coronary occlusion)
values for SST and arterial FFA concentration were both
significantly reduced relative to those recorded immediately
before treatment, while AP and HR remained unchanged.
In contrast, SST has previously been found to increase or
remain unchanged between 10 and 20 min following cor¬
onary occlusion during isoproterenol infusion in the absence
of CPIB administration (10 min: 61 ± 8 mV: 15 min 67 ± 8
mV: N = 12, P < 0.005, 10 min: 94 ± 19 mV: 20 min:
98 ± 16 mV: N = 5, P = NS). The reduction in arterial
FFA concentration was associated with a proportionate
decrease in the arterial-coronary sinus FFA concentration
difference (table 5). No significant uptake of CPIB by the
myocardium could be detected: mean arterial and coronary
sinus CPIB concentrations were 225 ± 18 and 218 ± 21
Table 3. Effects of Isoproterenol and CPIB on Regional Myocardial Blood Flow in Nonischemic and Ischemic





(3) p (5) p (5)
Epi 1.30 ± 0.09 <0.001 1.88 ± 0.09 NS 1.85 0.07
(N = 21) (N = 34) (N = 34)
Endo 1.36 ± 0.10 <0.001 1.62 ± 0.07 NS 1.61 0.05
(N = 21) (N = 34) (N = 34)
Epi/ 0.97 ± 0.04 <0.001 1.17 ± 0.04 NS 1.16 0.03
Endo (N = 21) (N = 34) (N = 34)
Epi 0.86 ± 0.16 NS 0.89 =fc 0.08 NS 0.94 =tz 0.10
(N = 6) (N = H) (N = 11)
Endo 0.71 ± 0.14 NS 0.71 ± 0.11 NS 0.76 =i= 0.12
(N = 6) (N = 11) (N = 11)
Epi/ 1.32 ± 0.12 NS 1.45 ± 0.16 NS 1.50 =iz 0.12
endo (N = 6) (N = ID (N = U)
Ischemic myocardiunf
Results are expressed as mean ± sem (number of biopsies).
NS = P > 0.05.
♦Myocardium distant from the occluded artery.
tMyocardium within the area of distribution of the occluded artery.
Abbreviations: MBF = myocardial blood flow; epi = epicardial; endo = endocardial.
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Table 4. Acute Effects of CPIB on ST, AP, HP and the Arterial Concentrations of FFA and Free Glycerol when Administered
Time (min) 0 5 10 15 20 25
Isoproterenol infusion (0.2 - 0.3 Mg/^g/niin)
Coronary artery occlusion
CPIB (20 mg/kg)
2ST (mV) 11 =<= 4(6)f 74 12 (6) 81 13 (6) 57 8 (6)* 53 6(6)*
ST > 2mV (number of sites) 1.4 ± 0.7 (6)f 9.6 =fc 0.9 (6) 9.2 ± 0.9 (6) 8.4 db 0.7 (6) 8.4 ± 0.8 (6)*
AP (mm Hg) 82 ± 4 (6) 84 ± 5(6) 84 =±= 5 (6) 86 =fc 5(6) 85 d= 5 (6)
HR (beats/min) 154 ± 13 (6) 152 ± 13 (6) 150 13 (6) 148 =fc 12 (6) 146 =1= 12 (6)
FFA GdEq/L) — 1540 20 (2) 1993 ± 259 (6) 1218 155 (6 )f 1108 156 (6)*
Glycerol (mhioI/1) — — 254 =fc 31 (6) — 185 21 (6)t
Arterial CPIB cone (Mg/ml) 0 0 0 251 =fc 15 (6) 223 12 (6)
Results are expressed as mean ± sem (number of dogs).
Statistical comparisons were performed by paired <-test analysis against those results (3rd column) obtained immediately before the administration of CPIB.
*P < 0.025.
tP < 0.01.
Other differences were not statistically significant.
Abbreviations: cone = concentration; for others see table 1.
/ug/ml respectively: CPIB reduced the arterial free glycerol
concentration from 254 ± 31 to 185 ± 21 /umol/L (P < 0.01).
Discussion
The present observations demonstrate that pretreatment
with CPIB substantially reduced the extent and magni¬
tude of epicardial ST-segment elevation after experimental
coronary artery occlusion in dogs, and reduces the augmen¬
tation of ST-segment elevation induced by isoproterenol
infusion. The absolute reduction in ST elevation during
isoproterenol infusion was greater than that recorded during
occlusion in the absence of an isoproterenol infusion. This
difference was observed both when the administration of
Table 5. Effects of CPIB on Arterial FFA Concentration,
Arterial-Coronary Sinus FFA Concentration Difference and






















323 760 365 360 50 47 14
324 460 370 60 30 13 8
During isoproterenol (0.2 - 0.3 tig/kg/min)
321 3020 1125 750 155 25 14
323 2800 2155 450 400 16 19
324 1210 920 360 300 30 33
325 1070 730 120 105 11 14
326 2250 1780 300 180 13 10
327 1850 905 420 375 23 41
328 1890 850 420 315 22 37
Mean 1701 1022 260 212 22 21
SEM 297 199 67 46 3.8 4.2
P <0.01 <0.01 NS
*Extraction ratio =
(arterial concentration — coronary sinus concentration) X 100%
arterial concentration
fValues obtained 10 minutes after i.v. CPIB (20 mg/kg).
Arterial FFA concentration versus arterial-coronary sinus FFA con¬
centration difference: rs = + 0.76, P < 0.01.
CPIB preceded a subsequent re-occlusion of the artery, and
when the drug was given during an occlusion established 10
minutes earlier.
Epicardial ST-segment elevation has been reported to
reflect the severity of experimentally induced myocardial
ischemia,26 and to correlate with both the local reduction in
myocardial oxygen tension produced by acute coronary oc¬
clusion27 and the subsequent depletion of myocardial
creatine kinase activity during sustained occlusion.10, 17 The
latter relationship has been shown to persist under a variety
of conditions, including antilipolytic therapy.10 Since irre¬
versible myocardial injury does not occur during the first 20
minutes of ischemia,28 and reproducible results for 2ST
were obtained in the absence of intervention, the reduction
in ST-segment elevation achieved with CPIB probably indi¬
cates limitation of the acute myocardial ischemic injury.
The severity of acute myocardial ischemic injury has been
shown to be influenced by factors which alter the oxygen
requirements of the heart relative to oxygen supply.17 The
major determinants of myocardial oxygen requirements in¬
clude the mechanical factors of contractility, heart rate, and
wall tension.29 However, the lack of any effect of CPIB on
AP or HR in the present investigation renders it unlikely
that there was reduction in ischemic injury due to altered
mechanical activity.
An effect of CPIB on the coronary collateral circulation
can be excluded from the results of the microsphere studies,
which demonstrated that blood flow to both the ischemic
and non-ischemic zones of the left ventricular wall was un¬
altered by treatment. Furthermore, the failure of CPIB to
alter regional myocardial blood flow suggests that the reduc¬
tion in ST-segment elevation was also unrelated to its known
effects on platelet aggregation, blood clotting mechanisms,
and blood viscosity.30 32
CPIB reduced the arterial concentration of FFA by a
mean of 40%, and this was associated with a proportionate
decrease in the arterial-coronary sinus difference in FFA
concentration. We have shown in other studies that CPIB
also reduces the myocardial uptake of radioactive FFA from
plasma during a continuous infusion of albumin-bound
radiolabeled palmitate (Miller, N.E., Mj^s, O.D.: un-
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published observations). The association of these changes
with the failure of CPIB to alter myocardial blood flow in¬
dicates a reduction in the utilization of FFA by the heart as a
consequence of the fall in arterial FFA concentration.
Although proportionality between the arterial concentration
and myocardial extraction of FFA has been well
documented in other situations,12' 16'33-34 it could not have
been predicted that this would apply after CPIB administra¬
tion in view of reports that CPIB may displace FFA to
weaker binding sites on the albumin molecule.15 The reduc¬
tion in arterial glycerol concentration suggests that the
FFA-lowering effect of CPIB derived, at least in part, from
an inhibition of lipolysis, in accordance with in vitro studies
of adipose tissue metabolism.35,36
In 1965 Challoner and Steinberg37 reported that high con¬
centrations of FFA raised the oxygen requirements of the
isolated perfused rat heart. This finding was extended by
Mj0s" who reported that raised arterial FFA concentrations
increased MV02 in healthy dogs without influencing the
mechanical activity of the heart. Furthermore, by inhibiting
catecholamine-induced lipolysis with /3-pyridyl-carbinol, it
was shown that as much as 30% of the rise in MV02 induced
by catecholamines was attributable to FFA, and was in¬
dependent of their inotropic and chronotropic actions.12 /?-
pyridyl-carbinol was subsequently shown to reduce the
severity of myocardial ischemic injury, as assessed by myo¬
cardial creatine kinase depletion, during experimental cor¬
onary occlusion in dogs,10 and it was suggested that this
reflected a decrease in myocardial oxygen demand as a
result of the fall in arterial FFA. The present demonstration
that the reduction of myocardial FFA extraction by CPIB is
associated with a decrease in epicardial ST-segment eleva¬
tion in the absence of changes in hemodynamics or regional
myocardial blood flow is consistent with this proposal.
In addition to their calorigenic activity, FFA have other
metabolic actions which might also be expected to increase
the severity of acute myocardial ischemic injury. Thus, the
inhibition of glycolysis by FFA in the normally perfused
heart38 raises the possibility that they may impair carbo¬
hydrate utilization during coronary occlusion. More
recently it has been proposed that FFA may augment
myocardial ischemic injury by increasing the intracellular
concentration of long-chain acyl CoA esters, which have
been shown in vitro to inhibit the translocation of adenine
nucleotides across the mitochondrial membrane,39 and
which are known to accumulate within the heart during ex¬
perimental coronary occlusion.40
Acute coronary occlusion has been shown to stimulate the
release of catecholamine stores within the myocardium,41
and this would be expected to enhance the hydrolysis of in-
tramyocardial triglyceride with a local release of FFA.42
Studies in this laboratory have indicated that CPIB inhibits
catecholamine induced lipolysis in the isolated rat heart (de
Deckere, E.A.M., Mj0s, O.D., Miller, N.E: unpublished
observations). Thus, any limitation of myocardial ischemic
injury achieved with CPIB could have been related not only
to the fall in arterial FFA concentration but also to an in¬
hibition of intramyocardial lipolysis within the ischemic
zone.
Although it seems likely that the reduction in epicardial
ST-segment elevation achieved with CPIB reflected a limita¬
tion of myocardial ischemic injury, there is also the
possibility that it may have reflected, at least in part, a direct
effect of FFA on cellular membrane potentials. An altera¬
tion in cellular action potentials by sodium palmitate has
been noted in the isolated guinea pig heart,43 an observation
which may be relevant to the possible arrhythmogenic ac¬
tivity of FFA.7 9 It was not established in these studies,
however, whether the effect of FFA on action potentials was
direct, i.e., at membrane level, or indirect and mediated
through a disturbance of cellular metabolism.43 In the pres¬
ent investigation it was not possible to examine the effect of
CPIB on ventricular arrhythmias, since these were uncom¬
mon, probably due to the use of an open-chest preparation
and to the production of relatively small areas ofmyocardial
ischemia.
The antilipolytic activity of CPIB in most human subjects
appears to be substantially less than that in animals,13,14,44 48
and the results of the present study cannot be interpreted as
indicating that CPIB might similarly reduce the conse¬
quences of acute myocardial ischemia in man. However,
they strengthen the proposal47 that effective antilipolytic
therapy during the early phase of AMI in man, when FFA
concentrations may be increased by three-fold or more,1,2'4
might be of value in aiding the survival of the ischemic cells.
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Effects of prostaglandin-E., on ST segment elevation
and regional myocardial blood flow during
experimental myocardial ischaemia in dogs
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Abstract. The effects of prostaglandin Ei (PGEi) on
myocardial ischaemia (as measured by epicardial ST seg¬
ment changes), myocardial flow and substrate exchange
has been studied in dogs. Myocardial ischaemia was
induced by intermittent external clipping of a branch of
the left anterior descending coronary artery.
During occlusion with a continuous intravenous infu¬
sion of isoprenaline, elevated epicardial ST segments
(EST), were raised to 46 ± 6 mV (mean ± SEM). Pre-
treatment with PGEj reduced EST to 34 ± 6 mV (P <
0.001), but had no effect on mean aortic blood pressure
(AP) or on regional myocardial blood flow. Isoprenaline
infusion increased plasma free fatty acids (FFA) to
1925 ± 150 jumol/l and this was reduced to 1320 ± 220
jumol/1 by PGEj (P< 0.005).
During occlusion without isoprenaline, PGEj did not
effect EST or plasma FFA when infused intravenously
or into the left atrium. Mean aortic blood pressure de¬
creased from 131 + 7 to 108 ± 10 (PGE2 i.v.) or 109 ±
8 mmHg (PGE! i.a.) (P< 0.001). This was associated
with a decrease in regional myocardial blood flow, both
in the ischaemic and non-ischaemic myocardium. How¬
ever, when blood pressure was maintained constant,
intravenous PGEj tended to decrease occlusion-induced
ST segment elevation.
These results suggest that PGEj can reduce isoprena-
line-stimulated myocardial ischaemia through its antilipo-
lytic action but in the absence of catecholamine stimula¬
tion the main effect is to reduce blood pressure thereby
counterbalancing any potentially beneficial effects on
the ischaemic myocardium.
Key words. ST segment elevation, free fatty acids, myo¬
cardial ischaemia, blood flow, prostaglandin Ej, dog.
Introduction
Prostaglandins are naturally occurring substances with
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wide-ranging haemodynamic [1] and metabolic effects
[2]. Prostaglandins E and A increase coronary blood
flow in normal dogs [1] and it has been suggested that
they might be used clinically to increase blood flow to
the ischaemic myocardium [3].
In addition to increasing coronary blood flow prosta¬
glandin Ex (PGE0 also reduces tissue mobilization of free
fatty acids (FFA) [4-6]. This might also be desirable
since marked elevation of plasma FFA concentration in
patients with acute myocardial infarction has been asso¬
ciated with a poor immediate prognosis, ventricular
arrhythmias and death [7], and it is known that reduc¬
tion of raised plasma FFA concentration by antilipolytic
drugs during experimental myocardial ischaemia in dogs
decreases electrocardiographic signs of myocardial isch¬
aemia [8-12] and conserves the loss of myocardial
creatinine kinase (EC 2.7.3.2) activity [8].
Other haemodynamic effects of PGEi, such as de¬
creased peripheral vascular resistance and increased
cardiac work, may counteract or even outweigh the
benefits to the ischaemic myocardium of its metabolic
effects. Studies have therefore been made to assess the
value of PGEj in experimental ischaemia by measuring
its effects on metabolism, epicardial electrocardiographic
changes and regional myocardial blood flow in dogs.
Methods
Animal preparations
Mongrel dogs weighing between 12 and 25 kg were
anaesthetized with sodium pentobarbitone (25 mg/kg,
i.v.) followed by a continuous infusion of sodium pento¬
barbitone (approx. 4 mg/h, i.v.) or occasionally by intra¬
venous maintenance doses of 50 mg. Ventilation was
maintained with a Harvard respirator and monitored
using IL313 blood gas equipment. Arterial p02 was 89 ±
5 mmHg, pC0233 ± 2 mmHg, pH 7.44 ± 0.01.
The left and right femoral veins were cannulated for
the measurement of mean aortic blood pressure (AP),
which was monitored using a Statham Instruments pres¬
sure transducer (P23 Db) and recorded on a Devices
Instruments M8 recorder.
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The heart was exposed through a left thoracotomy
and suspended in a pericardial cradle. Care was taken not
to obstruct the caval veins. A distal branch of the left
anterior descending (LAD) coronary artery was dissected
free over a distance of 0.5-1.0 cm. The left atrium was
cannulated using a PE90 catheter for atrial infusions of
PGE!, since PGE] is up to 90% eliminated by passage
through the pulmonary circulation [1].
Electrocardiographic recordings were performed with
a mobile cotton wick electrode at ten to fifteen anatomi¬
cally well-defined sites on the epicardial surface [13]
and recorded with a sensitivity of 1 mV/mm deflection
and a paper speed of 25 mm/s on a Devices Instruments
MB recorder. A 10 mV signal was used for calibration.
The results were expressed as the sum of ST segment
elevations of all sites (EST), and were corrected for ST
segment elevation if any existed prior to the coronary
artery occlusion.
Regional myocardial blood flow was measured accord¬
ing to the method of Utley et al. [14] as described pre¬
viously [12]. Radioactive microspheres, 15 gm nominal
mean diameter, labelled with 85Sr, 141Ce or 125I (3M
Company Ltd, Loughborough, U.K.) were used. In
recent experiments, microspheres labelled with 169Yb
were used in preference to I25I. Between 5 and 30 min
after the last injection the dogs were killed with an intra¬
venous overdose of sodium pentobarbitone. The heart
was excised, the free wall of the left ventricle dissected
out, visual fat and large vessels removed. Between ten
and fourteen full thickness sections were made and
separated into epicardial and endocardial layers of wet
weight 1.5-4.0 g. Each section was then cut into ten to
twenty-blocks to produce relatively constant geometric
factors for the measurement of radioactivity. By com¬
parison with the radioactivity collected in a reference
arterial blood sample withdrawn at a known fixed rate,
absolute flow was calculated. The sections were allo¬
cated to one of two groups: (1) normal myocardium; (2)
peripheral plus central ischaemic myocardium. The
results were expressed as the mean regional blood flow
in the ischaemic area. Estimations of regional myocardial
blood flow were made with differently labelled micro¬
spheres used at random in order to avoid systematic
errors.
A different preparation was used in four dogs where¬
by heart rate, left ventricular end diastolic pressure
(LVEDP) and mean aortic pressure could be kept con¬
stant [15]. The heart was exposed by a mid-sternal split.
The left atrium was cannulated and connected to a reser¬
voir. LVEDP was computed on-line using an analogue
computer and maintained constant by varying the height
of the fluid column in the left atrial reservoir. Mean
aortic blood pressure was kept constant using a pressur¬
ized flask connected to both femoral arteries.
If changes in peripheral resistance occurred, equili¬
brium between two reservoirs was maintained by pump¬
ing blood from one to the other with a Watson-Marlow
MHRE roller pump. A water jacket and a heated, silicon¬
ized glass coil in the reservoir were used to maintain the
fluid in the system near 37°C. The system was primed
with a solution of 2.5% w/v dextran, which was allowed
to mix with the blood in the dog in order to minimize
later changes in haematocrit during the observation
periods. Right atrial pacing was used to keep the heart
rate constant. Arterial pressure was measured through a
carotid arterial cannula. Left ventricular pressure was
measured using a metal cannula inserted through the
dimple of the apex and directly connected to the pressure
transducer (L223, Consolidated Electrodynamics,
England). The frequency response of the overall system
was flat within 5% at 40 Hz. dP/dt max. was derived by
the analogue computer. The initial values of heart rate
(HR), AP and LVEDP were chosen close to those ob¬
served prior to the first infusion and then maintained
constant during the observation periods. After release of
the occlusion HR, LVEDP and AP were no longer con¬
trolled.
PGE! dissolved in methanol was stored at — 30°C.
Prior to the administration the methanol was evaporated
under a stream of nitrogen at room temperature and
PGE, was immediately dissolved in 150 mmol/1 sodium
chloride solution.
Isoprenaline was freshly prepared in 150 mmol/1
sodium chloride.
Plasma FFA concentrations were determined from
femoral arterial plasma according to the titrimetric
method of Trout et al. [16]. Arterial plasma glucose was
determined using an automated technique using glucose
oxidase [17], and arterial plasma free glycerol by an
enzymatic method [18].
Experimental procedures
The basic design was to induce two or three discrete
periods of myocardial ischaemia each of 10-14 min
duration, separated by a recovery period of 30 min. Irre¬
versible damage does not occur within the first 20 min
of ischaemia [19]. The degree of ST segment elevation
during three successive occlusions of the same artery has
been shown to be reproducible, provided a recovery
period of 30 min is allowed [8, 12, 13]. This design per¬
mits comparison of ischaemic electrocardiographic
changes under different experimental conditions in the
same animal. Three series of experiments were per¬
formed.
In the first series (Procedure 1, Fig. 1) the effect of
PGE] was studied on EST segment elevation during lipo-
lysis stimulated by a continuous infusion of isoprenaline
in nine dogs (dogs 1-9). Isoprenaline 0.1-0.2 yug kg"1
min"1 i.v. was commenced 5 min prior to the control
occlusion and maintained throughout. At 10 min of
ischaemia the epicardial electrocardiogram, HR and
AP were recorded and microspheres injected into the
left atrium for measurement of regional myocardial
blood flow. An arterial blood sample was taken for the
determination of plasma FFA concentration. The occlu¬
sion was released and the isoprenaline infusion stopped.
After a 30 min recovery period an infusion of PGE! 0.6
Mg kg^min"1 i.v. was given, followed 5 min later by an
isoprenaline infusion. Both infusions were maintained
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Figure 1. Protocol for the study of the effect of PGE, on ST segment elevation during isoprenaline-stimulated and
basal lipolysis. The basic experimental design consisted of two or three intermittent occlusions (Occl.) of the termin¬
al branch of the left anterior descending coronary artery of 10-14 min duration. Prior to release, recordings of epi-
cardial electrocardiograms of ten to fifteen anatomically well defined sites were made, and an arterial blood sample
was obtained for biochemical parameters (arrows). After release a 30 min recovery period was allowed for ST seg¬
ments to revert to normal.
Procedure 1 was used to study the effect of PGE, (0.6 Mg kg"1 min"1 i.v.) during isoprenaline (0.1-0.2 Mg kg"1
min"1 i.v.) stimulated lipolysis. Regional myocardial blood flow was determined by injection of 1.5-3.0X 106
microspheres into the left atrium immediately before the release of the occlusions.
Procedure 2 was used to study the effect of PGE,, either infused into the left atrium (0.03 Mg kg"1 min"1) or
intravenously (0.6 Mg kg"1 min"1) during basal lipolysis. Using three differently labelled radioactive microspheres,
regional myocardial blood flow was estimated immediately prior to release of each occlusion.
during this occlusion. All measurements: epicardial ECG
(EST), HR, AP and regional myocardial blood flow were
repeated (Fig. 1).
In two experiments (dogs 7 and 9) the sequence was
reversed, isoprenaline and PGE] being infused during the
first occlusion period. After release and recovery, iso¬
prenaline alone was infused for the second occlusion
period. This was done in order to check whether the
effects of PGE] were related to the time of administra¬
tion.
In the second series (Procedure 2, Fig. 1) the effect of
PGE], administered intravenously (0.6 pg kg-1 min""1) or
intra-atrially (0.03 pg kg"1 min"1) was studied in eight
dogs (dogs 10-17). Three occlusions of approximately
10 min duration were made as described above. The first
occlusion served as a control. The other occlusions were
made 5 min after the start of either a continuous PGE]
infusion into the femoral vein or into the left atrium.
The infusion of PGE] into the left atrium was made in
order to check whether PGE] or its metabolites were the
active components. Normally up to 90% of PGEj is
removed on a single passage through the lungs. The order
in which the PGE] infusions were administered was
randomized. EST segment elevation, HR and AP were
measured immediately prior to the release of the occlu¬
sion. In five dogs, microspheres were injected for mea¬
surement of regional myocardial blood flow after 10 min
of occlusion during each of the three experimental occlu¬
sions described above. Isoprenaline was not given to dogs
in the second series.
In the third series the effect of intravenous PGE] (0.6
pg kg"1 min"1) was studied in four dogs (dogs 18-21),
whilst HR, AP and LVEDP were maintained constant.
Two occlusions of approximately 10 min duration were
made as described above (Procedure 2, Fig. 1), each 5
min after the start of a continuous infusion of either
PGE] or saline. The order of these infusions was random¬
ized. Epicardial ECG (EST segment elevation) HR, AP,
LVEDP and LV dP/dt max were measured immediately
before and at 5 min intervals during the occlusion.
Arterial (carotid artery) blood samples were obtained for
the estimation of plasma FFA and free glycerol.
Statistics
Each dog served as its own control. Student's t-test
for paired data was used to calculate probability values.
Results
The effects ofPGEnduring isoprenaline infusions
After the occlusion of a distal branch of the left
anterior descending coronary artery, the onset of acute
myocardial ischaemia was characterized by localized
cyanosis, contractile asynergy and ST segment elevation
in the distribution of the ligated artery.
When the induction of myocardial ischaemia was
made in the presence of isoprenaline EST segment eleva¬
tion averaged 46 ± 6 mV (mean ± SEM) after 10 min of
occlusion (Table 1). When the isoprenaline infusion was
preceded by a continuous infusion of PGEj EST aver¬
aged 34 ± 6 mV (P<0.001). This effect of PGE] was
independent of the sequence of administration. The data
from all dogs were pooled.
The lipolytic activity of isoprenaline was apparent
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Table 1. The effect of PGE, i.v. on ischaemia and isoprenaline-induced ST segment elevation, mean aortic pressure, heart rate and arterial
plasma FFA concentrations during experimental myocardial ischaemia of 10 min duration






















1 38 27 2100 1190 103 90 175 172
2 36 25 1290 520 69 55 172 151
3 42 35 1860 1550 103 109 195 189
4f 21 14 2650 2550 73 81 150 150
5 36 24 2520 2040 85 72 164 146
6t 78 62 2065 790 110 96 169 164
n 74 62 1650 1070 130 130 173 175
n 53 36 1600 750 105 88 142 141
n 39 25 1580 1400 106 106 147 140
Mean 46 34 1925 1320 98 92 165 159
+ SEM 6 6 150 220 6 7 6 6
P* <0.001 < 0.005 NS < 0.05
Isoprenaline was administered intravenously at a dose of 0.1-0.2 pg kg-1 min"1. PGE, at 0.6 ug kg"1 min"1.
In dogs 1-6 and 8 the first occlusion was made during isoprenaline infusion, followed by an occlusion made during an isoprenaline
plus PGE, infusion, whereas in dog 7 and 9 the first occlusion was made during an isoprenaline plus PGE, infusion, followed by an occlu¬
sion during an infusion of isoprenaline alone.
* Probability values for comparison of paired data of occlusion + isoprenaline vs. occlusion + isoprenaline + PGE,. NS = not signifi¬
cant (P > 0.05).
f Dose of PGE, = 0.3 pg kg"1 min"1.
$ Regional myocardial blood flow estimation (see Table 2).
from the high plasma FFA concentrations (1925 ±150
limol/1). This was partly inhibited when PGEt was simul¬
taneously administered (1320 ± 220 /imol/1: P< 0.005)
(Table 1).
The intravenous administration of PGE! did not signi¬
ficantly alter AP during isoprenaline infusions, but a
small and significant decrease in HR was observed (Table
1). PGEi administration had no effect on regional myo¬
cardial blood flow in the endocardial and epicardial layers
of the ischaemic and non-ischaemic part of the left ven¬
tricle during the isoprenaline infusions (Table 2).
The reproducibility of the effects of isoprenaline was
good in separate control experiments. In ten comparisons
of two consecutive occlusions EST was 46 ±12 mV
(first occlusion) 47 ± 12 mV (second occlusion): P>
0.30.
Table 2. The effect of PGE, i.v. on regional myocardial blood flow in non-ischaemic and central plus peripheral ischaemic left ventricle
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* Probability values for comparison of paired data of occlusion + isoprenaline vs. occlusion + isoprenaline + PGE, i.v. NS = not
significant (P > 0.05).
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Table 3. The effect of PGE, i.v. or i.a. on ischaemia-induced ST segment elevation, mean aortic pressure, heart rate and arterial plasma
FFA concentrations during experimental myocardial ischaemia of 10 min duration
EST (mV) FFA (jumol/1) AF (mmHg) HR (beats/min)
Dog No. Occl. Occl. + Occl. + Occl. Occl. + Occl. + Occl. Occl. + Occl. + Occl. Occl. + Occl. +
PGE, i.v. PGE, i.a. PGE, i.v. PGE, i.a. PGE, i.v. PGE, i.a. PGE, i.v. PGE, i.a.
10 15 11 - 780 700 - 145 125 - 168 175 -
11 27 24 21 640 600 660 100 75 80 132 125 128
12 23 29 31 500 520 400 147 133 133 159 164 160
13f 8 - 8 400 - 460 135 — 124 - - —
14) 3 8 6 350 370 270 155 123 125 - - -
15) 27 9 19 370 440 565 115 88 86 190 182 184
16) 13 6 8 1050 - 880 112 97 100 218 220 224
17) 24 - 16 410 - 440 141 - 118 186 - 180
Mean 17 14 15 560 525 525 131 108 109 176 173 175
± SEM 3 4 3 85 60 75 7 10 8 12 15 16
p* NS NS NS NS < 0.001 <0.001 NS NS
The first occlusion was a control occlusion. In dogs 11,12 and 15 the second occlusion was made during an intravenous infusion of
PGE,, followed by a third occlusion during an intra-atrial infusion of PGE,. In dogs 13, 14, 16 and 17 the second occlusion was made
during an intra-atrial infusion of PGE,, followed by a third occlusion during intravenous infusion of PGE, (dogs 14 and 16).
* Probability value for comparison of paired data vs. occlusion. NS = not significant (P > 0-05).
t Regional myocardial blood flow estimation (see Table 4).
Effects ofPGE i infusions alone.
In the absence of isoprenaline, PGE! did not reduce
plasma FFA concentrations (Table 3), or alter plasma
free glycerol and glucose concentrations.
The haemodynamic effects of PGE! alone, were also
different from those observed during isoprenaline infm
sions. PGE! alone did not change HR. PGEi reduced AP
significantly, irrespective of which route was used (Table
3). This drop in AP was associated with a marked reduc¬
tion in regional myocardial blood flow in epicardial and
endocardial layers of the non-ischaemic myocardium
(Table 4). The reduction was slightly more marked in the
endocardial layers of the non-ischaemic myocardium,
giving rise to a significant decrease in the endocardial-
epicardial blood flow ratio (P< 0.005). PGEi (both i.v.
and i.a.) also reduced myocardial blood flow in the
ischaemic epi- and endocardial layers (P< 0.005), and
the reduction was possibly more pronounced in the
endocardial layers. However, no change was observed in
Table 4. The effect of PGE, i.v. or i.a. on regional myocardial blood flow in non-ischaemic and central plus peripheral ischaemic left






































































Results are expressed as mean ± SEM (number of observations).
* Probability value of comparison of paired data vs. control. NS = not significant (P > 0-05).
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Table 5. The electrocardiographic, haemodynamic and metabolic effects of PGE, i.v. during coronary artery occlusion under conditions
of controlled preload, afterload and heart rate
2ST dP/dt max. AF LVEDP FFA
(mV) (mmHg s"1) (mmHg) (mmHg) (umol/1)
Occl. Occl. Occl. Occl. Occl.
Dog No. Occl. + PGE, Occl. + PGE, Occl. + PGE, Occl. + PGE, Occl. + PGE,
18 148 136 3520 3720 96 84 3.9 3.0 360 260
19* 202 155 1250 3300 67 68 2.0 2.5 360 460
20* 151 122 3060 2790 80 83 9.0 8.9 410 600
21* 59 74 1750 1740 77 73 5.3 5.5 455 520
* In dog 18 an occlusion of 10 min duration was made during an infusion of saline followed by a second occlusion of 10 min during
an infusion of PGE,, whereas in dogs 19, 20 and 21 the first occlusion was made during infusion of PGE, and the second occlusion
during the infusion of saline.
ST segment elevation after 10 min of occlusion (Table 3).
Therefore the studies were extended to another series in
which the blood pressure as well as HR and LVEDP were
controlled. Under these conditions PGE! i.v. reduced
EST in three out of four experiments. This effect was
not related to plasma FFA concentrations, which tended
to increase.
Discussion
The effect ofPGE\ during isoprenaline infusions
During experimental myocardial ischaemia under con¬
ditions of high adrenergic drive (isoprenaline infusions),
PGE, reduced EST segment elevation. Epicardial ST seg¬
ment elevation reflects the severity of acute myocardial
ischaemia [20] and is inversely related to myocardial
oxygen tension [21].
Arterial plasma FFA concentrations were lowered by
PGE, due presumably to its inhibitory effect on the lipo¬
lytic activity of isoprenaline. This is likely to have led to
reduced myocardial extraction of FFA. Arterial-coro¬
nary venous differences were not measured but propor¬
tionality between arterial concentration and myocardial
extraction has previously been found [23-25]. Reduced
plasma FFA and myocardial FFA uptake leads to reduced
myocardial oxygen consumption (MV02) when the lipo¬
lytic action of isoprenaline is blocked by an antilipolytic
agent [26]. In the presence of acute myocardial isch¬
aemia, such reduction of MV02 would be expected to be
associated with reduced signs of ischaemia, such as EST.
Reduction of FFA uptake may also reduce their accumu¬
lation as long-chain acyl-CoA esters [27]. In vitro these
inhibit adenine nucleotide translocase and impede trans¬
port of ADP across the inner mitochondrial membrane
[28, 29]. A decrease in long-chain acyl CoA esters in the
ischaemic myocardium might facilitate ADP transport
and restore oxidative metabolism resulting in decrease
ST segment elevation. Whatever the explanation, these
effects of PGE, on induced myocardial ischaemia in the
presence of isoprenaline are consistent with those pre¬
viously reported for other antilipolytic drugs [8-12]
and for lipid-free albumin [30].
Factors changing myocardial oxygen requirements
relative to oxygen supply, such as heart rate and blood
pressure, also influence the extent of ST segment eleva¬
tion [13, 22]. In the present study AP was unchanged,
and the small reduction in heart rate which was observed
seems too small to account for the reduction in ST
segment elevation.
Direct effects of PGE, have also to be considered. ST
segment elevation can occur when resting membrane
potential is reduced [31]. PGE, had no effect on resting
membrane potential in mammalian, well oxygenated
myocardial cells and, when used in very high concentra¬
tions, caused a decrease [32]. This would tend to increase
ST segment elevation. Since PGE, reduced EST, it seems
unlikely that an effect on the resting membrane poten¬
tial could explain our findings.
The effect ofPGEX in the absence of isoprenaline
During experimental myocardial ischaemia but in the
absence of isoprenaline, the effect of PGE, on occlusion-
induced ST segment elevation was dependent on the ex¬
perimental conditions. In the main series of experiments
during basal lipolysis, PGE, effected no change in occlu¬
sion-induced ST segment elevation. But a marked reduc¬
tion was observed in AP and regional myocardial blood
flow both in the ischaemic and non-ischaemic areas of
the myocardium. Similar haemodynamic effects were
reported while this study was in progress when PGE,
was given to cats with acute myocardial ischaemia [33],
but ST segment measurements were not made. Since
hypotension has been shown to increase occlusion-
induced ST segment elevation [13, 22] the observation
of unaltered ST segments by PGE, needs comment. It
cannot be explained by increased myocardial uptake of
FFA since plasma concentrations of FFA were unaltered
by PGE,. A possible explanation was that the expected
increase in EST due to hypotension was counteracted by
some opposing influence. In studies conducted with con-
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trolled AP and LVEDP, PGEi reduced ST segment eleva¬
tion. While these studies do not explain the nature of
this opposite action, they appear to exclude mechanisms
based on changes in FFA metabolism.
Patients with acute myocardial infarction have in¬
creased adrenergic drive. During nervous stimulation and
hypoxia endogenous prostaglandins are released and are
thought to prevent excessive stimulation of the myo¬
cardium by noradrenaline.
In the present study pharmacological doses of PGE!
were used and due to its side effects PGE! may not be
useful to reduce myocardial infarct size in man.
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Myocardial metabolism was studied in open-chest dogs before
and during induction of myocardial ischaemia by coronary artery
occlusion. Blood was sampled from a local coronary vein draining
ischaemic tissue and from coronary sinus draining predominantly
non-ischaemic tissue. In the basal state, induction of myocardial
ischaemia stimulated myocardial lipolysis as shown by release of
glycerol from the ischaemic zone. During isoprenaline infusion,
free fatty acids (FFA) extraction across the ischaemic myocardium
was substantially increased, but no glycerol release occurred.
Pretreatment with nicotinic acid or sodium salicylate markedly
depressed FFA extraction across ischaemic myocardium both during
basal and isoprenaline stimulated lipolysis and nicotinic acid
most likely inhibited lipolysis in the ischaemic zone. Thus,
reduced severity of acute ischaemic injury by antilipolytic treatment
might be due to a combination of inhibited myocardial lipolysis
and reduced FFA extraction.
2.
INTRODUCTION
High supply of free fatty acids (FFA) to the ischaemic
myocardium has been claimed to increase infarct size (25) and
mortality (22) in patients with acute myocardial infarction.
Antilipolytic treatment has recently been shown to reduce the
ischaemic injury in these patients (11, 30) and to reduce the
exercise-induced ST-segment depression in patients with angina
pectoris (15). In experimental studies elevated plasma FFA
concentrations enhance myocardial oxygen consumption (3, 17),
suggesting that the deleterious effect of FFA during myocardial
ischaemia may reflect an increased oxygen requirement in ischaemic
tissue. Accordingly, during coronary artery occlusion the
increased myocardial damage following catecholamine infusion is
substantially limited when the rise in arterial FFA concentration
is inhibited by j3-pyridylacarbinol (12), p-chlorophenoxyisobutyrate
(19), prostaglandin (29) or salicylates (39). In vitro
experiments further suggest that infusion of catecholamines
(6, 37, 42) or induction of myocardial ischaemia per se (9)
might activate myocardial lipolytic activity with consequent
hydrolysis of endogenous triglycerides. The beneficial effect
of antilipolytic agents on myocardial ischaemia might therefore
in part be due to inhibition of local release of FFA within the
ischaemic tissue.
In the present study, the influence of arterial FFA availability
on substrate exchange in ischaemic and non-ischaemic myocardium
was investigated in open-chest, anaesthetized dogs following
coronary artery occlusion. This was accomplished by measurement
of arterio-venous differences of FFA, glucose and lactate across
ischaemic and non-ischaemic myocardium both during basal and
isoprenaline-stimulated lipolysis, as well as after pretreatment
with the antilipolytic agents nicotinic acid or sodium salicylate.
Furthermore, since glycerol is not utilised in the myocardium to
any significant amount (14, 20, 31), the possible role of endogenous





Studies were performed on 20 overnight-fasted mongrel dogs
of either sex on average 22 kg body weight (b.w.). They were
anaesthetised with sodium pentobarbital, 25 mg/kg b.w., intravenously
(i.v.), and followed by continuous infusion of 3.5 mg/h kg b.w.
The dogs were ventilated with a volume controlled respirator
(Servo Ventillator 900, Elema-Schonander AB, Solna, Sweden)
through a cuffed endotracheal tube. A thoracomtomy was performed
through the fifth left intercostal space. The pericardium
was incised, and the heart suspended in a cradle. Care was
talc en not to obstruct central veins. A branch of the left
anterior descending coronary artery was dissected for about 0.5 cm,
and left in situ with a ligature placed loosely around it.
Intermittent myocardial ischaemia was induced by coronary artery
occlusion using a releasable metal clip.
A plastic catheter was inserted into a local vein draining
the area supplied by the dissected coronary artery, and kept
patent by flushing with a dilute heparin!sed saline solution
(1 i.u./ml).
The coronary sinus was catheterised with a plastic catheter
introduced through a jugular vein in 14 of the animals. At least
30 min recovery period was allowed from the end of surgical
procedure and introduction of catheters to the first blood sampling.
Both femoral veins were cannulated for intravenous infusions.
Saline (0.9%), at a rate of 10 ml/h kg b.w. i.v., was given throughout
the experimental period.
Haemodynamic measurements:
Aortic blood pressure (AP) was recorded through a catheter
introduced from a femoral artery with a Statham P23 Gb pressure
transducer (Statham Instruments, Inc., Oxnard, Calif., USA). A
short catheter through the ventricular apex permitted measurement
of left ventricular pressure. The first derivative of left
ventricular pressure with regard to time (LV dP/dt) was recorded
from that pressure channel. LVSP, LVdP/dt, AP and heart rate
(HR) were recorded on a Dynograph recorder (Type 411, Beckman
Instruments, Inc., Schiller Park, 111., USA).
Epicardial ST-segment mapping:
Epicardial electrocardiograms (ECG) were recorded using a
cotton-wick electrode immediately before and 12 min after coronary
artery occlusion from 1Q-15 anatomically well recognisable sites
within and around the area supplied by the occluded artery, as
described by Maroko et al. (16). The epicardial ECG was recorded
with the limb leads serving as the ground electrode, and recorded with
a sensitivity of 1 mV/mm and a paper speed of 25 mm/sec on a
Dynograph recorder. The sum of all occlusion induced ST-segment
elevations (2ST, mV) and the number of sites at which ST-segment
elevation exceeded 2 mV were used as an index of the severity of
myocardial ischaemia in each dog (16, 32).
Metabolic measurements:
Myocardial metabolism was assessed by arterio-venous differences.
Blood was drawn simultaneously from the aorta, coronary sinus and
local coronary vein into heparinised syringes and immediately
centrifuged at 4°C. Plasma FFA concentrations were estimated
by a radio-chemical method (8), glucose concentrations by a glucose
oxidase method using a commercial kit (Boehringer Mannheim GmbH,
Mannheim, Germany), glycerol by an enzymatic method (4), and
lactate concentrations according to the method of Passonneau (28).
Packed cell volumes were determined by a micro-haematocrit centrifuge
and the oxygen saturations were measured spectrophotometrically
(The Oxygen Saturation Meter, type OSM 1, Radiometer, Copenhagen,
Denmark).
All analyses were performed in triplicate. The coefficients
of variations for the assays are: FFA 3%, glucose 2%, glycerol 3%
and lactate 6%.
Experimental procedure:
Experiments were carried out both under basal conditions and
during continuous i.v. infusion of isoprenaline at a rate of
0.10 - 0.20 jug/min kg b.w. Generally four intermittent occlusions
were performed in each animal. This allowed each animal to serve
as its own control for the assessment of the effect of treatment
during basal and isoprenaline stimulated conditions. Haemodynamic
measurements were performed immediately before and 12 min following
the occlusion of the coronary artery. Blood samples were obtained
before and from 6 to 12 min after induction of myocardial ischaemia.
The coronary artery occlusion was released after 12 min and a
recovery period of 45 min was allowed.
A second occlusion was performed after 10 min of isoprenaline
infusion when the haemodynamic variables had stabilised. All
measurements were repeated. After release and recovery, nicotinic
acid (0.3 mg/min kg b.w.; 7 dogs) or sodium salicylate (60 mg/kg
b.w. as a slow injection followed by 0.15 mg/min kg b.w. dissolved
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in 0.9/5 saline, pH 7.40; 7 dogs) or 0.9% saline (6 dogs) was
started. After 30 min a third occlusion was made, followed
after release and recovery by a fourth occlusion during isoprenaline.
Care was taken that the haemodynamic and electrocardiographic
measurements were always done and blood samples were always obtained
in the same order, and at the same time after occlusion.
The three series of experiments were performed in sequence:
firstly the sodium salicylate experiments, secondly the nicotinic
acid experiments and thirdly the control experiments with saline.
In three of the seven dogs given sodium salicylate only experiments
without infusion of isoprenaline were conducted. Furthermore, in
the salicylate experiments plasma glycerol concentrations were not
measured. Epicardial ST-segment mapping was only performed in
the control experiments.
Statistics:
Each dog served as its own control. Wilcoxon's non-parametric
test (two-tailed) for paired data was used to calculate probabilities
(36). Statistical comparisons are not performed between samples
of 5 or less. P>0.05 was regarded as not statistically significant.
Standard error of the methods was calculated from triplicate analyses
of 4 randomly selected experiments, and is expressed relative to
the mean as coefficient of variation.
8.
RESULTS
Myocardial metabolism and performance before coronary artery
occlusion. Effects of isoprenaline infusion (Table I)
Before coronary artery occlusion the arterio-coronary sinus
(a-cs) and arterio-local venous (a-lv) differences of oxygen
saturation, plasma glucose, lactate, FFA and glycerol concentrations
were not significantly different either during basal or isoprenaline
stimulated conditions. This indicates that before induction
of myocardial ischaemia the a-lv differences were representative
for myocardial metabolism in the whole left ventricle as represented
by a-cs differences.
In the absence of isoprenaline the coronary artery occlusion
did not change the arterial concentrations of any of the measured
substrates - oxygen, glucose, lactate, FFA or glycerol. Induction
of myocardial ischaemia produced release of glycerol from the
ischaemic area, as reflected in negative a-lv differences of
glycerol in all the experiments where plasma glycerol concentrations
were measured. Compared with the a-lv differences before induction
of myocardial ischaemia the glycerol release was significant
(p<0.02, n = 7). This was also true when a-lv differences were
compared with a-cs differences of glycerol measured simultaneously
(p<0.05, n = 7). In contrast to the effect of coronary occlusion
on glycerol release, no effect was observed on plasma FFA a-lv differ¬
ences. As expected the extraction of oxygen and glucose increased
across the ischaemic myocardium and lactate was produced. Coronary
artery occlusion had no effect on a-cs differences of oxygen and
substrates. HR, LVSP and LV dP/dt were not changed by the
induction of myocardial ischaemia.
During isoprenaline infusion, a steady metabolic state had
not been obtained after 10 min of infusion. Since the arterial
concentrations of glucose, FFA and glycerol during myocardial
ischaemia were constantly increasing compared with preocclusion
values, only comparisons of a-lv and a-cs differences obtained
simultaneously are valid. No glycerol release was observed from
the ischaemic myocardium during isoprenaline infusion by comparison
of a-lv and a-cs differences (n.s., n = 10), nor were the a-lv
differences significantly different from zero (n.s., n = 10).
The extraction of FFA across the ischaemic myocardium increased
(p<0.01, n = 14). Comparison of a-lv and a-cs differences shoxved
that after the induction of myocardial ischaemia glucose and
oxygen extraction were increased and lactate was produced.
Haemodynamic variables were unchanged by the induction of myocardial
ischaemia during isoprenaline infusion.
Effects of two repeated coronary artery occlusions before and during
isoprenaline infusion (Table II)
The reproducibility of our model was tested in 6 dogs. In
absence of isoprenaline infusion the arterial oxygen saturation
and concentrations of glucose, lactate and FFA during the repeated
occlusion did not significantly differ fromthose during the first
occlusion, and the a-lv and a-cs differences were not significantly
altered. In all the 5 experiments where glycerol concentrations
were measured induction of myocardial ischaemia produced release
of glycerol from the ischaemic area, as reflected in negative
a-lv differences of glycerol, while a-cs differences measured
simultaneously remained positive. During the second of the two
occlusions arterial concentrations were higher. Glycerol release
was found in 4 of the 5 experiments during the repeated occlusion,
but no glycerol release was observed across the whole heart (a-cs).
The severity of the acute myocardial ischaemia expressed as
Est was the same during the two repeated coronary artery occlusions
(occlusion I: 25.3 + 6.9, occlusion II: 27.2 +_ 7.3 mV, n.s., n = 6)
and the number of sites with ST-segments exceeding 2 mV was unchanged
(occlusion I: 5.5 0.8, occlusion II: 6.2 + 0.8 sites, n.s., n = 6).
During infusion of isoprenaline arterial levels of oxygen, glucose,
lactate, FFA and glycerol were not significantly different between
the two repeated occlusions. The a-lv differences of glycerol,
as well as of the other substrates and oxygen, were the same
during the two occlusions. HR, LVSP and LV dP/dt were unaltered
from first to second occlusion.
The electrocardiographic changes were reproduceable as shown
by unchanged SST (isoprenaline + occlusion I: 57.3 +_ 10.6,
isoprenaline + occlusion II: 57.6 + 11.6 mV, n.s., n = 6) and
unchanged number of sites with ST-segments exceeding 2 mV
(isoprenaline + occlusion I: 9.0 + 0.5, isoprenaline + occlusion II:
8.7 + 0.4, n.s., n = 6).
Metabolic and haemodynamic effects of nicotinic acid (Table III)
Nicotinic acid significantly reduced the arterial concentrations
of FFA in absence of isoprenaline (p = 0.03, n = 7), whereas no
other significant changes in arterial levels of oxygen, glucose
of lactate were observed. The a-lv differences of FFA were
significantly reduced by nicotinic acid (p<0.02, n = 7), but
no change in a-lv differences for oxygen, glucose or lactate
occurred. Arterial glycerol concentrations were reduced after
administration of nicotinic acid in only 2 of the 5 experiments
where glycerol concentrations were measured. In 4 out of 5
experiments coronary occlusion induced glycerol release into
the local vein. After administration of nicotinic acid this
was observed in 3 experiments. In order to cancel the effect
of the increased arterial glycerol concentrations, the exchange
of glycerol was also calculated from a-lv differences before
and during coronary artery occlusion. The change in a-lv
differences induced by myocardial ischaemia were then -6.5 + 10.2
pmol/1 during nicotinic acid administration and -30.9 + 12.9 pmol/1
before drug administration. Nicotinic acid did not alter
haemodynamic variables in the absence of isoprenaline.
During isoprenaline infusion and myocardial ischaemia the
arterial concentrations of FFA (p<0.02, n = 7) and glycerol
(p<0.02, n = 7) were substantially reduced by nicotinic acid,
whereas the other substrate concentrations were unaltered.
The a-lv differences of FFA (p<0.02, n = 7) and oxygen (p<0.02,
n = 7) were markedly reduced. No significant change in the
a-lv differences of glycerol occurred during administration of
nicotinic acid and isoprenaline. The a-lv differences of glycerol
during coronary artery occlusion were not different from preocclusion
values (4.7 +_ 4.6 ^amol/1; n.s., n = 6), nor were they different
from zero (n.s., n = 6). Hr, LVSP and LV dP/dt were not changed
by nicotinic acid during isoprenaline infusion.
Metabolic and haemodynamic effects of sodium salicylate (Table IV)
In the basal state sodium salicylate administration reduced
arterial concentrations of FFA (p<0.05, n = 7), whereas no changes
in arterial oxygen saturation or plasma concentrations of glucose
and lactate were observed. Only extraction of plasma FFA across
ischaemic myocardium was significantly reduced by sodium salicylate
(p = 0.03, n = 7). The drug did not modify the haemodynamic
state.
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During isoprenaline infusion and sodium salicylate administration
the arterial concentrations of FFA were reduced in all the 5
experiments, and the a-lv differences of FFA were also consistently
reduced. During unaltered arterial lactate concentrations the
average lactate release increased after sodium salicylate
administration, but in 2 out of 3 experiments it was actually
reduced. No other striking differences in arterial concentrations
and a-lv differences were found, and the mechanical activity of
the heart was mainly unaltered.
DISCUSSION
The method used in this study for induction of small ischaemic
areas and local venous sampling from a vein draining the ischaemic
area is a well-established procedure for obtaining blood for
study of metabolic changes secondary to induction of ischaemia
(23, 26, 27). Ischaemic areas involving less than 15% of the
whole heart do not produce any significant changes in coronary
sinus blood (24), as also demonstrated in this study. The
experimental model therefore allows comparison of a-v differences
across ischaemic tissue (a-lv differences) with non-ischaemic
tissue (a-cs differences), as shown for oxygen, glucose, lactate,
FFA and glycerol. The fact that during isoprenaline infusion
a steady state for arterial concentrations of glucose, glycerol
and FFA was not obtained, complicates the interpretations of the
data. However, simultaneous use of a-lv and a-cs differences
during myocardial ischaemia overcomes this possible criticism.
The severity of an acute myocardial ischaemia is reproduceable
following several repetitive coronary artery occlusions (1, 16),
as also demonstrated in the present study in the basal state as
well as during isoprenaline infusion. The metabolic consequences
of myocardial ischaemia were also found to be fully reproduceable
for oxygen, glucose, lactate and FFA. In interpretation of the
glycerol data, however, it should be noted that the arterial
glycerol concentrations during the second occlusion in the basal
state were higher than during the first occlusion, most likely
related to an effect of the preceding isoprenaline infusion.
But the arterial concentrations of glycerol were not altered by
coronary artery occlusion in the basal state, thus allowing the
assessment of the effect of myocardial ischaemia also by comparing
a-lv differences of glycerol before and after coronary artery
occlusion. A comparison of the substrate exchanges across
ischaemic myocardium following pharmacological interventions in
this animal model should therefore be allowed. It should be
pointed out, however, that the amount of uptake or release of
substrates cannot be calculated from the a-v differences since
blood flow is not known.
During coronary artery occlusion release of glycerol to
the local vein was observed, whereas no significant a-v differences
were found before induction of myocardial ischaemia. The
glycerol released from the ischaemic area might come from
endogenous myocardial triglycerides. The glycero-kinase
activity is very low in the myocardium (31), and glycerol
oxidation is presumed to be insignificant (14, 20). Consequently,
the heart is unable to reutilise the glycerol in any significant
amount, and mobilization of the myocardial triglyceride stores
would release glycerol into the venous effluent. Alternatively,
hydrolysis of plasma triglycerides by lipoprotein lipase in the
endothelium of myocardial capillaries might be responsible for
the release of glycerol into the local vein. It is, however,
unlikely that contribution from this source is significant in
these experiments since plasma triglycerides are low in overnight
fasted dogs (13), and moreover, lipoprotein lipase activity is
markedly depressed following myocardial ischaemia of short
duration (10). Glycerol release in ischaemic myocardium might
also be due to activation of lysosomal lipolytic activity.
However, this possibility is also unlikely since lysosomal
integrity is maintained up to 30 min after induction of anoxia (41).
It is therefore reasonable to assume that the glycerol released
from the ischaemic myocardium is a measure of endogenous lipolysis
within the tissue. Our finding of enhanced lipolysis in the
myocardium during ischaemia, as evidenced by release of glycerol,
is in accordance with Hough and Gevers (9), recently reporting
increased activity of hormone-sensitive lipase in ischaemically
perfused rat hearts. This increase was markedly reduced by
reserpinisation, indicating that local release of noradrenaline
within the ischaemic myocardium might be the stimulus for enhanced
lipolysis (34).
Before induction of myocardial ischaemia we could not demonstrate
any significant glycerol release from themyocardium either before
or during isoprenaline infusion, although isoprenaline substantially
increased the lipolysis in adipose tissue as evidenced by increased
arterial FFA concentrations. Isoprenaline (37) or adrenaline
(6, 42) stimulates myocardial lipolysis in rat hearts perfused
without FFA. However, when fatty acids were included in the
perfusate, Crass et al. (6) found that the stimulatory effect of
adrenaline on mobilisation of triglyceride was abolished consistent
with an inhibitory effect of exogenous FFA on myocardial lipolysis.
At variance with the effect of myocardial ischaemia in the basal
state, no release of glycerol into the local vein was observed
during isporenaline infusion. In the present study, therefore,
the high arterial FFA concentration during isoprenaline infusion
might have effected an inhibition of myocardial lipolysis both
in ischaemic and non-ischaemic myocardium. Alternatively, during
isoprenaline infusion and high arterial glycerol concentration
some glycerol might be taken up and metabolised in the myocardium,
and thereby outbalancing the glycerol released from the myocardium
during ischaemia.
During myocardial ischaemia the oxidation of fatty acids is
impaired (33), and the alternatives to FFA oxidation are accumulation
of intracellular FFA either free or as long-chain acyl-CoA esters
or esterification of FFA to triglycerides. Long-chain acyl-CoA
esters are shown to accumulate in ischaemic myocardium (35), but
although FFA are found in elevated concentrations in hypoxic
perfused myocardium (7), as yet intracellular accumulation of
FFA is not documented in ischaemic myocardium (23, 33).
Esterification of FFA to triglycerides is stimulated in ischaemic
myocardium (33). Therefore, increased esterification and the
demonstration of enhanced lipolysis in this study might indicate
a wasting of energy by recycling triglyceride. Thus, it has
been shown that rat hearts with high triglyceride content exposed
to ischaemic perfusion exhibit a more pronounced lipolytic
activity and higher oxygen requirement than rats with normal
triglyceride content (2).
The antilipolytic agents nicotinic acid or sodium salicylate
have been shown to reduce the size of an acute myocardial ischaemic
injury in experimental studies (12, 38, 39). In the present
study we demonstrate that the extraction of FFA across ischaemic
myocardium is substantially decreased by antilipolytic agents.
Since blood flow in ischaemic area is not affected by any of
the drugs (38), the reduced a-lv differences also reflect reduced
uptake of FFA in ischaemic myocardium. It should be noted that
these changes in FFA extraction by the antilipolytic agents
occurred without any significant changes in glucose and lactate
exchange. This most probably means that during myocardial ischaemia
nicotinic acid,lowers the ©^-glycerophosphate requirements for
triglyceride synthesis and thereby making the glucose available
for immediate energy purposes.
No consistent glycerol release across the ischaemic myocardium
was found after administration of nicotinic acid either in the
basal or isoprenaline stimulated state. The interpretation
of this effect of nicotinic acid was hampered by the fact that
a trend of reduced glycerol release was observed during two
repeated occlusions. Furthermore, the arterial glycerol
concentrations were higher during nicotinic acid in the basal
state. The reason for the apparent failure of nicotinic acid
to reduce arterial glycerol concentrations, while FFA concentrations
were reduced, is most likely an effect of the preceding isoprenaline
infusion. It has been shown that nicotinic acid inhibited
glycerol release from ischaemically perfused rat heart (2, 5).
These studies cannot be compared directly,however, since plasma
FFA seems to have a modulating activity on myocardial lipolysis.
If the only effect of nicotinic acid was to reduce plasma FFA
concentrations, then an enhanced lipolysis in the myocardium
might be expected. However, the finding of no glycerol release
from ischaemic myocardium after administration of nicotinic
acid, suggests that inhibition by nicotinic acid of lipolytic
activity in myocardium overrules the effect of the concomitantly
reduced exogenous FFA supply to the myocardium. Further studies,
are, however, needed to investigate the regulatory role of plasma
FFA in ischaemia-induced lipolysis.
This study was not designed to compare two antilipolytic
agents. However, taken together with other investigations,
nicotinic acid reduces myocardial uptake of FFA and oxygen more
markedly than sodium salicylate (18, 40), probably as a consequence
of a more potent lowering of arterial FFA concentrations (18, 40).
In line with the possibility of a more effective lowering of
myocardial oxygen requirement by nicotinic acid than by sodium
salicylate, Oliver (21) reported that the effect of different
antilipolytic agents on myocardial ischaemia-induced epicardial
ST-segment changes were closely associated with the change in fatty
acid/albumin ratio obtained by the antilipolytic agent.
In conclusion, the results of this investigation show that
myocardial ischaemia stimulates endogenous lipolysis. According
to the present study, reduced severity of acute myocardial
infarction by antilipolytic treatment shortly after onset of
symptoms might be due to the combination of inhibited myocardial
lipolysis and decreased FFA extraction from the circulation.
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Effects of dichloroacetate on myocardial substrate
extraction, epicardial ST-segment elevation, and
ventricular blood flow following coronary
occlusion in dogs1
O. D. M J0S2, n. E. MILLER3, R. a. RIEMERSMA, and M. F. OLIVER
From the Departments of Cardiology and Medicine and the Lipid Research Laboratory,
Department of Clinical Chemistry, Royal Infirmary, Edinburgh
authors' synopsis Glucose metabolism in the healthy heart is stimulated by dichloroacetate
(DCA). The possibility has been examined in dogs that DCA, by increasing glucose utilization,
might limit the severity of acute myocardial ischaemic injury.
Intravenous administration of DCA reduced the degree of epicardial ST-segment elevation in¬
duced by subsequent coronary occlusion, both under basal conditions and during isoprenaline
infusion. A similar result was obtained when DCA was given during an established coronary
occlusion. This effect could not be explained by changes in mean aortic blood pressure, heart
rate, or regional myocardial blood flow as measured by radioactive microspheres. Measurements
in arterial and coronary sinus blood demonstrated an increase in the extraction of glucose and a
decrease in that of FFA by the heart. Glucose extraction also tended to be increased in the ischaemic
zone, as shown by the differences in the concentrations of these substrates between arterial blood
and blood obtained from the local vein draining that zone. Lactate release by the ischaemic zone
was markedly reduced.
Under normal circumstances the energy require¬
ments of the heart are derived principally from
the oxidation of free fatty acids (FFA) (Lassers
et al, 1972). During myocardial ischaemia the
oxidation of FFA is impaired to a greater
extent than that of glucose, and the heart be¬
comes more dependent upon both aerobic and
anaerobic glucose metabolism for its energy re¬
1 Supported by grants from the Medical Research Council and the
Wellcome Trust.
Reprint requests to M.F.O., Department of Cardiology, Royal
Infirmary, Edinburgh.
2Present address: Institute for Medical Biology, University ofTromso,
Troms0 9OOO, Norway.
3 Present address: Division of Metabolic Disease, Department of
Medicine, University of California at San Diego, La Jolla, California
92037, USA.
quirements (Opie et al, 1973). Under such cir¬
cumstances an increased delivery of FFA to the
heart has been associated experimentally with
the development of ventricular arrhythmias
(Kurien et al, 1971) and with further deteriora¬
tion in cellular function (Kjekshus and Mjos,
1972; de Leiris et al, 1974).
For these reasons it was proposed that the
survival of the ischaemic myocardium might be
improved by measures which promote the utiliza¬
tion of glucose and decrease that of FFA
(Kurien and Oliver, 1970; Opie, 1970). Recent
animal studies have supported this hypothesis,
and intravenous (iv) infusions of glucose and
insulin were reported by Maroko et a! (1972) to
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reduce myocardial ischaemic injury following
coronary occlusion in dogs; and similar results
were obtained by Kjekshus and Mjos (1973)
when arterial FFA concentrations were lowered
by (3-pyridyl-carbinol and by Mjos et al (1976)
using clofibrate to reduce myocardial FFA
extraction.
In 1962, Lorini and Ciman reported that di-
isopropyl-ammonium dichloroacetate raised the
respiratory quotient in alloxan-diabetic rats,
suggesting an increased utilization of glucose
relative to that of FFA. Stacpoole and Felts
(1970; 1971) demonstrated that the active com¬
ponent was dichloroacetate (DCA), and that
this stimulated glucose oxidation and inhibited
FFA oxidation in rat diaphragm muscle.
McAllister et al (1973) subsequently showed
that DCA had similar effects on the metabolism
of the isolated perfused rat heart and the
intact dog heart. Associated changes in
lactate and pyruvate metabolism and in intra¬
cellular intermediates suggested that DCA
was stimulating both glycolysis and glucose
oxidation by increasing the activities of phospho-
fructokinase and pyruvate dehydrogenase. An
activation of pyruvate dehydrogenase in rat myo¬
cardium by DCA was observed by Whitehouse
and Randle (1973).
In the present study we have investigated
further the metabolic and haemodynamic effects
of DCA in dogs, and have examined the possi¬
bility that the stimulation of myocardial glucose
utilization by DCA might limit the severity of




Experiments were performed on 29 healthy mongrel
dogs of both sexes (12-19 kg body weight). Each
dog was fasted overnight and anaesthetized with
sodium pentobarbitone (25 mg/kg, iv), followed by
maintenance doses of 50 mg. Ventilation was main¬
tained throughout a cuffed endotracheal tube with
a positive pressure respirator (Harvard Apparatus
Co Inc, Mass, USA). Thoracotomy was performed
through the left fifth intercostal space and the heart
suspended in a pericardial cradle. A branch of the
left anterior descending (LAD) coronary artery
was then dissected free for 0.5 cm. Subsequent
occlusions of the artery were performed with a
releasable metal clip. The left femoral vein was
cannulated as a route for infusion, and the left
femoral artery for measurement of mean aortic
blood pressure (AP). AP was monitored with a Sta-
tham P23Db transducer. A catheter for withdrawal
of arterial blood was inserted into the right femoral
artery. Coronary sinus blood was sampled through a
catheter introduced via the left jugular vein under
fluoroscopic guidance. In 10 experiments the local
vein draining the ischaemic area was cannulated for
the assessment of metabolic changes in the ischaemic
myocardium.
Experimental designs
Effects of DCA on the response to subsequent
coronary occlusion
Experiments were carried out both under basal con¬
ditions and during a continuous iv infusion of iso-
prenaline. In six animals the experimental design
conformed to procedure 1 of Fig. 1. In one animal a
similar sequence of occlusions was performed with¬
out the use of isoprenaline; in another animal iso-
prenaline was given during all four occlusions. In
three animals the experimental design was reversed
in accordance with procedure 2 of Fig. 1. In these
experiments DCA was given before the first and
second occlusions, and a period of 95 min was then
allowed for the metabolic effects ofDCA to diminish
before repeating the occlusions. The effects of DCA
were assessed by paired analysis of the data for all
11 experiments.
In five separate animals the effect of DCA (120
mg/kg) on the metabolic pattern across the ischaemic
zone was studied during basal lipolysis. A constant
infusion of albumin bound 3H-oleate (Radiochemi¬
cal Centre, Amersham), prepared as described by
Opie et al (1973) was commenced at least 90 min
before and maintained throughout the experiment.
Between 5 and 15 min after the occlusion of the
branch of the LAD coronary artery, arterial, local
venous, and coronary sinus blood samples were
taken for the measurement of FFA, :!H-FFA, glu¬
cose, and lactate. After release and recovery DCA
was administered and the occlusion repeated 10 min
later. Care was taken that blood samples were ob¬
tained at the same relative times during the two
occlusions. In another five animals the identical
procedure was repeated except that now the occlu¬
sions were preceded by a continuous isoprenaline
infusion (0.1-0.15 pg-kg-1 /min).
In four additional animals the effects of DCA on
regional myocardial blood flow 15 min after coron¬
ary occlusion were assessed by means of radioactive
microspheres. Measurements were made during an
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PROCEDURE 1





fig. 1 Experimental proce¬
dures for assessing the effect of
dichloroacetate (DCA) on the
response to subsequent coronary
occlusion. Four identical occlu¬
sions of 15 min duration were
performed in each animal, two
in the absence of DCA and two
in its presence. One of each
pair of occlusions was perform¬
ed during a continuous iv infu¬
sion of isoprenaline (0.2-0.3 \±g-
kg~xlmin), started 5 min before
the occlusion. Recovery periods
of 30 min were allowed between
successive occlusions. Immedi¬
ately before the release of each
occlusion (indicated by vertical
arrows) epicardial electrocar¬
diograms from 10-15 sites in the
ischaemic and non-ischaemic
zones, mean aortic blood pressure and heart rate were recorded, and blood was sampled from a femoral
artery and the coronary sinus. Sodium DCA was administered at the dose of 120 mglkg body weight by iv















initial control occlusion, and then during a second
occlusion performed 10 min after iv administration
of sodium dichloroacetate (120mg/kg). The order
of injection of the differently labelled microspheres
was varied to avoid systematic errors due to possible
differences in their behaviour.
Effects of DCA administration during established
coronary occlusion
In another four animals iv infusion of isoprena¬
line (0.2-0.3 (Ag-kg_1/min) was maintained for the
duration of the study. Five minutes after its com¬
mencement control recordings of the epicardial
electrocardiogram (ECG), AP, and HR were made
before a branch of the LAD coronary artery was
permanently occluded. Further ECG and haemo-
dynamic measurements were made 5, 10, and 15
min following coronary occlusion. Sodium di¬
chloroacetate (120mg/kg iv) was then infused over
2 min, and the ECG and haemodynamic recordings
repeated 5, 10, 15, and 20 min later. Arterial and
coronary sinus blood was sampled immediately
before and 20 min after the injection of DCA for
measurement of plasma FFA and glucose concen¬
trations.
In the same animals the effect of DCA on the total
myocardial uptake of radiolabelled palmitate was
also examined. For this purpose a continuous iv
infusion of albumin-bound (9,10[n]-3H) palmitate
(Radiochemical Centre, Amersham). Arterial and
coronary sinus blood for measurement of plasma
FFA radioactivity was sampled immediately before
and 20 min after DCA injection.
Measurements
Epicardial ST-segment mapping
The severity of the acute myocardial ischaemic
injury was assessed by epicardial ST-segment
mapping (Maroko et al, 1971). Epicardial electro¬
cardiograms were recorded 15 min after coronary
occlusion from 10-15 anatomically recognizable
sites supplied by the occluded artery and within the
adjacent area, using a mobile cotton-wick electrode
(Devices M4 recorder; paper speed, 25 mm/s;
sensitivity, 1 mV/mm deflection). The sum of the
ST-segment elevations from all sites (LST) was used
as an approximate index of the severity of ischaemic
injury.
Regional myocardial blood flow
Regional myocardial blood flow was measured with
141Ce- and 85Sr-labelled radioactive microspheres
(3M Riker Laboratories, Loughborough, UK;
nominal diameter, 15 (i.) (Utley et at, 1974). Before
injection 2.0-2.5 x 106 microspheres (sufficient to
give at least 1000 microspheres/g of myocardium)
were sonicated in 10% dextrose for 10 min to
dispel aggregates (Dawe Sonicleaner, type 6441A),
and drawn into a syringe containing 0.1ml 5%
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Tween 30. The suspension was diluted with 10%
dextrose to a final concentration of Tween 80 of less
than 0.5%, and then continuously agitated until
injected. Fifteen min after coronary occlusion blood
for estimation of reference blood flow (RBF) was
withdrawn from a femoral artery into a weighed
heparinised syringe at constant rate (approximately
9 ml/min) for 2 min. Immediately after the com¬
mencement of blood withdrawal, the microspheres
were injected through a left atrial cannula over 10 s.
After each experiment the heart was excised, the
free wall of the left ventricle dissected out, and visual
fat and large vessels removed. Between eight and 10
full thickness tissue samples were taken and divided
into epicardial and endocardial layers (wet weight
1.5-4.0 g). Each layer was divided into 10-20
blocks to produce constant geometrical factors for
measurements of radioactivity in a three channel
gamma counter (GammaGuard, Tracerlab Ltd).
Approximately 27% of 85Sr radioactivity was
counted in the 141Ce channel. This factor was
determined during each counting procedure using
the reference blood samples as standards. RBF was
estimated by weighing, using an assumed blood
specific gravity of 1.05 g/ml. Regional myocardial
blood flow (MBF) was calculated for each tissue
sample using the formula:
CM
MBF = — X RBF
where MBF is expressed in mI-g~Vmin, CM is the
tissue sample radioactivity in cpm/g wet weight,
CR is the total cpm in the reference blood sample,
and RBF is expressed in ml/min (Utley et al, 1974).
Metabolic measurements
Plasma FFA concentrations were measured in
duplicate by the method ofTrout et al (1960). Plasma
glucose was assayed in quadruplicate using a semi-
automated glucose oxidase method (Nimmo et al,
1973). Blood lactate was measured in duplicate
according to Hohorst (1963), or when local venous
blood samples were obtained, plasma lactate concen¬
trations were estimated in triplicate according to the
method of Passonneau (1974). Plasma lipids were
extracted in duplicate and radioactive FFA isolated
by thin layer chromatography as described by Bo-
berg (1966). Radioactivity was measured using a
Packard Liquid Scintillation spectrometer Model
3390. Internal standards were used to correct for
quenching. Arterial oxygen saturation was monitored
with a Kipp type Mol Hemoreflector, and arterial
pH and pC02 with a Type AME lc Astrup Micro
Equipment (Radiometer, Copenhagen).
Statistics
Each dog served as its own control. Student's t test
for paired data was used to calculate probabilities.
P> 0.05 was regarded as not statistically significant.
Results
Effects of DCA on the response to subsequent
coronary occlusion
The effects of DCA on the response to subse¬
quent coronary occlusion under basal conditions
are summarized in Table 1. Coronary occlusion
raised epicardial ST segments in all experiments.
In the absence of DCA, XST averaged 18±3
mV (mean ± SEM) 15 min after coronary
occlusion. Values for SST were significantly less
when coronary occlusion was performed after
the administration of DCA (SST 6±2mV;
P <0.005). HR was decreased from 136 ±8 to
127 ±8 beats/min (P <0.05), while AP was un¬
changed. Arterial blood lactate concentration
was reduced by DCA from 1.10±0.24 to0.28±
0.03 mmol/litre (P<0.01). The arterial-coronary
sinus difference (Aa-cs) in lactate concentration
was reduced from 0.32±0.07 to 0.08±0.02
mmol/litre (P<0.02), while that in glucose
concentration was increased from 4.5 ± 1.4 to
9.9±1.0 mg/100 ml (P<0.005). Other metabolic
measurements were unchanged.
The effect of DCA on the a-v differences in
concentration of metabolites across the ischae-
mic zone is tabulated in Table 1 (series II). There
was a tendency for arterial-local venous differ¬
ence (Aa-lv) in plasma glucose concentration to
increase (three out of four experiments), although
arterial glucose concentration tended to decrease
and a decrease in Aa-lv of glucose actually
occurred when arterial glucose concentration
decreased as much as 18%. In three out of four
experiments lactate release was diminished. No
marked effect of DCA on the extraction of FFA
in the ischaemic area was found.
The effects of DCA on the response to subse¬
quent coronary occlusion during isoprenaline
infusion appear in Table 2. In the absence of
DCA, isoprenaline infusion increased SST from
18±3 to 62±8 mV (P<0.00l). This was
associated with a reduction in AP (P <0.005),
and increase in HR (P<0.001), and increases in
the arterial concentrations of FFA (P <0.001),
glucose (P<0.01) and lactate (P<0.025). Pre-
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table 1
Effects of pretreatment with sodium dichloroacetate (120 mg/kg) on epicardial ST-segment elevation and
haemodynamic and biochemical measurements 15 min after coronary occlusion under basal conditions
Measurement n* Mean :t SEM Pf
Control Dichloroacetate
EST (mV) 10 18 ±3 6 ±2 <0.005
HR (beats/min) 10 136 ±8 127 ±8 <0.05
AP (kPa) 10 15.3 ±0.80 15.3 ±0.80 NS
FFAa (umol/litre) 10 447 ±51 461 ±63 NS
FFAa-cs (umol/litre) 10 85 ±29 63 ±15 NS
Glucosea (mg/100 ml) 9 94 ±4 94 ±5 NS
Glucosea-cs (mg/100 ml) 9 4.5 ±1.4 9.9 ±1.0 <0.005
Lactatea (mmol/litre) 7 1.10 ±0.24 0.28 ±0.03 <0.01
Lactatea-cs (mmol/litre) 7 0.32 ±0.07 0.08 ±0.02 <0.02
Series lit
FFAa (umol/litre) 5 537 ±43 543 ±61 NS
3H-FFA(a-lv)/a(%) 3 38 ±6 28 ±12 NS
Glucosea (mg/100 ml) 5 110 ±13 100 ±12 <0.05
Glucosea.lv (mg/100 ml) 4 17.9 ±8.3 20.1 ±9.0 NS
Lactatea (mmol/litre)** 4 0.78 ±0.13 0.50 ±0.11 NS
Lactatea_iv (mmol/litre)** 4 -2.38+0.71 -1.72 ±0.44 NS
EST = sum of ST-segment elevations at 10-15 epicardial sites; HR = heart rate; AP = mean aortic pressure; 3H-FFA
= radioactive FFA. The subscripts indicate: a = arterial concentration; a-cs = arteriocoronary sinus concentration
difference; a-lv = arterio-local venous concentration difference (local vein, draining the ischaemic area); (a-lv)/a = ex¬
traction in the ischaemic area.
*Number of dogs studies.
|P values were obtained by the paired t test; NS = not statistically significant (P >0.05).
JSeparate study, observations were made between 5-15 min after coronary occlusion.
**Plasma lactate concentrations.
Conversion: SI to traditional units: 1 kPa ~ 7.5 mmHg.
table 2
Effects of pretreatment with sodium dichloroacetate (60 mg/kg) on epicardial ST-segment elevation and
haemodynamic and biochemical measurements 15 min after coronary occlusion during a continuous intravenous
infusion of isoprenaline (0.2-0.3 \xgjkglmin)
Measurement n Isoprenaline (mean ± SEM) P
Control Dichloroacetate
EST (mV) 10 62 ±8 45 ±7 <0.001
HR (beats/min) 10 162 ±6 155 ±6 <0.05
aP (kPa) 10 11.7 ±0.93 12.2 ±0.80 <0.02
FFAa (umol/litre) 9 1716 ±177 1719 ±167 NS
FFAa-cs (umol/litre) 9 310 ±41 192 ±19 <0.005
Glucosea (mg/100 ml) 9 122 ± 11 120 ±10 NS
Glucosea-cs (mg/100 ml) 9 7-1 ±1-9 12.3 ±2.5 <0.02
Lactatea (mmol/litre) 7 1.67 ±0.35 0.69 ±0.10 <0.02
Lactatea-cs (mmol/litre) 6 0.42 ±0.16 0.12 ±0.03 NS
Series II*
FFAa (umol/litre) 4 1363 ±118 1369 ±192 NS
3H-FFA(a_iv)/(%) 4 26.4 ±15.0 28.5 ±16.7 NS
Glucosea (mg/100 ml) 5 115.0 ±8.7 105.0 ±10.6 NS
Glucosea_iv (mg/100 ml) 5 23.0 ±3.8 29.9 ±7.1 NS
Lactatea (mmoI/Iitre)t 4 1.32 ±0.15 0.80 ±0.19 <0.01
Lactatea-iv (mmol/litre)f 4 -2.67 ±0.63 -1.88 ±0.51 <0.05
All abbreviations as in Table 1.
*Separate study: dose of sodium dichloroacetate 120 mg/kg; dose of isoprenaline 0.1-0.15 ug'kg Vmin; observations were
made between 5-15 min after coronary occlusion.
jPlasma lactate concentrations.
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treatment with DCA reduced isoprenaline-
induced increase in UST from 62±8 to 45±7
mV (P <0.001). Heart rate was reduced from
162±6 to 155±6 beats/min (P<0.05), while
AP was increased from 11.7±0.93 to 12.3 ±
0.80 kPa (88 ±7 to 92±6 mmHg) (P <0.02). The
effects of DCA on lactate and glucose meta¬
bolism during isoprenaline resembled those
observed under basal conditions: ie, decreases
in arterial lactate concentration (P<0.02) and in
the Aa-cs in lactate concentration (P <0.10),
and an increase in the Aa-cs in glucose con¬
centration of 5.2±1.7 mg/lOOml (P<0.02). In
addition, the Aa-cs in FFA concentration was de¬
creased from 310±41 to 192±19 pmol/litre (P<
0.005) in the absence of change in arterial
FFA concentration.
The effects of DCA on the a-v differences of
substrates across the ischaemic area during iso¬
prenaline infusion are summarized in Table 2
(series 11). DCA had a consistent and significant
lowering effect on lactate release from the
ischaemic left ventricle. The Aa-lv of glucose
increased in four out of five experiments, and
arterial plasma glucose concentrations tended to
decrease; when arterial glucose concentrations
table 3
Effects of sodium dichloroacetate, 120 mg/kg, on
regional myocardial blood flow in ischaemic and non-
ischaemic free left ventricular wall 15 min after
coronary occlusion in four dogs






Epicardial 1.16 ±0.05 1.35 ±0.06 <0.005
(25) (25)
Endocardial 1.25 ±0.05 1.41 ±0.06 <0.025
(25) (25)
Ischaemic myocardium%
Epicardial 0.29 ±0.07 0.34 ±0.07 NS
(ID (H)
Endocardial 0.30 ±0.08 0.35 ±0.10 NS
(11) (ID
Results are expressed as means ± SEM. The figures in
parentheses indicate the number of biopsies.
"Paired t test. NS: P >0.05.
tMyocardium distant from the occluded artery.
tMyocardium within the area of distribution of the occluded
artery.
decreased by as much as 25 %, glucose extraction
by the ischaemic area actually decreased after
DCA (one experiment). The extraction of (3H)
FFA appeared to be unchanged by DCA.
The results of the radioactive microsphere
studies are summarized in Table 3. Non-
ischaemic tissue of the free wall of the left
ventricle distant from the occluded artery was
taken to represent normal myocardium. On this
basis coronary occlusion produced an average
decrease of approximately 75% in blood flow to
the ischaemic zone, the reduction in flow being
greater in the endocardial (mean reduction,
0.95 ml-g~7min) than in the epicardial (0.87
ml/g) layers. DCA increased blood flow to both
the epicardial (±0.19 ml-g_1/min or 16%;
P <0.005) and endocardial (±0.16 ml-g~Vmin
or 13%; P<0.025) layers of the non-ischaemic
myocardium, but had no effect on that to the
ischaemic zone.
Effects of DCA administration during
established coronary occlusion
The effects of DCA administration during estab¬
lished coronary occlusion and isoprenaline in¬
fusion are presented in Table 4, and the changes
in epicardial ST segments in one experiment are
illustrated in Fig. 2. Ten, 15, and 20 min after
DCA, values for ST were significantly lower than
those observed immediately before treatment
(P<0.05). Mean aortic pressure and HR at these
times were similar to those recorded before
treatment, with the exception that HR had de¬
creased by 8 ±2 beats/min (P <0.01) after 20
min. The Aa-cs in glucose concentration was
increased from 2 to 11 mg/lOOml (one experi¬
ment), while that in FFA concentration was
decreased (P <0.05) in the presence of unchanged
arterial concentrations. DCA also reduced the
Aa-cs in FFA radioactivity in these experiments
(P<0.05).
Discussion
The most notable finding of the present study was
that DCA reduced the degree of epicardial ST-
segment elevation following acute coronary
occlusion in dogs, and prevented the augmenta¬
tion of ST-segment elevation induced by iso¬
prenaline. This latter effect was observed both
when DCA preceded subsequent reocclusion of
433 Dichloroacetate and myocardial ischaemic injury in dogs
table 4
Acute effects of sodium dichloroacetate (DCA), 120 mg/kg, oil epicardial ST-segment elevation, haemo-
dynamic measurements, and myocardial substrate utilization in four dogs when administered during an estab¬
lished coronary artery occlusion and isoprenaline infusion
Time (min)
0 5 10 15 20 25 30 35 40
■Isoprenaline infusion (0.2-0.3 v-g-kg-1imin)
Coronary artery occlusion
* Dichloroacetate (120 mg/kg, iv) >
rST (mV) 2(1) 48(8) 65(9) 70(10) 56(15) 49(1l)t 48(9)** 44(6)*
AP (kPa) 13.8(1.5) 13.7(1.5) 14.0(1.5) 13.7(1.5) 14.2(1.3) 14.2(1.2) 14.0(1.2) 14.0(1.2)
FIR (beats/min) 188(8) 190(9) 188(11) 187(14) 184(12) 184(13) 184(13) 179(l3)t
FFAa (iimol/litre) 1255(364) 1133(360)
FFAa_es (nmol/litre) 270(78) 198(68)*
3H-FFAa (dpm/ml) 2483(1240) 2426(1340)
3H-FFAa_cs (dpm/ml) 629(366) 444(391)*
Glucosea (mg/100 ml)ft 172 149 152 149 154
Glucosea_Cs (mg/100 ml)ft 3 2 14 9 11
Results are expressed as means. The SEMs are given in parentheses.
All abbreviations are as in Table I.
3H-FFAa r arterial FFA radioactivity as (9, 10(n)-3H) palmitate; 3H-FFAa_Cs = arterial-coronary sinus concentration
difference in FFA radioactivity.
Statistical comparisons were performed by paired t test against those results obtained immediately before DCA (time 20 min).
*P <0.05; tP <0.01; tP <0.005; **P <0.001.
ft One dog only.
the artery and when given during an occlusion
established 15 min earlier.
Epicardial ST-segment elevation has been
shown to reflect the severity of myocardial
ischaemia (Wegria et al, 1949), and to correlate
with the local changes in tissue oxygen tension
(Sayen et al, 1958) and cellular membrane
potential (Toyoshima et al, 1965) during coron¬
ary occlusion. The degree of ST-segment
elevation 15 min after coronary occlusion has
been correlated with the subsequent depletion of
myocardial creatine kinase activity (Maroko et
al, 1971; 1972; Kjekshus and Mjos, 1973) and
the development of histological, histochemical,
and ultrastructural evidence of cellular necrosis
(Maroko et al, 1972; Libby et al, 1973) after
24 h of sustained occlusion. It is likely, therefore,
that the reduction in ST-segment elevation
produced by DCA in the present study reflected
a limitation of the acute myocardial ischaemic
injury.
The severity of myocardial ischaemic injury is
influenced by factors which alter myocardial
oxygen requirement relative to oxygen supply.
The major determinants of myocardial oxygen
requirement are heart rate, wall tension, and
contractility (Sonnenblick et al, 1968), and the
possibility must be considered that the reduction
of ST-segment elevation by DCA may have been
secondary to a change in one of these para¬
meters. Although DCA reduced mean HR in all
experiments, this effect averaged only 5 %, and
was probably insufficient to account for the
mean reduction in ST-segment elevation of 44%
(Maroko et al, 1971; Wendt et al, 1974). Further¬
more, in six instances DCA administration was
associated with an unchanged or increased HR,
but nevertheless EST was significantly reduced.
Changes in AP, when present, were also insuffi¬
cient to explain the reduction in ST segment
elevation. An effect of DCA on myocardial
oxygen supply is unlikely as the results of the
microsphere studies showed that blood flow to
the ischaemic zone was unchanged by DCA.
The use of arterial-coronary sinus differences
has been shown to be justified for the study of
non-ischaemic myocardial metabolism when
small ischaemic lesions are produced (Owen et
al, 1970; Opie et al, 1973). Changes in arterial-
coronary sinus concentration differences have
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FIG. 2 Epicardial electrocardiographic recordings from four of 11 sites in one experiment. Five minutes after
the commencement of a continuous iv infusion of isoprenaline (0.2-0.3 y-g-kg ^/minj, a branch of the left
anterior descending coronary artery was permanently occluded. Fifteen min later sodium dichloroacetate was
given by iv injection at the dose of 120 mg! kg. Epicardial electrocardiograms were recorded immediately before
coronary occlusion (lime, 5 min), and subsequently at 5 min intervals until 20 min after the administration of
dichloroacetate. LV = left ventricle; LAD = left anterior descending coronary artery; occln = coronary
occlusion.
indicated that DCA had marked effects on the
pattern of substrate utilization by the non-
ischaemic left ventricle. In all experiments DCA
raised the total myocardial extraction of glucose
relative to that of FFA. In most instances this
reflected both an increase in the Aa-cs in glucose
concentration and a decrease in that of FFA,
although the latter reached statistical significance
only in the presence of isoprenaline. In all but
one of seven animals DCA also reduced the
arterial lactate concentrations and the Aa-cs
in lactate concentrations. The decrease in
Aa-cs in FFA (3H-palmitate experiments and
FFA during isoprenaline) can be interpreted
either as a decrease in the extraction of FFA or
an increase in intramyocardial lipolysis. The
latter does not seem likely, since DCA exerted an
antilipolytic effect in rats (Blackshear et al
1974).
These findings cannot be extrapolated to the
metabolism in the ischaemic area and therefore
should not be directly related to the ECG
changes recorded over that area. It is necessary
therefore to make comparable measurements
using local vein sampling techniques, thereby
deriving arterial-local vein concentration differ¬
ences which mostly reflect metabolic changes in
the ischaemic tissue (Owen et al, 1970; Opie et
al, 1973). DCA increased Aa-lv concentrations
of glucose, even when arterial glucose concen¬
trations fell. Lactate release was decreased.
These findings permit us to postulate that the
reduction of 2ST in the ischaemic area could be
related to these local metabolic changes.
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The stimulation of glucose metabolism by
DCA is in agreement with the observations of
McAllister et al (1973) who studied alloxan-
diabetic dogs and healthy dogs in which FFA
concentrations had been raised by infusions of a
triglyceride emulsion and heparin. The increase
in myocardial glucose utilization was attributed
by these workers to a stimulation of phospho-
fructokinase and to the activation of pyruvate
dehydrogenase. The reduction in arterial lactate
concentrations is also in agreement with earlier
studies in dogs and rats (McAllister et al, 1973;
Blackshear et al, 1974). In functionally hepa-
tectomized rats it was shown that the deciease in
arterial lactate concentrations is due to a reduced
release of lactate from extrahepatic tissues
(Blackshear et al, 1974). This and the observation
that DCA increases pyruvate dehydrogenase
activity in muscle (Whitehouse and Randle,
1973) may explain the decrease in arterial lactate
concentration. The decrease in total lactate ex¬
traction by the heart accords with its known
arterial concentration-extraction relationship
(Kaijser et al, 1972). The decrease in lactate re¬
lease could also be explained by the increased
activity of pyruvate dehydrogenase and/or
decreased arterial lactate concentrations.
The metabolism of the acutely ischaemic or
hypoxic myocardium has been reviewed (Opie,
1970; Rubier and Spieckermann, 1970; Oliver,
1972; Opie, 1972). In both situations the oxida¬
tion of glucose, FFA, and lactate by the heart is
immediately impaired. The consequent decline
in the intracellular concentrations of ATP and
citrate activates phosphofructokinase, which in
turn stimulates glycolysis, resulting in increased
lactic acid and ATP production. During hypoxia
but normal perfusion, when the excess lactic acid
can be adequately cleared, the stimulation of
anaerobic glycolysis in this way can supply up to
90% of myocardial energy requirements in the
presence of extracellular glucose (Kiibler and
Spieckermann, 1970). Following coronary occlu¬
sion, however, lactic acid accumulates within the
ischaemic tissue due to inadequate removal, and
the consequent fall in intracellular pH produces a
secondary inhibition of phosphofructokinase
and a decline in ATP production. For this reason,
glycolysis is normally unable to supply more than
70% of myocardial energy requirements during
ischaemia (Rubier and Spieckermann, 1970).
A considerable degree of glucose oxidation
persists in the ischaemic myocardium (Opie et al,
1973), and DCA could have increased the
capacity of ischaemic cells to metabolize glucose
aerobically. Other mechanisms whereby DCA
may have reduced ischaemic injury include the
inhibition of FFA metabolism and an enhance¬
ment of lactate removal from the ischaemic cell
secondary to the reduction in arterial lactate
concentration. Therefore, no certain conclusions
concerning the precise mechanism whereby
DCA reduces ST-segment elevation can be drawn
at this stage.
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P-pyridylcarbinol Kjekshus and Mj^s, 1973
nicotine Ilebekk and Mjf6s , 1974
isoprenaline Lekven et al, 1973
prostaglandin-E^ Section 3.2
p-chlorophenoxyisobutyrate Section 3.1
5-fluoronicotiny1-alcohol Riemersma, unpublished results
noradrenaline Mj/s et al, 1974
acebutolol Section 3.3
nicotinic acid Vik-Mo, 1977
sodium salicylate Vik-Mo and Mj/s , 1977; Vik-Mo, 1977
fat free albumin Miller et al, 1976
Antilipolytic agents were often
and absence of isoprenaline.
tested in the presence
